PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17424939-2	2007	Polymerase chain reaction (PCR) was used for the detection of several vancomycin resistance genes such as vanA ("high level"), vanB ("moderate high level"), vanC1 and vanC2 ("low level").	Vancomycin	70-80	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	106-110
17424939-2	2007	Polymerase chain reaction (PCR) was used for the detection of several vancomycin resistance genes such as vanA ("high level"), vanB ("moderate high level"), vanC1 and vanC2 ("low level").	Vancomycin	70-80	D-alanine--D-lactate ligase	Enterococcus faecium	127-131
17424939-7	2007	In addition, vanA gene was detected in 4 strains of 2005 E. faecium isolates, thus showing a high resistance to vancomycin.	Vancomycin	112-122	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	13-17
17164498-1	2007	Vancomycin precipitates fibrinogen.	Vancomycin	0-10	fibrinogen beta chain	Homo sapiens	24-34
17164498-2	2007	The turbidity induced by this vancomycin-fibrinogen interaction is used to establish a simple standardized antigenic assay for plasmatic fibrinogen, the FIATA.	Vancomycin	30-40	fibrinogen beta chain	Homo sapiens	41-51
17164498-2	2007	The turbidity induced by this vancomycin-fibrinogen interaction is used to establish a simple standardized antigenic assay for plasmatic fibrinogen, the FIATA.	Vancomycin	30-40	fibrinogen beta chain	Homo sapiens	137-147
17164498-3	2007	1 mM vancomycin or 2 mM chloramine-T inactivates 50% of fibrinogen in human plasma.	Vancomycin	5-15	fibrinogen beta chain	Homo sapiens	56-66
17164498-13	2007	The vancomycin/fibrinogen interaction (binding of about 16 molecules of vancomycin/molecule of fibrinogen) can be used to purify fibrinogen out of plasma.	Vancomycin	4-14	fibrinogen beta chain	Homo sapiens	15-25
17164498-13	2007	The vancomycin/fibrinogen interaction (binding of about 16 molecules of vancomycin/molecule of fibrinogen) can be used to purify fibrinogen out of plasma.	Vancomycin	4-14	fibrinogen beta chain	Homo sapiens	95-105
17164498-13	2007	The vancomycin/fibrinogen interaction (binding of about 16 molecules of vancomycin/molecule of fibrinogen) can be used to purify fibrinogen out of plasma.	Vancomycin	4-14	fibrinogen beta chain	Homo sapiens	95-105
17164498-13	2007	The vancomycin/fibrinogen interaction (binding of about 16 molecules of vancomycin/molecule of fibrinogen) can be used to purify fibrinogen out of plasma.	Vancomycin	72-82	fibrinogen beta chain	Homo sapiens	15-25
17164498-13	2007	The vancomycin/fibrinogen interaction (binding of about 16 molecules of vancomycin/molecule of fibrinogen) can be used to purify fibrinogen out of plasma.	Vancomycin	72-82	fibrinogen beta chain	Homo sapiens	95-105
17164498-13	2007	The vancomycin/fibrinogen interaction (binding of about 16 molecules of vancomycin/molecule of fibrinogen) can be used to purify fibrinogen out of plasma.	Vancomycin	72-82	fibrinogen beta chain	Homo sapiens	95-105
17164498-14	2007	Vancomycin also clouds dysfunctional fibrinogen (fibrinogen in presence of EDTA or chloramine-T)or soluble fibrin.	Vancomycin	0-10	fibrinogen beta chain	Homo sapiens	37-47
17164498-14	2007	Vancomycin also clouds dysfunctional fibrinogen (fibrinogen in presence of EDTA or chloramine-T)or soluble fibrin.	Vancomycin	0-10	fibrinogen beta chain	Homo sapiens	49-59
17164498-15	2007	Vancomycin-reacted fibrinogen stimulates tissue type plasminogen activator (t-PA) up to about 20-fold.	Vancomycin	0-10	fibrinogen beta chain	Homo sapiens	19-29
17164498-15	2007	Vancomycin-reacted fibrinogen stimulates tissue type plasminogen activator (t-PA) up to about 20-fold.	Vancomycin	0-10	plasminogen activator, tissue type	Homo sapiens	41-74
17164498-15	2007	Vancomycin-reacted fibrinogen stimulates tissue type plasminogen activator (t-PA) up to about 20-fold.	Vancomycin	0-10	plasminogen activator, tissue type	Homo sapiens	76-80
16876369-0	2006	High frequency of vancomycin-resistant Enterococcus faecium isolates with VanB phenotype and vanA genotype in Korean hospitals.	Vancomycin	18-28	D-alanine--D-lactate ligase	Enterococcus faecium	74-78
17220439-4	2007	It exhibited antibiosis against Enterococcus faecium VanA (a vancomycin-resistant clinical strain) and Mycobacterium aurum A+.	Vancomycin	61-71	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	53-57
18156760-0	2006	[Mechanism of VanB Phenotype in Vancomycin-Resistant Enterococci carrying vanA gene.].	Vancomycin	32-42	D-alanine--D-lactate ligase	Enterococcus faecium	14-18
18156760-0	2006	[Mechanism of VanB Phenotype in Vancomycin-Resistant Enterococci carrying vanA gene.].	Vancomycin	32-42	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	74-78
18156760-1	2006	BACKGROUND: Recently, vancomycin-resistant enterococci (VRE) with the vanA genotype that are susceptible to teicoplanin have been described in Japan, Taiwan, and Korea.	Vancomycin	22-32	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	70-74
17015835-3	2006	Some gain of function DDl mutants can use an alternate second substrate, causing resistance to vancomycin, one of the last lines of defense against life-threatening Gram-positive infections.	Vancomycin	95-105	AT695_RS07115	Staphylococcus aureus	22-25
17164498-19	2007	Fibrinogen precipitation by vancomycin within the blood vessel might explain why vancomycin has to be infused slowly (< 10 mg/min) to prevent nephrotoxicity.	Vancomycin	28-38	fibrinogen beta chain	Homo sapiens	0-10
17164498-19	2007	Fibrinogen precipitation by vancomycin within the blood vessel might explain why vancomycin has to be infused slowly (< 10 mg/min) to prevent nephrotoxicity.	Vancomycin	81-91	fibrinogen beta chain	Homo sapiens	0-10
16940078-0	2006	Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycin-resistant Enterococcus spp.	Vancomycin	125-135	ATPase, H+/K+ exchanging, gastric, alpha polypeptide	Mus musculus	42-53
16940078-2	2006	Proton pump inhibitor treatment of clindamycin-treated mice elevated the gastric pH and facilitated the establishment of colonization of the large intestine by vancomycin-resistant Enterococcus spp.	Vancomycin	160-170	ATPase, H+/K+ exchanging, gastric, alpha polypeptide	Mus musculus	0-11
17044690-4	2006	Dbv21 and Orf2* catalyze the deacetylation reaction of N-acetylglucosaminyl-teicoplanin pseudoaglycone, while Orf15 catalyzes the formation of dTDP-glucose that is required for the epi-vancosamine/vancosamine decoration of chloroeremomycin/vancomycin.	Vancomycin	240-250	retinitis pigmentosa GTPase regulator	Homo sapiens	110-115
16939481-8	2006	An increase in LPS-stimulated IL-10 release was observed with vancomycin.	Vancomycin	62-72	interleukin 10	Homo sapiens	30-35
17035423-1	2006	OBJECTIVE: The goal of this investigation was to determine whether vancomycin pharmacokinetic indexes (eg, serum trough concentrations or area under the concentration curve [AUC] values) were associated with mortality for patients with health-care-associated pneumonia (HCAP) attributed to methicillin-resistant Staphylococcus aureus (MRSA).	Vancomycin	67-77	structural maintenance of chromosomes 3	Homo sapiens	236-268
16982298-2	2006	OBJECTIVES: The aims of this study were to determine risk factors for infection with MRSA and to assess the differences in clinical and economic outcomes in patients undergoing hemodialysis with MRSA bacteremia with vancomycin MIC 2 microg/mL versus those with MRSA bacteremia with vancomycin MIC < or =0.5 microg/mL and uninfected controls.	Vancomycin	282-292	CD99 molecule (Xg blood group)	Homo sapiens	227-232
16940100-1	2006	Low-level vancomycin-resistant Staphylococcus aureus (vancomycin-intermediate S. aureus [VISA] and heterogenous VISA [hVISA]) is increasingly reported and leads to glycopeptide treatment failure.	Vancomycin	10-20	mitochondrial antiviral signaling protein	Homo sapiens	89-93
16940100-1	2006	Low-level vancomycin-resistant Staphylococcus aureus (vancomycin-intermediate S. aureus [VISA] and heterogenous VISA [hVISA]) is increasingly reported and leads to glycopeptide treatment failure.	Vancomycin	10-20	mitochondrial antiviral signaling protein	Homo sapiens	112-116
16940100-1	2006	Low-level vancomycin-resistant Staphylococcus aureus (vancomycin-intermediate S. aureus [VISA] and heterogenous VISA [hVISA]) is increasingly reported and leads to glycopeptide treatment failure.	Vancomycin	10-20	mitochondrial antiviral signaling protein	Homo sapiens	118-123
16940100-1	2006	Low-level vancomycin-resistant Staphylococcus aureus (vancomycin-intermediate S. aureus [VISA] and heterogenous VISA [hVISA]) is increasingly reported and leads to glycopeptide treatment failure.	Vancomycin	54-64	mitochondrial antiviral signaling protein	Homo sapiens	89-93
16733804-8	2006	Erdosteine co-administration with VCM injections caused significantly decreased malondialdehyde levels (p < 0.001), superoxide dismutase (p < 0.01) and catalase (p < 0.001) activities in liver tissue when compared with VCM alone.	Vancomycin	34-37	catalase	Rattus norvegicus	158-166
16982298-12	2006	CONCLUSIONS: Surgery within the previous 6 months and intensive care unit admission were identified as significant risk factors for patients with MRSA bacteremia with a vancomycin MIC 2 microg/mL undergoing hemodialysis.	Vancomycin	169-179	CD99 molecule (Xg blood group)	Homo sapiens	180-185
16936913-4	2006	Phenotype determination of resistance to vancomycin was verified by PCR detection of vanA and vanB genes.	Vancomycin	41-51	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	85-89
16801409-5	2006	In contrast, 14.7% of MRSA-WT, 69.3% of hVISA, and all VISA strains showed a vancomycin MBC/MIC ratio of > or = 32 or an MBC of > or = 16 microg/ml (tolerant).	Vancomycin	77-87	mitochondrial antiviral signaling protein	Homo sapiens	40-45
16801409-5	2006	In contrast, 14.7% of MRSA-WT, 69.3% of hVISA, and all VISA strains showed a vancomycin MBC/MIC ratio of > or = 32 or an MBC of > or = 16 microg/ml (tolerant).	Vancomycin	77-87	mitochondrial antiviral signaling protein	Homo sapiens	41-45
16936913-10	2006	Based on the macrorestriction analysis of genome DNA in 24 vancomycin-resistant Enterococcus faecium VanA strains isolated from the patients" clinical material, one strain from the bed-side table surface and one strain isolated from stools in 2004, 8 unique restriction profiles with similarity ranging from 90 % to 100 % were identified, which could be classified into 3 clonal types.	Vancomycin	59-69	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	101-105
16897201-11	2006	IL-6 levels in rats treated with cefuroxime were lower than in rats treated with tobramycin or vancomycin and the control group.	Vancomycin	95-105	interleukin 6	Rattus norvegicus	0-4
17121303-0	2006	Detection of heterogeneous, intermediate-vancomycin-resistant Staphylococcus aureus (hVISA) using low-concentration vancomycin disks.	Vancomycin	41-51	mitochondrial antiviral signaling protein	Homo sapiens	85-90
17121303-0	2006	Detection of heterogeneous, intermediate-vancomycin-resistant Staphylococcus aureus (hVISA) using low-concentration vancomycin disks.	Vancomycin	116-126	mitochondrial antiviral signaling protein	Homo sapiens	85-90
17121303-1	2006	Heterogeneous, intermediate-vancomycin-resistant Staphylococcus aureus (hVISA) represents a threat of an incurable infection since the first report in 1997.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	72-77
17121303-9	2006	The disk diffusion test with 15-microg vancomycin disk is simple and may be used as a screening method for the detection of hVISA.	Vancomycin	39-49	mitochondrial antiviral signaling protein	Homo sapiens	124-129
16778715-0	2006	Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.	Vancomycin	142-152	cystatin C	Homo sapiens	6-16
16922630-4	2006	All the 61 VRE isolates were vanA-type Enterococcus faecium expressing a high-level resistance to vancomycin, and showed resistance to teicoplanin as well except two poultry isolates.	Vancomycin	98-108	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	29-33
16597899-1	2006	We describe a 24-h protocol for the identification of patients who are positive for vancomycin-resistant Enterococcus faecium (VRE), using stool and rectal swab samples and VRE screening broth, automated DNA extraction, and real-time PCR for vanA and vanB genes.	Vancomycin	84-94	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	242-246
16584311-0	2006	Vancomycin-resistant Enterococci may obtain nutritional support by scavenging carbohydrate fragments generated during mucin degradation by the anaerobic microbiota of the colon.	Vancomycin	0-10	mucin 1, cell surface associated	Bos taurus	118-123
16506767-0	2006	Total synthesis and evaluation of [Psi[CH2NH]Tpg4]vancomycin aglycon: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding.	Vancomycin	50-60	lactase	Homo sapiens	128-131
16506767-5	2006	Consistent with expectations and relative to the vancomycin aglycon, 5 exhibited a 40-fold increase in affinity for D-Ala-D-Lac (K(a) = 5.2 x 10(3) M(-1)) and a 35-fold reduction in affinity for D-Ala-D-Ala (K(a) = 4.8 x 10(3) M(-1)), providing a glycopeptide analogue with balanced, dual binding characteristics.	Vancomycin	49-59	lactase	Homo sapiens	124-127
16570547-3	2006	The choice of vancomycin over a cephalosporin may be justified in patients who are known carriers of MRSA.	Vancomycin	14-24	solute carrier family 9 member A6	Homo sapiens	101-105
16566656-2	2006	Leuconostoc spp are gram-positive coccobacilli, catalase and oxidase negative, vancomycin resistant.	Vancomycin	79-89	histocompatibility minor 13	Homo sapiens	12-15
16547394-6	2006	In conclusion, the Maeda"s nomogram regimen with a 1,000 mg vancomycin dose was shown to achieve target plasma levels of vancomycin at a higher rate and provide higher clinical efficacy in vancomycin therapy of MRSA pneumonia patients, as compared with the currently available standard dosage regimen.	Vancomycin	60-70	solute carrier family 9 member A6	Homo sapiens	211-215
16428416-9	2006	Interestingly, 27 of the genes with altered expression in JH9 grown in drug-free medium were found to be also overexpressed when the parental strain JH1 was briefly exposed to inhibitory concentrations of vancomycin, and more than half (17 of 27) of the genes with altered expression belonged to determinants that were proposed to form part of a general cell wall stress stimulon (S. Utaida et al., Microbiology 149:2719-2732, 2003).	Vancomycin	205-215	immunoglobulin heavy joining 1	Homo sapiens	149-152
16547394-6	2006	In conclusion, the Maeda"s nomogram regimen with a 1,000 mg vancomycin dose was shown to achieve target plasma levels of vancomycin at a higher rate and provide higher clinical efficacy in vancomycin therapy of MRSA pneumonia patients, as compared with the currently available standard dosage regimen.	Vancomycin	121-131	solute carrier family 9 member A6	Homo sapiens	211-215
16547394-6	2006	In conclusion, the Maeda"s nomogram regimen with a 1,000 mg vancomycin dose was shown to achieve target plasma levels of vancomycin at a higher rate and provide higher clinical efficacy in vancomycin therapy of MRSA pneumonia patients, as compared with the currently available standard dosage regimen.	Vancomycin	121-131	solute carrier family 9 member A6	Homo sapiens	211-215
17009779-0	2006	[Small change, large effect--a new vancomycin derivative against MRSA].	Vancomycin	35-45	solute carrier family 9 member A6	Homo sapiens	65-70
16271057-0	2005	Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).	Vancomycin	51-61	mitochondrial antiviral signaling protein	Homo sapiens	98-102
16271057-2	2005	To date, low-level vancomycin resistance in the form of vancomycin-intermediate S. aureus (VISA) and heterogenous vancomycin-intermediate S. aureus (hVISA) have been more common, with only four cases of true vancomycin resistant S. aureus (VRSA) reported.	Vancomycin	19-29	mitochondrial antiviral signaling protein	Homo sapiens	91-95
16271057-2	2005	To date, low-level vancomycin resistance in the form of vancomycin-intermediate S. aureus (VISA) and heterogenous vancomycin-intermediate S. aureus (hVISA) have been more common, with only four cases of true vancomycin resistant S. aureus (VRSA) reported.	Vancomycin	19-29	mitochondrial antiviral signaling protein	Homo sapiens	149-154
16112787-6	2005	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.	Vancomycin	0-3	O-GlcNAcase	Rattus norvegicus	99-130
16112787-6	2005	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.	Vancomycin	0-3	O-GlcNAcase	Rattus norvegicus	132-135
16112787-6	2005	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.	Vancomycin	0-3	catalase	Rattus norvegicus	226-234
16112787-6	2005	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.	Vancomycin	0-3	catalase	Rattus norvegicus	236-239
16856450-2	2005	Here we report the first pediatric case of heterogeneous vancomycin intermediate resistance Staphylacoccus aureus (hVISA) causing endocarditis in Thailand.	Vancomycin	57-67	mitochondrial antiviral signaling protein	Homo sapiens	115-120
16856450-8	2005	The subsequent population analysis and testing for the emergence of mutants with reduced susceptible to vancomycin confirmed that this strain was hVISA.	Vancomycin	104-114	mitochondrial antiviral signaling protein	Homo sapiens	146-151
16856450-10	2005	hVISA should be suspected in MRSA infections that were refractory to vancomycin therapy could be due to.	Vancomycin	69-79	mitochondrial antiviral signaling protein	Homo sapiens	0-5
16204568-0	2005	High prevalence of VanA-type vancomycin-resistant Enterococci in Austrian poultry.	Vancomycin	29-39	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	19-23
15821901-8	2005	In addition, HBD-3 kills Gram-positive bacteria such as Streptococcus pyogenes or Staphylococcus aureus, including multi-resistant S. aureus strains, and even vancomycin-resistant Enterococcus faecium.	Vancomycin	159-169	defensin beta 103B	Homo sapiens	13-18
16186170-1	2005	OBJECTIVES: Potential intra- and inter-species transfers of vancomycin resistance genes (vanA gene cluster) between Enterococcus strains were evaluated in the gut of heteroxenic mice harbouring a human microbiota.	Vancomycin	60-70	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	89-93
16081891-0	2005	First nosocomial outbreak of vancomycin-resistant Enterococcus faecium expressing a VanD-like phenotype associated with a vanA genotype.	Vancomycin	29-39	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	122-126
16081891-6	2005	This so-called VanD-like phenotype of resistance (low-level resistance to vancomycin and mostly susceptibility to teicoplanin) was surprisingly associated with a vanA gene.	Vancomycin	74-84	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	162-166
16094598-0	2005	Efficacy of vancomycin-impregnated cement beads for the treatment of MRSA infection of failed graft tissue at the mandible.	Vancomycin	12-22	solute carrier family 9 member A6	Homo sapiens	69-73
15780422-0	2005	Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin.	Vancomycin	40-50	mitochondrial antiviral signaling protein	Homo sapiens	87-92
15889359-2	2005	We sought to determine the prevalence of and risk factors for carriage of potential heterogeneous vancomycin-intermediate S. aureus (hVISA).	Vancomycin	98-108	mitochondrial antiviral signaling protein	Homo sapiens	133-138
15855482-1	2005	Previously, we reported the isolation of 10 vancomycin-resistant gram-positive anaerobic bacilli carrying the vanB ligase gene from nine hemodialysis patients (S. A. Ballard et al., Antimicrob.	Vancomycin	44-54	D-alanine--D-lactate ligase	Enterococcus faecium	110-114
15855482-4	2005	In the present study, the molecular and evolutionary relationship of the vanB resistance element within these 10 anaerobes and two vancomycin-resistant Enterococcus faecium strains were examined.	Vancomycin	131-141	D-alanine--D-lactate ligase	Enterococcus faecium	73-77
16041045-3	2005	Furthermore, MAb T1-2 is shown to enhance the opsonophagocytic uptake of ClfA-coated latex beads, protect against an intravenous challenge in a prophylactic model of rabbit infective endocarditis, and enhance the efficacy of vancomycin therapy in a therapeutic model of established infective endocarditis.	Vancomycin	225-235	brachyury 2	Mus musculus	17-21
15785812-0	2005	An improved solid-phase methodology for the synthesis of putative hexa- and heptapeptide intermediates in vancomycin biosynthesis.	Vancomycin	106-116	hexosaminidase subunit alpha	Homo sapiens	66-70
15780422-0	2005	Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin.	Vancomycin	168-178	mitochondrial antiviral signaling protein	Homo sapiens	87-92
23118622-2	2005	The purpose of this article is to review the published literature related to vancomycin for treatment of pediatric CSF shunt infections.	Vancomycin	77-87	colony stimulating factor 2	Homo sapiens	115-118
15770018-0	2005	Evaluation of the EVIGENE VRE detection kit for detection of vanA and vanB genes in vancomycin-resistant enterococci.	Vancomycin	84-94	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	61-65
16400877-9	2005	The 1100 MRSA isolates distributed to four antibiotic resistance patterns on the basis of their resistance to oxacillin, penicillin, amoxicillin+clavulanic acid, azithromycin, clindamycin, amikacin, gentamicin, ciprofloxacin, trimethoprim+sulphamethoxasole, vancomycin and teicoplanin.	Vancomycin	258-268	solute carrier family 9 member A6	Homo sapiens	9-13
15690805-2	2005	The method is based on selective enrichment at 45+/-0.5 degrees C in lauryl sulfate tryptose broth supplemented with 0.5 M NaCl and 10 mg/liter vancomycin (mLST) for 22 to 24 h followed by streaking on tryptone soy agar with bile salts.	Vancomycin	144-154	aristaless-like homeobox 4	Mus musculus	156-160
23118622-8	2005	CSF vancomycin concentrations should be monitored and dosing adjustments made as needed to maintain CSF trough vancomycin concentrations between 5 and 20 mg/L.	Vancomycin	4-14	colony stimulating factor 2	Homo sapiens	0-3
15310263-0	2004	Emergence of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) infection in Western Australia.	Vancomycin	29-39	mitochondrial antiviral signaling protein	Homo sapiens	76-81
15628527-0	2004	[Transferability of vanA gene from vancomycin-resistant Enterococcus faecalis in the digestive tract of specific pathogen-free mice].	Vancomycin	35-45	VanA	Enterococcus faecalis	20-24
15628527-1	2004	We evaluated the transferability of vanA gene from vancomycin-resistant Enterococcus faecalis (VREF) to vancomycin-sensitive E. faecalis (VSEF) in vitro and in vivo.	Vancomycin	51-61	VanA	Enterococcus faecalis	36-40
15628527-1	2004	We evaluated the transferability of vanA gene from vancomycin-resistant Enterococcus faecalis (VREF) to vancomycin-sensitive E. faecalis (VSEF) in vitro and in vivo.	Vancomycin	104-114	VanA	Enterococcus faecalis	36-40
15593150-0	2004	An oxidative phenol coupling reaction catalyzed by oxyB, a cytochrome P450 from the vancomycin-producing microorganism.	Vancomycin	84-94	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	59-74
15561827-0	2004	Penicillin-binding protein 2 is essential for expression of high-level vancomycin resistance and cell wall synthesis in vancomycin-resistant Staphylococcus aureus carrying the enterococcal vanA gene complex.	Vancomycin	71-81	AT695_RS10295	Staphylococcus aureus	0-28
15561827-0	2004	Penicillin-binding protein 2 is essential for expression of high-level vancomycin resistance and cell wall synthesis in vancomycin-resistant Staphylococcus aureus carrying the enterococcal vanA gene complex.	Vancomycin	120-130	AT695_RS10295	Staphylococcus aureus	0-28
15561884-2	2004	The presence of strains that were heterointermediately resistant to vancomycin (hVISA) was confirmed by population analysis.	Vancomycin	68-78	mitochondrial antiviral signaling protein	Homo sapiens	80-85
15334199-11	2004	The dissemination of the E. faecalis VanA phenotype among hospitals located in different cities is of great concern because E. faecalis commonly colonizes the gastrointestinal tract of patients and healthy persons for periods varying from weeks to years, which, together with the persistence of vancomycin-resistant Enterococcus in hospital rooms after standard cleaning procedures, increases the risk of the dissemination and reservoir of the bacteria.	Vancomycin	295-305	VanA	Enterococcus faecalis	37-41
15188843-0	2004	Eradication of a large outbreak of a single strain of vanB vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital.	Vancomycin	59-69	D-alanine--D-lactate ligase	Enterococcus faecium	54-58
15320441-2	2004	THE IMPACT OF MRSA INFECTIONS: Is clinical to start, with a greater mortality rate in MRSA bacteremias than in staphylococcal sensitive, in vancomycin-resistant enterococcal infections than in enterococcal sensitive infections, and in acquired pneumonia under mechanical ventilation.	Vancomycin	140-150	solute carrier family 9 member A6	Homo sapiens	14-18
15190028-2	2004	The aim of this study was to compare the activation of human TLR2 pathways after exposure of S. pneumoniae to faropenem, cefotaxime and vancomycin.	Vancomycin	136-146	toll like receptor 2	Homo sapiens	61-65
15188843-2	2004	INTERVENTIONS: Two months after the index case was detected in the intensive care unit, 68 patients became either infected or colonized with an epidemic strain of vanB vancomycin-resistant Enterococcus faecium despite standard infection control procedures.	Vancomycin	168-178	D-alanine--D-lactate ligase	Enterococcus faecium	163-167
15188843-5	2004	One hundred sixty-nine patients in 23 wards were colonized with a single strain of vanB vancomycin-resistant E. faecium.	Vancomycin	88-98	D-alanine--D-lactate ligase	Enterococcus faecium	83-87
15066332-0	2004	Increasing vancomycin susceptibility in vancomycin resistant enterococci by vanH promoter and ddl transformation.	Vancomycin	11-21	VanH	Enterococcus faecalis	76-80
15059226-1	2004	BACKGROUND: Vancomycin-induced linear immunoglobulin A (IgA) disease, an autoimmune, blistering disease in response to vancomycin administration, is characterized by a subepidermal, vesiculobullous eruption and linear IgA deposition along the basement membrane zone on direct immunofluorescence.	Vancomycin	12-22	CD79a molecule	Homo sapiens	56-59
15059226-1	2004	BACKGROUND: Vancomycin-induced linear immunoglobulin A (IgA) disease, an autoimmune, blistering disease in response to vancomycin administration, is characterized by a subepidermal, vesiculobullous eruption and linear IgA deposition along the basement membrane zone on direct immunofluorescence.	Vancomycin	12-22	CD79a molecule	Homo sapiens	218-221
15059226-1	2004	BACKGROUND: Vancomycin-induced linear immunoglobulin A (IgA) disease, an autoimmune, blistering disease in response to vancomycin administration, is characterized by a subepidermal, vesiculobullous eruption and linear IgA deposition along the basement membrane zone on direct immunofluorescence.	Vancomycin	119-129	CD79a molecule	Homo sapiens	56-59
15059226-1	2004	BACKGROUND: Vancomycin-induced linear immunoglobulin A (IgA) disease, an autoimmune, blistering disease in response to vancomycin administration, is characterized by a subepidermal, vesiculobullous eruption and linear IgA deposition along the basement membrane zone on direct immunofluorescence.	Vancomycin	119-129	CD79a molecule	Homo sapiens	218-221
15059226-8	2004	His indirect immunofluorescence findings and immunoprecipitation results suggest that circulating non-IgA antibodies may represent a newly recognized immunopathologic feature of vancomycin-induced linear IgA disease, underscoring the variable and unpredictable manifestations of this drug-induced cutaneous disease.	Vancomycin	178-188	CD79a molecule	Homo sapiens	102-105
15066332-0	2004	Increasing vancomycin susceptibility in vancomycin resistant enterococci by vanH promoter and ddl transformation.	Vancomycin	40-50	VanH	Enterococcus faecalis	76-80
15066332-2	2004	We investigated the effect of vanH promoter and ddl gene transformation on vancomycin susceptibility in a vanA phenotype of Enterococcus faecalis.	Vancomycin	75-85	VanA	Enterococcus faecalis	106-110
15066332-9	2004	RESULTS: The transformation of the vanH promoter reduced the vancomycin MIC of VRE.	Vancomycin	61-71	VanH	Enterococcus faecalis	35-39
14727222-2	2004	Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006).	Vancomycin	97-107	mitochondrial antiviral signaling protein	Homo sapiens	14-19
15700681-1	2004	INTRODUCTION: Staphylococcus (S.) aureus with reduced susceptibility to vancomycin has attracted much attention all over the world since the first report of Staphylococcus aureus isolate intermediarily resistant to vancomycin (VISA) in Japan 1997.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	227-231
15700681-2	2004	Other authors from different parts of the world have also described VISA isolates in patients with treatment failures after prolonged vancomycin therapy.	Vancomycin	134-144	mitochondrial antiviral signaling protein	Homo sapiens	68-72
15700681-3	2004	Most of the isolates were heterogeneously resistant (hVISA), i. e. only a part of the population showed resistance and the rest showed susceptibility to vancomycin.	Vancomycin	153-163	mitochondrial antiviral signaling protein	Homo sapiens	53-58
15700681-13	2004	CONCLUSION: The prevalence of hVISA in Croatia is low, but there are some strains with reduced susceptibility to vancomycin.	Vancomycin	113-123	mitochondrial antiviral signaling protein	Homo sapiens	30-35
14660393-8	2003	An evident predominance of the vanA determinant among vancomycin-resistant enterococcal species from poultry and swine, but not from cattle, was observed and was similar to the situation in European countries before avoparcin was forbidden.	Vancomycin	54-64	VanA	Enterococcus faecalis	31-35
17639497-4	2003	The catheter was removed and the tip was cultured; it revealed colonization with hemolytic Staphylococcus sensitive to vancomycin and metilmycin.	Vancomycin	119-129	TOR signaling pathway regulator	Homo sapiens	33-36
14597004-6	2003	The second transmissible element was the plasmid harbouring the vancomycin resistance (VanA phenotype) from E. faecalis A256.	Vancomycin	64-74	VanA	Enterococcus faecalis	87-91
15449791-14	2003	For those infections acquired in the hospital therapy with third or fourth generation cephalosporins, carbapenems, beta-lactams with betalactamase inhibitors alone or in combination with an aminoglucoside and or vancomycin if MRSA is suspected is accepted therapy.	Vancomycin	212-222	solute carrier family 9 member A6	Homo sapiens	226-230
14727222-2	2004	Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006).	Vancomycin	238-248	mitochondrial antiviral signaling protein	Homo sapiens	14-19
12862465-2	2003	Here, we have carried out investigations to probe the role of peptide binding (Lys-d-Ala-d-Lac) in the high anti-VRE activities of covalently linked vancomycin dimers.	Vancomycin	149-159	lactase	Homo sapiens	91-94
12888592-10	2003	The majority (77.8%) of vancomycin-resistant E. faecium isolates displayed the VanA phenotype, and 538 of these 616 (87.3%) isolates were PCR-positive for vanA; the vanB genotype was detected in 78 (12.7%) isolates.	Vancomycin	24-34	D-alanine--D-lactate ligase	Enterococcus faecium	165-169
12889959-0	2003	Partitioning the loss in vancomycin binding affinity for D-Ala-D-Lac into lost H-bond and repulsive lone pair contributions.	Vancomycin	25-35	lactase	Homo sapiens	65-68
12654656-5	2003	Strains SF1 and SF2 had similar genotypes, and the vancomycin MICs for the strains were </=2 micro g/ml.	Vancomycin	51-61	splicing factor 1	Homo sapiens	8-11
12775678-2	2003	The MIC and MBC of daptomycin (in Mueller-Hinton broth supplemented with 50 mg/L Ca2+) or vancomycin for strain Rev1 were 1-2 and 2-4 or 1 and 2 mg/L, respectively.	Vancomycin	90-100	REV1, DNA directed polymerase	Rattus norvegicus	112-116
12775678-3	2003	In vitro elimination of strain Rev1 in the presence of 50% tissue cage fluid was more rapid with daptomycin 4 mg/L compared with vancomycin.	Vancomycin	129-139	REV1, DNA directed polymerase	Rattus norvegicus	31-35
12654656-6	2003	SF2 exhibited heterogeneous resistance to vancomycin.	Vancomycin	42-52	serine and arginine rich splicing factor 1	Homo sapiens	0-3
12654656-7	2003	Vancomycin eradicated SF1 in the rabbit model of endocarditis, while SF2 persisted at pretreatment levels.	Vancomycin	0-10	splicing factor 1	Oryctolagus cuniculus	22-25
12663927-2	2003	One of the predicted mobile elements is a previously unknown vanB vancomycin-resistance conjugative transposon.	Vancomycin	66-76	D-alanine--D-lactate ligase	Enterococcus faecalis	61-65
12696635-1	2003	PURPOSE: To investigate the in vitro effects of gentamicin sulfate, vancomycin hydrochloride, sodium cefazolin and ceftriaxone on glucose 6-phosphate dehydrogenase enzyme (G6PD) purified from sheep lenses.	Vancomycin	68-92	glucose-6-phosphate 1-dehydrogenase	Ovis aries	172-176
12604538-0	2003	Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin.	Vancomycin	138-148	AT695_RS10295	Staphylococcus aureus	33-61
12736987-10	2003	Seven strains were vancomycin-resistant enterococci (VRE), all of them identified as E. faecium; 5/7 with Van A and 2/7 with Van B phenotypes.	Vancomycin	19-29	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	106-117
12696635-7	2003	CONCLUSIONS: If a patient with G6PD deficiency requires gentamicin sulfate or vancomycin hydrochloride, routine ophthalmic did not inhibit this enzyme.	Vancomycin	78-102	glucose-6-phosphate dehydrogenase	Homo sapiens	31-35
12461029-0	2002	High occurrence of esp among ampicillin-resistant and vancomycin-susceptible Enterococcus faecium clones from hospitalized patients.	Vancomycin	54-64	protein tyrosine phosphatase receptor type V, pseudogene	Homo sapiens	19-22
12617235-12	2002	Vancomycin can be reserved for patients known to be colonized with MRSA (NNT: 51).	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	67-71
12461035-1	2002	The first heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) isolates to be identified in Poland were characterized.	Vancomycin	26-36	mitochondrial antiviral signaling protein	Homo sapiens	73-78
12641325-1	2003	Columns packed with vancomycin coupled to an achiral C18 column and beta-cyclodextrin were used for the separation and the determination of enantiomers of alkoxysubstituted esters of phenylcarbamic acid in blood serum.	Vancomycin	20-30	Bardet-Biedl syndrome 9	Homo sapiens	53-56
14994579-4	2003	Initial broad-spectrum antibiotic therapy was replaced with imipenem, amicacin and vancomycin after the bacteriological investigation revealed susceptibility to isolated acinetobacter spp, staphylococcus spp coagulase-negative, enterococcus and staphylococcus.	Vancomycin	83-93	histocompatibility minor 13	Homo sapiens	184-187
14994579-4	2003	Initial broad-spectrum antibiotic therapy was replaced with imipenem, amicacin and vancomycin after the bacteriological investigation revealed susceptibility to isolated acinetobacter spp, staphylococcus spp coagulase-negative, enterococcus and staphylococcus.	Vancomycin	83-93	histocompatibility minor 13	Homo sapiens	204-207
12833679-0	2003	[1st isolation of vancomycin-resistant Enterococcus faecium with the vanB genotype in Argentina: presentation of 2 cases].	Vancomycin	18-28	D-alanine--D-lactate ligase	Enterococcus faecium	69-73
12244054-4	2002	RNase 7 revealed broad spectrum antimicrobial activity against many pathogenic microorganisms and remarkably potent activity (lethal dose of 90% < 30 nm) against a vancomycin-resistant Enterococcus faecium.	Vancomycin	167-177	ribonuclease A family member 7	Homo sapiens	0-7
18159402-0	2002	VISA, hetero-VISA and VRSA: the end of the vancomycin era?	Vancomycin	43-53	mitochondrial antiviral signaling protein	Homo sapiens	0-4
12183272-1	2002	A beneficial effect of the combination of quinupristin-dalfopristin and vancomycin was observed against two methicillin-resistant strains of Staphylococcus aureus harboring or not harboring the ermC gene, which codes for constitutive macrolide, lincosamide, and streptogramin B resistance.	Vancomycin	72-82	ErmC	Staphylococcus aureus	194-198
12415474-4	2002	One Enterococcus faecalis (VanA) isolate resistant to both vancomycin and teicoplanin was recovered in 1996.	Vancomycin	59-69	VanA	Enterococcus faecalis	27-31
12197747-5	2002	This reaction is used to synthesize the C-O-D diaryl ether macrocycle found in vancomycin with high diastereoselectivity (de > 90%), providing the naturally occurring atropisomeric configuration.	Vancomycin	79-89	small nuclear ribonucleoprotein polypeptides B and B1	Homo sapiens	40-45
12161395-6	2002	Detailed phenotypic and genotypic analysis of vancomycin-intermediate S. aureus strain Mu50 was performed, since the published genome sequence of this organism suggests that mutS is inactive as a result of a frameshift.	Vancomycin	46-56	putative DNA mismatch repair protein	Staphylococcus aureus	174-178
12205065-1	2002	Twenty multidrug-resistant vancomycin-resistant Enterococcus faecium strains of the VanA phenotype were isolated over a 1 year period from five patients in the intensive care unit at the University Hospital of Antalya, Turkey.	Vancomycin	27-37	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	84-88
11758077-1	2001	We report the first instance in Australia of treatment failure due to a strain of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin--heteroresistant vancomycin-intermediate S. aureus (hVISA).	Vancomycin	164-174	mitochondrial antiviral signaling protein	Homo sapiens	227-232
12023924-2	2002	Vancomycin-resistant enterococci, all Enterococcus faecium of vanA genotype, were excreted by 4.6% of the woodmice and 1.2% of the badgers, but by none of the bank voles.	Vancomycin	0-10	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	62-66
11958980-0	2002	Antibody-catalyzed cleavage of the D-Ala-D-Lac depsipeptide: an immunological approach to the problem of vancomycin resistance.	Vancomycin	105-115	lactase	Homo sapiens	43-46
11952723-13	2002	Errors in detecting vancomycin resistance in VanB and VanC1 enterococci were made with all methods, most noticeably by disk diffusion users.	Vancomycin	20-30	D-alanine--D-lactate ligase	Enterococcus faecalis	45-49
11792392-1	2002	Sequencing of anti-vancomycin monoclonal antibody (mAb) Fab region (48,000 Da) was carried out using liquid chromatography-electrospray ionization ion trap mass spectrometry (LC/ESI-MS).	Vancomycin	19-29	FA complementation group B	Homo sapiens	56-59
11779208-0	2002	Salt resistance and synergistic effect with vancomycin of alpha-helical antimicrobial peptide P18.	Vancomycin	44-54	H3 histone pseudogene 12	Homo sapiens	94-97
11779208-7	2002	Furthermore, the combination study revealed that P18 has a relatively effective synergistic effect with vancomycin against VREF.	Vancomycin	104-114	H3 histone pseudogene 12	Homo sapiens	49-52
11679564-1	2001	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) may account for treatment failure with vancomycin and act as a precursor of vancomycin-intermediate or -resistant S. aureus.	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	61-66
11679564-1	2001	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) may account for treatment failure with vancomycin and act as a precursor of vancomycin-intermediate or -resistant S. aureus.	Vancomycin	107-117	mitochondrial antiviral signaling protein	Homo sapiens	61-66
11679564-1	2001	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) may account for treatment failure with vancomycin and act as a precursor of vancomycin-intermediate or -resistant S. aureus.	Vancomycin	107-117	mitochondrial antiviral signaling protein	Homo sapiens	61-66
11759086-1	2001	A total of 53 vancomycin-resistant vanA-positive enterococci isolates from poultry farms (17 Enterococcus faecium; 8 Enterococcus durans) and from different hospitals (23 E. faecium; 5 Enterococcus faecalis) in northeastern Italy were compared on the basis of their antibiotic susceptibilities, their SmaI pulsed-field gel electrophoresis (PFGE) patterns, and the organization of their Tn1546-related elements.	Vancomycin	14-24	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	35-39
11675980-8	2001	However, there is also reason for concern about the recent emergence of MRSA resistant to glycopeptides, such as vancomycin.	Vancomycin	113-123	solute carrier family 9 member A6	Homo sapiens	72-76
12217710-1	2002	OBJECTIVE: The present study was designed to analyze vancomycin disposition in adult patients undergoing coronary bypass grafting during and following cardiopulmonary bypass (CPB).	Vancomycin	53-63	carboxypeptidase B1	Homo sapiens	175-178
12217710-5	2002	The mean (SD) vancomycin clearance by the CPB machine was 9.51 (2.66) l/h, and the mean (SD) total vancomycin sequestrated by CPB was 331.7 (84) mg. A significant difference (6.3%; p = 0.001) was measured between the mean measured AUC during CPB (1088.1 +/- 253.9) and the same calculated parameter (1160.2 +/- 282).	Vancomycin	99-109	carboxypeptidase B1	Homo sapiens	126-129
12217710-5	2002	The mean (SD) vancomycin clearance by the CPB machine was 9.51 (2.66) l/h, and the mean (SD) total vancomycin sequestrated by CPB was 331.7 (84) mg. A significant difference (6.3%; p = 0.001) was measured between the mean measured AUC during CPB (1088.1 +/- 253.9) and the same calculated parameter (1160.2 +/- 282).	Vancomycin	99-109	carboxypeptidase B1	Homo sapiens	126-129
12217710-6	2002	Five minutes after starting CPB, a decrease in vancomycin level was detected; this difference was found to be nearly 11% in absolute values.	Vancomycin	47-57	carboxypeptidase B1	Homo sapiens	28-31
12217710-7	2002	CONCLUSIONS: This confirmatory study demonstrated that the vancomycin blood concentrations obtained during the study allow recommending a safety prophylactic dose of 12mg/kg in adults who undergo open-heart surgery under CPB conditions.	Vancomycin	59-69	carboxypeptidase B1	Homo sapiens	221-224
12217710-8	2002	Sequestration of vancomycin by the oxygenator or/and tubing system of the CPB machine had occurred and had been measured in this study.	Vancomycin	17-27	carboxypeptidase B1	Homo sapiens	74-77
12077451-6	2002	The crystallization of one of the enzymes in the chloroeremomycin biosynthetic pathway (a member of the vancomycin family), dTDP-3-amino-4-keto 2,3,6-trideoxy-3-C-methyl-glucose-5-epimerase (EvaD) from Amycolatopsis orientalis, is reported here.	Vancomycin	104-114	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	124-128
12166247-3	2002	Despite removal of the central venous catheter and administration of vancomycin, fever and increased C-reactive protein level persisted.	Vancomycin	69-79	C-reactive protein	Homo sapiens	101-119
12111578-2	2002	Therefore, this study investigated the effects of frequently used antimicrobial agents (beta-lactams, quinolones gentamicin, vancomycin and metronidazole) on the in-vitro tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 production of isolated human peripheral blood mononuclear cells (PBMNC), cultured with or without endotoxin, in comparison with those effects obtained in a whole-blood assay system.	Vancomycin	125-135	tumor necrosis factor	Homo sapiens	171-204
12111578-3	2002	In the presence of ciprofloxacin, ofloxacin, gentamicin, vancomycin, and metronidazole, a significant inhibition of the endotoxin-stimulated TNF-alpha production of human peripheral blood mononuclear cells (PBMNC) was found at therapeutic levels.	Vancomycin	57-67	tumor necrosis factor	Homo sapiens	141-150
11913373-0	2002	Incidence of pseudomembranous colitis after vancomycin-treated MRSA infection.	Vancomycin	44-54	solute carrier family 9 member A6	Homo sapiens	63-67
11921492-5	2002	Methicillin-resistant Staphylococcus aureus, a frequent cause of skin and soft-tissue infections, has shown PBP-mediated beta-lactam resistance, prompting the wide-spread use of vancomycin to eradicate this pathogen.	Vancomycin	178-188	phosphatidylethanolamine binding protein 1	Homo sapiens	108-111
11724832-0	2001	Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype.	Vancomycin	94-104	D-alanine--D-lactate ligase	Enterococcus faecium	136-140
11724832-9	2001	Its vanB gene variant differed by a single mutation from that found in other isolates; however, it also lacked a large part of the vanB gene cluster, including the regulatory genes vanR(B) and -S(B), and the vancomycin-inducible promoter P(YB).	Vancomycin	208-218	D-alanine--D-lactate ligase	Enterococcus faecium	4-8
11828710-6	2001	Vancomycin or teicoplanin is selected when MRSA or Enterococcus faecium infection is suspected.	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	43-47
11736908-0	2001	Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD285.	Vancomycin	0-10	collagen type XVII alpha 1 chain	Homo sapiens	61-66
11679564-2	2001	The activity of vancomycin was assessed against vancomycinsusceptible, hVISA and VISA strains in a dilutional pharmacokinetic model.	Vancomycin	16-26	mitochondrial antiviral signaling protein	Homo sapiens	71-76
11679564-2	2001	The activity of vancomycin was assessed against vancomycinsusceptible, hVISA and VISA strains in a dilutional pharmacokinetic model.	Vancomycin	16-26	mitochondrial antiviral signaling protein	Homo sapiens	72-76
11679564-4	2001	Total counts of hVISA were reduced by vancomycin in a similar way to a vancomycin-susceptible control.	Vancomycin	38-48	mitochondrial antiviral signaling protein	Homo sapiens	16-21
11679564-4	2001	Total counts of hVISA were reduced by vancomycin in a similar way to a vancomycin-susceptible control.	Vancomycin	71-81	mitochondrial antiviral signaling protein	Homo sapiens	16-21
11679564-7	2001	Short-term exposure of hVISA to vancomycin at gradient concentrations did not increase the proportion of cells with vancomycin-intermediate phenotype.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	23-28
11691577-0	2001	Lactoferrin-induced reduction of vanB vancomycin resistance in enterococci.	Vancomycin	38-48	D-alanine--D-lactate ligase	Enterococcus faecalis	33-37
11691577-2	2001	The purpose of this research was to investigate the effect of LF on the MIC of vancomycin for vanB resistant isolates of Enterococcus faecalis (Efs1) and E. faecium (Efm1).	Vancomycin	79-89	D-alanine--D-lactate ligase	Enterococcus faecalis	94-98
11758077-1	2001	We report the first instance in Australia of treatment failure due to a strain of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin--heteroresistant vancomycin-intermediate S. aureus (hVISA).	Vancomycin	192-202	mitochondrial antiviral signaling protein	Homo sapiens	227-232
11466288-4	2001	Functional studies of the BfpB-BfpG complex revealed that its presence confers vancomycin sensitivity, indicating that it may form an incompletely gated channel through the outer membrane.	Vancomycin	79-89	Lipoprotein	Escherichia coli	26-30
11376048-2	2001	The vancomycin resistance genes were amplified by the long vanB PCR, which amplifies the 6,373-bp vanB gene cluster including the vanR(B2), vanS(B2), vanY(B2), vanW(B2), vanH(B2), vanB2, and vanX(B2) genes.	Vancomycin	4-14	VanR	Enterococcus faecium	130-137
11477330-4	2001	The authors tested whether this increase in vancomycin in nonrenal failure patients is a result of CDP-1 interfering with FPIA or a change in the pharmacokinetics of the drug.	Vancomycin	44-54	cut like homeobox 1	Homo sapiens	99-104
11376048-2	2001	The vancomycin resistance genes were amplified by the long vanB PCR, which amplifies the 6,373-bp vanB gene cluster including the vanR(B2), vanS(B2), vanY(B2), vanW(B2), vanH(B2), vanB2, and vanX(B2) genes.	Vancomycin	4-14	VanS protein	Enterococcus faecium	140-147
11376048-2	2001	The vancomycin resistance genes were amplified by the long vanB PCR, which amplifies the 6,373-bp vanB gene cluster including the vanR(B2), vanS(B2), vanY(B2), vanW(B2), vanH(B2), vanB2, and vanX(B2) genes.	Vancomycin	4-14	VanY protein	Enterococcus faecium	150-157
11376048-2	2001	The vancomycin resistance genes were amplified by the long vanB PCR, which amplifies the 6,373-bp vanB gene cluster including the vanR(B2), vanS(B2), vanY(B2), vanW(B2), vanH(B2), vanB2, and vanX(B2) genes.	Vancomycin	4-14	VanH protein	Enterococcus faecium	170-177
11376048-2	2001	The vancomycin resistance genes were amplified by the long vanB PCR, which amplifies the 6,373-bp vanB gene cluster including the vanR(B2), vanS(B2), vanY(B2), vanW(B2), vanH(B2), vanB2, and vanX(B2) genes.	Vancomycin	4-14	VanX protein	Enterococcus faecium	191-198
11085990-3	2001	hBD-3 demonstrated a salt-insensitive broad spectrum of potent antimicrobial activity against many potentially pathogenic microbes including multiresistant S. aureus and vancomycin-resistant Enterococcus faecium.	Vancomycin	170-180	defensin beta 103B	Homo sapiens	0-5
11587401-11	2001	Vancomycin total CI (CI(T)) was 7.4 +/- 2.0 mL/min.	Vancomycin	0-10	citron rho-interacting serine/threonine kinase	Homo sapiens	21-26
11337180-5	2001	All vancomycin-resistant E. faecalis, E. durans, E. hirae and E. faecium isolates tested by the disk diffusion assay were positive in PCR detection for presence of vanA gene.	Vancomycin	4-14	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	164-168
11372783-8	2001	The selected 29ca showed anti-MRSA activity comparable to that of vancomycin (VCM) both in vitro and in vivo, high affinity (IC50)=2.7 microg/ml) for penicillin binding protein 2" (PBP2") of MRSA and potent activity against Gram-negative bacteria as well.	Vancomycin	66-76	AT695_RS10295	Staphylococcus aureus	150-178
11325990-4	2001	PCR analysis confirmed that the vancomycin-resistant E. faecium (VREM) isolates carried the vanB gene, which is responsible for the VanB phenotype.	Vancomycin	32-42	D-alanine--D-lactate ligase	Enterococcus faecium	92-96
11358057-7	2001	Two patients (0.7%) carried isolates (both VanB) with high level resistance to vancomycin (MIC > or = 256 microg/ml) while the rest had isolates of low level resistance (MIC = 8 microg/ml).	Vancomycin	79-89	D-alanine--D-lactate ligase	Enterococcus faecalis	43-47
11325548-2	2001	The presence of complex STEC was determined using PCR and vancomycin-cefixime-cefsulodin blood agar (BVCCA) using a dual approach which involved (i) direct culture of faecal samples on BVCCA followed by mutiplex PCR of BVCCA positive colonies and (ii) culture of faecal samples enriched in modified EC (mEC) broth (with a complex STEC profile determined by PCR) on BVCCA followed by multiplex PCR of BVCCA positive colonies.	Vancomycin	58-68	chemokine (C-C motif) ligand 28	Mus musculus	26-28
11326124-0	2001	Molecular and epidemiological study of the first outbreak of vanB type vancomycin-resistant Enterococcus faecalis in Japan.	Vancomycin	71-81	D-alanine--D-lactate ligase	Enterococcus faecalis	61-65
11326124-1	2001	In July, 1999, an outbreak of vancomycin-resistant Enterococcus faecalis (VREF) with the vanB genotype occurred for the first time in Japan at Hokushin General Hospital, Nakano City, Nagano Prefecture.	Vancomycin	30-40	D-alanine--D-lactate ligase	Enterococcus faecalis	89-93
10565910-0	1999	vanA and vanB incorporate into an endemic ampicillin-resistant vancomycin-sensitive Enterococcus faecium strain: effect on interpretation of clonality.	Vancomycin	63-73	D-alanine--D-lactate ligase	Enterococcus faecium	9-13
11354818-4	2000	All the MRSA isolates in India including in the present study were sensitive to vancomycin and resistance to netilmycin appears to be low among MRSA isolates in India.	Vancomycin	80-90	solute carrier family 9 member A6	Homo sapiens	8-12
10985787-1	2000	The dodecamer peptide SLCHDSVIGWEC, named E12, was selected from a combinatorial peptide library on the basis of its ability to bind to VanR, the two-component signal transduction response regulator which controls expression of vancomycin resistance in Enterococcus faecium.	Vancomycin	228-238	VanR	Enterococcus faecium	136-140
10923284-8	2000	Vancomycin (VCM) and arbekacin (ABK) showed the most potent activities against MRSA.	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	79-83
10923284-8	2000	Vancomycin (VCM) and arbekacin (ABK) showed the most potent activities against MRSA.	Vancomycin	12-15	solute carrier family 9 member A6	Homo sapiens	79-83
10754628-9	2000	Phospholipase C and phospholipase A2 inhibitors decreased vancomycin-induced histamine release, but not calcium ionophore A23187-induced release.	Vancomycin	58-68	phospholipase A2 group IB	Homo sapiens	20-36
10714971-5	2000	Selective use of vancomycin in patients with a history suggesting an IgE-mediated reaction to penicillin was associated with an added cost and a slightly lower rate of anaphylaxis.	Vancomycin	17-27	immunoglobulin heavy constant epsilon	Homo sapiens	69-72
11234222-9	2000	The group which was given vancomycin 200 mg/kg/day had significantly elevated urinary NAG levels compared with the other groups (p < 0.05).	Vancomycin	26-36	O-GlcNAcase	Rattus norvegicus	86-89
11036050-1	2000	The influence of vancomycin and flavophospholipol (FPL) on the transfer rate of conjugative plasmids harboring the vancomycin resistance operon vanA was determined in several clinical and animal isolates of Enterococcus faecium.	Vancomycin	17-27	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	144-148
11036050-1	2000	The influence of vancomycin and flavophospholipol (FPL) on the transfer rate of conjugative plasmids harboring the vancomycin resistance operon vanA was determined in several clinical and animal isolates of Enterococcus faecium.	Vancomycin	115-125	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	144-148
10933665-0	2000	PCR detection of the vanA gene in a vancomycin-resistant Enterococcus faecalis clinical isolate from Hungary.	Vancomycin	36-46	VanA	Enterococcus faecalis	21-25
10760929-0	2000	New Selenium-Based Safety-Catch Linkers: Solid-Phase Semisynthesis of Vancomycin We thank Drs.	Vancomycin	70-80	sushi repeat containing protein X-linked	Homo sapiens	90-93
10729656-7	2000	CART analysis revealed that isolation of Enterococcus faecium, prior vancomycin exposure, and serum creatinine values > or = 1.1 mg/dl were predictors of VRE bacteremia.	Vancomycin	69-79	CART prepropeptide	Homo sapiens	0-4
10696133-0	2000	Successful treatment of vancomycin-resistant Enterococcus sepsis in a neutropenic patient with G-CSF-mobilized granulocyte transfusions.	Vancomycin	24-34	colony stimulating factor 3	Homo sapiens	95-100
10563691-1	1999	Rifampicin has been successfully used as an adjunct to vancomycin therapy in several clinical conditions of MRSA infections such as endocarditis, ventriculoperitoneal shunts and septicaemia.	Vancomycin	55-65	solute carrier family 9 member A6	Homo sapiens	108-112
10563691-11	1999	Institution of rifampicin, as an adjunct to vancomycin therapy to which the MRSA isolates were susceptible, showed a dramatic clinical response and survival of grafts.	Vancomycin	44-54	solute carrier family 9 member A6	Homo sapiens	76-80
10585815-1	1999	Clinical isolates of Staphylococcus aureus displaying intermediate resistance to vancomycin (VISA) have been identified.	Vancomycin	81-91	mitochondrial antiviral signaling protein	Homo sapiens	93-97
10585815-2	1999	The objective of our study was to identify VISA colonization among patients known to be colonized or infected with vancomycin-resistant enterococci (VRE).	Vancomycin	115-125	mitochondrial antiviral signaling protein	Homo sapiens	43-47
10565121-1	1999	Eleven clinical strains of MRSA which were detected as heterogeneously-resistant to vancomycin (hetero-VRSA) on Mu3-medium (a newly devised hetero-VRSA detecting medium) were subjected to a study to explore the therapeutic possibility of combination therapy.	Vancomycin	84-94	solute carrier family 9 member A6	Homo sapiens	27-31
10470557-2	1999	Penicillins, certain cephalosporins, carbapenems, fluoroquinolones, vancomycin, and rifampin provide the highest ratios of CSF levels to the MBC for common infecting organisms.	Vancomycin	68-78	colony stimulating factor 2	Homo sapiens	123-126
10417422-0	1999	Crystallization and preliminary X-ray characterization of VanA from Enterococcus faecium BM4147: towards the molecular basis of bacterial resistance to the glycopeptide antibiotic vancomycin.	Vancomycin	180-190	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	58-62
10510970-6	1999	Multiresistant enterococci, including vancomycin-resistant strains resistant to all commercially available antibiotics, were inhibited by the IFN-gamma-induced expression of IDO and subsequent L-tryptophan degradation.	Vancomycin	38-48	interferon gamma	Homo sapiens	142-151
10510970-6	1999	Multiresistant enterococci, including vancomycin-resistant strains resistant to all commercially available antibiotics, were inhibited by the IFN-gamma-induced expression of IDO and subsequent L-tryptophan degradation.	Vancomycin	38-48	indoleamine 2,3-dioxygenase 1	Homo sapiens	174-177
10432277-0	1999	First confirmed case of a vancomycin-resistant Enterococcus faecium with vanA phenotype from Brazil: isolation from a meningitis case in Sao Paulo.	Vancomycin	26-36	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	73-77
10493606-2	1999	It has been demonstrated in vitro that interferon-gamma (IFN-gamma) significantly augments the activities of gentamicin and vancomycin against Enterococcus faecalis resistant to these antibiotics.	Vancomycin	124-134	interferon gamma	Mus musculus	57-66
10493606-7	1999	The addition of IFN-gamma to therapy with gentamicin or vancomycin, or a combination of both antibiotics was associated with a marked increase in survival of infected non-neutropenic mice compared to treatments with the agents alone.	Vancomycin	56-66	interferon gamma	Mus musculus	16-25
10390201-11	1999	The time to a nephrotoxic event was significantly influenced by vancomycin use and the schedule of administration, as assessed by Cox proportional hazards modeling (P </= 0.002).	Vancomycin	64-74	cytochrome c oxidase subunit 8A	Homo sapiens	130-133
10326611-0	1999	New cases of vancomycin-intermediate MRSA infection reported.	Vancomycin	13-23	solute carrier family 9 member A6	Homo sapiens	37-41
10423963-7	1999	For one month after the operation, we used Vancomycin which is effective against MRSA, however, rather severe side effects were seen, and finally and MRSA vanished.	Vancomycin	43-53	solute carrier family 9 member A6	Homo sapiens	81-85
10423963-7	1999	For one month after the operation, we used Vancomycin which is effective against MRSA, however, rather severe side effects were seen, and finally and MRSA vanished.	Vancomycin	43-53	solute carrier family 9 member A6	Homo sapiens	150-154
10391415-2	1999	Both time and increased temperature potentiate production of vancomycin crystalline degradation products (CDP-1).	Vancomycin	61-71	cut like homeobox 1	Homo sapiens	106-111
10391415-3	1999	Commercially available vancomycin assays, such as fluorescence polarization immunoassay (FPI) and radioimmunoassay, cross-react with CDP-1 isomers.	Vancomycin	23-33	cut like homeobox 1	Homo sapiens	133-138
10391415-4	1999	Overestimation of vancomycin concentrations by 40-53% due to cross-reactivity of CDP-1 with active factor B vancomycin occurs with FPI.	Vancomycin	18-28	cut like homeobox 1	Homo sapiens	81-86
10391415-4	1999	Overestimation of vancomycin concentrations by 40-53% due to cross-reactivity of CDP-1 with active factor B vancomycin occurs with FPI.	Vancomycin	108-118	cut like homeobox 1	Homo sapiens	81-86
10348061-6	1999	Vancomycin or other glycopeptide intermediately resistant Staphylococcus aureus (VISA/GISA) also has emerged.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	81-85
10348061-7	1999	The mechanisms of resistance to vancomycin for VRE, and probably for VISA/GISA, relate to the acquired ability of these organisms to circumvent the vancomycin-mediated disruption of bacterial cell wall synthesis.	Vancomycin	148-158	mitochondrial antiviral signaling protein	Homo sapiens	69-73
10348770-6	1999	Furthermore, the msbB mutant was resistant to glycopeptides (vancomycin, teicoplanin), whereas the rfa, lpxA, and lpxD mutants were susceptible.	Vancomycin	61-71	lipid A biosynthesis (KDO)2-(lauroyl)-lipid IVA acyltransferase	Escherichia coli	17-21
10472217-0	1999	High-dose aprotinin with gentamicin-vancomycin antibiotic prophylaxis increases blood concentrations of creatinine and cystatin C in patients undergoing coronary artery bypass grafting.	Vancomycin	36-46	cystatin C	Homo sapiens	119-129
10472217-8	1999	We conclude that simultaneous administration of high-dose aprotinin and prophylactic use of gentamicin with vancomycin increased serum concentrations of cystatin C and creatinine in the first postoperative week in patients undergoing cardiac surgery.	Vancomycin	108-118	cystatin C	Homo sapiens	153-163
10216856-1	1999	The vanB gene cluster confers resistance to vancomycin but not to the related antibiotic teicoplanin, as the VanRB SB two-component regulatory system triggers expression of the glycopeptide resistance genes only in response to vancomycin.	Vancomycin	44-54	D-alanine--D-lactate ligase	Enterococcus faecalis	4-8
10216856-1	1999	The vanB gene cluster confers resistance to vancomycin but not to the related antibiotic teicoplanin, as the VanRB SB two-component regulatory system triggers expression of the glycopeptide resistance genes only in response to vancomycin.	Vancomycin	227-237	D-alanine--D-lactate ligase	Enterococcus faecalis	4-8
10077465-0	1999	Structure-binding relationships for the interaction between a vancomycin monoclonal antibody Fab fragment and a library of vancomycin analogues and tracers.	Vancomycin	62-72	FA complementation group B	Homo sapiens	93-96
10077465-0	1999	Structure-binding relationships for the interaction between a vancomycin monoclonal antibody Fab fragment and a library of vancomycin analogues and tracers.	Vancomycin	123-133	FA complementation group B	Homo sapiens	93-96
10077465-1	1999	A series of vancomycin analogues and tracers were synthesized, and their binding interactions with an anti-vancomycin Fab fragment were evaluated under mass transport limiting conditions using surface plasmon resonance detection.	Vancomycin	12-22	FA complementation group B	Homo sapiens	118-121
10077465-3	1999	Major structural regions of vancomycin shown to play an important role in anti-vancomycin Fab fragment recognition include two sugar moieties and one chlorinated phenyl ring.	Vancomycin	28-38	FA complementation group B	Homo sapiens	90-93
10093595-14	1999	CONCLUSION: For cases of community-acquired meningococcal meningitis diagnosed in 1999, it would be advisable to prescribe a combination C3G-vancomycin regimen as the first line empirical treatment while waiting for results of susceptibility tests.	Vancomycin	141-151	Rap guanine nucleotide exchange factor 1	Homo sapiens	137-140
10452645-5	1999	In a multivariate linear regression model, rates of MRSA, central line-associated bloodstream infection, and the type of ICU were independent predictors of vancomycin use.	Vancomycin	156-166	solute carrier family 9 member A6	Homo sapiens	52-56
10452645-7	1999	Vancomycin use is heavily determined by rates of endemic MRSA and central line-associated bloodstream infection.	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	57-61
21380904-1	1999	The endo aryl-aryl and aryl-alkyl ether bonds exist in a number of biologically important macrocyclic natural products, such as vancomycin family glycopeptide antibiotics (1-3), antitumor series RA I-XIV (4), K-13 (5), OF4949 (6), piperazinomycin (7), cyclopeptide alkaloids (8,9), nonpeptidic diarylheptanoids (10), and so on.	Vancomycin	128-138	keratin 13	Homo sapiens	209-213
10481526-7	1999	We suggest that local administration of vancomycin is an effective method in postpneumonectomy empyema with MRSA infection.	Vancomycin	40-50	solute carrier family 9 member A6	Homo sapiens	108-112
9660985-4	1998	beta-Lactamase activity in the beta-lactamase-positive strain changed over time parallel to viability, decreasing with amoxicillin-clavulanic acid or vancomycin and increasing in the amoxicillin and control groups.	Vancomycin	150-160	beta-lactamase	Staphylococcus aureus	0-14
9751113-5	1998	For example, in 1997, an avian strain of influenza that had never before infected humans began to kill previously healthy persons in Hong Kong, and strains of Sta phylococcus aureus with diminished susceptibility to the antibiotic vancomycin were reported in Japan and the United States.	Vancomycin	231-241	GCY	Homo sapiens	159-162
9728853-10	1998	In conclusion, oral H1 and H2 antihistamine pretreatment is a practical, safe, and inexpensive option to attenuate histamine-mediated side effects associated with rapid vancomycin infusion.	Vancomycin	169-179	H1.5 linker histone, cluster member	Homo sapiens	20-29
9728853-12	1998	Our randomized, double-blind, placebo-controlled study showed that oral H1 and H2 antihistamine pretreatment significantly reduced the histamine-related side effects of rapid vancomycin infusion.	Vancomycin	175-185	H1.5 linker histone, cluster member	Homo sapiens	72-81
9736536-3	1998	Although generally less potent than PG-1, LL-37 showed considerable activity (MIC, <10 microgram/ml) against Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci, even in media that contained 100 mM NaCl.	Vancomycin	257-267	cathelicidin antimicrobial peptide	Homo sapiens	42-47
9827256-2	1998	In contrast, the pharmacokinetics of hydrophilic agents (beta-lactams and vancomycin) in CSF often differ from those in serum.	Vancomycin	74-84	colony stimulating factor 2	Homo sapiens	89-92
9756787-13	1998	The corresponding figures for S. epidermidis were 10.3 and less than 6 h. The shorter PMEs achieved with a t1/2 of 5 h and the lack of concentration-dependent killing indicate that the time above the MIC is the parameter most important for the efficacy of vancomycin.	Vancomycin	256-266	CD5 molecule	Homo sapiens	107-116
9819690-5	1998	These results suggest that clonal spread of VanA phenotype E. faecium within and possibly between hospitals is the major vancomycin-resistant enterococcal problem in Edinburgh.	Vancomycin	121-131	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	44-48
9818969-3	1998	The I:E:F clonal type and a stable drug multidrug resistant phenotype (sensitivity only to trimethoprim/sulfamethoxazole and vancomycin) indicated that these isolates were closely related to the Iberian clone of MRSA, which is widely spread in Europe.	Vancomycin	125-135	solute carrier family 9 member A6	Homo sapiens	212-216
9660985-4	1998	beta-Lactamase activity in the beta-lactamase-positive strain changed over time parallel to viability, decreasing with amoxicillin-clavulanic acid or vancomycin and increasing in the amoxicillin and control groups.	Vancomycin	150-160	beta-lactamase	Staphylococcus aureus	31-45
9605319-1	1998	The gene encoding the vancomycin resistance protein VanH from Enterococcus faecium, a D-lactate dehydrogenase, has been cloned into a thioredoxin expression system (pTRxFus) and expressed as a fusion protein.	Vancomycin	22-32	VanH protein	Enterococcus faecium	52-56
9650924-8	1998	All vanA isolates were highly resistant to both vancomycin and teicoplanin except for three isolates which were susceptible to teicoplanin.	Vancomycin	48-58	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	4-8
9702193-0	1998	The structure of VanX reveals a novel amino-dipeptidase involved in mediating transposon-based vancomycin resistance.	Vancomycin	95-105	VanX protein	Enterococcus faecium	17-21
9702193-1	1998	VanX is a zinc-dependent D-alanyl-D-alanine dipeptidase that is a critical component in a system that mediates transposon-based vancomycin resistance in enterococci.	Vancomycin	128-138	VanX protein	Enterococcus faecium	0-4
9400512-5	1997	H1 (MIC 2 mg/L), which is a representative vancomycin-susceptible MRSA strain, was isolated from a patient with pneumonia who responded favourably to vancomycin therapy.	Vancomycin	43-53	CD99 molecule (Xg blood group)	Homo sapiens	4-9
9558134-2	1998	The immunoassay allows for the accurate quantification of vancomycin in the presence of the crystalline degradation product (CDP).	Vancomycin	58-68	cut like homeobox 1	Homo sapiens	92-123
9558134-2	1998	The immunoassay allows for the accurate quantification of vancomycin in the presence of the crystalline degradation product (CDP).	Vancomycin	58-68	cut like homeobox 1	Homo sapiens	125-128
9761883-1	1998	Balhimycin is a naturally occurring glycopeptide antibiotic, related to vancomycin which acts by binding nascent bacterial cell-wall peptide ending in the sequence D-Ala-D-Ala. Crystals of balhimycin are monoclinic, space group P21, a = 20.48 (10), b = 43.93 (21), c = 27.76 (14) A, beta = 100.5 (5) degrees with four independent antibiotic molecules, three molecules of 2-methyl-2,4-pentanediol, two citrate ions, three acetate ions and 127.5 water molecules in the asymmetric unit.	Vancomycin	72-82	H3 histone pseudogene 16	Homo sapiens	228-231
9605273-7	1998	Records of a random sample of 344 patients receiving vancomycin between May 1, 1994, and April 30, 1995, were reviewed for an indication meeting published guidelines.	Vancomycin	53-63	protein kinase C delta	Homo sapiens	72-77
9542900-6	1998	We also suggest that the use of simple tests, such as testing susceptibility to vancomycin for gram-negative bacteria and colistin for gram-positive bacteria, could prevent misinterpretation of Gram staining in gram-variable bacteria such as Gemella spp.	Vancomycin	80-90	histocompatibility minor 13	Homo sapiens	250-253
9777601-0	1998	Quantitation of vancomycin and its crystalline degradation product (CDP-1) in human serum by high performance liquid chromatography.	Vancomycin	16-26	cut like homeobox 1	Homo sapiens	68-73
9777601-1	1998	The delayed clearance of vancomycin results in accumulation of vancomycin crystalline degradation product, CDP-1, in the bodies of renally impaired patients.	Vancomycin	25-35	cut like homeobox 1	Homo sapiens	107-112
9777601-1	1998	The delayed clearance of vancomycin results in accumulation of vancomycin crystalline degradation product, CDP-1, in the bodies of renally impaired patients.	Vancomycin	63-73	cut like homeobox 1	Homo sapiens	107-112
9988050-0	1998	Transmission of VanA-type vancomycin-resistant enterococci and vanA resistance elements between chicken and humans at avoparcin-exposed farms.	Vancomycin	26-36	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	16-20
9400512-5	1997	H1 (MIC 2 mg/L), which is a representative vancomycin-susceptible MRSA strain, was isolated from a patient with pneumonia who responded favourably to vancomycin therapy.	Vancomycin	150-160	CD99 molecule (Xg blood group)	Homo sapiens	4-9
9310213-4	1997	In August 1997, the first S. aureus isolate intermediately resistant to vancomycin (VISA; MIC=8 micro/mL) in the United States was reported in Michigan.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	84-88
9294451-0	1997	Transcriptional regulation of the Enterococcus faecium BM4147 vancomycin resistance gene cluster by the VanS-VanR two-component regulatory system in Escherichia coli K-12.	Vancomycin	62-72	VanS protein	Enterococcus faecium	104-108
9303415-1	1997	Cerebrospinal fluid (CSF) was taken from 19 children with bacterial meningitis treated with cefotaxime (300 mg/kg of body weight/day) and vancomycin (60 mg/kg/day).	Vancomycin	138-148	colony stimulating factor 2	Homo sapiens	0-25
9303415-2	1997	Median levels of drugs in CSF were smaller than expected, as follows: 4.4 microg/ml for cefotaxime, 3.2 microg/ml for desacetylcefotaxime, and 1.7 microg/ml for vancomycin.	Vancomycin	161-171	colony stimulating factor 2	Homo sapiens	26-29
9294451-1	1997	An Escherichia coli K-12 model system was developed for studying the VanS-VanR two-component regulatory system required for high-level inducible vancomycin resistance in Enterococcus faecium BM4147.	Vancomycin	145-155	VanS protein	Enterococcus faecium	69-73
9272582-2	1997	In 1996, the first documented case of infection caused by a strain of S. aureus with intermediate levels of resistance to vancomycin (VISA; minimum inhibitory concentration [MIC]=8 microg/mL) was reported from Japan.	Vancomycin	122-132	mitochondrial antiviral signaling protein	Homo sapiens	134-138
9276414-5	1997	Nineteen (90%) of the vancomycin-resistant E. faecium isolates were of the VanB phenotype, with vanB resistance genes detected by PCR and hybridization with gene-specific probes; and the E. gallinarum isolates demonstrated the VanC phenotype with the vanC1 gene.	Vancomycin	22-32	D-alanine--D-lactate ligase	Enterococcus faecium	75-79
9276414-5	1997	Nineteen (90%) of the vancomycin-resistant E. faecium isolates were of the VanB phenotype, with vanB resistance genes detected by PCR and hybridization with gene-specific probes; and the E. gallinarum isolates demonstrated the VanC phenotype with the vanC1 gene.	Vancomycin	22-32	D-alanine--D-lactate ligase	Enterococcus faecium	96-100
9276414-6	1997	One vancomycin-resistant E. faecium isolate was highly resistant to both teicoplanin and vancomycin, corresponding to the VanA phenotype; however, it was found to have the vanB gene.	Vancomycin	4-14	D-alanine--D-lactate ligase	Enterococcus faecium	172-176
9276414-9	1997	Our study has documented that the emerging vancomycin resistance in our city was mainly due to the clonal dissemination of a single strain of E. faecium VanB.	Vancomycin	43-53	D-alanine--D-lactate ligase	Enterococcus faecium	153-157
9457607-8	1997	When only positive blood-cultures associated with a rise in C-reactive protein were considered, there were six episodes of CONS bacteraemia in the vancomycin group compared with 18 in the control group.	Vancomycin	147-157	C-reactive protein	Homo sapiens	60-78
9257766-0	1997	Identification and characterization of IS1476, an insertion sequence-like element that disrupts VanY function in a vancomycin-resistant Enterococcus faecium strain.	Vancomycin	115-125	VanY protein	Enterococcus faecium	96-100
9257766-1	1997	The vanY gene of vancomycin-resistant enterococci encodes a D,D-carboxypeptidase.	Vancomycin	17-27	VanY protein	Enterococcus faecium	4-8
9279965-8	1997	A weak inhibition of phospholipase-A2 activity was demonstrated by betamethasone, bupivacaine, digoxin, hydrocortisone, lidocaine, metoprolol, propranolol, and vancomycin.	Vancomycin	160-170	phospholipase A2 group IB	Homo sapiens	21-37
9272582-3	1997	This report describes the first isolation of VISA from a patient in the United States, which may be an early warning that S. aureus strains with full resistance to vancomycin will emerge.	Vancomycin	164-174	mitochondrial antiviral signaling protein	Homo sapiens	45-49
18611815-19	1997	In conclusion only vancomycin as a systemic agent and mupirocin as a topical agent, offer sufficient reliability for use against MSRA.	Vancomycin	19-29	methionine sulfoxide reductase A	Homo sapiens	129-133
9192247-0	1997	[Effect of imipenem/cilastatin combined with vancomycin for MRSA infection].	Vancomycin	45-55	solute carrier family 9 member A6	Homo sapiens	60-64
9041416-9	1997	The vancomycin MICs for the isolates with restriction fragment length patterns consistent with vanA and vanB were all > and = 64 micrograms/ml.	Vancomycin	4-14	D-alanine--D-lactate ligase	Enterococcus faecalis	104-108
8843309-3	1996	All vancomycin-resistant isolates examined carried the vanA, vanX, and vanR genes, suggesting that a gene cluster similar to that of the transposon Tn1546 was responsible for the resistance.	Vancomycin	4-14	VanX	Enterococcus faecalis	61-65
9376130-2	1997	To better understand how these antibiotics recognize polypeptide determinants, we have developed dynamic models of the complexes formed by the vancomycin aglycon and two different dipeptide ligands, Ac-D-ala-D-ala and Ac-D-ala-gly.	Vancomycin	143-153	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	199-203
9376130-2	1997	To better understand how these antibiotics recognize polypeptide determinants, we have developed dynamic models of the complexes formed by the vancomycin aglycon and two different dipeptide ligands, Ac-D-ala-D-ala and Ac-D-ala-gly.	Vancomycin	143-153	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	218-222
8913478-0	1996	In vivo activities of ceftriaxone and vancomycin against Borrelia spp.	Vancomycin	38-48	sphingosine-1-phosphate phosphatase 1	Mus musculus	66-69
8810499-6	1996	The vancomycin-resistant staphylococcal mutant gave no signal with the vanA or vanB DNA probes and contained no detectable D-lactate terminating cell wall precursors.	Vancomycin	4-14	D-alanine--D-lactate ligase	Staphylococcus aureus	79-83
9029761-1	1997	Commercially available immunoassays for vancomycin have been reported to overestimate serum vancomycin concentrations by varying degrees in patients with renal impairment, particularly those on peritoneal dialysis, by interference with crystalline degradation product-1 (CDP-1).	Vancomycin	40-50	cut like homeobox 1	Homo sapiens	236-269
9029761-1	1997	Commercially available immunoassays for vancomycin have been reported to overestimate serum vancomycin concentrations by varying degrees in patients with renal impairment, particularly those on peritoneal dialysis, by interference with crystalline degradation product-1 (CDP-1).	Vancomycin	92-102	cut like homeobox 1	Homo sapiens	236-269
9043940-0	1997	Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha (TNF alpha) production and TNF alpha-mRNA accumulation in human blood monocytes.	Vancomycin	0-10	tumor necrosis factor	Homo sapiens	83-92
9043940-0	1997	Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha (TNF alpha) production and TNF alpha-mRNA accumulation in human blood monocytes.	Vancomycin	0-10	tumor necrosis factor	Homo sapiens	109-118
9043940-4	1997	To investigate the effect of Vancomycin on TNF alpha production, an in vitro model of LPS-stimulated monocytes was used.	Vancomycin	29-39	tumor necrosis factor	Homo sapiens	43-52
9043940-6	1997	Vancomycin down-regulated, in dose-dependent manner, the TNF alpha production.	Vancomycin	0-10	tumor necrosis factor	Homo sapiens	57-66
9043940-7	1997	Vancomycin also inhibited TNF alpha-mRNA accumulation in LPS-stimulated monocytes, as assessed by fluorescence in situ hybridization (FISH) in cell suspension.	Vancomycin	0-10	tumor necrosis factor	Homo sapiens	26-35
9043940-8	1997	The down-regulation of TNF alpha production in LPS-stimulated monocytes may indicate that inhibition of this cytokine release is one of the important therapeutic effects of Vancomycin in sepsis.	Vancomycin	173-183	tumor necrosis factor	Homo sapiens	23-32
9255897-2	1997	Septicaemia caused by the vancomycin-resistant Gram-positive bacteria Leuconostoc spp.	Vancomycin	26-36	histocompatibility minor 13	Homo sapiens	82-85
8631706-0	1996	Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583.	Vancomycin	24-34	D-alanine--(R)-lactate ligase VanB	Enterococcus faecalis V583	14-18
8818911-3	1996	Detection of the 72 vancomycin-intermediate enterococci (MIC = 6 to 16 micrograms/ml) ranged from 94% for B-D Microbiology Systems to 99% for PML Microbiologicals.	Vancomycin	20-30	PML nuclear body scaffold	Homo sapiens	142-145
9053533-0	1996	[Clinical studies on vancomycin in the treatment of MRSA infection].	Vancomycin	21-31	solute carrier family 9 member A6	Homo sapiens	52-56
8792949-8	1996	Vancomycin resistance in E. faecalis and E. faecium has been subdivided into phenotypes, VanA and VanB.	Vancomycin	0-10	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	89-93
8792949-8	1996	Vancomycin resistance in E. faecalis and E. faecium has been subdivided into phenotypes, VanA and VanB.	Vancomycin	0-10	D-alanine--D-lactate ligase	Enterococcus faecium	98-102
8675038-0	1996	Mobilization of vancomycin resistance by transposon-mediated fusion of a VanA plasmid with an Enterococcus faecium sex pheromone-response plasmid.	Vancomycin	16-26	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	73-77
8621822-0	1996	Vancomycin-induced linear IgA bullous dermatosis (LABD).	Vancomycin	0-10	CD79a molecule	Homo sapiens	26-29
8758482-2	1996	Vancomycin distribution into CSF is improved when administered by a continuous intravenous route and staphylococcal shunt related infection have been reported to be cured.	Vancomycin	0-10	colony stimulating factor 2	Homo sapiens	29-32
8631706-9	1996	Vancomycin, but not teicoplanin, was an inducer, which explains teicoplanin susceptibility of VanB-type enterococci.	Vancomycin	0-10	D-alanine--(R)-lactate ligase VanB	Enterococcus faecalis V583	94-98
8848826-2	1996	This phenomenon has generally been thought to result from interference by vancomycin crystalline degradation products (CDP-1).	Vancomycin	74-84	cut like homeobox 1	Homo sapiens	119-124
8904441-0	1996	Factors influencing the vitek gram-positive susceptibility system"s detection of vanB-encoded vancomycin resistance among enterococci.	Vancomycin	94-104	D-alanine--D-lactate ligase	Enterococcus faecium	81-85
8904441-2	1996	to reliably detect vanB-mediated vancomycin resistance among enterococci.	Vancomycin	33-43	D-alanine--D-lactate ligase	Enterococcus faecium	19-23
8611145-0	1996	Peptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB type.	Vancomycin	59-69	D-alanine--D-lactate ligase	Enterococcus faecium	88-92
8929749-8	1996	The dialysis clearance of vancomycin ranged from 50.6 ml.min-1 to 76.8 ml.min-1 (average: 62.4 +/- 10.4 ml.min-1.	Vancomycin	26-36	CD59 molecule (CD59 blood group)	Homo sapiens	57-62
8929749-8	1996	The dialysis clearance of vancomycin ranged from 50.6 ml.min-1 to 76.8 ml.min-1 (average: 62.4 +/- 10.4 ml.min-1.	Vancomycin	26-36	CD59 molecule (CD59 blood group)	Homo sapiens	74-79
8929749-8	1996	The dialysis clearance of vancomycin ranged from 50.6 ml.min-1 to 76.8 ml.min-1 (average: 62.4 +/- 10.4 ml.min-1.	Vancomycin	26-36	CD59 molecule (CD59 blood group)	Homo sapiens	74-79
8929749-10	1996	In accordance to our kinetic study 1 g of vancomycin given every 7 days is adequate treatment for methicillin-resistant Staphylococcus aureus infections in patients with severe renal failure whose creatinine clearance is lower than 10 ml.min-1.	Vancomycin	42-52	CD59 molecule (CD59 blood group)	Homo sapiens	238-243
8848826-5	1996	When the vancomycin calibrators for FPIA were stored at 4 degrees C for 30 days, their concentrations determined by FPIA and HPLC decreased by 14 and 20%, respectively, and CDP-1 corresponding to 20% of primary vancomycin was formed.	Vancomycin	9-19	cut like homeobox 1	Homo sapiens	173-178
8848826-7	1996	We concluded that not only the cross-reactivity of FPIA to CDP-1 but also the instability of calibrators may cause the overestimation of serum vancomycin concentrations determined by FPIA.	Vancomycin	143-153	cut like homeobox 1	Homo sapiens	59-64
8927737-10	1996	Vancomycin was the most effective antibacterial drug against gram-positive, catalase-negative cocci isolated from patients hospitalized in our hospital.	Vancomycin	0-10	catalase	Homo sapiens	76-84
8727883-1	1996	Sixty vancomycin-resistant vanA mutant Enterococcus faecium (VRE) isolates, collected during a 40-month period from 48 patients hospitalized in a French Cancer Referral Center, were typed by using random amplified polymorphic DNA (RAPD), and the results were compared with those previously obtained by typing with SmaI pulsed-field gel electrophoresis (PFGE), which is currently recognized as the "gold standard."	Vancomycin	6-16	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	27-31
8787900-7	1996	The gene encodes a 36.7-kDa protein with homology to a family of bacterial NAD+-dependent, D-specific 2-hydroxyacid dehydrogenases which includes both D-lactate dehydrogenase and the enterococcal vancomycin resistance protein VanH and is therefore designated ddh.	Vancomycin	196-206	vancomycin resistance protein VanH	Staphylococcus aureus	226-230
8787900-9	1996	The increased D-lactate dehydrogenase activity in strain 523k and the structural similarities among Ddh, D-lactate dehydrogenase, and VanH suggest that overproduction of Ddh might play a role in vancomycin resistance in this strain.	Vancomycin	195-205	vancomycin resistance protein VanH	Staphylococcus aureus	134-138
8807826-3	1996	A mutant enzyme (VanA) from vancomycin-resistant Enterococcus faecium has been found to incorporate alpha-hydroxy acids at the terminal site instead of D-Ala; the resulting depsipeptides do not bind vancomycin, yet function in the crosslinking reaction.	Vancomycin	28-38	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	17-21
8641304-0	1996	In vitro conjugative transfer of VanA vancomycin resistance between Enterococci and Listeriae of different species.	Vancomycin	38-48	VanA	Enterococcus faecalis	33-37
8641304-1	1996	In a study designed to gain data on the in vitro transferability of vancomycin resistance from enterococci of the VanA phenotype to listeriae of different species, three clinical Enterococcus isolates-Enterococcus faecium LS10, Enterococcus faecalis LS4, and Enterococcus faecalis A3208, all harboring a plasmid that strongly hybridized with a vanA probe-were used as donors in transfer experiments.	Vancomycin	68-78	VanA	Enterococcus faecalis	114-118
8524812-0	1995	Phosphinate analogs of D-, D-dipeptides: slow-binding inhibition and proteolysis protection of VanX, a D-, D-dipeptidase required for vancomycin resistance in Enterococcus faecium.	Vancomycin	134-144	VanX protein	Enterococcus faecium	95-99
8524812-1	1995	VanX is a D-Ala-D-Ala dipeptidase that is essential for vancomycin resistance in Enterococcus faecium.	Vancomycin	56-66	VanX protein	Enterococcus faecium	0-4
8559623-3	1995	Using 1994 National Committee for Clinical Laboratory Standards breakpoints for pneumococci (unavailable for oral cephalosporins except cefuroxime), highly PRSP strains were almost uniformly susceptible to clindamycin and vancomycin.	Vancomycin	222-232	HtrA serine peptidase 3	Homo sapiens	156-160
8591934-0	1995	vanA genes in vancomycin-resistant clinical isolates of Oerskovia turbata and Arcanobacterium (Corynebacterium) haemolyticum.	Vancomycin	14-24	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	0-4
8591934-1	1995	We report the cloning and sequencing of vanA genes present in the high-level vancomycin- and teicoplanin-resistant clinical isolates Oerskovia turbata 892 and Arcanobacterium (Corynebacterium) haemolyticum 872.	Vancomycin	77-87	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	40-44
8591934-4	1995	The A. haemolyticum 872 DNA sequence was identical to the published vanA sequence of vancomycin-resistant Enterococcus faecium BM4147, but the O. turbata 892 sequence showed three coding changes.	Vancomycin	85-95	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	68-72
8591934-7	1995	Since A. haemolyticum and O. turbata are naturally susceptible to vancomycin, the high-level constitutive resistance seen in these isolates appears to be mediated by vanA.	Vancomycin	66-76	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	166-170
9158780-3	1995	Vancomycin resistance in all but one of these strains was mediated by transferable plasmids that carried the vanB glycopeptide resistance gene.	Vancomycin	0-10	D-alanine--D-lactate ligase	Enterococcus faecium	109-113
7559459-2	1995	VanS is a two-component transmembrane sensory kinase that, together with its response regulator VanR, activates the expression of genes responsible for vancomycin resistance in Enterococcus faecium BM4147.	Vancomycin	152-162	VanS protein	Enterococcus faecium	0-4
8157610-0	1994	Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum.	Vancomycin	78-88	D-alanine--D-lactate ligase	Enterococcus faecium	99-103
7957913-0	1994	Purification and characterization of the VanB ligase associated with type B vancomycin resistance in Enterococcus faecalis V583.	Vancomycin	76-86	D-alanine--(R)-lactate ligase VanB	Enterococcus faecalis V583	41-45
7957913-3	1994	Production of a similar protein, VanB, is induced in strains that display variable levels of vancomycin resistance but remain susceptible to teicoplanin (VanB phenotype).	Vancomycin	93-103	D-alanine--(R)-lactate ligase VanB	Enterococcus faecalis V583	33-37
7824326-2	1994	Continuous administration of vancomycin was used because it is usual with infusions prepared daily for catheterized patients, and because continuous infusions are well tolerated and achieve better penetration in tissues and CSF.	Vancomycin	29-39	colony stimulating factor 2	Homo sapiens	224-227
7873524-0	1995	Overexpression, purification, and characterization of VanX, a D-, D-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147.	Vancomycin	103-113	VanX protein	Enterococcus faecium	54-58
7873524-1	1995	Vancomycin resistance in Enterococcus faecium requires five genes: vanR, vanS, vanH, vanA, and vanX.	Vancomycin	0-10	VanR	Enterococcus faecium	67-71
7873524-1	1995	Vancomycin resistance in Enterococcus faecium requires five genes: vanR, vanS, vanH, vanA, and vanX.	Vancomycin	0-10	VanH protein	Enterococcus faecium	79-83
7873524-1	1995	Vancomycin resistance in Enterococcus faecium requires five genes: vanR, vanS, vanH, vanA, and vanX.	Vancomycin	0-10	VanX protein	Enterococcus faecium	95-99
7873524-11	1995	VanX is unable to hydrolyze D-Ala-D-lactate, the substituted moiety in the peptidoglycan that leads to vancomycin resistance, not only because of low binding affinity (Ki estimated at 242 mM) but also due to a kcat less than 0.005 s-1.	Vancomycin	103-113	VanX protein	Enterococcus faecium	0-4
7670152-1	1995	Complexation in aqueous solutions between vancomycin, ristocetin A, teicoplanin and two bacterial cell-wall analogues, Ac2-L-Lys-D-Ala-D-Ala (tripeptide) and Ac-D-Ala-D-Ala (dipeptide) has been examined by positive-ion electrospray mass spectrometry (ES-MS) and capillary zone electrophoresis (CZE)/ES-MS.	Vancomycin	42-52	adenylate cyclase 2	Homo sapiens	119-122
8072182-6	1994	These results are comparable with, or superior to the vancomycin therapy in the treatment of MRSA pneumonia.	Vancomycin	54-64	solute carrier family 9 member A6	Homo sapiens	93-97
8051238-0	1994	Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance.	Vancomycin	82-92	D-alanine--D-lactate ligase	Enterococcus faecium	71-75
8051238-2	1994	Three isolates with vancomycin MICs ranging from 8 to 256 micrograms/ml all hybridized with a vanB probe.	Vancomycin	20-30	D-alanine--D-lactate ligase	Enterococcus faecium	94-98
8051238-8	1994	These findings suggest that multidrug-resistant E. faecium strains with transferable vanB class vancomycin resistance will emerge as important nosocomial pathogens.	Vancomycin	96-106	D-alanine--D-lactate ligase	Enterococcus faecium	85-89
8161518-0	1994	Identification of the DNA-binding site for the phosphorylated VanR protein required for vancomycin resistance in Enterococcus faecium.	Vancomycin	88-98	VanR	Enterococcus faecium	62-66
8161518-1	1994	The vancomycin resistance operon of Enterococcus faecium encodes a two-component regulatory system comprising VanS and VanR.	Vancomycin	4-14	VanS protein	Enterococcus faecium	110-114
8161518-1	1994	The vancomycin resistance operon of Enterococcus faecium encodes a two-component regulatory system comprising VanS and VanR.	Vancomycin	4-14	VanR	Enterococcus faecium	119-123
8157610-3	1994	Nuclear magnetic resonance analysis by sequential assignment showed that the new precursor encountered in Enterococcus faecium D366, a strain belonging to the VANB class, which expresses low-level resistance to vancomycin, was UDP-MurNAc-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-lactate, identical to that previously found in the VANA class, which expresses high-level resistance to vancomycin.	Vancomycin	211-221	D-alanine--D-lactate ligase	Enterococcus faecium	159-163
8157610-3	1994	Nuclear magnetic resonance analysis by sequential assignment showed that the new precursor encountered in Enterococcus faecium D366, a strain belonging to the VANB class, which expresses low-level resistance to vancomycin, was UDP-MurNAc-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-lactate, identical to that previously found in the VANA class, which expresses high-level resistance to vancomycin.	Vancomycin	374-384	D-alanine--D-lactate ligase	Enterococcus faecium	159-163
8125347-0	1994	Sequence of the vanB and ddl genes encoding D-alanine:D-lactate and D-alanine:D-alanine ligases in vancomycin-resistant Enterococcus faecalis V583.	Vancomycin	99-109	D-alanine--(R)-lactate ligase VanB	Enterococcus faecalis V583	16-20
8203839-1	1994	Derivatives of the highly vancomycin-resistant Enterococcus faecalis strain 221 (MIC, 1,024 micrograms/ml) harboring Tn917 insertions in vanR, vanH, and vanA were compared with the parent strain and the susceptible plasmid-free strain JH2-2 (MIC, 2 micrograms/ml).	Vancomycin	26-36	two component regulator protein	Enterococcus faecalis	137-141
8203839-3	1994	Insertional inactivation of vanR resulted in the loss of carboxypeptidase activity, full susceptibility to vancomycin, and precursor pools similar to those of JH2-2.	Vancomycin	107-117	two component regulator protein	Enterococcus faecalis	28-32
8203839-6	1994	These findings suggest that DD-carboxypeptidase activity, under the control of vanR, results in increased pools of both tripeptide and tetrapeptide precursors, which may contribute to survival in the presence of vancomycin.	Vancomycin	212-222	two component regulator protein	Enterococcus faecalis	79-83
8129380-6	1994	For treatment of MRSA infections in patients with malignancy, a combination chemotherapy with vancomycin (VCM), or arbekacin (ABK) plus beta-lactam antibiotic is recommended, and granulocyte colony stimulating factor (G-CSF) is clinically useful when the granulocytopenia was induced by chemotherapy.	Vancomycin	94-104	solute carrier family 9 member A6	Homo sapiens	17-21
8040119-0	1994	vanA-mediated vancomycin-resistant Enterococcus spp.	Vancomycin	14-24	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	0-4
8040119-4	1994	The VanA protein was detected in each strain by immunoblotting of membrane extracts of the vancomycin-induced cells, and the vanA gene was demonstrated in the wild strains and their transconjugants by DNA-DNA hybridization.	Vancomycin	91-101	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	4-8
8040119-5	1994	This is the first, confirmed report of vanA mediated vancomycin resistance in E. durans.	Vancomycin	53-63	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	39-43
8494882-0	1993	Purification and characterization of VanR and the cytosolic domain of VanS: a two-component regulatory system required for vancomycin resistance in Enterococcus faecium BM4147.	Vancomycin	123-133	VanR	Enterococcus faecium	37-41
8215270-0	1993	A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci.	Vancomycin	32-42	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	158-162
8517702-1	1993	A synthesis of studies of serum protein binding of vancomycin and its reported abnormal binding in serum with very high concentrations of immunoglobulin A (IgA) suggests that this antibiotic may be bound to more than one serum protein.	Vancomycin	51-61	CD79a molecule	Homo sapiens	138-154
8517702-1	1993	A synthesis of studies of serum protein binding of vancomycin and its reported abnormal binding in serum with very high concentrations of immunoglobulin A (IgA) suggests that this antibiotic may be bound to more than one serum protein.	Vancomycin	51-61	CD79a molecule	Homo sapiens	156-159
8517702-2	1993	Using an ultrafiltration method for separating free from bound drug and high-performance liquid chromatography to measure drug concentration, we studied the binding characteristics of vancomycin for alpha-1 acid glycoprotein, IgG, IgM, IgA, and albumin.	Vancomycin	184-194	CD79a molecule	Homo sapiens	236-239
8517702-6	1993	Very high concentrations of IgA in serum (i.e., grams per deciliter), such as in patients with IgA myeloma, may result in the paradox of high (total) concentrations of vancomycin in serum that may be clinically ineffective.	Vancomycin	168-178	CD79a molecule	Homo sapiens	28-31
8486958-0	1993	The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci.	Vancomycin	72-82	D-alanine--(R)-lactate ligase VanB	Enterococcus faecalis V583	4-8
8096216-0	1993	Application of DNA probes for rRNA and vanA genes to investigation of a nosocomial cluster of vancomycin-resistant enterococci.	Vancomycin	94-104	VanA	Enterococcus faecalis	39-43
8096216-1	1993	DNA probes specific for genes encoding rRNA and the glycopeptide resistance gene vanA were used to investigate a cluster of vancomycin-resistant (MICs, > 512 mg/liter) Enterococcus faecalis and Enterococcus faecium isolated from separate patients in a renal unit in a London hospital.	Vancomycin	124-134	VanA	Enterococcus faecalis	81-85
8096216-4	1993	The other isolate of vancomycin-resistant E. faecalis had a different ribotype and the vanA gene was located on plasmid DNA.	Vancomycin	21-31	VanA	Enterococcus faecalis	87-91
8096216-7	1993	Twenty-one of these 23 isolates harbored a 24-MDa plasmid which hybridized with the vanA probe, implying that interstrain dissemination of a vancomycin resistance plasmid may have occurred among E. faecium isolates in the renal unit.	Vancomycin	141-151	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	84-88
8407120-3	1993	However, ERG amplitude depression and abnormal histologic changes occurred when the concentration of 100 micrograms/ml of vancomycin was used.	Vancomycin	122-132	transcriptional regulator ERG	Oryctolagus cuniculus	9-12
8486958-3	1993	Part of the vancomycin resistance gene vanB from E. faecalis V583 hybridized with a single but variably sized HindIII-KpnI fragment of total DNA from all 39 strains.	Vancomycin	12-22	D-alanine--(R)-lactate ligase VanB	Enterococcus faecalis V583	39-43
8486958-8	1993	It thus appears that vanB confers various levels of conjugative vancomycin resistance in enterococci.	Vancomycin	64-74	D-alanine--(R)-lactate ligase VanB	Enterococcus faecalis V583	21-25
1398115-0	1992	Sequence of the vanY gene required for production of a vancomycin-inducible D,D-carboxypeptidase in Enterococcus faecium BM4147.	Vancomycin	55-65	VanY protein	Enterococcus faecium	16-20
8440477-0	1993	The vanB gene of vancomycin-resistant Enterococcus faecalis V583 is structurally related to genes encoding D-Ala:D-Ala ligases and glycopeptide-resistance proteins VanA and VanC.	Vancomycin	17-27	D-alanine--(R)-lactate ligase VanB	Enterococcus faecalis V583	4-8
8440477-1	1993	We report the cloning and sequencing of a 632-bp amplified fragment internal to the vanB gene of vancomycin-resistant (VmR) Enterococcus (En.)	Vancomycin	97-107	D-alanine--D-lactate ligase	Enterococcus faecalis	84-88
8492751-9	1993	The overall rate of success with modifications (Amphotericin B, Vancomycin, Clindamycin, Metronidazole) was higher in Reg.	Vancomycin	64-74	regenerating family member 1 alpha	Homo sapiens	118-121
1398115-1	1992	Cloning and nucleotide sequencing identified the vanY gene as a member of the vancomycin-resistance van gene cluster of enterococcal plasmid, pIP816.	Vancomycin	78-88	VanY protein	Enterococcus faecium	49-53
1398115-2	1992	The vanY gene was necessary for synthesis of the vancomycin-inducible D,D-carboxypeptidase activity previously proposed to be responsible for glycopeptide resistance.	Vancomycin	49-59	VanY protein	Enterococcus faecium	4-8
1931965-0	1991	Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA.	Vancomycin	20-30	VanH protein	Enterococcus faecium	163-167
1503450-1	1992	The VanA ligase encoded by the vancomycin resistance plasmid pIP816 of Enterococcus faecium BM4147 condenses D-alanine with various D-2-hydroxy and D-2-amino acids in vitro.	Vancomycin	31-41	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	4-8
1503450-2	1992	D-Lactate added to the culture medium restored the vancomycin resistance of a strain that does not produce the VanH dehydrogenase and therefore appears to be a substrate of VanA in vivo.	Vancomycin	51-61	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	173-177
1623904-4	1992	At a blood flow of 219 ml.min-1, HD clearance of vancomycin was 62.3 ml.min-1.	Vancomycin	49-59	CD59 molecule (CD59 blood group)	Homo sapiens	26-31
1623904-4	1992	At a blood flow of 219 ml.min-1, HD clearance of vancomycin was 62.3 ml.min-1.	Vancomycin	49-59	CD59 molecule (CD59 blood group)	Homo sapiens	72-77
1380722-0	1992	IgE-mediated reaction to vancomycin and teicoplanin after treatment with vancomycin.	Vancomycin	25-35	immunoglobulin heavy constant epsilon	Homo sapiens	0-3
1380722-0	1992	IgE-mediated reaction to vancomycin and teicoplanin after treatment with vancomycin.	Vancomycin	73-83	immunoglobulin heavy constant epsilon	Homo sapiens	0-3
1380722-2	1992	By the basophil histamine release test, the patient"s isolated basophil leucocytes were shown to react IgE dependent after challenge with vancomycin and teicoplanin.	Vancomycin	138-148	immunoglobulin heavy constant epsilon	Homo sapiens	103-106
1522072-1	1992	Vancomycin resistance plasmids in enterococci carry the genes vanH and vanA, which encode enzymes catalyzing, respectively, the reduction of 2-keto acids to 2-D-hydroxy acids and the addition of D-hydroxy acids to D-alanine.	Vancomycin	0-10	VanA	Enterococcus faecalis	71-75
1510448-0	1992	Characterization of vanY, a DD-carboxypeptidase from vancomycin-resistant Enterococcus faecium BM4147.	Vancomycin	53-63	VanY protein	Enterococcus faecium	20-24
1510448-1	1992	VanY is a protein with a molecular mass of 34.8 kDa encoded by vanY, a member of the high-level vancomycin resistance gene cluster found on plasmid pIP816 in Enterococcus faecium BM4147.	Vancomycin	96-106	VanY protein	Enterococcus faecium	0-4
1510448-1	1992	VanY is a protein with a molecular mass of 34.8 kDa encoded by vanY, a member of the high-level vancomycin resistance gene cluster found on plasmid pIP816 in Enterococcus faecium BM4147.	Vancomycin	96-106	VanY protein	Enterococcus faecium	63-67
1510448-5	1992	VanY released the C-terminal D-hydroxy acid from depsipeptides produced by the vancomycin resistance protein VanA.	Vancomycin	79-89	VanY protein	Enterococcus faecium	0-4
1507428-3	1992	Arbekacin, a newly developed aminoglycoside antibiotic, showed more active than vancomycin to MRSA in vitro.	Vancomycin	80-90	solute carrier family 9 member A6	Homo sapiens	94-98
1507428-5	1992	Combined activity of arbekacin and vancomycin against 27 MRSA strains was evaluated by checkerboard technique.	Vancomycin	35-45	solute carrier family 9 member A6	Homo sapiens	57-61
1507434-5	1992	In a postoperative multiple trauma patient, with pneumonia, thoracic empyema, intraabdominal abscess, wound infection and sepsis caused by MRSA, surgical drainage of the abscess with systemic infusion of vancomycin was effective and resulted in full recovery.	Vancomycin	204-214	solute carrier family 9 member A6	Homo sapiens	139-143
1931965-0	1991	Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA.	Vancomycin	20-30	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	172-176
1931965-0	1991	Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA.	Vancomycin	132-142	VanH protein	Enterococcus faecium	163-167
1931965-0	1991	Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA.	Vancomycin	132-142	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	172-176
2275003-1	1990	A new reverse-phase high-performance liquid chromatographic (HPLC) procedure has been developed for the quantitation of vancomycin and its crystalline degradation product, CDP-1.	Vancomycin	120-130	cut like homeobox 1	Homo sapiens	172-177
1949924-9	1991	Although vancomycin protein binding changes with serum albumin, this finding may have limited clinical significance.	Vancomycin	9-19	albumin	Homo sapiens	49-62
1713735-0	1991	Vancomycin-induced release of histamine from rat peritoneal mast cells and a rat basophil cell line (RBL-1).	Vancomycin	0-10	RB transcriptional corepressor like 1	Rattus norvegicus	101-106
1713735-10	1991	On the other hand, treatment-related degranulation effects of either vancomycin or CP 48/80 on RBL-1 cells could not be reliably distinguished from controls by qualitative evaluation.	Vancomycin	69-79	RB transcriptional corepressor like 1	Rattus norvegicus	95-100
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Vancomycin	140-150	solute carrier family 9 member A6	Homo sapiens	4-8
1863618-10	1991	Our MRSA strain belong to phage type III, and shows a characteristic multiple antibiotic resistant pattern, the MRSA strain is sensitive to vancomycin, fusidic acid, phosphomycin and cotrimoxazole.	Vancomycin	140-150	solute carrier family 9 member A6	Homo sapiens	112-116
1672320-5	1991	Out of the 38 PRSA isolates, 35 (92%) were methicillin- and multiply-resistant; however, all PRSA isolates were sensitive to vancomycin and coumermycin.	Vancomycin	125-135	glutaredoxin 5	Homo sapiens	93-97
1968484-1	1990	To assess whether vancomycin administration at the time of central venous catheter insertion would prevent catheter-related sepsis (CRS) in immunocompromised patients, 98 cancer patients were entered into a randomized placebo-controlled trial.	Vancomycin	18-28	twist family bHLH transcription factor 1	Homo sapiens	107-130
2233663-0	1990	[Intravenous administration of vancomycin for postoperative MRSA infection and its pharmacokinetics: preliminary report].	Vancomycin	31-41	solute carrier family 9 member A6	Homo sapiens	60-64
2138543-2	1990	Both strains were resistant to teicoplanin (MIC 16 and 8 mg/l respectively), but remained sensitive to vancomycin (MIC 2 and 4 mg/l respectively).	Vancomycin	103-113	CD99 molecule (Xg blood group)	Homo sapiens	115-126
34633852-0	2022	Population pharmacokinetics of vancomycin in critically ill adult patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).	Vancomycin	31-41	microtubule associated protein 9	Homo sapiens	125-129
34848155-9	2022	Moreover, histological and immunohistochemical examination of scopoletin-treated group showed remarkable improvement in histological structure and reduced vancomycin-induced renal expression of iNOS, NF-kappaB and p38 MAPK.	Vancomycin	155-165	nitric oxide synthase 2	Rattus norvegicus	194-198
34874001-1	2021	OBJECTIVE: To evaluate the change in vancomycin days of therapy (DOT) and vancomycin-associated acute kidney injury (AKI) after an antimicrobial stewardship program (ASP) intervention to decrease vancomycin use in stable patients after hematopoietic stem cell transplantation (HSCT).	Vancomycin	37-47	assembly factor for spindle microtubules	Homo sapiens	166-169
34715137-7	2022	KEY FINDINGS: Levels of malondialdehyde (MDA), inducible nitric oxide synthase (iNOS), nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and kidney injury molecule-1 (KIM-1) were significantly increased in kidney tissue after VCM administration.	Vancomycin	236-239	nitric oxide synthase 2	Rattus norvegicus	47-78
34715137-7	2022	KEY FINDINGS: Levels of malondialdehyde (MDA), inducible nitric oxide synthase (iNOS), nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and kidney injury molecule-1 (KIM-1) were significantly increased in kidney tissue after VCM administration.	Vancomycin	236-239	nitric oxide synthase 2	Rattus norvegicus	80-84
34715137-7	2022	KEY FINDINGS: Levels of malondialdehyde (MDA), inducible nitric oxide synthase (iNOS), nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and kidney injury molecule-1 (KIM-1) were significantly increased in kidney tissue after VCM administration.	Vancomycin	236-239	tumor necrosis factor	Rattus norvegicus	106-133
34715137-7	2022	KEY FINDINGS: Levels of malondialdehyde (MDA), inducible nitric oxide synthase (iNOS), nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and kidney injury molecule-1 (KIM-1) were significantly increased in kidney tissue after VCM administration.	Vancomycin	236-239	tumor necrosis factor	Rattus norvegicus	135-144
34715137-7	2022	KEY FINDINGS: Levels of malondialdehyde (MDA), inducible nitric oxide synthase (iNOS), nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and kidney injury molecule-1 (KIM-1) were significantly increased in kidney tissue after VCM administration.	Vancomycin	236-239	hepatitis A virus cellular receptor 1	Rattus norvegicus	151-175
34715137-7	2022	KEY FINDINGS: Levels of malondialdehyde (MDA), inducible nitric oxide synthase (iNOS), nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), and kidney injury molecule-1 (KIM-1) were significantly increased in kidney tissue after VCM administration.	Vancomycin	236-239	hepatitis A virus cellular receptor 1	Rattus norvegicus	177-182
34715137-8	2022	Expression of adenosine 5"-monophosphate-activated protein kinase (AMPK), Bcl-2 associated X protein (Bax), caspase 3 and caspase 9 in kidney tissue was significantly increased, while the antioxidant enzymes, mitochondrial complexes, the ATP levels and B-cell lymphoma protein 2 (Bcl-2) were decreased in kidney in the VCM-treated rats compared to the normal control group.	Vancomycin	319-322	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	14-65
34715137-8	2022	Expression of adenosine 5"-monophosphate-activated protein kinase (AMPK), Bcl-2 associated X protein (Bax), caspase 3 and caspase 9 in kidney tissue was significantly increased, while the antioxidant enzymes, mitochondrial complexes, the ATP levels and B-cell lymphoma protein 2 (Bcl-2) were decreased in kidney in the VCM-treated rats compared to the normal control group.	Vancomycin	319-322	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	67-71
34715137-8	2022	Expression of adenosine 5"-monophosphate-activated protein kinase (AMPK), Bcl-2 associated X protein (Bax), caspase 3 and caspase 9 in kidney tissue was significantly increased, while the antioxidant enzymes, mitochondrial complexes, the ATP levels and B-cell lymphoma protein 2 (Bcl-2) were decreased in kidney in the VCM-treated rats compared to the normal control group.	Vancomycin	319-322	BCL2 associated X, apoptosis regulator	Rattus norvegicus	74-100
34715137-8	2022	Expression of adenosine 5"-monophosphate-activated protein kinase (AMPK), Bcl-2 associated X protein (Bax), caspase 3 and caspase 9 in kidney tissue was significantly increased, while the antioxidant enzymes, mitochondrial complexes, the ATP levels and B-cell lymphoma protein 2 (Bcl-2) were decreased in kidney in the VCM-treated rats compared to the normal control group.	Vancomycin	319-322	BCL2 associated X, apoptosis regulator	Rattus norvegicus	102-105
34715137-8	2022	Expression of adenosine 5"-monophosphate-activated protein kinase (AMPK), Bcl-2 associated X protein (Bax), caspase 3 and caspase 9 in kidney tissue was significantly increased, while the antioxidant enzymes, mitochondrial complexes, the ATP levels and B-cell lymphoma protein 2 (Bcl-2) were decreased in kidney in the VCM-treated rats compared to the normal control group.	Vancomycin	319-322	caspase 3	Rattus norvegicus	108-117
34715137-8	2022	Expression of adenosine 5"-monophosphate-activated protein kinase (AMPK), Bcl-2 associated X protein (Bax), caspase 3 and caspase 9 in kidney tissue was significantly increased, while the antioxidant enzymes, mitochondrial complexes, the ATP levels and B-cell lymphoma protein 2 (Bcl-2) were decreased in kidney in the VCM-treated rats compared to the normal control group.	Vancomycin	319-322	caspase 9	Rattus norvegicus	122-131
34715137-8	2022	Expression of adenosine 5"-monophosphate-activated protein kinase (AMPK), Bcl-2 associated X protein (Bax), caspase 3 and caspase 9 in kidney tissue was significantly increased, while the antioxidant enzymes, mitochondrial complexes, the ATP levels and B-cell lymphoma protein 2 (Bcl-2) were decreased in kidney in the VCM-treated rats compared to the normal control group.	Vancomycin	319-322	BCL2, apoptosis regulator	Rattus norvegicus	253-278
34715137-8	2022	Expression of adenosine 5"-monophosphate-activated protein kinase (AMPK), Bcl-2 associated X protein (Bax), caspase 3 and caspase 9 in kidney tissue was significantly increased, while the antioxidant enzymes, mitochondrial complexes, the ATP levels and B-cell lymphoma protein 2 (Bcl-2) were decreased in kidney in the VCM-treated rats compared to the normal control group.	Vancomycin	319-322	BCL2, apoptosis regulator	Rattus norvegicus	280-285
34718605-0	2021	A vanA vancomycin-resistant Enterococcus faecium ST80 outbreak resulting from a single importation event.	Vancomycin	7-17	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	2-6
34718605-1	2021	BACKGROUND: A marked genotype shift among vancomycin-resistant Enterococcus faecium (VREfm) from vanB to vanA in Australia between 2011 and 2015 is a well-known phenomenon.	Vancomycin	42-52	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	105-109
34874001-1	2021	OBJECTIVE: To evaluate the change in vancomycin days of therapy (DOT) and vancomycin-associated acute kidney injury (AKI) after an antimicrobial stewardship program (ASP) intervention to decrease vancomycin use in stable patients after hematopoietic stem cell transplantation (HSCT).	Vancomycin	74-84	assembly factor for spindle microtubules	Homo sapiens	166-169
34874001-1	2021	OBJECTIVE: To evaluate the change in vancomycin days of therapy (DOT) and vancomycin-associated acute kidney injury (AKI) after an antimicrobial stewardship program (ASP) intervention to decrease vancomycin use in stable patients after hematopoietic stem cell transplantation (HSCT).	Vancomycin	196-206	assembly factor for spindle microtubules	Homo sapiens	166-169
34874001-7	2021	INTERVENTION: An ASP intervention in April 2017 creating a new practice guideline to decrease prolonged (>72 hours) vancomycin courses for stable HSCT patients with febrile neutropenia.	Vancomycin	116-126	assembly factor for spindle microtubules	Homo sapiens	17-20
34966584-2	2021	We established a rapid approach for detecting E. faecium and vancomycin-resistance genes (vanA and vanB) in clinical samples using isothermal recombinase polymerase amplification (RPA) combined with a lateral-flow (LF) strip.	Vancomycin	61-71	D-alanine--D-lactate ligase	Enterococcus faecium	99-103
34874001-11	2021	CONCLUSIONS: An ASP intervention successfully decreased vancomycin use after HSCT and resulted in a decrease in AKI.	Vancomycin	56-66	assembly factor for spindle microtubules	Homo sapiens	16-19
34425727-8	2021	Vancomycin solid lipid nanoparticle and its constituents SLN and LA disrupted testicular morphometry and the hormonal milieu sufficient to potentially induce altered reproductive function.	Vancomycin	0-10	sarcolipin	Rattus norvegicus	57-60
34867012-8	2021	Moreover, large number of MRSA isolates were identified as multidrug resistance and 28.6% of MRSA-mecA positive isolates were also carried vancomycin resistance genes (i.e., vanB).	Vancomycin	139-149	D-alanine--D-lactate ligase	Staphylococcus aureus	174-178
34826629-0	2021	Successful treatment with daptomycin and ceftaroline of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) endocarditis: a case report.	Vancomycin	70-80	mitochondrial antiviral signaling protein	Homo sapiens	117-122
34446352-1	2021	INTRODUCTION: Combination therapy with vancomycin (VCM) and piperacillin/tazobactam (PIPC/TAZ) increases the risk of acute kidney injury (AKI).	Vancomycin	39-49	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	85-93
34844579-7	2021	C-reactive protein and erythrocyte sedimentation rate in both groups were significantly lower than before treatment, but the improvement effect of vancomycin calcium sulfate implantation was better (p < 0.05).	Vancomycin	147-157	C-reactive protein	Homo sapiens	0-18
34785083-9	2022	Quantitation of gene expression related to osteogenesis (Col1a, Alp, and Runx2), vascularization (Vegf, Tgfb1, and vWF), and proliferation (Oct4 and Stro-1) by real-time PCR revealed slight increases in the expression of selected genes at low vancomycin concentrations (1-4 g per cement dose), and relatively lower gene expression when the concentration of vancomycin was more than 6 g per cement dose.	Vancomycin	357-367	runt-related transcription factor 2	Oryctolagus cuniculus	73-78
34785083-9	2022	Quantitation of gene expression related to osteogenesis (Col1a, Alp, and Runx2), vascularization (Vegf, Tgfb1, and vWF), and proliferation (Oct4 and Stro-1) by real-time PCR revealed slight increases in the expression of selected genes at low vancomycin concentrations (1-4 g per cement dose), and relatively lower gene expression when the concentration of vancomycin was more than 6 g per cement dose.	Vancomycin	357-367	vascular endothelial growth factor A	Oryctolagus cuniculus	98-102
34785083-9	2022	Quantitation of gene expression related to osteogenesis (Col1a, Alp, and Runx2), vascularization (Vegf, Tgfb1, and vWF), and proliferation (Oct4 and Stro-1) by real-time PCR revealed slight increases in the expression of selected genes at low vancomycin concentrations (1-4 g per cement dose), and relatively lower gene expression when the concentration of vancomycin was more than 6 g per cement dose.	Vancomycin	357-367	transforming growth factor beta-1	Oryctolagus cuniculus	104-109
34785083-9	2022	Quantitation of gene expression related to osteogenesis (Col1a, Alp, and Runx2), vascularization (Vegf, Tgfb1, and vWF), and proliferation (Oct4 and Stro-1) by real-time PCR revealed slight increases in the expression of selected genes at low vancomycin concentrations (1-4 g per cement dose), and relatively lower gene expression when the concentration of vancomycin was more than 6 g per cement dose.	Vancomycin	357-367	LOW QUALITY PROTEIN: von Willebrand factor	Oryctolagus cuniculus	115-118
34785083-9	2022	Quantitation of gene expression related to osteogenesis (Col1a, Alp, and Runx2), vascularization (Vegf, Tgfb1, and vWF), and proliferation (Oct4 and Stro-1) by real-time PCR revealed slight increases in the expression of selected genes at low vancomycin concentrations (1-4 g per cement dose), and relatively lower gene expression when the concentration of vancomycin was more than 6 g per cement dose.	Vancomycin	357-367	POU domain, class 5, transcription factor 1	Oryctolagus cuniculus	140-144
34748415-1	2022	Vancomycin is widely used for treatment of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) leading to an increasing appearance of low-level vancomycin-resistant isolates called heterogeneous vancomycin-intermediate S. aureus (hVISA).	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	249-254
34748415-1	2022	Vancomycin is widely used for treatment of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) leading to an increasing appearance of low-level vancomycin-resistant isolates called heterogeneous vancomycin-intermediate S. aureus (hVISA).	Vancomycin	163-173	mitochondrial antiviral signaling protein	Homo sapiens	249-254
34748415-1	2022	Vancomycin is widely used for treatment of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) leading to an increasing appearance of low-level vancomycin-resistant isolates called heterogeneous vancomycin-intermediate S. aureus (hVISA).	Vancomycin	214-224	mitochondrial antiviral signaling protein	Homo sapiens	249-254
34748415-2	2022	The mechanism of vancomycin tolerance in hVISA is still unclear.	Vancomycin	17-27	mitochondrial antiviral signaling protein	Homo sapiens	41-46
34830266-8	2021	Whereas, the antibiotic vancomycin abrogates the effects of lactoferrin on dry eye disease and significantly reduces short-chain fatty acid concentrations.	Vancomycin	24-34	lactotransferrin	Mus musculus	60-71
34763754-1	2021	BackgroundHospital-acquired infections (HAI) caused by Enterococcus spp., especially vancomycin-resistant Enterococcus spp.	Vancomycin	85-95	histocompatibility minor 13	Homo sapiens	119-122
34763754-10	2021	Hospital wide, the pooled vancomycin resistance proportion among Enterococcus spp.	Vancomycin	26-36	histocompatibility minor 13	Homo sapiens	78-81
34366231-1	2021	INTRODUCTION: Combined use of vancomycin (VCM) and piperacillin/tazobactam (PIPC/TAZ) has been reported to increase the incidence of acute kidney injury (AKI).	Vancomycin	30-40	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	81-84
34733265-5	2021	Similarly, IL-26 sensitivity was also detectable in vancomycin-resistant Enterococcus species, methicillin-resistant S. aureus, and carbapenem-resistant A. baumannii clinical isolates.	Vancomycin	52-62	interleukin 26	Homo sapiens	11-16
34718966-0	2022	Genetic description of VanD phenotype vanA genotype in vancomycin-resistant Enterococcus faecium isolates from a Bone Marrow Transplantation Unit.	Vancomycin	55-65	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	38-42
34718966-2	2022	VanA phenotype is characterized by resistance to high levels of vancomycin and teicoplanin and is encoded by the vanA gene, whereas VanD phenotype is characterized by resistance to vancomycin and susceptibility or intermediate resistance to teicoplanin; however, some isolates carry a VanD phenotype with a vanA genotype, but there are many gaps in the knowledge about the genetic mechanisms behind this pattern.	Vancomycin	64-74	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	0-4
34718966-2	2022	VanA phenotype is characterized by resistance to high levels of vancomycin and teicoplanin and is encoded by the vanA gene, whereas VanD phenotype is characterized by resistance to vancomycin and susceptibility or intermediate resistance to teicoplanin; however, some isolates carry a VanD phenotype with a vanA genotype, but there are many gaps in the knowledge about the genetic mechanisms behind this pattern.	Vancomycin	64-74	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	113-117
34718966-2	2022	VanA phenotype is characterized by resistance to high levels of vancomycin and teicoplanin and is encoded by the vanA gene, whereas VanD phenotype is characterized by resistance to vancomycin and susceptibility or intermediate resistance to teicoplanin; however, some isolates carry a VanD phenotype with a vanA genotype, but there are many gaps in the knowledge about the genetic mechanisms behind this pattern.	Vancomycin	64-74	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	307-311
34718966-4	2022	RESULTS: All vanA VRE-fm isolates displayed minimum inhibitory concentration (MIC) for vancomycin > 32microg/mL and intermediate or susceptible MIC range for teicoplanin (8-16microg/mL).	Vancomycin	87-97	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	13-17
34675565-11	2021	Conclusion: The results of this study suggest that higher CRP might be one of the risk factors associated with lower VCM concentration in both normal and low renal function patients.	Vancomycin	117-120	C-reactive protein	Homo sapiens	58-61
34665771-7	2021	Among the vancomycin-resistant Staphylococcus aureus (VRSA) isolates, the prevalence rates of vanA and vanB resistance-encoding genes were 46.5 and 59.3%, respectively.	Vancomycin	10-20	D-alanine--D-lactate ligase	Staphylococcus aureus	103-107
34675565-7	2021	Elderly age, short stature, and higher C-reactive protein (CRP) level were significantly more common in the lower VCM concentration group compared with appropriate VCM concentration group.	Vancomycin	114-117	C-reactive protein	Homo sapiens	39-57
34675565-7	2021	Elderly age, short stature, and higher C-reactive protein (CRP) level were significantly more common in the lower VCM concentration group compared with appropriate VCM concentration group.	Vancomycin	114-117	C-reactive protein	Homo sapiens	59-62
34579971-4	2021	METHODS: This retrospective cohort study identified adult patients who received vancomycin either as monotherapy or in combination with PTZ or carbapenem (VAN + CAR) for at least 48 hours at Jiangsu Province Hospital from January 1, 2017, to December 31, 2018.	Vancomycin	80-90	CXADR pseudogene 1	Homo sapiens	161-164
34175955-7	2021	Naive T-cells from HLA-A*02:01 positive and negative donors were activated with vancomycin; however the strength of the induced response was significantly stronger in donors expressing HLA-A*32:01.	Vancomycin	80-90	major histocompatibility complex, class I, A	Homo sapiens	19-24
34333022-0	2021	Biomimetic pH/ lipase dual responsive vitamin-based solid lipid nanoparticles for on-demand delivery of vancomycin.	Vancomycin	104-114	lipase, endothelial	Mus musculus	15-21
34630082-3	2021	Objective: The aim of this study was to evaluate the role of urinary IL-18, KIM-1, NGAL, TIMP-2, and IGFBP7 as diagnostic and prognostic predictors of AKI related to vancomycin.	Vancomycin	166-176	interleukin 18	Homo sapiens	69-74
34630082-3	2021	Objective: The aim of this study was to evaluate the role of urinary IL-18, KIM-1, NGAL, TIMP-2, and IGFBP7 as diagnostic and prognostic predictors of AKI related to vancomycin.	Vancomycin	166-176	hepatitis A virus cellular receptor 1	Homo sapiens	76-81
34630082-3	2021	Objective: The aim of this study was to evaluate the role of urinary IL-18, KIM-1, NGAL, TIMP-2, and IGFBP7 as diagnostic and prognostic predictors of AKI related to vancomycin.	Vancomycin	166-176	lipocalin 2	Homo sapiens	83-87
34630082-3	2021	Objective: The aim of this study was to evaluate the role of urinary IL-18, KIM-1, NGAL, TIMP-2, and IGFBP7 as diagnostic and prognostic predictors of AKI related to vancomycin.	Vancomycin	166-176	TIMP metallopeptidase inhibitor 2	Homo sapiens	89-95
34630082-3	2021	Objective: The aim of this study was to evaluate the role of urinary IL-18, KIM-1, NGAL, TIMP-2, and IGFBP7 as diagnostic and prognostic predictors of AKI related to vancomycin.	Vancomycin	166-176	insulin like growth factor binding protein 7	Homo sapiens	101-107
34630082-13	2021	Age, plasmatic vancomycin concentrations, and NGAL between 96 and 144 h were identified as predictors of AKI related to vancomycin use.	Vancomycin	120-130	lipocalin 2	Homo sapiens	46-50
34575453-8	2021	The results of this study showed that, a vancomycin AUC/MIC of >=400 mg h/L was associated with significant differences in clinical response compared to a vancomycin AUC/MIC of <400 mg h/L (aHR: 0.50, 95% CI: 0.26-0.97; p = 0.042).	Vancomycin	41-51	lipase C, hepatic type	Homo sapiens	72-75
34575453-8	2021	The results of this study showed that, a vancomycin AUC/MIC of >=400 mg h/L was associated with significant differences in clinical response compared to a vancomycin AUC/MIC of <400 mg h/L (aHR: 0.50, 95% CI: 0.26-0.97; p = 0.042).	Vancomycin	155-165	lipase C, hepatic type	Homo sapiens	185-188
34575453-13	2021	We found a target vancomycin AUC/MIC of >=400 mg h/L and this AUC/MIC target value could be optimal for the use for monitoring treatment of enterococcal infections.	Vancomycin	18-28	lipase C, hepatic type	Homo sapiens	49-52
34175955-0	2021	Deciphering adverse drug reactions: in vitro priming and characterization of vancomycin-specific T-cells from healthy donors expressing HLA-A*32:01.	Vancomycin	77-87	major histocompatibility complex, class I, A	Homo sapiens	136-141
34175955-2	2021	Vancomycin-induced DRESS is associated with the expression of HLA-A*32:01, suggesting that the drug interacts with this HLA to activate CD8+ T-cells.	Vancomycin	0-10	major histocompatibility complex, class I, A	Homo sapiens	62-67
34175955-2	2021	Vancomycin-induced DRESS is associated with the expression of HLA-A*32:01, suggesting that the drug interacts with this HLA to activate CD8+ T-cells.	Vancomycin	0-10	CD8a molecule	Homo sapiens	136-139
34175955-3	2021	The purpose of this study was to utilize PBMC from healthy donors to: (i) investigate whether expression of HLA-A*32:01 is critical for the priming naive of T-cells with vancomycin and (ii) generate T-cell clones (TCC) to determine whether vancomycin exclusively activates CD8+ T-cells and to define cellular phenotype, pathways of drug presentation and cross-reactivity.	Vancomycin	170-180	major histocompatibility complex, class I, A	Homo sapiens	108-113
34181479-4	2021	The MRSA-PJI rats treated with IA injection of vancomycin showed a better outcome in skin temperature, bacterial counts, biofilm on the prosthesis, serum alpha-1-acid glycoprotein (alpha1-AGP), residual bone volume and inflammatory reaction in the joint tissues than those with IP vancomycin, while rats with IP & IA administration showed the best outcomes.	Vancomycin	47-57	orosomucoid 1	Rattus norvegicus	154-179
34407000-10	2022	Strong correlations were found between AUC24-48 and serum concentrations at 24 h after the initiation of VCM treatment following the 1st HD (C24h, R = 0.983 and P < 0.001), between AUC0-24 and C24h (R = 0.967 and P < 0.001), and between AUC24-48 and serum concentration just before the 2nd HD (Cpre(HD2), R = 0.965 and P < 0.001).	Vancomycin	105-108	histone deacetylase 2	Homo sapiens	294-302
34397910-7	2021	Overall, 220 (80%) respondents indicated that ARC would impact the treatment effect of vancomycin, but 149/220 (68%) were willing to adjust the vancomycin regimen; only 22/149 (8%) considered that the dose should be increased, but no one knew how to increase.	Vancomycin	87-97	activity regulated cytoskeleton associated protein	Homo sapiens	46-49
34151364-1	2021	BACKGROUND: During 2018-19, an increase of vanB vancomycin-resistant Enterococcus faecium (VREfm) was observed in the Capital Region of Denmark.	Vancomycin	48-58	D-alanine--D-lactate ligase	Enterococcus faecium	43-47
34408414-9	2021	Results: The nanofibrous fixators released vancomycin, ceftazidime, and lidocaine in a sustained manner under both in vitro and in vivo conditions and protected BMP-2 from burst release.	Vancomycin	43-53	bone morphogenetic protein 2	Homo sapiens	161-166
34175955-7	2021	Naive T-cells from HLA-A*02:01 positive and negative donors were activated with vancomycin; however the strength of the induced response was significantly stronger in donors expressing HLA-A*32:01.	Vancomycin	80-90	major histocompatibility complex, class I, A	Homo sapiens	185-190
34175955-8	2021	Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN-gamma, IL-13 and cytolytic molecules.	Vancomycin	0-10	CD4 molecule	Homo sapiens	22-25
34175955-8	2021	Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN-gamma, IL-13 and cytolytic molecules.	Vancomycin	0-10	CD8a molecule	Homo sapiens	31-34
34175955-8	2021	Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN-gamma, IL-13 and cytolytic molecules.	Vancomycin	0-10	major histocompatibility complex, class I, A	Homo sapiens	45-50
34175955-8	2021	Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN-gamma, IL-13 and cytolytic molecules.	Vancomycin	0-10	C-X-C motif chemokine receptor 3	Homo sapiens	90-95
34175955-8	2021	Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN-gamma, IL-13 and cytolytic molecules.	Vancomycin	0-10	C-C motif chemokine receptor 4	Homo sapiens	100-104
34175955-8	2021	Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN-gamma, IL-13 and cytolytic molecules.	Vancomycin	0-10	interferon gamma	Homo sapiens	119-128
34175955-8	2021	Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN-gamma, IL-13 and cytolytic molecules.	Vancomycin	0-10	interleukin 13	Homo sapiens	130-135
34175955-9	2021	Activation of CD8+ TCC was HLA class I-restricted and dependent on a direct vancomycin HLA binding interaction with no requirement for processing.	Vancomycin	76-86	CD8a molecule	Homo sapiens	14-17
34175955-11	2021	To conclude, this study provides evidence that vancomycin primes naive T-cells from healthy donors expressing HLA-A*32:01 through a direct pharmacological binding interaction.	Vancomycin	47-57	major histocompatibility complex, class I, A	Homo sapiens	110-115
34175955-12	2021	Cross-reactivity of CD8+ TCC with teicoplanin provides an explanation for the teicoplanin reactions observed in vancomycin hypersensitive patients.	Vancomycin	112-122	CD8a molecule	Homo sapiens	20-23
34285270-0	2021	Transmission dynamics of a linear vanA-plasmid during a nosocomial multiclonal outbreak of vancomycin-resistant enterococci in a non-endemic area, Japan.	Vancomycin	91-101	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	34-38
34170886-0	2021	Editor"s Spotlight/Take 5: Can Topical Vancomycin Prevent Periprosthetic Joint Infection in Hip and Knee Arthroplasty?	Vancomycin	39-49	hedgehog interacting protein	Homo sapiens	92-95
34060906-0	2021	Effect of vancomycin on cytoplasmic peptidoglycan intermediates and van operon mRNA levels in VanA-type vancomycin resistant Enterococcus faecium.	Vancomycin	10-20	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	94-98
34060906-0	2021	Effect of vancomycin on cytoplasmic peptidoglycan intermediates and van operon mRNA levels in VanA-type vancomycin resistant Enterococcus faecium.	Vancomycin	104-114	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	94-98
34060906-1	2021	Resistance in VanA-type vancomycin resistant Enterococcus faecium (VREfm) is due to an inducible gene cassette encoding seven proteins (vanRSHAXYZ).	Vancomycin	24-34	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	14-18
34060906-3	2021	This study aimed to quantify cytoplasmic levels of normal and alternative pathway PG intermediates in VanA-type VREfm by liquid chromatograph tandem mass spectrometry before and after vancomycin exposure, and to correlate these changes with changes in vanA operon mRNA levels measured by RT-qPCR.	Vancomycin	184-194	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	102-106
34060906-14	2021	In VanA-type resistance these alternative pathway enzymes replace the d-Ala-d-Ala terminus of normal PG intermediates with d-Ala-d-Lac terminated intermediates, to which vancomycin cannot bind.	Vancomycin	170-180	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	3-7
34060906-15	2021	While the general features of this resistance mechanism are well known, the details of the choreography between vancomycin exposure, VanA gene induction, and changes in the normal and alternative pathway intermediate levels has not been described previously.	Vancomycin	112-122	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	133-137
34299362-0	2021	A Bioglass-Based Antibiotic (Vancomycin) Releasing Bone Void Filling Putty to Treat Osteomyelitis and Aid Bone Healing.	Vancomycin	29-39	activation-induced cytidine deaminase	Rattus norvegicus	102-105
34187949-0	2021	Protective effects of lutein against vancomycin-induced acute renal injury in mice via upregulation of peroxisome proliferator-activated receptor gamma/nuclear factor erythroid 2-related factor 2 and inhibition nuclear factor-kappaB/caspase 3.	Vancomycin	37-47	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	211-232
34187949-0	2021	Protective effects of lutein against vancomycin-induced acute renal injury in mice via upregulation of peroxisome proliferator-activated receptor gamma/nuclear factor erythroid 2-related factor 2 and inhibition nuclear factor-kappaB/caspase 3.	Vancomycin	37-47	caspase 3	Mus musculus	233-242
34187949-6	2021	Results showed that the levels of protein carbonyl and malondialdehyde, and the activity of NAG, creatine kinase and caspase-3, were significantly increased in the vancomycin-treatment groups.	Vancomycin	164-174	caspase 3	Mus musculus	117-126
34187949-10	2021	Therefore, we conclude that lutein protects against vancomycin-induced renal injury by potentially upregulating PPARgamma/Nrf2 expression in the renal tissues, and consequently downregulating the pathways: inflammation by NF-kappaB and apoptosis by caspase-3.	Vancomycin	52-62	peroxisome proliferator activated receptor gamma	Mus musculus	112-121
34172092-6	2021	Exogenous acetate supplement or fecal microbiota transplant recovered hippocampal SYP level in vancomycin-treated T1D mice, and this effect was attenuated by vagal inhibition or vagotomy.	Vancomycin	95-105	synaptophysin	Mus musculus	82-85
34188574-1	2021	Background: Nowadays, with the emergence of vancomycin-resistant strains, the clinical use of vancomycin has been followed closely by applying the antimicrobial stewardship program (ASP) to enhance effectiveness in treatment and reduce cost burden for patients.	Vancomycin	44-54	assembly factor for spindle microtubules	Homo sapiens	182-185
34188574-10	2021	Conclusion: The implementation and improvement of the ASP at the Hospital for Tropical Diseases have initially shown benefits for patients using intravenous vancomycin.	Vancomycin	157-167	assembly factor for spindle microtubules	Homo sapiens	54-57
34188574-11	2021	Specifically, the ASP helps to reduce treatment costs, improve patient outcomes, reduce length of stay and decrease the average daily dose of vancomycin.	Vancomycin	142-152	assembly factor for spindle microtubules	Homo sapiens	18-21
34484661-10	2021	Interestingly, VCM (600 mg/kg, body weight) resulted in the induction of Oct2-Mate1 and Oat1/3-Mrp2/Mrp4/Bcrp pathways.	Vancomycin	15-18	POU domain, class 2, transcription factor 2	Mus musculus	73-77
34484661-10	2021	Interestingly, VCM (600 mg/kg, body weight) resulted in the induction of Oct2-Mate1 and Oat1/3-Mrp2/Mrp4/Bcrp pathways.	Vancomycin	15-18	solute carrier family 47, member 1	Mus musculus	78-83
34484661-10	2021	Interestingly, VCM (600 mg/kg, body weight) resulted in the induction of Oct2-Mate1 and Oat1/3-Mrp2/Mrp4/Bcrp pathways.	Vancomycin	15-18	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	88-94
34484661-10	2021	Interestingly, VCM (600 mg/kg, body weight) resulted in the induction of Oct2-Mate1 and Oat1/3-Mrp2/Mrp4/Bcrp pathways.	Vancomycin	15-18	prolactin family 2, subfamily c, member 3	Mus musculus	95-99
34484661-10	2021	Interestingly, VCM (600 mg/kg, body weight) resulted in the induction of Oct2-Mate1 and Oat1/3-Mrp2/Mrp4/Bcrp pathways.	Vancomycin	15-18	prolactin family 2, subfamily c, member 5	Mus musculus	100-104
34484661-10	2021	Interestingly, VCM (600 mg/kg, body weight) resulted in the induction of Oct2-Mate1 and Oat1/3-Mrp2/Mrp4/Bcrp pathways.	Vancomycin	15-18	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	105-109
34484661-11	2021	However, VCM (400 mg/kg, body weight) caused the induction of Oct2-Mate1/Mate2 and Oat1/3-Mrp4/Bcrp pathways.	Vancomycin	9-12	POU domain, class 2, transcription factor 2	Mus musculus	62-66
34484661-11	2021	However, VCM (400 mg/kg, body weight) caused the induction of Oct2-Mate1/Mate2 and Oat1/3-Mrp4/Bcrp pathways.	Vancomycin	9-12	solute carrier family 47, member 1	Mus musculus	67-72
34484661-11	2021	However, VCM (400 mg/kg, body weight) caused the induction of Oct2-Mate1/Mate2 and Oat1/3-Mrp4/Bcrp pathways.	Vancomycin	9-12	solute carrier family 47, member 2	Mus musculus	73-78
34484661-11	2021	However, VCM (400 mg/kg, body weight) caused the induction of Oct2-Mate1/Mate2 and Oat1/3-Mrp4/Bcrp pathways.	Vancomycin	9-12	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	83-89
34484661-11	2021	However, VCM (400 mg/kg, body weight) caused the induction of Oct2-Mate1/Mate2 and Oat1/3-Mrp4/Bcrp pathways.	Vancomycin	9-12	prolactin family 2, subfamily c, member 5	Mus musculus	90-94
34484661-11	2021	However, VCM (400 mg/kg, body weight) caused the induction of Oct2-Mate1/Mate2 and Oat1/3-Mrp4/Bcrp pathways.	Vancomycin	9-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	95-99
34084697-11	2021	High vancomycin concentrations were found in the tibial cancellous bone with a mean peak drug concentration of 1236 (range 28-5295)  micro g / mL  , which remained high throughout the sampling period.	Vancomycin	5-15	thrombopoietin	Mus musculus	143-145
34069103-0	2021	Apt (Adenine Phosphoribosyltransferase) Mutation in Laboratory-Selected Vancomycin-Intermediate Staphylococcus aureus.	Vancomycin	72-82	AT695_RS09340	Staphylococcus aureus	0-3
34069103-0	2021	Apt (Adenine Phosphoribosyltransferase) Mutation in Laboratory-Selected Vancomycin-Intermediate Staphylococcus aureus.	Vancomycin	72-82	AT695_RS09340	Staphylococcus aureus	5-38
34069103-1	2021	Comparative genomic sequencing of laboratory-derived vancomycin-intermediate Staphylococcusaureus (VISA) (MM66-3 and MM66-4) revealed unique mutations in both MM66-3 (in apt and ssaA6), and MM66-4 (in apt and walK), compared to hetero-VISA parent strain MM66.	Vancomycin	53-63	AT695_RS09340	Staphylococcus aureus	170-173
34069103-1	2021	Comparative genomic sequencing of laboratory-derived vancomycin-intermediate Staphylococcusaureus (VISA) (MM66-3 and MM66-4) revealed unique mutations in both MM66-3 (in apt and ssaA6), and MM66-4 (in apt and walK), compared to hetero-VISA parent strain MM66.	Vancomycin	53-63	AT695_RS09340	Staphylococcus aureus	201-204
34069103-7	2021	MM66 apt mutants isolated via 2-fluoroadenine selection also demonstrated reduced susceptibility to the cell wall lytic dye Congo red and vancomycin.	Vancomycin	138-148	AT695_RS09340	Staphylococcus aureus	5-8
34069103-8	2021	Finding that apt mutations contribute to reduced vancomycin susceptibility once again suggests a role for altered purine metabolism in a VISA mechanism.	Vancomycin	49-59	AT695_RS09340	Staphylococcus aureus	13-16
34296627-9	2021	The response of the cytokines TNFalpha, IL-6, and IL-10 was measured in vitro using murine peritoneal macrophages stimulated with LPS and VAN or DMC.	Vancomycin	138-141	interleukin 10	Mus musculus	50-55
35579889-9	2022	Between June 2015 and March 2016, a quasi-experimental study consisting on a joint ASP and hospital-acquired infection control (HAIC) initiative, which included kidney transplant recipients, reported a significant reduction in the consumption of meropenem, vancomycin and ciprofloxacin, and a reduction in the incidence of global bacterial infections, upper urinary tract infections and cystitis.	Vancomycin	257-267	assembly factor for spindle microtubules	Homo sapiens	83-86
35388920-0	2022	New enantioselective liquid chromatography method development and validation of dipeptidyl peptidase IV inhibitors using a macrocyclic glycopeptide (vancomycin) chiral stationary phase under polar ionic mode condition.	Vancomycin	149-159	dipeptidyl peptidase 4	Homo sapiens	80-103
35388920-1	2022	The direct separation of dipeptidyl peptidase IV (DPP-4) inhibitors such as Sitagliptin (STG), Linagliptin (LIG), and Saxagliptin (SAG) enantiomers in normal phase conditions have been achieved on immobilized polysaccharide-based chiral stationary phases (CSPs), as well as on the macrocyclic glycopeptide vancomycin chiral stationary phase (Chirobiotic V2) under polar ionic mode.	Vancomycin	306-316	dipeptidyl peptidase 4	Homo sapiens	25-48
35388920-1	2022	The direct separation of dipeptidyl peptidase IV (DPP-4) inhibitors such as Sitagliptin (STG), Linagliptin (LIG), and Saxagliptin (SAG) enantiomers in normal phase conditions have been achieved on immobilized polysaccharide-based chiral stationary phases (CSPs), as well as on the macrocyclic glycopeptide vancomycin chiral stationary phase (Chirobiotic V2) under polar ionic mode.	Vancomycin	306-316	dipeptidyl peptidase 4	Homo sapiens	50-55
35092578-8	2022	MRGPRX2 has been implicated in vancomycin infusion reactions.	Vancomycin	31-41	MAS related GPR family member X2	Homo sapiens	0-7
35446133-11	2022	Finally, lysozyme was also effective in reducing viable biofilm cells of several other E. faecalis strains, including the vancomycin-resistant strain V583 and multidrug-resistant strain MMH594.	Vancomycin	122-132	lysozyme	Homo sapiens	9-17
35582415-3	2022	Methods: VCM-induced nephrotoxicity was established using HK-2 cells and SD rats and observed by measuring cell survival, kidney histological changes, renal function and kidney injury related markers (KIM-1 and NGAL).	Vancomycin	9-12	hepatitis A virus cellular receptor 1	Rattus norvegicus	201-206
35153286-19	2022	DISCUSSION: In CP patients undergoing pediatric spinal deformity surgery, the use of vancomycin powder was independently associated with increased risk for proteus infections.	Vancomycin	85-95	ceruloplasmin	Homo sapiens	15-17
35582415-3	2022	Methods: VCM-induced nephrotoxicity was established using HK-2 cells and SD rats and observed by measuring cell survival, kidney histological changes, renal function and kidney injury related markers (KIM-1 and NGAL).	Vancomycin	9-12	lipocalin 2	Rattus norvegicus	211-215
35022718-1	2022	BACKGROUND: It is unclear whether Staphylococcus aureus with heterogeneous intermediate vancomycin resistance (hVISA) can develop vancomycin resistance faster than vancomycin-susceptible S. aureus (VSSA) strains.	Vancomycin	88-98	mitochondrial antiviral signaling protein	Homo sapiens	111-116
35395119-0	2022	Nigella sativaoil extract: A natural novel specific conjugal transfer inhibitor of vancomycin resistance from vanA/B Resistant Enterococcus faecium to Staphylococcus aureus.	Vancomycin	83-93	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	110-114
35022718-2	2022	METHODS: We compared the kinetics of vancomycin MIC increase for 15 days of sustained in vitro vancomycin exposure for clinical hVISA (n = 12) and VSSA (n = 24) isolates, as well as for reference strains Mu3 (hVISA) and ATCC 29213 (VSSA).	Vancomycin	37-47	mitochondrial antiviral signaling protein	Homo sapiens	209-214
35339734-0	2022	Novel linear plasmids carrying vanA cluster drives the spread of vancomycin resistance in Enterococcus faecium in India.	Vancomycin	65-75	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	31-35
34996658-2	2022	Vancomycin-variable enterococci (VVE) are vanA-positive, yet phenotypically vancomycin-susceptible enterococci that can switch to a vancomycin-resistant phenotype when exposed to vancomycin.	Vancomycin	0-10	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	42-46
34996658-2	2022	Vancomycin-variable enterococci (VVE) are vanA-positive, yet phenotypically vancomycin-susceptible enterococci that can switch to a vancomycin-resistant phenotype when exposed to vancomycin.	Vancomycin	179-189	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	42-46
34996658-4	2022	METHODS: Isolates of phenotypically vancomycin susceptible Enterococcus faecium from 20 tertiary care hospitals across India were collected and tested for the presence of vanA, vanR, vanS, vanB and vanC genes by conventional PCR using previously published primers.	Vancomycin	36-46	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	171-175
34996658-9	2022	Silenced vanA able to escape detection and revert to resistance during vancomycin therapy represents a new challenge in clinical settings.	Vancomycin	71-81	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	9-13
35339734-12	2022	CONCLUSION: Multiple vanA carrying plasmids and Tn1546 like elements were involved in the dissemination of vancomycin resistance in VREfm.	Vancomycin	107-117	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	21-25
35305556-7	2022	In patients taking vancomycin, miR-155-5p and miR-192-5p positively correlated with creatinine and NGAL values, and miR-192-5p and miR-423-5p positively correlated with procalcitonin and interleukin-6 in patients treated with a non-nephrotoxic antibiotic.	Vancomycin	19-29	microRNA 155	Homo sapiens	31-38
35303186-9	2022	Results: Associated with vancomycin, disulfiram it had a reduction in MIC of up to 64 times, with values of 0.5-4 microg mL-1.	Vancomycin	25-35	L1 cell adhesion molecule	Mus musculus	121-125
35303186-10	2022	Vancomycin had a MIC of 128-1024 microg mL-1; combined, reduced this value by up to 124 times (8 microg mL-1), with synergy occurring against all strains.	Vancomycin	0-10	L1 cell adhesion molecule	Mus musculus	40-44
35303186-10	2022	Vancomycin had a MIC of 128-1024 microg mL-1; combined, reduced this value by up to 124 times (8 microg mL-1), with synergy occurring against all strains.	Vancomycin	0-10	L1 cell adhesion molecule	Mus musculus	104-108
35305556-7	2022	In patients taking vancomycin, miR-155-5p and miR-192-5p positively correlated with creatinine and NGAL values, and miR-192-5p and miR-423-5p positively correlated with procalcitonin and interleukin-6 in patients treated with a non-nephrotoxic antibiotic.	Vancomycin	19-29	microRNA 192	Homo sapiens	46-53
35305556-7	2022	In patients taking vancomycin, miR-155-5p and miR-192-5p positively correlated with creatinine and NGAL values, and miR-192-5p and miR-423-5p positively correlated with procalcitonin and interleukin-6 in patients treated with a non-nephrotoxic antibiotic.	Vancomycin	19-29	lipocalin 2	Homo sapiens	99-103
35007142-9	2022	Kidney function decline and increased KIM-1 were observed among rats that received VAN only, but not TZP or VAN+TZP.	Vancomycin	83-86	hepatitis A virus cellular receptor 1	Rattus norvegicus	38-43
35326799-6	2022	Fifty-two patients were treated in 58 procedures with tobramycin and vancomycin-loaded PMMA, CS, or both.	Vancomycin	69-79	citrate synthase	Homo sapiens	93-95
35240740-20	2022	The predominant serotypes are 19F and 19A and all isolated strains were susceptible to vancomycin and linezolid.	Vancomycin	87-97	SLAM family member 7	Homo sapiens	38-41
32777947-13	2022	INTERPRETATION: Revision total hip arthroplasty for PJI with vancomycin-loaded impaction bone grafting is a safe method that achieves both the restoration of bone stock and resolution of the infection.	Vancomycin	61-71	hedgehog interacting protein	Homo sapiens	31-34
35172112-1	2022	The emergence of vancomycin-resistant Enterococcus faecium (Efm) harboring vanA gene and multidrug-resistant determinants is a relevant public health concern.	Vancomycin	17-27	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	75-79
35356685-2	2022	Methyl-CpG-binding domain protein 2 (MBD2), a protein reader of methylation, is involved in the development of acute kidney injury (AKI) caused by vancomycin.	Vancomycin	147-157	methyl-CpG binding domain protein 2	Mus musculus	0-35
35356685-2	2022	Methyl-CpG-binding domain protein 2 (MBD2), a protein reader of methylation, is involved in the development of acute kidney injury (AKI) caused by vancomycin.	Vancomycin	147-157	methyl-CpG binding domain protein 2	Mus musculus	37-41
35091889-6	2022	Furthermore, vancomycin pretreatment reduced the number of astrocytes and microglial cells in the substantia nigra pars compacta (SNpc) to alleviate neuroinflammation, decreased the expression of TLR4/MyD88/NF-kappaB/TNF-alpha signaling pathway in both brain and gut.	Vancomycin	13-23	toll-like receptor 4	Mus musculus	196-200
35155711-1	2022	Background: Presoaking anterior cruciate ligament (ACL) grafts in vancomycin has been reported to reduce the occurrence of septic arthritis (SA).	Vancomycin	66-76	acyl-CoA synthetase medium chain family member 3	Homo sapiens	141-143
35155711-3	2022	Purpose: The primary objective was to investigate whether presoaking ACL grafts in vancomycin was associated with a reduction in the rate of SA in a large series of patients.	Vancomycin	83-93	acyl-CoA synthetase medium chain family member 3	Homo sapiens	141-143
35155711-4	2022	The secondary objective was to perform an updated systematic review and meta-analysis to determine the efficacy of vancomycin in reducing the rate of SA.	Vancomycin	115-125	acyl-CoA synthetase medium chain family member 3	Homo sapiens	150-152
35155711-15	2022	The meta-analysis demonstrated a significantly greater risk of SA in those patients who did not receive grafts presoaked in vancomycin (OR, 14.39 (95% CI, 5.90-35.10); fragility index = 23).	Vancomycin	124-134	acyl-CoA synthetase medium chain family member 3	Homo sapiens	63-65
35155711-17	2022	Conclusion: The meta-analysis demonstrated that presoaking ACL grafts in vancomycin was associated with significant reductions in the rates of SA when all graft types were analyzed together.	Vancomycin	73-83	acyl-CoA synthetase medium chain family member 3	Homo sapiens	143-145
35155711-20	2022	However, it should be noted that only a trend toward reduced SA rates was demonstrated with presoaking bone-patellar tendon-bone autografts in vancomycin.	Vancomycin	143-153	acyl-CoA synthetase medium chain family member 3	Homo sapiens	61-63
34870949-0	2022	Letter to the Editor: Can Topical Vancomycin Prevent Periprosthetic Joint Infection in Hip and Knee Arthroplasty?	Vancomycin	34-44	hedgehog interacting protein	Homo sapiens	87-90
34870950-0	2022	Reply to the Letter to the Editor: Can Topical Vancomycin Prevent Periprosthetic Joint Infection in Hip and Knee Arthroplasty?	Vancomycin	47-57	hedgehog interacting protein	Homo sapiens	100-103
35091889-6	2022	Furthermore, vancomycin pretreatment reduced the number of astrocytes and microglial cells in the substantia nigra pars compacta (SNpc) to alleviate neuroinflammation, decreased the expression of TLR4/MyD88/NF-kappaB/TNF-alpha signaling pathway in both brain and gut.	Vancomycin	13-23	myeloid differentiation primary response gene 88	Mus musculus	201-206
35091889-6	2022	Furthermore, vancomycin pretreatment reduced the number of astrocytes and microglial cells in the substantia nigra pars compacta (SNpc) to alleviate neuroinflammation, decreased the expression of TLR4/MyD88/NF-kappaB/TNF-alpha signaling pathway in both brain and gut.	Vancomycin	13-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	207-216
35091889-6	2022	Furthermore, vancomycin pretreatment reduced the number of astrocytes and microglial cells in the substantia nigra pars compacta (SNpc) to alleviate neuroinflammation, decreased the expression of TLR4/MyD88/NF-kappaB/TNF-alpha signaling pathway in both brain and gut.	Vancomycin	13-23	tumor necrosis factor	Mus musculus	217-226
35091889-6	2022	Furthermore, vancomycin pretreatment reduced the number of astrocytes and microglial cells in the substantia nigra pars compacta (SNpc) to alleviate neuroinflammation, decreased the expression of TLR4/MyD88/NF-kappaB/TNF-alpha signaling pathway in both brain and gut.	Vancomycin	13-23	glucuronidase, beta	Mus musculus	263-266
35091889-8	2022	The abundance of Akkermansia and Blautia increased significantly after vancomycin pretreatment, which might be related to inflammation and inhibition of TLR4 signaling pathway.	Vancomycin	71-81	toll-like receptor 4	Mus musculus	153-157
35091889-9	2022	In summary, these results demonstrate that the variation of gut microbiota and its metabolites induced by vancomycin pretreatment might decrease dopamine metabolic rate and relieve inflammation in both gut and brain via the microbiota-gut-brain axis in MPTP-induced PD mice.	Vancomycin	106-116	glucuronidase, beta	Mus musculus	60-63
35091889-9	2022	In summary, these results demonstrate that the variation of gut microbiota and its metabolites induced by vancomycin pretreatment might decrease dopamine metabolic rate and relieve inflammation in both gut and brain via the microbiota-gut-brain axis in MPTP-induced PD mice.	Vancomycin	106-116	glucuronidase, beta	Mus musculus	202-205
35091889-9	2022	In summary, these results demonstrate that the variation of gut microbiota and its metabolites induced by vancomycin pretreatment might decrease dopamine metabolic rate and relieve inflammation in both gut and brain via the microbiota-gut-brain axis in MPTP-induced PD mice.	Vancomycin	106-116	glucuronidase, beta	Mus musculus	235-238
35091889-10	2022	The neuroprotection of vancomycin pretreatment on MPTP-induced Parkinson"s disease mice The alterations of gut microbiota and SCFAs induced by vancomycin pretreatment might not only improve motor dysfunction, but also decrease dopamine metabolism and relieve inflammation in both brain and gut via TLR4/MyD88/NF-kappaB/TNF-alpha pathway in MPTP-induced PD mice.	Vancomycin	23-33	glucuronidase, beta	Mus musculus	107-110
35091889-10	2022	The neuroprotection of vancomycin pretreatment on MPTP-induced Parkinson"s disease mice The alterations of gut microbiota and SCFAs induced by vancomycin pretreatment might not only improve motor dysfunction, but also decrease dopamine metabolism and relieve inflammation in both brain and gut via TLR4/MyD88/NF-kappaB/TNF-alpha pathway in MPTP-induced PD mice.	Vancomycin	143-153	glucuronidase, beta	Mus musculus	107-110
35091889-10	2022	The neuroprotection of vancomycin pretreatment on MPTP-induced Parkinson"s disease mice The alterations of gut microbiota and SCFAs induced by vancomycin pretreatment might not only improve motor dysfunction, but also decrease dopamine metabolism and relieve inflammation in both brain and gut via TLR4/MyD88/NF-kappaB/TNF-alpha pathway in MPTP-induced PD mice.	Vancomycin	143-153	glucuronidase, beta	Mus musculus	290-293
35091889-10	2022	The neuroprotection of vancomycin pretreatment on MPTP-induced Parkinson"s disease mice The alterations of gut microbiota and SCFAs induced by vancomycin pretreatment might not only improve motor dysfunction, but also decrease dopamine metabolism and relieve inflammation in both brain and gut via TLR4/MyD88/NF-kappaB/TNF-alpha pathway in MPTP-induced PD mice.	Vancomycin	143-153	toll-like receptor 4	Mus musculus	298-302
35091889-10	2022	The neuroprotection of vancomycin pretreatment on MPTP-induced Parkinson"s disease mice The alterations of gut microbiota and SCFAs induced by vancomycin pretreatment might not only improve motor dysfunction, but also decrease dopamine metabolism and relieve inflammation in both brain and gut via TLR4/MyD88/NF-kappaB/TNF-alpha pathway in MPTP-induced PD mice.	Vancomycin	143-153	myeloid differentiation primary response gene 88	Mus musculus	303-308
35091889-10	2022	The neuroprotection of vancomycin pretreatment on MPTP-induced Parkinson"s disease mice The alterations of gut microbiota and SCFAs induced by vancomycin pretreatment might not only improve motor dysfunction, but also decrease dopamine metabolism and relieve inflammation in both brain and gut via TLR4/MyD88/NF-kappaB/TNF-alpha pathway in MPTP-induced PD mice.	Vancomycin	143-153	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	309-318
35091889-10	2022	The neuroprotection of vancomycin pretreatment on MPTP-induced Parkinson"s disease mice The alterations of gut microbiota and SCFAs induced by vancomycin pretreatment might not only improve motor dysfunction, but also decrease dopamine metabolism and relieve inflammation in both brain and gut via TLR4/MyD88/NF-kappaB/TNF-alpha pathway in MPTP-induced PD mice.	Vancomycin	143-153	tumor necrosis factor	Mus musculus	319-328
35127558-0	2021	Vancomycin-Induced Modulation of Gram-Positive Gut Bacteria and Metabolites Remediates Insulin Resistance in iNOS Knockout Mice.	Vancomycin	0-10	nitric oxide synthase 2, inducible	Mus musculus	109-113
35127558-5	2021	Vancomycin, which largely depletes gram-positive bacteria, reversed the insulin resistance (IR), dyslipidemia, and related metabolic anomalies in iNOS-/- mice.	Vancomycin	0-10	nitric oxide synthase 2, inducible	Mus musculus	146-150
35127558-7	2021	The rescue of IR in vancomycin-treated iNOS-/- mice was accompanied with the changes in select serum metabolites such as 10-hydroxydecanoate, indole-3-ethanol, allantoin, hippurate, sebacic acid, aminoadipate, and ophthalmate, along with improvement in phosphatidylethanolamine to phosphatidylcholine (PE/PC) ratio.	Vancomycin	20-30	nitric oxide synthase 2, inducible	Mus musculus	39-43
35127558-8	2021	In the present study, we demonstrate that vancomycin-mediated depletion of gram-positive bacteria in iNOS-/- mice reversed the metabolic perturbations, dyslipidemia, and insulin resistance.	Vancomycin	42-52	nitric oxide synthase 2, inducible	Mus musculus	101-105
35070271-8	2022	Vancomycin and dapsone use in HLA-A*32:01 and HLA-B*13:01 carriers, respectively, showed trends toward increased risk of type B ADRs.	Vancomycin	0-10	major histocompatibility complex, class I, A	Homo sapiens	30-35
35091889-0	2022	Vancomycin Pretreatment on MPTP-Induced Parkinson"s Disease Mice Exerts Neuroprotection by Suppressing Inflammation Both in Brain and Gut.	Vancomycin	0-10	glucuronidase, beta	Mus musculus	134-137
35091889-5	2022	Although vancomycin pretreatment had no effect on dopamine (DA) or the process of DA synthesis, it inhibited the metabolism of DA by suppressing the expression of striatal monoamine oxidase B (MAO-B).	Vancomycin	9-19	monoamine oxidase B	Mus musculus	172-191
35091889-5	2022	Although vancomycin pretreatment had no effect on dopamine (DA) or the process of DA synthesis, it inhibited the metabolism of DA by suppressing the expression of striatal monoamine oxidase B (MAO-B).	Vancomycin	9-19	monoamine oxidase B	Mus musculus	193-198
35186526-2	2022	They are Gram-positive, catalase-negative cocci that are intrinsically resistant to glycopeptides, including vancomycin.	Vancomycin	109-119	catalase	Homo sapiens	24-32
35129072-4	2022	We found that the gut microbiota from gentamycin (Gen)-treated mice significantly alleviated concanavalin A (ConA)-induced liver injury compared to vancomycin (Van)-treated mice by inhibiting CD95 expression on the surface of hepatocytes and reducing CD95/CD95L-mediated hepatocyte apoptosis.	Vancomycin	148-158	Fas (TNF receptor superfamily member 6)	Mus musculus	192-196
33637370-1	2022	BACKGROUND/PURPOSE: To compare the risk of acute kidney injury (AKI) among patients receiving teicoplanin (TA) plus piperacillin/tazobactam (TZP) versus vancomycin (VAN) plus TZP.	Vancomycin	165-168	PHD finger protein 20	Homo sapiens	141-144
33637370-7	2022	RESULTS: The final sample contained 211 pairs of patients receiving either TA + TZP or VAN + TZP.	Vancomycin	87-92	PHD finger protein 20	Homo sapiens	93-96
33637370-11	2022	The auxiliary analysis showed a higher risk of AKI in the VAN + TZP group than in the VAN + beta-lactam group (13.2% vs. 9.6%; HR = 1.63 (1.04-2.55), p = 0.03).	Vancomycin	58-61	PHD finger protein 20	Homo sapiens	64-67
35129072-4	2022	We found that the gut microbiota from gentamycin (Gen)-treated mice significantly alleviated concanavalin A (ConA)-induced liver injury compared to vancomycin (Van)-treated mice by inhibiting CD95 expression on the surface of hepatocytes and reducing CD95/CD95L-mediated hepatocyte apoptosis.	Vancomycin	160-163	Fas (TNF receptor superfamily member 6)	Mus musculus	192-196
2687368-5	1989	For patients infected with MRSA, vancomycin is the drug of choice.	Vancomycin	33-43	solute carrier family 9 member A6	Homo sapiens	27-31
35373135-0	2022	Vancomycin-Associated Cast Nephropathy: Reality or Fantasy?	Vancomycin	0-10	calpastatin	Homo sapiens	22-26
2796369-4	1989	The vancomycin was applied in a hemostatic paste of topical thrombin and powdered absorbable gelatin; in the control group only the hemostatic paste was applied.	Vancomycin	4-14	coagulation factor II, thrombin	Homo sapiens	60-68
2683253-0	1989	Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients.	Vancomycin	81-91	cut like homeobox 1	Homo sapiens	112-117
2683253-3	1989	Since it has been reported in the scientific literature that vancomycin degrades into an antibiotically inactive crystalline degradation product (CDP-1) in vitro, we developed high-performance liquid chromatography (HPLC) and liquid chromatography/mass spectrometry (LC/MS) methods to determine whether CDP-1 is present in patient sera.	Vancomycin	61-71	cut like homeobox 1	Homo sapiens	146-151
2683253-3	1989	Since it has been reported in the scientific literature that vancomycin degrades into an antibiotically inactive crystalline degradation product (CDP-1) in vitro, we developed high-performance liquid chromatography (HPLC) and liquid chromatography/mass spectrometry (LC/MS) methods to determine whether CDP-1 is present in patient sera.	Vancomycin	61-71	cut like homeobox 1	Homo sapiens	303-308
15945973-0	1989	Case report: ABO discrepancy due to vancomycin complicating a transfusion reaction investigation.	Vancomycin	36-46	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	13-16
3300580-2	1987	A prospective randomized trial was conducted comparing the effect of three antibiotics: cefamandole (CM), cefazolin (CZ), and vancomycin (V), used as prophylaxis for prosthetic valve surgery, on the prothrombin (PT) response to warfarin (W) on the third day of anticoagulant therapy.	Vancomycin	126-136	coagulation factor II, thrombin	Homo sapiens	199-210
3415386-2	1988	A two-stage process including methanolysis followed by acidolysis in a mixture of trifluoracetic acid and HC1 in the presence of nucleophile was shown optimal for formation of a biologically active aglycone of ristomycin A while for formation of the vancomycin aglycone a one-stage process (trifluoracetic acid/HC1--acidolysis) was optimal.	Vancomycin	250-260	CYCS pseudogene 39	Homo sapiens	106-109
3360685-0	1988	Monitoring vancomycin concentrations in CSF after intraventricular administration.	Vancomycin	11-21	colony stimulating factor 2	Homo sapiens	40-43
2893584-0	1987	Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicin.	Vancomycin	80-90	beta-2-microglobulin	Homo sapiens	27-47
2893584-7	1987	Although the beta 2M values were elevated as early as day 1 in all treatment groups, they were significantly elevated only in the vancomycin-gentamicin group on day 1 and only in the gentamicin group on day 5 compared with the vancomycin and the control groups.	Vancomycin	130-140	beta-2-microglobulin	Homo sapiens	13-20
3177373-2	1988	"Continuous" therapy consisted of an IP 1-g loading dose of vancomycin followed by 30 mg/L dialysate effluent.	Vancomycin	60-70	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	37-41
3415206-9	1988	The relationship of vancomycin CL and CLCR was utilized to develop the following equation to dose vancomycin in the majority of renally impaired patients: dose (milligrams per kilogram per 24 h) = 0.227CLCR + 5.67, where CLCR is standardized to milliliters per minute per 70 kg.	Vancomycin	20-30	chymotrypsin C	Homo sapiens	38-42
3492375-2	1986	The most pronounced effects were seen after administration of bacitracin, clindamycin or vancomycin: the electrophoretic mucin pattern in faeces changed from a normal conventional pattern to a specific pattern similar to that found in germ-free rats.	Vancomycin	89-99	solute carrier family 13 member 2	Rattus norvegicus	121-126
6524101-0	1984	The use of intraventricular vancomycin in the treatment of CSF shunt-associated ventriculitis.	Vancomycin	28-38	colony stimulating factor 2	Homo sapiens	59-62
6229176-0	1984	Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures.	Vancomycin	21-31	colony stimulating factor 2	Homo sapiens	56-59
301760-8	1977	These results indicate that vancomycin interacts with normal, von Willebrand, and formalin-treated platelets and inhibits the binding of ristocetin (or ristocetin-vWF complexes).	Vancomycin	28-38	von Willebrand factor	Homo sapiens	163-166
6250464-1	1980	The effect of 4 vancomycin antibiotics on factor VIII-dependent agglutination of thrombocytes was studied.	Vancomycin	16-26	coagulation factor VIII	Bos taurus	42-53
6250464-4	1980	Actinoidin and vancomycin inhibited agglutination of platelets induced by ristocetin or ristomycin in platelet-enriched plasma with citrate or EDTA the same as in the system contaning platelets treated with formalin and did not inhibit agglutination induced by the bovine factor VIII.	Vancomycin	15-25	coagulation factor VIII	Bos taurus	272-283
307833-0	1978	Vancomycin effect on thrombin-induced platelet aggregation: evidence against a common platelet membrane receptor for thrombin and ristocetin.	Vancomycin	0-10	coagulation factor II, thrombin	Homo sapiens	21-29
7247352-1	1981	A radioimmunoassay for vancomycin has been developed which uses rabbit antiserum induced by vancomycin-bovine serum albumin conjugates and vancomycin labeled with 3H or 125I.	Vancomycin	23-33	albumin	Homo sapiens	110-123
7247352-1	1981	A radioimmunoassay for vancomycin has been developed which uses rabbit antiserum induced by vancomycin-bovine serum albumin conjugates and vancomycin labeled with 3H or 125I.	Vancomycin	92-102	albumin	Homo sapiens	110-123
7247352-1	1981	A radioimmunoassay for vancomycin has been developed which uses rabbit antiserum induced by vancomycin-bovine serum albumin conjugates and vancomycin labeled with 3H or 125I.	Vancomycin	92-102	albumin	Homo sapiens	110-123
7434044-0	1980	Vancomycin penetration into CSF during treatment of patients receiving hemodialysis.	Vancomycin	0-10	colony stimulating factor 2	Homo sapiens	28-31
7434044-1	1980	Penetration of vancomycin into CSF was determined during therapy with the regimens recently used to treat staphylococcal infections in patients receiving hemodialysis: 1 gm weekly or 750 mg twice weekly.	Vancomycin	15-25	colony stimulating factor 2	Homo sapiens	31-34
7434044-2	1980	During three episodes in two patients with proved or suspected central nervous system infection, CSF levels of vancomycin ranged from &lt; 0.5 to 1.54 microgram/ml; in only two of six CSF specimens did the antibiotic level exceed its in vitro inhibitory concentration for the infecting organism.	Vancomycin	111-121	colony stimulating factor 2	Homo sapiens	97-100
7434044-3	1980	Thus, the vancomycin hemodialysis regimens may provide marginal to subtherapeutic CSF drug levels.	Vancomycin	10-20	colony stimulating factor 2	Homo sapiens	82-85
306689-0	1978	Effect of vancomycin on ristocetin and bovine PAF-induced agglutination of human platelets.	Vancomycin	10-20	PCNA-associated factor	Bos taurus	46-49
5124385-6	1971	The stability of the vancomycin-peptide complex in the range pH1-13 showed that complex-formation occurred only when carboxyl groups were ionized and the phenolic groups were non-ionized.	Vancomycin	21-31	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	61-64
5674051-6	1968	Vancomycin stimulates the transfer of phospho-NAc-muramyl-pentapeptide to the acceptor, and the addition of cell walls to this assay mixture prevented the stimulation of transfer.	Vancomycin	0-10	synuclein alpha	Homo sapiens	46-49
33202067-7	2021	Creatinine clearance (ClCr ) and CSF-lactate were detected as significant covariates, showing that the total vancomycin plasma clearance (Cl) depends on ClCr and furthermore, the clearance (Cldif ) between the central and CSF compartment correlates with CSF lactate concentration.	Vancomycin	109-119	chymotrypsin C	Homo sapiens	153-157
33202067-9	2021	CONCLUSION: Based on our analysis, the dosing of vancomycin should be referred to the degree of inflammation (derived from the CSF lactate concentration) and renal function (derived from ClCr ).	Vancomycin	49-59	chymotrypsin C	Homo sapiens	187-191
33855441-0	2021	Failure of Vitek2 to reliably detect vanB-mediated vancomycin resistance in Enterococcus faecium.	Vancomycin	51-61	D-alanine--D-lactate ligase	Enterococcus faecium	37-41
34039850-2	2021	RECENT FINDINGS: Recent HLA associations relevant to our understanding of immunopathogenesis and clinical practice include HLA-B*13:01 with co-trimoxazole-induced SCAR, and HLA-A*32:01 with vancomycin-DRESS, for which an extended HLA class II haplotype is implicated in glycopeptide antibiotic cross-reactivity.	Vancomycin	190-200	major histocompatibility complex, class I, A	Homo sapiens	173-178
34012328-7	2021	Of the 14 vancomycin-resistant Enterococcus faecium, 8 (57.1%) harbored vanB genes, while 6 (42.8%) harbored vanA genes.	Vancomycin	10-20	D-alanine--D-lactate ligase	Enterococcus faecium	72-76
33257290-0	2021	The application of topical vancomycin powder for the prevention of surgical site infections in primary total hip and knee arthroplasty: A meta-analysis.	Vancomycin	27-37	hedgehog interacting protein	Homo sapiens	109-112
33257290-12	2021	In the total hip arthroplasty group, the vancomycin powder treatment decreased the rate of SSIs and PJI by 66% (RR=0.34, 95% CI=0.15-0.78 [p=0.01]) and 74% (RR=0.26, 95% CI=0.10-0.67 (p=0.005)), respectively.	Vancomycin	41-51	hedgehog interacting protein	Homo sapiens	13-16
33855441-2	2021	In this prospective study we analysed if vanB-mediated vancomycin resistance can be reliably detected by Vitek2.	Vancomycin	55-65	D-alanine--D-lactate ligase	Enterococcus faecium	41-45
33927725-6	2021	Moreover, EPO ameliorated inflammation and increased the actions of ciprofloxacin and vancomycin in resolution-delayed E. coli- and S. aureus-initiated infections.	Vancomycin	86-96	erythropoietin	Mus musculus	10-13
32955795-0	2021	Comparative analysis of beneficial effects of Vancomycin treatment on Th1- and Th2-biased mice and the role of gut microbiota.	Vancomycin	46-56	negative elongation factor complex member C/D, Th1l	Mus musculus	70-73
32955795-0	2021	Comparative analysis of beneficial effects of Vancomycin treatment on Th1- and Th2-biased mice and the role of gut microbiota.	Vancomycin	46-56	heart and neural crest derivatives expressed 2	Mus musculus	79-82
32955795-2	2021	METHODS AND RESULTS: Vancomycin was administered at 50 mg kg-1 of body weight twice daily for 6 consecutive days to perturb the gut microbiota of C57BL/6 (Th1-biased) and BALB/c (Th2-biased) mice.	Vancomycin	21-31	negative elongation factor complex member C/D, Th1l	Mus musculus	155-158
32955795-2	2021	METHODS AND RESULTS: Vancomycin was administered at 50 mg kg-1 of body weight twice daily for 6 consecutive days to perturb the gut microbiota of C57BL/6 (Th1-biased) and BALB/c (Th2-biased) mice.	Vancomycin	21-31	heart and neural crest derivatives expressed 2	Mus musculus	179-182
33412230-0	2021	Whole genome sequencing analysis reveals the spread of a vanB carrying transposon among different vancomycin-resistant Enterococcus faecium clinical isolates in a non-endemic setting.	Vancomycin	98-108	D-alanine--D-lactate ligase	Enterococcus faecium	57-61
33691494-2	2021	Along with clinical concerns of MRSA infection, infection with heterogeneous vancomycin-intermediate S. aureus (hVISA) is closely associated with treatment failure.	Vancomycin	77-87	mitochondrial antiviral signaling protein	Homo sapiens	112-117
33967770-0	2021	Serum Creatinine and Serum Cystatin C are Both Relevant Renal Markers to Estimate Vancomycin Clearance in Critically Ill Neonates.	Vancomycin	82-92	cystatin C	Homo sapiens	27-37
33536296-3	2021	In this Point-Counter Point, Dr. Sara Revolinski discusses the pros of reporting MICs for vancomycin while Dr. Christopher Doern argues for the use of caution.	Vancomycin	90-100	zinc finger FYVE-type containing 9	Homo sapiens	33-37
33728578-0	2021	Cystatin C and/or creatinine-based estimated glomerular filtration rate for prediction of vancomycin clearance in long-stay critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome (PICS): a population pharmacokinetics analysis.	Vancomycin	90-100	cystatin C	Homo sapiens	0-10
33705643-4	2021	RESULTS: The combination of vancomycin with imipenem, meropenem and cefotaxime exhibited synergistic effects against 17 (2 VISA, 9 hVISA and 6 VSSA), 14 (3 VISA, 9 hVISA and 2 VSSA), and 5 (3 VISA and 2 hVISA) isolates respectively.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	123-127
33705643-4	2021	RESULTS: The combination of vancomycin with imipenem, meropenem and cefotaxime exhibited synergistic effects against 17 (2 VISA, 9 hVISA and 6 VSSA), 14 (3 VISA, 9 hVISA and 2 VSSA), and 5 (3 VISA and 2 hVISA) isolates respectively.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	131-136
33705643-4	2021	RESULTS: The combination of vancomycin with imipenem, meropenem and cefotaxime exhibited synergistic effects against 17 (2 VISA, 9 hVISA and 6 VSSA), 14 (3 VISA, 9 hVISA and 2 VSSA), and 5 (3 VISA and 2 hVISA) isolates respectively.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	132-136
33705643-4	2021	RESULTS: The combination of vancomycin with imipenem, meropenem and cefotaxime exhibited synergistic effects against 17 (2 VISA, 9 hVISA and 6 VSSA), 14 (3 VISA, 9 hVISA and 2 VSSA), and 5 (3 VISA and 2 hVISA) isolates respectively.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	164-169
33705643-4	2021	RESULTS: The combination of vancomycin with imipenem, meropenem and cefotaxime exhibited synergistic effects against 17 (2 VISA, 9 hVISA and 6 VSSA), 14 (3 VISA, 9 hVISA and 2 VSSA), and 5 (3 VISA and 2 hVISA) isolates respectively.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	132-136
33705643-4	2021	RESULTS: The combination of vancomycin with imipenem, meropenem and cefotaxime exhibited synergistic effects against 17 (2 VISA, 9 hVISA and 6 VSSA), 14 (3 VISA, 9 hVISA and 2 VSSA), and 5 (3 VISA and 2 hVISA) isolates respectively.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	164-169
33705643-6	2021	Using time-kill assay, the vancomycin combined with either imipenem or cefotaxime demonstrated synergism against both VISA and hVISA isolates, while the synergistic effect with meropenem was obtained in the VISA isolates only.	Vancomycin	27-37	mitochondrial antiviral signaling protein	Homo sapiens	118-122
33705643-6	2021	Using time-kill assay, the vancomycin combined with either imipenem or cefotaxime demonstrated synergism against both VISA and hVISA isolates, while the synergistic effect with meropenem was obtained in the VISA isolates only.	Vancomycin	27-37	mitochondrial antiviral signaling protein	Homo sapiens	127-132
33705643-6	2021	Using time-kill assay, the vancomycin combined with either imipenem or cefotaxime demonstrated synergism against both VISA and hVISA isolates, while the synergistic effect with meropenem was obtained in the VISA isolates only.	Vancomycin	27-37	mitochondrial antiviral signaling protein	Homo sapiens	128-132
33705643-7	2021	CONCLUSION: This study demonstrated in vitro enhanced antibacterial activity of vancomycin plus ss-lactams against clinical hVISA or VISA isolates.	Vancomycin	80-90	mitochondrial antiviral signaling protein	Homo sapiens	124-129
33705643-7	2021	CONCLUSION: This study demonstrated in vitro enhanced antibacterial activity of vancomycin plus ss-lactams against clinical hVISA or VISA isolates.	Vancomycin	80-90	mitochondrial antiviral signaling protein	Homo sapiens	125-129
33704051-0	2021	Impact of urinary albumin excretion on the onset of adverse reactions to vancomycin hydrochloride.	Vancomycin	73-97	albumin	Homo sapiens	18-25
33704051-1	2021	OBJECTIVE: Vancomycin dose needs to be reduced for decreased kidney function; however, impact of urinary albumin excretion (UAE) on serum vancomycin level is unknown.	Vancomycin	138-148	albumin	Homo sapiens	105-112
33929342-0	2021	Can Topical Vancomycin Prevent Periprosthetic Joint Infection in Hip and Knee Arthroplasty?	Vancomycin	12-22	hedgehog interacting protein	Homo sapiens	65-68
33929342-4	2021	QUESTIONS/PURPOSES: In this systematic review, we asked: (1) Does topical vancomycin (vancomycin powder) reduce PJI risk in hip and knee arthroplasty?	Vancomycin	74-84	hedgehog interacting protein	Homo sapiens	124-127
33929342-4	2021	QUESTIONS/PURPOSES: In this systematic review, we asked: (1) Does topical vancomycin (vancomycin powder) reduce PJI risk in hip and knee arthroplasty?	Vancomycin	86-96	hedgehog interacting protein	Homo sapiens	124-127
33929342-5	2021	(2) Does topical vancomycin lead to an increased risk of complications after hip and knee arthroplasty?	Vancomycin	17-27	hedgehog interacting protein	Homo sapiens	77-80
33526494-2	2021	The specific AKI risk when VAN is combined with imipenem-cilastatin/relebactam (IMP-C/REL) or piperacillin/tazobactam (TZP) has not been clearly defined.Objectives: To quantify the dose-AKI relationships of VAN alone and in combination with TZP or imipenem-cilastatin/relebactam (IMP-C/REL).Methods: Ten to twelve week old male C57BL/6J mice (Charles River Laboratory) were dosed with study drug regimens in three stages.	Vancomycin	27-30	reticuloendotheliosis oncogene	Mus musculus	284-289
33526494-10	2021	Biomarker results were concordant with histopathologic findings.Conclusions: The VAN dose-AKI relationship can be attenuated with single daily HEDs of TZP or IMP-C/REL in mice.	Vancomycin	81-84	reticuloendotheliosis oncogene	Mus musculus	162-167
33840539-0	2021	Incomplete Administration of Intravenous Vancomycin Prophylaxis is Common and Associated With Increased Infectious Complications After Primary Total Hip and Knee Arthroplasty.	Vancomycin	41-51	hedgehog interacting protein	Homo sapiens	149-152
33840539-1	2021	BACKGROUND: Vancomycin is often used as antimicrobial prophylaxis in patients undergoing total hip or knee arthroplasty.	Vancomycin	12-22	hedgehog interacting protein	Homo sapiens	95-98
33731764-11	2021	Postmenstrual age (PMA) and creatinine clearance (CLcr) affected the clearance of vancomycin, and model evaluation confirmed the robustness of the final model.	Vancomycin	82-92	chymotrypsin C	Homo sapiens	50-54
33731764-12	2021	Population pharmacokinetic modeling and dose optimization of vancomycin in Korean neonates showed that vancomycin clearance was related to PMA and CLcr, as well as body weight.	Vancomycin	61-71	chymotrypsin C	Homo sapiens	147-151
33731764-12	2021	Population pharmacokinetic modeling and dose optimization of vancomycin in Korean neonates showed that vancomycin clearance was related to PMA and CLcr, as well as body weight.	Vancomycin	103-113	chymotrypsin C	Homo sapiens	147-151
33367710-11	2021	CONCLUSIONS: Our data support a mechanism by which vancomycin-susceptible VVE strains may revert to a resistant phenotype through the use of an alternative, constitutive, vanR-activator-independent promoter and a vanA-plasmid copy number increase.	Vancomycin	51-61	VanR	Enterococcus faecium	171-175
33406371-11	2021	Vancomycin was associated with a reduction in inflammatory proteins from treated tendon supernatants (IL-6; P < .05).	Vancomycin	0-10	interleukin 6	Homo sapiens	102-106
32919344-3	2021	Vancomycin-immobilized gold nanoparticles (VAN-Au NPs) were utilized as the first identifier to capture S. aureus and the specificity was guaranteed by the second recognition agent of pig immunoglobulin G (IgG).	Vancomycin	0-10	IGG	Sus scrofa	188-204
32919344-3	2021	Vancomycin-immobilized gold nanoparticles (VAN-Au NPs) were utilized as the first identifier to capture S. aureus and the specificity was guaranteed by the second recognition agent of pig immunoglobulin G (IgG).	Vancomycin	0-10	IGG	Sus scrofa	206-209
33549144-9	2021	Furthermore, ex vivo cultures of human intestinal lamina propria mononuclear cells and iNKT cell clones from IBD patients with vancomycin pre-treated sterile fecal water showed a Th1/Th17 skewing in CD4+ T-cell populations; metronidazole, on the other hand, induced the polarization of iNKT cells toward the production of IL10.	Vancomycin	127-137	CD4 molecule	Homo sapiens	199-202
33549144-9	2021	Furthermore, ex vivo cultures of human intestinal lamina propria mononuclear cells and iNKT cell clones from IBD patients with vancomycin pre-treated sterile fecal water showed a Th1/Th17 skewing in CD4+ T-cell populations; metronidazole, on the other hand, induced the polarization of iNKT cells toward the production of IL10.	Vancomycin	127-137	interleukin 10	Homo sapiens	322-326
33551346-6	2021	The aspirated fluid was sent for culture and sensitivity that revealed MRSA sensitive to vancomycin and linezolid.	Vancomycin	89-99	solute carrier family 9 member A6	Homo sapiens	71-75
33358258-13	2021	IMPLICATIONS: This study confirmed that the changes in bacterial counts and CRP levels were well described with mechanistic exposure-response modeling of vancomycin.	Vancomycin	154-164	C-reactive protein	Homo sapiens	76-79
33538550-0	2021	Initial Serum C-reactive Protein Level as a Predictor of Increasing Serum Vancomycin Concentration During Treatment.	Vancomycin	74-84	C-reactive protein	Homo sapiens	14-32
33538550-7	2021	Changes in vancomycin concentration/dose ratio were associated with C-reactive protein (CRP) and sodium (Na) levels on the initial day of TDM and with changes in white blood cell count, Na, and estimated glomerular filtration rates (eGFRs).	Vancomycin	11-21	C-reactive protein	Homo sapiens	68-86
33538550-7	2021	Changes in vancomycin concentration/dose ratio were associated with C-reactive protein (CRP) and sodium (Na) levels on the initial day of TDM and with changes in white blood cell count, Na, and estimated glomerular filtration rates (eGFRs).	Vancomycin	11-21	C-reactive protein	Homo sapiens	88-91
33538550-9	2021	CONCLUSION: A high serum CRP level on the initial day of TDM is an independent predictor of increasing vancomycin concentration/dose ratio in patients receiving intravenous vancomycin treatment, even if eGFR remains unchanged.	Vancomycin	103-113	C-reactive protein	Homo sapiens	25-28
33538550-9	2021	CONCLUSION: A high serum CRP level on the initial day of TDM is an independent predictor of increasing vancomycin concentration/dose ratio in patients receiving intravenous vancomycin treatment, even if eGFR remains unchanged.	Vancomycin	173-183	C-reactive protein	Homo sapiens	25-28
33496976-0	2021	Correlation between vancomycin clearance and cystatin C-based glomerular filtration rate in paediatric patients.	Vancomycin	20-30	cystatin C	Homo sapiens	45-55
33496976-1	2021	AIMS: Because of limitations with the serum creatinine-based glomerular filtration rate (GFRcr), estimates of the serum cystatin C-based glomerular filtration rate (GFRcys) are getting attention to predict vancomycin clearance (CLvan).	Vancomycin	206-216	cystatin C	Homo sapiens	120-130
33496976-10	2021	CONCLUSIONS: Serum cystatin C-based GFR strongly correlates with vancomycin clearance, suggesting the possibility of better prediction models than creatinine-based GFR.	Vancomycin	65-75	cystatin C	Homo sapiens	19-29
33472670-0	2021	Mode and dynamics of vanA-type vancomycin resistance dissemination in Dutch hospitals.	Vancomycin	31-41	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	21-25
33472670-3	2021	Vancomycin resistance can be conferred by the vanA gene cluster on the transposon Tn1546, which is frequently present in plasmids.	Vancomycin	0-10	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	46-50
33219679-7	2021	RESULTS: Statistically significant decreases in the level of antibiotic use, after the introduction of the ASP, were observed for the following antibiotics: imipenem/cilastatin (P = 0.0008), all carbapenems (P = 0.0001), vancomycin (P = 0.0006), colistin (P = 0.0016) and third-generation cephalosporins (P = 0.0004).	Vancomycin	221-231	assembly factor for spindle microtubules	Homo sapiens	107-110
32495366-10	2021	CONCLUSIONS: Bed side Bayesian-guided personalised dosing of vancomycin increases the proportion of patients achieving target AUC24 and the %TTR.	Vancomycin	61-71	transthyretin	Homo sapiens	141-144
33011300-3	2021	OBJECTIVE: To describe vancomycin HSR epidemiology from EHR allergy data.	Vancomycin	23-33	HSR	Homo sapiens	34-37
33649734-6	2021	This study selected these drugs for MD simulation investigation whose results demonstrated that ledipasvir with ACE2, estradiol benzoate with CD147, and vancomycin with RDRP represented the most favorable DeltaG.	Vancomycin	153-163	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	169-173
33649734-7	2021	Also, paritaprevir and vancomycin have good binding energy with both targets (ACE2 and RdRp).	Vancomycin	23-33	angiotensin converting enzyme 2	Homo sapiens	78-82
33649734-7	2021	Also, paritaprevir and vancomycin have good binding energy with both targets (ACE2 and RdRp).	Vancomycin	23-33	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	87-91
32439433-0	2021	Cross-reactivity between vancomycin, teicoplanin and telavancin in HLA-A*32:01 positive vancomycin DRESS patients sharing an HLA-Class II haplotype.	Vancomycin	25-35	major histocompatibility complex, class I, A	Homo sapiens	67-72
32439433-0	2021	Cross-reactivity between vancomycin, teicoplanin and telavancin in HLA-A*32:01 positive vancomycin DRESS patients sharing an HLA-Class II haplotype.	Vancomycin	88-98	major histocompatibility complex, class I, A	Homo sapiens	67-72
32439433-1	2021	CAPSULE SUMMARY: All fifteen patients with HLA-A*32:01 restricted vancomycin-induced DRESS, showed negative ex vivo responses to dalbavancin however two showed cross-reactivity to teicoplanin and telavancin.	Vancomycin	66-76	major histocompatibility complex, class I, A	Homo sapiens	43-48
33642514-0	2021	[Assessment of Renal Function and Simulation Using Serum Cystatin-C in an Elderly Patient with Uncontrollable Plasma Vancomycin Levels Due to Muscular Dystrophy: A Case Report].	Vancomycin	117-127	cystatin C	Homo sapiens	57-67
33642514-2	2021	The pharmacist initially carried out therapeutic drug monitoring using an estimate of the creatinine clearance (CLcr) level, which was based on the serum creatinine (SCr) and serum cystatin-C (CysC) levels, but was ultimately unable to control the plasma VCM concentration.	Vancomycin	255-258	chymotrypsin C	Homo sapiens	112-116
33317904-0	2021	Vancomycin variable Enterococcus (VVE), E. faecium, harbouring the vanA gene complex.	Vancomycin	0-10	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	67-71
33106257-0	2020	Prediction of Vancomycin Levels using Cystatin C in Overweight and Obese Patients: A Retrospective Cohort Study of Hospitalized Patients.	Vancomycin	14-24	cystatin C	Homo sapiens	38-48
33106257-1	2020	The use of the kidney function biomarker cystatin C (cysC) can improve the accuracy of vancomycin dosing for target trough attainment in non-obese patients.	Vancomycin	87-97	cystatin C	Homo sapiens	41-51
33106257-1	2020	The use of the kidney function biomarker cystatin C (cysC) can improve the accuracy of vancomycin dosing for target trough attainment in non-obese patients.	Vancomycin	87-97	cystatin C	Homo sapiens	53-57
33106257-9	2020	This study is the first to examine the role of cysC in predicting vancomycin levels in an exclusively overweight or obese population.	Vancomycin	66-76	cystatin C	Homo sapiens	47-51
32557716-5	2020	The vancomycin PPK model was established by non-linear mixed-effects modelling programme.	Vancomycin	4-14	kallikrein B1	Homo sapiens	15-18
32557716-13	2020	WHAT IS NEW AND CONCLUSION: A one-compartment vancomycin PPK model was established in haematologic malignancy with augmented renal clearance children with weight with allometric scaling as a significant covariate.	Vancomycin	46-56	kallikrein B1	Homo sapiens	57-60
33425450-4	2020	In our study, we found that vancomycin (Vac) pretreatment (100 mg/kg, twice a day for 4 days) attenuated AP-induced liver injury, altered the composition of gut microbiota, and changed serum metabolic profile.	Vancomycin	28-38	LIM homeobox protein 2	Mus musculus	105-107
33425450-4	2020	In our study, we found that vancomycin (Vac) pretreatment (100 mg/kg, twice a day for 4 days) attenuated AP-induced liver injury, altered the composition of gut microbiota, and changed serum metabolic profile.	Vancomycin	40-43	LIM homeobox protein 2	Mus musculus	105-107
32947558-9	2020	RESULTS: A two-compartment model with drug CL values that changed with time-varying CrCL adequately described vancomycin pharmacokinetics in the evaluated heterogeneous patient population with unstable renal function.	Vancomycin	110-120	CRCL	Homo sapiens	84-88
32947558-10	2020	Vancomycin CL was related to time-varying CrCL as follows: CL(t)=0.11+0.021xCrCL(t) (CrCL < 120 mL/min).	Vancomycin	0-10	CRCL	Homo sapiens	42-46
32947558-10	2020	Vancomycin CL was related to time-varying CrCL as follows: CL(t)=0.11+0.021xCrCL(t) (CrCL < 120 mL/min).	Vancomycin	0-10	CRCL	Homo sapiens	76-80
32947558-12	2020	CONCLUSION: In hospitals with a high incidence of unstable renal function, incorporating time-varying CrCL with Bayesian estimation and at least one measured drug concentration, along with frequent CrCL monitoring, improves the predictive performance of therapeutic drug monitoring of vancomycin.	Vancomycin	285-295	CRCL	Homo sapiens	102-106
32947559-0	2020	Effect of Cystatin C on Vancomycin Clearance Estimation in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach.	Vancomycin	24-34	cystatin C	Homo sapiens	10-20
32947559-14	2020	CONCLUSIONS: CysC-based equations help better estimate vancomycin CL than bedside Schwartz in critically ill children.	Vancomycin	55-65	cystatin C	Homo sapiens	13-17
33252820-6	2021	The intervention resulted in a significant reduction in individuals receiving post-op broad-spectrum gram-negative antibiotics for > 48 hours (76% PreI vs 44% PostI OLT recipients, P = 0.01) and post-op vancomycin use (50% PreI, vs 7.4% PostI, P < 0.001).	Vancomycin	203-213	solute carrier family 35 member G1	Homo sapiens	195-199
33135425-0	2020	Efficacy and safety of intrawound vancomycin in primary hip and knee arthroplasty.	Vancomycin	34-44	hedgehog interacting protein	Homo sapiens	56-59
33240280-6	2020	We found that administration of vancomycin to female MRL/lpr mice early, only during the pre-disease period but not from 3 to 15 weeks of age, led to disease exacerbation.	Vancomycin	32-42	Fas (TNF receptor superfamily member 6)	Mus musculus	57-60
33240280-7	2020	Early vancomycin administration also reduced splenic regulatory B (Breg) cell numbers, as well as reduced circulating IL-10 and IL-35 in 8-week old mice.	Vancomycin	6-16	interleukin 10	Mus musculus	118-123
33240280-8	2020	Further, we found that during the pre-disease period, administration of activated IL-10 producing Breg cells to mice treated with vancomycin suppressed lupus initiation, and that bacterial DNA from the gut microbiota was an inducer of Breg function.	Vancomycin	130-140	interleukin 10	Mus musculus	82-87
32871377-0	2020	HPLC enantio-separation and chiral recognition mechanism of quinolones on vancomycin CSP.	Vancomycin	74-84	DnaJ heat shock protein family (Hsp40) member C5	Homo sapiens	85-88
32871377-1	2020	A new HPLC method was developed for the enantio-separation and chiral recognition mechanism of quinolones (lomefloxacine, ofloxacine, primaquine and quinacrine) on Vancomycin CSP.	Vancomycin	164-174	DnaJ heat shock protein family (Hsp40) member C5	Homo sapiens	175-178
33135425-1	2020	AIMS: The efficacy and safety of intrawound vancomycin for preventing surgical site infection in primary hip and knee arthroplasty is uncertain.	Vancomycin	44-54	hedgehog interacting protein	Homo sapiens	105-108
33135425-11	2020	CONCLUSION: The current literature suggests that intrawound vancomycin used in primary hip and knee arthroplasty may reduce incidence of PJI, but it may also increase risk of aseptic wound complications.	Vancomycin	60-70	hedgehog interacting protein	Homo sapiens	87-90
32993185-8	2020	In addition, five miRNAs: miR-15a-5p, miR-192-5p, miR-155-5p, miR-486-5p and miR-423-5p specific to septic and toxic acute kidney injury in septic patients, treated by nephrotoxic antibiotic agents (vancomycin and gentamicin) were identified.	Vancomycin	199-209	microRNA 192	Homo sapiens	38-45
32868529-4	2020	Numerous studies have evaluated medication dosing based on either GFR estimate; vancomycin was the most frequently studied drug and its target level and elimination were better predicted by cystatin C.	Vancomycin	80-90	cystatin C	Homo sapiens	190-200
33078712-1	2020	Herein, the pH-sensitive vancomycin (VANCO) loaded silk fibroin-sodium alginate nanoparticles (NPs) embedded in poly(N-isopropylacrylamide) (PNIPAM) hydrogel containing epidermal growth factor (EGF) are introduced for treating chronic burn wound infections.	Vancomycin	25-35	epidermal growth factor like 1	Rattus norvegicus	169-192
33078712-1	2020	Herein, the pH-sensitive vancomycin (VANCO) loaded silk fibroin-sodium alginate nanoparticles (NPs) embedded in poly(N-isopropylacrylamide) (PNIPAM) hydrogel containing epidermal growth factor (EGF) are introduced for treating chronic burn wound infections.	Vancomycin	25-35	epidermal growth factor like 1	Rattus norvegicus	194-197
33078712-1	2020	Herein, the pH-sensitive vancomycin (VANCO) loaded silk fibroin-sodium alginate nanoparticles (NPs) embedded in poly(N-isopropylacrylamide) (PNIPAM) hydrogel containing epidermal growth factor (EGF) are introduced for treating chronic burn wound infections.	Vancomycin	37-42	epidermal growth factor like 1	Rattus norvegicus	169-192
33078712-1	2020	Herein, the pH-sensitive vancomycin (VANCO) loaded silk fibroin-sodium alginate nanoparticles (NPs) embedded in poly(N-isopropylacrylamide) (PNIPAM) hydrogel containing epidermal growth factor (EGF) are introduced for treating chronic burn wound infections.	Vancomycin	37-42	epidermal growth factor like 1	Rattus norvegicus	194-197
33078712-3	2020	VANCO had a pH responsive release behavior from the nanoparticle (NP) and showed higher release rate in an alkaline pH compared to the neutral pH during 10 d. About 30% of EGF was also released from the hydrogel within 20 d. The released VANCO and EGF preserved their bioactivity more than ~ 80%.	Vancomycin	0-5	epidermal growth factor like 1	Rattus norvegicus	172-175
33078712-3	2020	VANCO had a pH responsive release behavior from the nanoparticle (NP) and showed higher release rate in an alkaline pH compared to the neutral pH during 10 d. About 30% of EGF was also released from the hydrogel within 20 d. The released VANCO and EGF preserved their bioactivity more than ~ 80%.	Vancomycin	0-5	epidermal growth factor like 1	Rattus norvegicus	248-251
32940458-8	2020	The method was linear in the range of 1-2000 ng mL-1 and 1-1000 ng mL-1 with detection limits (S/N of 3) of 0.18 and 0.09 ng mL-1 for VCM and GTM, respectively.	Vancomycin	134-137	L1 cell adhesion molecule	Mus musculus	48-58
33076936-6	2020	RESULTS: Vancomycin-colistin administration induces widespread cellular immunosuppression in both the lung and spleen, decreases circulating hematopoietic cytokine Flt3-Ligand, and depresses dendritic cell bone marrow progenitors leading to worsening of P. aeruginosa lung infection outcomes (bacterial loads, lung injury, and survival).	Vancomycin	9-19	FMS-like tyrosine kinase 3 ligand	Mus musculus	164-175
32690649-0	2020	RNA sequencing identifies a common physiology in vancomycin- and ciprofloxacin-tolerant Staphylococcus aureus induced by ileS mutations.	Vancomycin	49-59	isoleucyl-tRNA synthetase	Staphylococcus aureus	121-125
32690649-1	2020	Little is known about the mechanisms by which ileS mutations induce vancomycin tolerance in Staphylococcus aureus This study showed that transcriptome profiles were similar in vancomycin-tolerant mutants and IleRS-inhibitor-treated parent.	Vancomycin	68-78	isoleucyl-tRNA synthetase	Staphylococcus aureus	46-50
32959542-0	2020	A Meta-Analysis on the Performance of Cystatin C- versus Creatinine-based eGFR Equations in Predicting Vancomycin Clearance.	Vancomycin	103-113	cystatin C	Homo sapiens	38-48
32959542-7	2020	This indicates the presence of unbiased results in vancomycin clearance prediction by the cystatin C-based eGFR equations.	Vancomycin	51-61	cystatin C	Homo sapiens	90-100
32959542-9	2020	CONCLUSION: Cystatin C-based eGFR equations are better than creatinine-based eGFR equations in predicting the clearance of vancomycin.	Vancomycin	123-133	cystatin C	Homo sapiens	12-22
32959542-10	2020	This suggests that utilising cystatin C-based eGFR equations could result in better accuracy and precision to predict vancomycin pharmacokinetic parameters.	Vancomycin	118-128	cystatin C	Homo sapiens	29-39
32971249-1	2020	This study aimed to characterize the antimicrobial susceptibility and genetic features of a heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) strain Guangzhou-SauVS2 recovered from a female patient in Guangzhou, representative of southern China.	Vancomycin	106-116	mitochondrial antiviral signaling protein	Homo sapiens	153-158
32971249-4	2020	Results showed that Guangzhou-SauVS2 was susceptible and resistant to 7 and 11 antibiotic drugs, respectively, and exhibited hVISA with a minimum inhibitory concentration of vancomycin as 4 mug/mL.	Vancomycin	174-184	mitochondrial antiviral signaling protein	Homo sapiens	125-130
33116547-8	2020	On the other hand, the increase of estimated glomerular filtration rate (eGFR) (aOR=0.993) and albumin levels (aOR=0.944) were associated with lower odds of initial therapeutic vancomycin trough levels.	Vancomycin	177-187	albumin	Homo sapiens	95-102
32734419-0	2020	Etest Methods for Screening Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) strains.	Vancomycin	42-52	mitochondrial antiviral signaling protein	Homo sapiens	89-94
32734419-1	2020	The importance of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) as a preceding stage for the development of vancomycin-resistant S. aureus is growing.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	79-84
32734419-1	2020	The importance of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) as a preceding stage for the development of vancomycin-resistant S. aureus is growing.	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	79-84
33335794-1	2021	Our previous study demonstrated that the methyl-CpG-binding domain protein 2 (MBD2) mediates vancomycin (VAN)-induced acute kidney injury (AKI).	Vancomycin	93-103	methyl-CpG binding domain protein 2	Mus musculus	41-76
33335794-1	2021	Our previous study demonstrated that the methyl-CpG-binding domain protein 2 (MBD2) mediates vancomycin (VAN)-induced acute kidney injury (AKI).	Vancomycin	93-103	methyl-CpG binding domain protein 2	Mus musculus	78-82
33335794-1	2021	Our previous study demonstrated that the methyl-CpG-binding domain protein 2 (MBD2) mediates vancomycin (VAN)-induced acute kidney injury (AKI).	Vancomycin	105-108	methyl-CpG binding domain protein 2	Mus musculus	41-76
33335794-1	2021	Our previous study demonstrated that the methyl-CpG-binding domain protein 2 (MBD2) mediates vancomycin (VAN)-induced acute kidney injury (AKI).	Vancomycin	105-108	methyl-CpG binding domain protein 2	Mus musculus	78-82
32899240-6	2020	Vancomycin significantly induced IL-10 and TNFalpha expression, whereas daptomycin had no effects on cytokine response or expression of cell surface receptors.	Vancomycin	0-10	interleukin 10	Homo sapiens	33-38
32899240-6	2020	Vancomycin significantly induced IL-10 and TNFalpha expression, whereas daptomycin had no effects on cytokine response or expression of cell surface receptors.	Vancomycin	0-10	tumor necrosis factor	Homo sapiens	43-51
32993185-8	2020	In addition, five miRNAs: miR-15a-5p, miR-192-5p, miR-155-5p, miR-486-5p and miR-423-5p specific to septic and toxic acute kidney injury in septic patients, treated by nephrotoxic antibiotic agents (vancomycin and gentamicin) were identified.	Vancomycin	199-209	microRNA 155	Homo sapiens	50-57
32993185-8	2020	In addition, five miRNAs: miR-15a-5p, miR-192-5p, miR-155-5p, miR-486-5p and miR-423-5p specific to septic and toxic acute kidney injury in septic patients, treated by nephrotoxic antibiotic agents (vancomycin and gentamicin) were identified.	Vancomycin	199-209	microRNA 423	Homo sapiens	77-84
32562543-2	2020	The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure.	Vancomycin	18-28	mitochondrial antiviral signaling protein	Homo sapiens	65-70
32562543-3	2020	However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures.	Vancomycin	48-58	mitochondrial antiviral signaling protein	Homo sapiens	9-14
32562543-8	2020	Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes.	Vancomycin	131-141	mitochondrial antiviral signaling protein	Homo sapiens	98-102
32856529-4	2022	In this work, LPO inhibition effects of some antibiotics including cefazolin, oxytetracycline, flunixin meglumine, cefuroxime, tylosin, vancomycin, chloramphenicol and lincomycin were tested.	Vancomycin	136-146	lactoperoxidase	Bos taurus	14-17
32854266-9	2020	The expression of claudin 4 in the colonic mucosa was decreased in both vancomycin- and polymyxin B-treated mice.	Vancomycin	72-82	claudin 4	Mus musculus	18-27
32753585-0	2020	Human antimicrobial peptide, LL-37, induces non-inheritable reduced susceptibility to vancomycin in Staphylococcus aureus.	Vancomycin	86-96	cathelicidin antimicrobial peptide	Homo sapiens	29-34
32691784-1	2020	A rationally designed mannosylated amphiphilic pillar[5]arene (Man@AP5) self-assembles into supramolecular vesicles with encapsulated vancomycin (Man@AP5-Van), which target macrophages, respond to both acid and cathepsin B, and release vancomycin (Van) rapidly inside macrophages.	Vancomycin	134-144	adaptor related protein complex 5 subunit beta 1	Homo sapiens	67-70
32691784-1	2020	A rationally designed mannosylated amphiphilic pillar[5]arene (Man@AP5) self-assembles into supramolecular vesicles with encapsulated vancomycin (Man@AP5-Van), which target macrophages, respond to both acid and cathepsin B, and release vancomycin (Van) rapidly inside macrophages.	Vancomycin	134-144	cathepsin B	Homo sapiens	211-222
32691784-1	2020	A rationally designed mannosylated amphiphilic pillar[5]arene (Man@AP5) self-assembles into supramolecular vesicles with encapsulated vancomycin (Man@AP5-Van), which target macrophages, respond to both acid and cathepsin B, and release vancomycin (Van) rapidly inside macrophages.	Vancomycin	236-246	adaptor related protein complex 5 subunit beta 1	Homo sapiens	67-70
32691784-1	2020	A rationally designed mannosylated amphiphilic pillar[5]arene (Man@AP5) self-assembles into supramolecular vesicles with encapsulated vancomycin (Man@AP5-Van), which target macrophages, respond to both acid and cathepsin B, and release vancomycin (Van) rapidly inside macrophages.	Vancomycin	236-246	adaptor related protein complex 5 subunit beta 1	Homo sapiens	150-153
32691784-1	2020	A rationally designed mannosylated amphiphilic pillar[5]arene (Man@AP5) self-assembles into supramolecular vesicles with encapsulated vancomycin (Man@AP5-Van), which target macrophages, respond to both acid and cathepsin B, and release vancomycin (Van) rapidly inside macrophages.	Vancomycin	154-157	adaptor related protein complex 5 subunit beta 1	Homo sapiens	67-70
32691784-1	2020	A rationally designed mannosylated amphiphilic pillar[5]arene (Man@AP5) self-assembles into supramolecular vesicles with encapsulated vancomycin (Man@AP5-Van), which target macrophages, respond to both acid and cathepsin B, and release vancomycin (Van) rapidly inside macrophages.	Vancomycin	154-157	adaptor related protein complex 5 subunit beta 1	Homo sapiens	150-153
32691784-1	2020	A rationally designed mannosylated amphiphilic pillar[5]arene (Man@AP5) self-assembles into supramolecular vesicles with encapsulated vancomycin (Man@AP5-Van), which target macrophages, respond to both acid and cathepsin B, and release vancomycin (Van) rapidly inside macrophages.	Vancomycin	154-157	cathepsin B	Homo sapiens	211-222
32691784-2	2020	Man@AP5-Van significantly increases the intracellular concentration of Van, enhancing its antibacterial efficacy against intracellular MRSA.	Vancomycin	8-11	adaptor related protein complex 5 subunit beta 1	Homo sapiens	4-7
32747743-0	2020	Intraarticular vancomycin powder is effective in preventing infections following total hip and knee arthroplasty.	Vancomycin	15-25	hedgehog interacting protein	Homo sapiens	87-90
32747743-1	2020	Locally applied vancomycin is increasingly being used in primary hip and knee arthroplasty to reduce the risk of infection.	Vancomycin	16-26	hedgehog interacting protein	Homo sapiens	65-68
32747743-12	2020	On the basis of the results of this study, intraarticular application of vancomycin powder in total hip and knee arthroplasty may be considered.	Vancomycin	73-83	hedgehog interacting protein	Homo sapiens	100-103
32843769-0	2020	Successful Vancomycin Dose Adjustment in a Sepsis patient with Bacterial Meningitis Using Cystatin C.	Vancomycin	11-21	cystatin C	Homo sapiens	90-100
32843769-1	2020	Cystatin C-guided vancomycin (VCM) dosing is useful in critically ill patients.	Vancomycin	18-28	cystatin C	Homo sapiens	0-10
32843769-1	2020	Cystatin C-guided vancomycin (VCM) dosing is useful in critically ill patients.	Vancomycin	30-33	cystatin C	Homo sapiens	0-10
32304024-0	2020	A Population Pharmacokinetics Model for Vancomycin Dosage Optimization Based on Serum Cystatin C.	Vancomycin	40-50	cystatin C	Homo sapiens	86-96
32304024-1	2020	BACKGROUND AND OBJECTIVES: Renal function has an important influence on the pharmacokinetics of vancomycin, and serum cystatin C (CysC) exhibits accurate predictive performance as a marker for renal function.	Vancomycin	96-106	cystatin C	Homo sapiens	118-128
32304024-1	2020	BACKGROUND AND OBJECTIVES: Renal function has an important influence on the pharmacokinetics of vancomycin, and serum cystatin C (CysC) exhibits accurate predictive performance as a marker for renal function.	Vancomycin	96-106	cystatin C	Homo sapiens	130-134
32304024-2	2020	This study aimed to develop a population pharmacokinetics (PopPK) model of vancomycin based on serum CysC in pediatric patients.	Vancomycin	75-85	cystatin C	Homo sapiens	101-105
32304024-7	2020	Serum CysC and age were significant covariates affecting the pharmacokinetics of vancomycin.	Vancomycin	81-91	cystatin C	Homo sapiens	6-10
32304024-10	2020	CONCLUSIONS: The pharmacokinetic parameters for vancomycin in pediatric patients were estimated using a serum CysC model.	Vancomycin	48-58	cystatin C	Homo sapiens	110-114
32753585-3	2020	We demonstrate that the human AMP LL-37 lowers the susceptibility to vancomycin in the community-associated methicillin-resistant S. aureus (CA-MRSA) strain FPR3757 (USA300).	Vancomycin	69-79	cathelicidin antimicrobial peptide	Homo sapiens	34-39
32753585-5	2020	Exposure to physiologically relevant concentrations of LL-37 increased the minimum inhibitory concentration (MIC) of S. aureus towards vancomycin by 75%, and resulted in shortened lag-phase and increased colony formation at sub-inhibitory concentrations of vancomycin.	Vancomycin	135-145	cathelicidin antimicrobial peptide	Homo sapiens	55-60
32753585-5	2020	Exposure to physiologically relevant concentrations of LL-37 increased the minimum inhibitory concentration (MIC) of S. aureus towards vancomycin by 75%, and resulted in shortened lag-phase and increased colony formation at sub-inhibitory concentrations of vancomycin.	Vancomycin	257-267	cathelicidin antimicrobial peptide	Homo sapiens	55-60
32753585-7	2020	This prediction was supported in a Galleria mellonella infection model, where exposure of S. aureus to LL-37 abolished the antimicrobial effect of vancomycin.	Vancomycin	147-157	cathelicidin antimicrobial peptide	Homo sapiens	103-108
32753585-8	2020	Thus, physiological relevant concentrations of LL-37 reduce susceptibility to vancomycin, indicating that tissue and host specific variations in LL-37 concentrations may influence vancomycin susceptibility in vivo.	Vancomycin	78-88	cathelicidin antimicrobial peptide	Homo sapiens	47-52
32753585-8	2020	Thus, physiological relevant concentrations of LL-37 reduce susceptibility to vancomycin, indicating that tissue and host specific variations in LL-37 concentrations may influence vancomycin susceptibility in vivo.	Vancomycin	78-88	cathelicidin antimicrobial peptide	Homo sapiens	145-150
32753585-8	2020	Thus, physiological relevant concentrations of LL-37 reduce susceptibility to vancomycin, indicating that tissue and host specific variations in LL-37 concentrations may influence vancomycin susceptibility in vivo.	Vancomycin	180-190	cathelicidin antimicrobial peptide	Homo sapiens	47-52
32753585-8	2020	Thus, physiological relevant concentrations of LL-37 reduce susceptibility to vancomycin, indicating that tissue and host specific variations in LL-37 concentrations may influence vancomycin susceptibility in vivo.	Vancomycin	180-190	cathelicidin antimicrobial peptide	Homo sapiens	145-150
32128641-0	2020	Emergence of vancomycin-resistant Enterococcus faecium ST1421 lacking the pstS gene in Korea.	Vancomycin	13-23	kallikrein related peptidase 4	Homo sapiens	74-78
32729248-8	2020	Further top ACE2 regulators in vivo or in primary cells include erlotinib and bleomycin in the lung and vancomycin, cisplatin, and probenecid in the kidney.	Vancomycin	104-114	angiotensin converting enzyme 2	Homo sapiens	12-16
32638317-7	2020	Expression of p53, p21, and cyt-c in Vero cells was elevated in response to vancomycin treatment, whereas after S. marianum administration expression of these genes reduced.	Vancomycin	76-86	transformation related protein 53, pseudogene	Mus musculus	14-17
32638317-7	2020	Expression of p53, p21, and cyt-c in Vero cells was elevated in response to vancomycin treatment, whereas after S. marianum administration expression of these genes reduced.	Vancomycin	76-86	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	19-22
32517758-15	2020	CONCLUSIONS: E. faecalis and E. faecium were the major enterococci strains which are the main pathogens of urinary traction infections; vanA and vanM were the main determinants conferring resistance to vancomycin; ST78, ST192 and ST570 were the leading STs of VREM which displayed a decreasing trend of prevalence year by year.	Vancomycin	202-212	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	136-140
32340989-2	2020	Risk factors of the hosts and causative EFM isolates were assessed to determine associations with the 30-day mortality of EFM BSI patients via multivariable logistic regression analyses.Results: The vanA gene was detected in 35.2% (179/509) of EFM isolates; 131 EFM isolates exhibited typical VanA phenotypes (group vanA-VanA), while the remaining 48 EFM isolates exhibited atypical phenotypes (group vanA-Atypical), including VanD (n = 43) and vancomycin-variable phenotypes (n = 5).	Vancomycin	445-455	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	199-203
32661494-5	2020	Ergotamine, amphotericin b, and vancomycin are most promising to block the interaction of the SARS-CoV-2 S-protein with human ACE-2.	Vancomycin	32-42	vitronectin	Homo sapiens	105-114
32661494-5	2020	Ergotamine, amphotericin b, and vancomycin are most promising to block the interaction of the SARS-CoV-2 S-protein with human ACE-2.	Vancomycin	32-42	angiotensin converting enzyme 2	Homo sapiens	126-131
32685120-0	2020	The effect of immunoregulatory bacteria on the transcriptional activity of Foxp3 and RORyt genes in the gut-associated lymphoid tissue with Salmonella-induced inflammation in the presence of vancomycin and Bacteroides fragilis.	Vancomycin	191-201	forkhead box P3	Rattus norvegicus	75-80
32685120-2	2020	This study was conducted to investigate the levels of key immunoregulatory bacteria in the intestinal wall-associated microflora and its effect on the transcriptional activity of the Foxp3 and RORyt genes in the gut-associated lymphoid tissue (GALT) of rats with Salmonella-induced inflammation, both untreated and treated with vancomycin and Bacteroides fragilis.	Vancomycin	328-338	forkhead box P3	Rattus norvegicus	183-188
32347709-6	2020	We demonstrate that the loaded vancomycin was able to kill intracellular S. aureus efficiently in an in vitro model of S. aureus infected RAW-264.7 macrophage cells, and U87-MG (p53-wt) and LN229 (p53-mt) cancer cells, compared to free-vancomycin treatment (P<0.001).	Vancomycin	31-41	transformation related protein 53, pseudogene	Mus musculus	178-181
32347709-6	2020	We demonstrate that the loaded vancomycin was able to kill intracellular S. aureus efficiently in an in vitro model of S. aureus infected RAW-264.7 macrophage cells, and U87-MG (p53-wt) and LN229 (p53-mt) cancer cells, compared to free-vancomycin treatment (P<0.001).	Vancomycin	31-41	tumor protein p53	Homo sapiens	197-200
32373986-0	2020	Curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP and hs-CRP.	Vancomycin	20-30	C-reactive protein	Homo sapiens	140-143
32011685-9	2020	Urinary KIM-1 and clusterin were increased with vancomycin from Day 1 versus controls (P &lt; 0.001) and only on Day 3 with vancomycin + piperacillin/tazobactam (P &lt; 0.001, KIM-1; P &lt; 0.05, clusterin).	Vancomycin	48-58	hepatitis A virus cellular receptor 1	Rattus norvegicus	8-13
31611508-10	2020	CONCLUSIONS: The combined use of TZP in patients receiving VAN increased the incidence of AKI in both non-ICU and ICU settings.	Vancomycin	59-62	PHD finger protein 20	Homo sapiens	33-36
32404057-1	2020	BACKGROUND: The aim of this study was to evaluate the influence of patient body mass index (BMI) and estimated creatinine clearance (CrCl) on serum vancomycin concentrations to define a possible optimal dosage regimen in overweight patients based on data obtained during therapeutic drug monitoring.	Vancomycin	148-158	CRCL	Homo sapiens	133-137
32404057-7	2020	RESULTS: Serum vancomycin concentration was significantly related to BMI (P <  0.001) and CrCl (P <  0.05) in adult patients.	Vancomycin	15-25	CRCL	Homo sapiens	90-94
32404057-8	2020	Furthermore, the trough serum vancomycin concentration showed a logarithmic correlation with BMI (R = - 0.5108, 95% CI: - 0.6082 to - 0.3982, P <  0.001) and CrCl (R = - 0.5739, 95% CI: - 0.6616 to - 0.4707, P <  0.001).	Vancomycin	30-40	CRCL	Homo sapiens	158-162
32404057-9	2020	The multivariate analysis showed that BMI and CrCl are independent contributors to the trough vancomycin concentration.	Vancomycin	94-104	CRCL	Homo sapiens	46-50
32404057-10	2020	Moreover, some of the patients with higher BMI (>= 24 kg/m2) met the goal trough concentration after an adjustment from 1000 mg every 12 h to 1000 mg every 8 h. CONCLUSIONS: Serum vancomycin concentration decreases progressively with increasing BMI and the augmentation in CrCl in adult patients.	Vancomycin	180-190	CRCL	Homo sapiens	273-277
32269153-0	2020	First Report of the Local Spread of Vancomycin-Resistant Enterococci Ascribed to the Interspecies Transmission of a vanA Gene Cluster-Carrying Linear Plasmid.	Vancomycin	36-46	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	116-120
32269153-2	2020	In 2017, a local spread of VanA-type vancomycin-resistant enterococci (VRE) occurred in Japan, and 25 enterococcal isolates, including 14 Enterococcus faecium, 8 E. raffinosus, and 3 E. casseliflavus isolates, were identified from four inpatients.	Vancomycin	37-47	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	27-31
32269153-12	2020	Among vancomycin resistance types, the VanA type is one of the most prevalent, and outbreaks caused by VanA-type vancomycin-resistant enterococci (VRE) have occurred worldwide.	Vancomycin	6-16	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	39-43
32269153-12	2020	Among vancomycin resistance types, the VanA type is one of the most prevalent, and outbreaks caused by VanA-type vancomycin-resistant enterococci (VRE) have occurred worldwide.	Vancomycin	113-123	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	103-107
32373986-0	2020	Curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP and hs-CRP.	Vancomycin	20-30	C-reactive protein	Homo sapiens	151-154
32373986-1	2020	OBJECTIVE: To explore the curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP, and hs-CRP, so as to provide references for clinical treatment.	Vancomycin	46-56	C-reactive protein	Homo sapiens	166-169
32373986-1	2020	OBJECTIVE: To explore the curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP, and hs-CRP, so as to provide references for clinical treatment.	Vancomycin	46-56	C-reactive protein	Homo sapiens	178-181
32277698-10	2020	The VAN-DCS antagonism is due to a mechanism that we named van-mediated Ddl inhibition bypass.	Vancomycin	4-7	AT695_RS07115	Staphylococcus aureus	72-75
32883934-13	2020	Conclusion: VanA and vanB are the prevalent genotypes responsible for vancomycin resistance.	Vancomycin	70-80	D-alanine--D-lactate ligase	Enterococcus faecalis	21-25
31931148-0	2020	Expression of VanA-type vancomycin resistance in a clinical isolate of Enterococcus faecium showing insertion of IS19 in the vanS gene.	Vancomycin	24-34	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	14-18
31931148-0	2020	Expression of VanA-type vancomycin resistance in a clinical isolate of Enterococcus faecium showing insertion of IS19 in the vanS gene.	Vancomycin	24-34	VanS protein	Enterococcus faecium	125-129
31931148-5	2020	The results suggest that the insertion of IS19 within vanS gene may be associated with constitutive expression of resistance to vancomycin in clinical isolate CL-6729, either by not impairing the VanS activity or inducing the emergence of another pathway that acts on vanA expression, which still needs to be fully investigated.	Vancomycin	128-138	VanS protein	Enterococcus faecium	54-58
31931148-5	2020	The results suggest that the insertion of IS19 within vanS gene may be associated with constitutive expression of resistance to vancomycin in clinical isolate CL-6729, either by not impairing the VanS activity or inducing the emergence of another pathway that acts on vanA expression, which still needs to be fully investigated.	Vancomycin	128-138	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	268-272
32308438-0	2020	Emergence of vanA-Type Vancomycin-Resistant Enterococcus faecium ST 78 Strain with a rep2-Type Plasmid Carrying a Tn1546-Like Element Isolated from a Urinary Tract Infection in China.	Vancomycin	23-33	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	13-17
32308438-4	2020	Here, we report the whole-genome sequence of a vanA-type vancomycin-resistant E. faecium belonging to sequence type (ST) 78 isolated from a urinary tract infection in China.	Vancomycin	57-67	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	47-51
32308438-15	2020	Conclusion: Our study characterizes the genomic feature of a vancomycin-resistant E. faecium ST78 strain harboring a vanA-carrying plasmid in China.	Vancomycin	61-71	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	117-121
32235931-0	2020	The Extracellular Domain of Two-component System Sensor Kinase VanS from Streptomyces coelicolor Binds Vancomycin at a Newly Identified Binding Site.	Vancomycin	103-113	sensor histidine kinase VanS	Staphylococcus aureus	63-67
32235931-5	2020	Diverging evidence in the literature supports activation models in which the VanS protein binds either vancomycin, or Lipid II, to induce resistance.	Vancomycin	103-113	sensor histidine kinase VanS	Staphylococcus aureus	77-81
32235931-6	2020	Here we investigated the interaction between vancomycin and VanS from Streptomyces coelicolor (VanSSC), a model Actinomycete.	Vancomycin	45-55	sensor histidine kinase VanS	Staphylococcus aureus	60-64
32235931-9	2020	In targeting a separate site on vancomycin, the effective VanS ligand concentration includes both free and lipid-bound molecules, facilitating VanS activation.	Vancomycin	32-42	sensor histidine kinase VanS	Staphylococcus aureus	58-62
32235931-9	2020	In targeting a separate site on vancomycin, the effective VanS ligand concentration includes both free and lipid-bound molecules, facilitating VanS activation.	Vancomycin	32-42	sensor histidine kinase VanS	Staphylococcus aureus	143-147
32235931-10	2020	This is the first molecular description of the VanS binding site within vancomycin, and could direct engineering of future therapeutics.	Vancomycin	72-82	sensor histidine kinase VanS	Staphylococcus aureus	47-51
32265867-5	2020	Deletion of greA results in growth retardation and poor survival in response to adverse stress, besides rendering M. tuberculosis more susceptible to vancomycin and rifampicin.	Vancomycin	150-160	transcription elongation factor GreA	Mycobacterium tuberculosis H37Rv	12-16
31545160-1	2020	Aims: Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) could be misinterpreted as "susceptible" with routine susceptibility testing procedures, and the subpopulations with reduced susceptibility to glycopeptides can lead to therapeutic failure.	Vancomycin	20-30	mitochondrial antiviral signaling protein	Homo sapiens	67-72
31154618-8	2019	In contrast, systemic clearance of vancomycin was significantly lower in the total cancer cachexia patients compared with the non-cachexia patients when analyzed by the traditional one-compartment model [median (range)-49.7 (9.8-98.7) vs 70.2 (12.5-211.8) mL/min, p < 0.01] and by the Bayesian method [45.6 (12.5-84.7) vs 63.3 (12.2-102.5) mL/min, p < 0.05].	Vancomycin	35-45	thrombopoietin	Mus musculus	256-258
31575499-8	2020	Multivariable logistic regression analyses for vancomycin-treated populations revealed that abnormal white blood cell count (odds ratio [OR] 4.34, 95% confidence interval [CI] 1.31-14.39) was a risk factor for clinical failure and that no therapeutic drug monitoring (OR 3.10, 95% CI 1.35-7.12) and abnormally high C-reactive protein level (OR 3.54, 95% CI 1.26-9.92) were risk factors for mortality.	Vancomycin	47-57	C-reactive protein	Homo sapiens	315-333
31955251-4	2020	Characterization of hVISA/VISA by new technologies is necessary to differentiate them rapidly from the vancomycin-susceptible isolates (VSSA).	Vancomycin	103-113	mitochondrial antiviral signaling protein	Homo sapiens	20-25
31955251-4	2020	Characterization of hVISA/VISA by new technologies is necessary to differentiate them rapidly from the vancomycin-susceptible isolates (VSSA).	Vancomycin	103-113	mitochondrial antiviral signaling protein	Homo sapiens	21-25
31897733-1	2020	A copper(II) benzene-1,3,5-tricarboxylate (BTC) metal-organic framework (MOF) was modified with poly(acrylic acid) (PAA) and then used in an electrochemical sensor for vancomycin.	Vancomycin	168-178	lysine acetyltransferase 8	Homo sapiens	0-77
32999156-8	2020	Trend analysis showed that there were significant correlations between vancomycin trough level and age, body weight, estimated glomerular filtration rate, and serum albumin levels.	Vancomycin	71-81	albumin	Homo sapiens	159-172
32999156-10	2020	The higher vancomycin concentration tended to be associated with the shorter time to 50% decline in CRP.	Vancomycin	11-21	C-reactive protein	Homo sapiens	100-103
31902925-1	2020	This study aimed to construct an optimal algorithm for initial dose settings of vancomycin (VCM) using machine learning (ML) with decision tree (DT) analysis.	Vancomycin	80-90	thrombopoietin	Mus musculus	121-123
31832205-11	2019	Finally, we showed that the glycopeptide antibiotic vancomycin, which is associated with clinical pseudo-allergic reactions known as red man syndrome, is an agonist of MrgX2.	Vancomycin	52-62	MAS related GPR family member X2	Homo sapiens	168-173
32104012-12	2020	Also, serum concentration of vancomycin >21.5 mg/L was the only variable associated with death in the Cox model.	Vancomycin	29-39	cytochrome c oxidase subunit 8A	Homo sapiens	102-105
31670958-0	2020	C1-CBP-vancomycin: Impact of a Vancomycin C-Terminus Trimethylammonium Cation on Pharmacological Properties and Insights into Its Newly Introduced Mechanism of Action.	Vancomycin	31-43	CREB binding protein	Mus musculus	3-6
31670958-1	2020	C1-CBP-vancomycin (3) was examined alongside CBP-vancomycin for susceptibility to acquired resistance upon serial exposure against two vancomycin-resistant enterococci strains where its activity proved more durable and remarkably better than many current therapies.	Vancomycin	7-17	CREB binding protein	Mus musculus	3-6
31670958-2	2020	Combined with earlier studies, this observation confirmed an added mechanism of action was introduced by incorporation of the trimethylammonium cation and that C1-CBP-vancomycin exhibits activity against vancomycin-resistant organisms through two synergistic mechanisms of action, both independent of d-Ala-d-Ala/d-Lac binding.	Vancomycin	167-177	CREB binding protein	Mus musculus	163-166
31670958-4	2020	Further studies indicate that the trimethylammonium cation does not introduce new liabilities in common pharmacological properties of the analogue and established that 3 is well tolerated in mice, displays substantial PK improvements over both vancomycin and CBP-vancomycin, and exhibits in vivo efficacy against a challenging multidrug-resistant and vancomycin-resistant S. aureus strain that is representative of the resistant pathogens all fear will emerge in the general population.	Vancomycin	263-273	CREB binding protein	Mus musculus	259-262
31541402-0	2020	Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.	Vancomycin	84-94	cystatin C	Homo sapiens	49-59
31541402-2	2020	Therefore, we established a cystatin C-based model of vancomycin.	Vancomycin	54-64	cystatin C	Homo sapiens	28-38
31541402-3	2020	OBJECTIVES: The purpose of this study was to externally verify the PopPK model of vancomycin based on the glomerular filtration rate (GFR) estimated by serum cystatin C in our previous study and to compare the prediction performance of cystatin C (Cys C) and serum creatinine (SCR)-based models.	Vancomycin	82-92	cystatin C	Homo sapiens	158-168
31541402-3	2020	OBJECTIVES: The purpose of this study was to externally verify the PopPK model of vancomycin based on the glomerular filtration rate (GFR) estimated by serum cystatin C in our previous study and to compare the prediction performance of cystatin C (Cys C) and serum creatinine (SCR)-based models.	Vancomycin	82-92	cystatin C	Homo sapiens	236-246
31541402-14	2020	CONCLUSION: After comparison, we suggest that cystatin C is a superior renal function marker to serum creatinine for vancomycin PopPK models.	Vancomycin	117-127	cystatin C	Homo sapiens	46-56
31463971-9	2020	In the Cys C model, age, body weight and cGFR were significant covariates on the clearance rate (CL) of vancomycin (typical value, 6.4 L/hour).	Vancomycin	104-114	cystatin C	Homo sapiens	7-12
31715528-7	2020	According to the final model, for patients with CrCl = 120 ml/min, the median vancomycin total CL is 4.81 l/h, while CrCl-dependent fraction accounts for approximately 60% of CL.	Vancomycin	78-88	CRCL	Homo sapiens	48-52
31715528-8	2020	CONCLUSIONS: The developed population vancomycin model may be used in estimating individual CL for adult critically ill septic patients, and could be applied for individualizing dosage regimens taking into account the continuous effect of CrCl.	Vancomycin	38-48	CRCL	Homo sapiens	239-243
31969624-6	2020	Our demonstration - for the first time - of complexation/depletion interactions for model mucin systems with vancomycin provides the basis for further study on the implications of complexation on glycopeptide transit in humans, antibiotic bioavailability for target inhibition, in situ generation of resistance and future development strategies for absorption of the antibiotic across the mucus barrier.	Vancomycin	109-119	mucin 1, cell surface associated	Bos taurus	90-95
32305658-9	2020	And vancomycin (van) attenuated HFS-increased blood pressure (HFS: 121.3 +- 2.8 mm Hg; HFS-van: 111.1 +- 1.7 mm Hg) and heart rate (HFS: 360.5 +- 9.0 bpm; HFS-van: 318.7 +- 5.6 bpm) as well as the content of angiotensinogen, renin, and angiotensin II in the urine and the angiotensinogen mRNA level in renal cortical tissues.	Vancomycin	4-14	angiotensinogen	Rattus norvegicus	208-223
32305658-9	2020	And vancomycin (van) attenuated HFS-increased blood pressure (HFS: 121.3 +- 2.8 mm Hg; HFS-van: 111.1 +- 1.7 mm Hg) and heart rate (HFS: 360.5 +- 9.0 bpm; HFS-van: 318.7 +- 5.6 bpm) as well as the content of angiotensinogen, renin, and angiotensin II in the urine and the angiotensinogen mRNA level in renal cortical tissues.	Vancomycin	4-14	renin	Rattus norvegicus	225-230
32305658-9	2020	And vancomycin (van) attenuated HFS-increased blood pressure (HFS: 121.3 +- 2.8 mm Hg; HFS-van: 111.1 +- 1.7 mm Hg) and heart rate (HFS: 360.5 +- 9.0 bpm; HFS-van: 318.7 +- 5.6 bpm) as well as the content of angiotensinogen, renin, and angiotensin II in the urine and the angiotensinogen mRNA level in renal cortical tissues.	Vancomycin	4-14	angiotensinogen	Rattus norvegicus	236-250
32305658-9	2020	And vancomycin (van) attenuated HFS-increased blood pressure (HFS: 121.3 +- 2.8 mm Hg; HFS-van: 111.1 +- 1.7 mm Hg) and heart rate (HFS: 360.5 +- 9.0 bpm; HFS-van: 318.7 +- 5.6 bpm) as well as the content of angiotensinogen, renin, and angiotensin II in the urine and the angiotensinogen mRNA level in renal cortical tissues.	Vancomycin	4-14	angiotensinogen	Rattus norvegicus	272-287
32305658-9	2020	And vancomycin (van) attenuated HFS-increased blood pressure (HFS: 121.3 +- 2.8 mm Hg; HFS-van: 111.1 +- 1.7 mm Hg) and heart rate (HFS: 360.5 +- 9.0 bpm; HFS-van: 318.7 +- 5.6 bpm) as well as the content of angiotensinogen, renin, and angiotensin II in the urine and the angiotensinogen mRNA level in renal cortical tissues.	Vancomycin	4-7	angiotensinogen	Rattus norvegicus	208-223
32305658-9	2020	And vancomycin (van) attenuated HFS-increased blood pressure (HFS: 121.3 +- 2.8 mm Hg; HFS-van: 111.1 +- 1.7 mm Hg) and heart rate (HFS: 360.5 +- 9.0 bpm; HFS-van: 318.7 +- 5.6 bpm) as well as the content of angiotensinogen, renin, and angiotensin II in the urine and the angiotensinogen mRNA level in renal cortical tissues.	Vancomycin	4-7	renin	Rattus norvegicus	225-230
32305658-9	2020	And vancomycin (van) attenuated HFS-increased blood pressure (HFS: 121.3 +- 2.8 mm Hg; HFS-van: 111.1 +- 1.7 mm Hg) and heart rate (HFS: 360.5 +- 9.0 bpm; HFS-van: 318.7 +- 5.6 bpm) as well as the content of angiotensinogen, renin, and angiotensin II in the urine and the angiotensinogen mRNA level in renal cortical tissues.	Vancomycin	4-7	angiotensinogen	Rattus norvegicus	236-250
32305658-9	2020	And vancomycin (van) attenuated HFS-increased blood pressure (HFS: 121.3 +- 2.8 mm Hg; HFS-van: 111.1 +- 1.7 mm Hg) and heart rate (HFS: 360.5 +- 9.0 bpm; HFS-van: 318.7 +- 5.6 bpm) as well as the content of angiotensinogen, renin, and angiotensin II in the urine and the angiotensinogen mRNA level in renal cortical tissues.	Vancomycin	4-7	angiotensinogen	Rattus norvegicus	272-287
31938716-5	2020	SOC was empiric treatment with vancomycin or daptomycin and any subsequent combination antibiotic(s), except for DAP-CPT.	Vancomycin	31-41	UBX domain protein 11	Homo sapiens	0-3
31887179-2	2019	There is an increasing evidence of heterogeneous vancomycin-intermediate S. aureus (hVISA) associated treatment failure.	Vancomycin	49-59	mitochondrial antiviral signaling protein	Homo sapiens	84-89
31154618-8	2019	In contrast, systemic clearance of vancomycin was significantly lower in the total cancer cachexia patients compared with the non-cachexia patients when analyzed by the traditional one-compartment model [median (range)-49.7 (9.8-98.7) vs 70.2 (12.5-211.8) mL/min, p < 0.01] and by the Bayesian method [45.6 (12.5-84.7) vs 63.3 (12.2-102.5) mL/min, p < 0.05].	Vancomycin	35-45	thrombopoietin	Mus musculus	340-342
31366440-0	2019	Impact of mutations in hVISA isolates on decreased susceptibility to vancomycin, through population analyses profile - area under curve (PAP-AUC).	Vancomycin	69-79	mitochondrial antiviral signaling protein	Homo sapiens	23-28
32074094-0	2019	First detection of vanB phenotype-vanA genotype vancomycin-resistant enterococci in Egypt.	Vancomycin	48-58	VanA	Enterococcus faecalis	34-38
31315136-5	2019	ALP reduction was greatest for vancomycin (65.6%, p < 0.002) and smallest with metronidazole (22.7%, p = 0.18).	Vancomycin	31-41	alkaline phosphatase, placental	Homo sapiens	0-3
31454121-3	2019	alpha-Glycosidase, butyrylcholinesterase, aldose reductase, acetylcholinesterase, paraoxonase-1, and carbonic anhydrase enzyme activities were significantly (P &lt; .05) decreased in VCM group when compared with the control group.	Vancomycin	183-186	butyrylcholinesterase	Rattus norvegicus	19-40
31454121-3	2019	alpha-Glycosidase, butyrylcholinesterase, aldose reductase, acetylcholinesterase, paraoxonase-1, and carbonic anhydrase enzyme activities were significantly (P &lt; .05) decreased in VCM group when compared with the control group.	Vancomycin	183-186	aldo-keto reductase family 1 member B1	Rattus norvegicus	42-58
31454121-3	2019	alpha-Glycosidase, butyrylcholinesterase, aldose reductase, acetylcholinesterase, paraoxonase-1, and carbonic anhydrase enzyme activities were significantly (P &lt; .05) decreased in VCM group when compared with the control group.	Vancomycin	183-186	acetylcholinesterase	Rattus norvegicus	60-80
31454121-3	2019	alpha-Glycosidase, butyrylcholinesterase, aldose reductase, acetylcholinesterase, paraoxonase-1, and carbonic anhydrase enzyme activities were significantly (P &lt; .05) decreased in VCM group when compared with the control group.	Vancomycin	183-186	paraoxonase 1	Rattus norvegicus	82-95
31929701-3	2019	Detection of hVISA was done by glycopeptide resistance detection Etest according to the manufacturer"s instructions in strains with vancomycin minimum inhibitory concentration of 1-2 mug/ml.	Vancomycin	132-142	mitochondrial antiviral signaling protein	Homo sapiens	13-18
31662606-10	2019	Van A gene was detected in 71.4% of vancomycin-resistant isolates.	Vancomycin	36-46	VanA	Enterococcus faecalis	0-5
31662606-13	2019	In the studied isolates, erythromycin resistance mainly related to the presence of ere(B) and erm(B) genes and vancomycin resistance was mainly related to the presence of vanA gene.	Vancomycin	111-121	VanA	Enterococcus faecalis	171-175
31591125-1	2019	Concomitant use of vancomycin plus piperacillin/tazobactam (TZP) has been associated with increased risk of acute kidney injury (AKI) in hospitalized adults.	Vancomycin	19-29	PHD finger protein 20	Homo sapiens	60-63
31240688-3	2019	OBJECTIVE: An evaluation of the pharmacokinetics of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding-protein 7 (IGFBP7) for patients receiving vancomycin alone, piperacillin-tazobactam alone, and vancomycin plus piperacillin-tazobactam in combination was conducted to understand the impact on acute kidney cell stress and compare the rates of dialysis or death at 9 months among these three drug exposure types.	Vancomycin	190-200	TIMP metallopeptidase inhibitor 2	Homo sapiens	60-99
31240688-3	2019	OBJECTIVE: An evaluation of the pharmacokinetics of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding-protein 7 (IGFBP7) for patients receiving vancomycin alone, piperacillin-tazobactam alone, and vancomycin plus piperacillin-tazobactam in combination was conducted to understand the impact on acute kidney cell stress and compare the rates of dialysis or death at 9 months among these three drug exposure types.	Vancomycin	190-200	TIMP metallopeptidase inhibitor 2	Homo sapiens	101-107
31240688-3	2019	OBJECTIVE: An evaluation of the pharmacokinetics of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding-protein 7 (IGFBP7) for patients receiving vancomycin alone, piperacillin-tazobactam alone, and vancomycin plus piperacillin-tazobactam in combination was conducted to understand the impact on acute kidney cell stress and compare the rates of dialysis or death at 9 months among these three drug exposure types.	Vancomycin	190-200	insulin like growth factor binding protein 7	Homo sapiens	113-157
31240688-3	2019	OBJECTIVE: An evaluation of the pharmacokinetics of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding-protein 7 (IGFBP7) for patients receiving vancomycin alone, piperacillin-tazobactam alone, and vancomycin plus piperacillin-tazobactam in combination was conducted to understand the impact on acute kidney cell stress and compare the rates of dialysis or death at 9 months among these three drug exposure types.	Vancomycin	190-200	insulin like growth factor binding protein 7	Homo sapiens	159-165
32074094-8	2019	VanA phenotype, vanA genotype was identified in (47.4%) of isolates, while vanB phenotype, vanA genotype was identified in (33.3%) of vancomycin resistant isolates.	Vancomycin	134-144	VanA	Enterococcus faecalis	91-95
32074094-9	2019	CONCLUSION: VanB phenotype-vanA genotype was identified in (33.3%) of vancomycin resistant enterococcal isolates.	Vancomycin	70-80	D-alanine--D-lactate ligase	Enterococcus faecalis	12-16
32074094-9	2019	CONCLUSION: VanB phenotype-vanA genotype was identified in (33.3%) of vancomycin resistant enterococcal isolates.	Vancomycin	70-80	VanA	Enterococcus faecalis	27-31
31203362-1	2019	OBJECTIVES: Most vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) are derived from hospital-associated MRSA due to treatment failure; however, the prevalence of hVISA/VISA in community settings remains unclear.	Vancomycin	17-27	mitochondrial antiviral signaling protein	Homo sapiens	64-68
31332061-11	2019	KIM-1 concentrations in pup kidneys were significantly higher when dams were administered vancomycin in trimesters 1 (P = 0.0001) and 2 (P = 0.0024) than in controls in trimester 3.	Vancomycin	90-100	hepatitis A virus cellular receptor 1	Rattus norvegicus	0-5
31332061-12	2019	Data demonstrate persistence of vancomycin in maternal and rat pup kidneys in all three trimesters of pregnancy with associated damage to the kidney, as indicated by expression of KIM-1.	Vancomycin	32-42	hepatitis A virus cellular receptor 1	Rattus norvegicus	180-185
31158526-0	2019	A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms.	Vancomycin	79-89	major histocompatibility complex, class I, A	Homo sapiens	34-39
31158526-2	2019	The authors recently reported a strong association between HLA-A*32:01 and vancomycin-induced drug reaction with eosinophilia and systemic symptoms.	Vancomycin	75-85	major histocompatibility complex, class I, A	Homo sapiens	59-64
31158526-9	2019	The assay demonstrates a sensitivity and specificity to differentiate the HLA-A*32:01 allele from closely related non-HLA-A*32 alleles and may be used in clinical settings to identify individuals with the risk allele before or during the course of vancomycin therapy.	Vancomycin	248-258	major histocompatibility complex, class I, A	Homo sapiens	74-79
30913295-1	2019	Topical vancomycin has been shown to effectively reduce infections after spinal surgery while remaining safe and cost-effective; however, there are few studies evaluating topical vancomycin in total hip arthroplasty.	Vancomycin	179-189	hedgehog interacting protein	Homo sapiens	199-202
30913295-2	2019	The authors hypothesized that the incidence of periprosthetic joint infection would decrease with the use of topical vancomycin in total hip arthroplasty and that topical vancomycin would be cost-effective.	Vancomycin	117-127	hedgehog interacting protein	Homo sapiens	137-140
31474962-0	2019	IS256-Mediated Overexpression of the WalKR Two-Component System Regulon Contributes to Reduced Vancomycin Susceptibility in a Staphylococcus aureus Clinical Isolate.	Vancomycin	95-105	IS256, transposase	Staphylococcus aureus	0-5
31474962-1	2019	Vancomycin (VAN)-intermediate-resistant Staphylococcus aureus (VISA) is continually isolated globally, with a systematic review suggesting a prevalence of 2% in all blood culture samples.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	63-67
31474962-1	2019	Vancomycin (VAN)-intermediate-resistant Staphylococcus aureus (VISA) is continually isolated globally, with a systematic review suggesting a prevalence of 2% in all blood culture samples.	Vancomycin	12-15	mitochondrial antiviral signaling protein	Homo sapiens	63-67
31474962-11	2019	We conclude that KG-18 achieved reduced susceptibility to VAN by IS256-mediated WalKR overexpression, leading to a markedly thickened cell wall for trapping free VAN molecules with redundant D-Ala-D-Ala targets.	Vancomycin	58-61	IS256, transposase	Staphylococcus aureus	65-70
31457102-0	2019	Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial beta-glucuronidase activity.	Vancomycin	0-10	glucuronidase, beta	Mus musculus	105-123
31457102-4	2019	In the mouse, vancomycin eliminated GUS-expressing bacteria and prevented MMF-induced weight loss and colonic inflammation.	Vancomycin	14-24	glucuronidase, beta	Mus musculus	36-39
31215556-4	2019	The tested compounds showed significant inhibitory activity and high selectivity (MIC = 1 mug mL-1, SI = 80) against a wide variety of methicillin and vancomycin-resistant S. aureus strains.	Vancomycin	151-161	L1 cell adhesion molecule	Mus musculus	94-98
31203362-1	2019	OBJECTIVES: Most vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) are derived from hospital-associated MRSA due to treatment failure; however, the prevalence of hVISA/VISA in community settings remains unclear.	Vancomycin	17-27	mitochondrial antiviral signaling protein	Homo sapiens	196-201
31456560-0	2019	Surveillance of vancomycin-resistant enterococci reveals shift in dominating clones and national spread of a vancomycin-variable vanA Enterococcus faecium ST1421-CT1134 clone, Denmark, 2015 to March 2019.	Vancomycin	16-26	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	129-133
31456560-0	2019	Surveillance of vancomycin-resistant enterococci reveals shift in dominating clones and national spread of a vancomycin-variable vanA Enterococcus faecium ST1421-CT1134 clone, Denmark, 2015 to March 2019.	Vancomycin	109-119	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	129-133
31456560-2	2019	During Q1 2019, the vancomycin-variable enterococci (VVE) ST1421-CT1134 vanA E. faecium became the most dominant vanA E. faecium clone and has spread to all five regions in Denmark.	Vancomycin	20-30	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	72-76
31456560-2	2019	During Q1 2019, the vancomycin-variable enterococci (VVE) ST1421-CT1134 vanA E. faecium became the most dominant vanA E. faecium clone and has spread to all five regions in Denmark.	Vancomycin	20-30	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	113-117
31670275-1	2019	Background &amp; objectives: Although there are reports of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) across the globe, there is a lack of reliable data on hVISA in India.	Vancomycin	73-83	mitochondrial antiviral signaling protein	Homo sapiens	120-125
31065686-14	2019	A vancomycin AUC0-24h of 482.2 corresponded to a 90% of maximal rise in KIM-1.	Vancomycin	2-12	hepatitis A virus cellular receptor 1	Rattus norvegicus	72-77
31505641-9	2019	MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%).	Vancomycin	97-107	solute carrier family 9 member A6	Homo sapiens	0-4
31286887-7	2019	The prevalence of vanA gene among vancomycin resistant E. faecium and vancomycin resistant E. faecalis was 95 and 50%, respectively.	Vancomycin	34-44	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	18-22
31384433-0	2019	Near-ubiquitous presence of a vancomycin-resistant Enterococcus faecium ST117/CT71/vanB -clone in the Rhine-Main metropolitan area of Germany.	Vancomycin	30-40	D-alanine--D-lactate ligase	Enterococcus faecium	83-87
31384433-1	2019	Whole-genome sequencing analysis of Vancomycin-resistant Enterococcus faecium isolates from the Frankfurt metropolitan region revealed that 78/94 isolates were MLST type ST117, cgMLST complex type CT71 with a common vanB chromosomal insertion site.	Vancomycin	36-46	D-alanine--D-lactate ligase	Enterococcus faecium	216-220
31308707-5	2019	Results: Vancomycin-resistant Staphylococcus aureus strain 1 (VRSA-1) was positive for vanA, ermA, ermC, aph(2")-Ic, aph(3")-IIIa, sea, sep, icaD genes, belonging to agr type I; SCCmec type III; spa type t030; and ST239.	Vancomycin	9-19	ErmC	Staphylococcus aureus	99-103
31681475-4	2019	While the cement component converting to the amorphous phase during gelation (HAp2) exhibited a faster, but also more anomalous, non-Fickian mechanism of release of vancomycin, the cement component retaining its crystalline state all throughout gelation, setting and hardening (HAp1) stabilized at the ideal, Fickian diffusion case corresponding to the Korsmeyer-Peppas exponent value of 0.45 +- 0.02.	Vancomycin	165-175	huntingtin associated protein 1	Homo sapiens	78-82
31312589-1	2019	Robenidine (E)-N"-((E)-1-(4-chlorophenyl)ethylidene)-2-(1-(4-chlorophenyl)ethylidene)hydrazine-1-carboximidhydrazide displays methicillin-resistant Staphyoccoccus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) MICs of 2 mug mL-1.	Vancomycin	181-191	L1 cell adhesion molecule	Mus musculus	234-238
30867532-0	2019	Alteration of GLP-1/GPR43 expression and gastrointestinal motility in dysbiotic mice treated with vancomycin.	Vancomycin	98-108	glucagon	Mus musculus	14-19
31278356-6	2019	Kinetic cell viability testing showed that 500 mug/mL of moxifloxacin exposure induced significant decrease (29%) in the viability as early as 1 h. When the inflammatory effects of the antibiotics were examined, a significant induction of IL-8 was observed especially by RVECs after exposure to cefuroxime or vancomycin which was exacerbated by L-alanyl-gamma-D-glutamyl-meso-diaminopimelic acid (Tri-DAP), a NOD1 ligand.	Vancomycin	309-319	C-X-C motif chemokine ligand 8	Homo sapiens	239-243
30873627-0	2019	A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function.	Vancomycin	38-48	cystatin C	Homo sapiens	91-101
30873627-1	2019	OBJECTIVES: This study aimed to establish a vancomycin population pharmacokinetics (PPK) model based on serum cystatin C and to optimize dosing for achieving targeted steady-state trough concentrations (Css ) of 10-15 and 15-20 mg/l.	Vancomycin	44-54	cystatin C	Homo sapiens	110-120
30873627-3	2019	A vancomycin PPK model was built with glomerular filtration rate (GFR) as a renal covariate estimated by cystatin C.	Vancomycin	2-12	cystatin C	Homo sapiens	105-115
30873627-11	2019	CONCLUSIONS: A vancomycin PPK model with cystatin C as the renal marker has good stability and predictability.	Vancomycin	15-25	cystatin C	Homo sapiens	41-51
31133071-4	2019	All of the 53 vancomycin-resistant E. faecalis isolates carried the vanA and ermB genes; whereas aac (6")-Ie aph (2""), msrA, and ermA gene were found in 96.2%, 30.2% and 3.8% of vancomycin-resistant isolates, respectively.	Vancomycin	14-24	erythromycin resistance protein	Enterococcus faecalis	77-81
31133071-6	2019	In our results, the high level of resistance to gentamicin, erythromycin and vancomycin in enterococci isolates were mainly related to the presence of aac (6")-Ie aph (2""), ermB and vanA genes, respectively.	Vancomycin	77-87	erythromycin resistance protein	Enterococcus faecalis	174-178
30638872-1	2019	BACKGROUND: In Australia, vanB vancomycin-resistant Enterococcus faecium (VREfm) has been endemic for over 20 years, but vanA VREfm isolates have rarely been reported.	Vancomycin	31-41	D-alanine--D-lactate ligase	Enterococcus faecium	26-30
30726929-0	2019	Genomic characterization of inpatient evolution of MRSA resistant to daptomycin, vancomycin and ceftaroline.	Vancomycin	81-91	solute carrier family 9 member A6	Homo sapiens	51-55
31232334-0	2019	VanA-type vancomycin-resistant Enterococcus faecium ST1336 isolated from mussels in an anthropogenically impacted ecosystem.	Vancomycin	10-20	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	0-4
31232334-1	2019	We report the occurrence and genomic features of multidrug-resistant vancomycin-resistant Enterococcus faecium vanA belonging to a novel sequence type (designated ST1336), carrying a Tn1546-like element, in marine brown mussels (Perna perna) from anthropogenically affected coastal waters of the Atlantic coast of Brazil, highlighting a potential source of dissemination for related ecosystems, with additional consequences for seafood safety and quality.	Vancomycin	69-79	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	111-115
31131063-9	2019	Interestingly, AKI caused by VAN was markedly attenuated in waved-2 mice at the early stage, as evidenced by the suppression of renal dysfunction, renal cell apoptosis and caspase3 activation.	Vancomycin	29-32	caspase 3	Mus musculus	172-180
31531080-6	2019	Compared with children with normal renal function as glomerular filtration rate (GFR) &gt;= 90 mL/min 1.73 m2, the clearance of vancomycin decreased by 39.4% and the half life increased 1.74 fold respectively in children with moderate renal inadequacy (30 &lt;= GFR &lt; 60 mL/min 1.73 m2).	Vancomycin	128-138	CD59 molecule (CD59 blood group)	Homo sapiens	98-103
31531080-6	2019	Compared with children with normal renal function as glomerular filtration rate (GFR) &gt;= 90 mL/min 1.73 m2, the clearance of vancomycin decreased by 39.4% and the half life increased 1.74 fold respectively in children with moderate renal inadequacy (30 &lt;= GFR &lt; 60 mL/min 1.73 m2).	Vancomycin	128-138	CD59 molecule (CD59 blood group)	Homo sapiens	277-282
30689877-12	2019	Vancomycin demonstrated poor penetration into CSF, with a median CSF/serum ratio of 3% and high intersubject pharmacokinetic variability of its penetration.	Vancomycin	0-10	colony stimulating factor 2	Homo sapiens	46-49
30689877-0	2019	CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study.	Vancomycin	19-29	colony stimulating factor 2	Homo sapiens	0-3
30689877-12	2019	Vancomycin demonstrated poor penetration into CSF, with a median CSF/serum ratio of 3% and high intersubject pharmacokinetic variability of its penetration.	Vancomycin	0-10	colony stimulating factor 2	Homo sapiens	65-68
30867532-11	2019	Vancomycin-induced dysbiosis promotes body weight gain and prolongs GITT, accompanied by an increase of colonic GLP-1/GPR43 expression.	Vancomycin	0-10	glucagon	Mus musculus	112-117
30867532-11	2019	Vancomycin-induced dysbiosis promotes body weight gain and prolongs GITT, accompanied by an increase of colonic GLP-1/GPR43 expression.	Vancomycin	0-10	free fatty acid receptor 2	Mus musculus	118-123
30776417-0	2019	HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.	Vancomycin	40-50	major histocompatibility complex, class I, A	Homo sapiens	0-5
30776417-9	2019	Time-to-event analysis of DRESS development during vancomycin treatment among the HLA-A*32:01-positive group indicated that 19.2% had DRESS and did so within 4 weeks.	Vancomycin	51-61	major histocompatibility complex, class I, A	Homo sapiens	82-87
30776417-10	2019	CONCLUSIONS: HLA-A*32:01 is strongly associated with vancomycin-induced DRESS in a population of predominantly European ancestry.	Vancomycin	53-63	major histocompatibility complex, class I, A	Homo sapiens	13-18
30776417-11	2019	HLA-A*32:01 testing could improve antibiotic safety, help implicate vancomycin as the causal drug, and preserve future treatment options with coadministered antibiotics.	Vancomycin	68-78	major histocompatibility complex, class I, A	Homo sapiens	0-5
32851295-12	2019	Vancomycin minimal inhibitory concentration (MIC) creep was found in the study period in all MRSA and ST59-SCC mec IV isolates.	Vancomycin	0-10	nuclear receptor subfamily 4 group A member 1	Homo sapiens	102-106
31216164-6	2019	The aim of this study was to validate an immunological method based on the kinetic interaction of microparticles in solution (KIMS) for the determination of VAN in CSF.	Vancomycin	157-160	colony stimulating factor 2	Homo sapiens	164-167
31216164-12	2019	Conclusion: The KIMS method demonstrated to have an adequate sensitivity and specificity to determine VAN in CSF and being a useful tool for monitoring patients who present complicated infections at CNS level.	Vancomycin	102-105	colony stimulating factor 2	Homo sapiens	109-112
31216164-18	2019	Conclusion: The KIMS method demonstrated to have an adequate sensitivity and specificity to determine VAN in CSF and being a useful tool for monitoring patients who present complicated infections at CNS level.	Vancomycin	102-105	colony stimulating factor 2	Homo sapiens	109-112
31410331-0	2019	Linear IgA Disease: A Rare Complication of Vancomycin.	Vancomycin	43-53	CD79a molecule	Homo sapiens	7-10
31410331-5	2019	We report a case of linear IgA disease secondary to vancomycin.	Vancomycin	52-62	CD79a molecule	Homo sapiens	27-30
30981206-3	2019	We assigned C57BL/6 mice randomly to four experimental groups: normal saline control (NS), ovalbumin (OVA), vancomycin pretreated NS (VAN-NS), and vancomycin pretreated OVA (VAN-OVA).	Vancomycin	147-157	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	169-172
30981206-3	2019	We assigned C57BL/6 mice randomly to four experimental groups: normal saline control (NS), ovalbumin (OVA), vancomycin pretreated NS (VAN-NS), and vancomycin pretreated OVA (VAN-OVA).	Vancomycin	147-157	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	169-172
31131063-14	2019	EGFR/STAT3 signaling mediated VAN-induced HIPK2 expression in HK-2 cells.	Vancomycin	30-33	epidermal growth factor receptor	Mus musculus	0-4
31131063-14	2019	EGFR/STAT3 signaling mediated VAN-induced HIPK2 expression in HK-2 cells.	Vancomycin	30-33	signal transducer and activator of transcription 3	Mus musculus	5-10
31131063-14	2019	EGFR/STAT3 signaling mediated VAN-induced HIPK2 expression in HK-2 cells.	Vancomycin	30-33	homeodomain interacting protein kinase 2	Mus musculus	42-47
30841436-5	2019	The lipid peroxidation, GSH, SOD, catalase and Gpx levels recovered to near-normal levels following combined treatment with vancomycin and omega-3 fatty acids.	Vancomycin	124-134	catalase	Rattus norvegicus	34-42
30867532-0	2019	Alteration of GLP-1/GPR43 expression and gastrointestinal motility in dysbiotic mice treated with vancomycin.	Vancomycin	98-108	free fatty acid receptor 2	Mus musculus	20-25
30589566-0	2019	Atg7 mediates renal tubular cell apoptosis in vancomycin nephrotoxicity through activation of PKC-delta.	Vancomycin	46-56	autophagy related 7	Homo sapiens	0-4
30589566-13	2019	In sum, autophagy inhibition may serve as a novel therapeutic target for treating nephrotoxic AKI induced by Van.-Xu, X., Pan, J., Li, H., Li, X., Fang, F., Wu, D., Zhou, Y., Zheng, P., Xiong, L., Zhang, D. Atg7 mediates renal tubular cell apoptosis in vancomycin nephrotoxicity through activation of PKC-delta.	Vancomycin	109-112	protein kinase C delta	Homo sapiens	301-310
30460607-1	2019	INTRODUCTION: Heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) bacteremia may result in clinical failure of vancomycin therapy, together with prolonged infection and hospitalization.	Vancomycin	30-40	mitochondrial antiviral signaling protein	Homo sapiens	77-82
30460607-1	2019	INTRODUCTION: Heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) bacteremia may result in clinical failure of vancomycin therapy, together with prolonged infection and hospitalization.	Vancomycin	129-139	mitochondrial antiviral signaling protein	Homo sapiens	77-82
30460607-5	2019	RESULTS: Twenty-one isolates, 15 hVISA and 6 MRSA, showed synergy between oxacillin and vancomycin by checkerboard assay with fractional inhibitory concentration indices of &lt;= 0.5.	Vancomycin	88-98	mitochondrial antiviral signaling protein	Homo sapiens	33-38
30460607-6	2019	The addition of oxacillin to vancomycin resulted in a reduction in baseline vancomycin MIC from 1-2 to 0.06-0.5 microg/ml against MRSA and hVISA isolates.	Vancomycin	29-39	mitochondrial antiviral signaling protein	Homo sapiens	139-144
30460607-6	2019	The addition of oxacillin to vancomycin resulted in a reduction in baseline vancomycin MIC from 1-2 to 0.06-0.5 microg/ml against MRSA and hVISA isolates.	Vancomycin	76-86	mitochondrial antiviral signaling protein	Homo sapiens	139-144
30460607-7	2019	In the time-kill assay, the combination of oxacillin and vancomycin resulted in synergistic activity against hVISA (n = 23) and MRSA (n = 7) isolates.	Vancomycin	57-67	mitochondrial antiviral signaling protein	Homo sapiens	109-114
30460607-9	2019	Overall, for hVISA and MRSA, the combination of oxacillin plus vancomycin had greater antibacterial effect than each individual drug alone.	Vancomycin	63-73	mitochondrial antiviral signaling protein	Homo sapiens	13-18
30460607-10	2019	CONCLUSION: The present study showed the potential activity of vancomycin plus oxacillin combination against hVISA and MRSA isolates.	Vancomycin	63-73	mitochondrial antiviral signaling protein	Homo sapiens	109-114
30339895-1	2019	OBJECTIVES: Vancomycin resistance in Enterococcus spp., mediated mainly by the vanA resistance gene, has become a major health concern as it has spread worldwide.	Vancomycin	12-22	VanA	Enterococcus faecalis	79-83
30663951-0	2019	Utilizing genomic analyses to investigate the first outbreak of vanA vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility.	Vancomycin	69-79	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	64-68
30589566-0	2019	Atg7 mediates renal tubular cell apoptosis in vancomycin nephrotoxicity through activation of PKC-delta.	Vancomycin	46-56	protein kinase C delta	Homo sapiens	94-103
30589566-3	2019	This study was the first to indicate that autophagy was rapidly activated in both human kidney-2 cells and renal tissues, and mammalian target of rapamycin (mTOR) was inactivated via the suppression of ERK1/2 and mTOR during Van treatment.	Vancomycin	225-228	mechanistic target of rapamycin kinase	Homo sapiens	126-155
30589566-3	2019	This study was the first to indicate that autophagy was rapidly activated in both human kidney-2 cells and renal tissues, and mammalian target of rapamycin (mTOR) was inactivated via the suppression of ERK1/2 and mTOR during Van treatment.	Vancomycin	225-228	mechanistic target of rapamycin kinase	Homo sapiens	157-161
30589566-3	2019	This study was the first to indicate that autophagy was rapidly activated in both human kidney-2 cells and renal tissues, and mammalian target of rapamycin (mTOR) was inactivated via the suppression of ERK1/2 and mTOR during Van treatment.	Vancomycin	225-228	mitogen-activated protein kinase 3	Homo sapiens	202-208
30589566-3	2019	This study was the first to indicate that autophagy was rapidly activated in both human kidney-2 cells and renal tissues, and mammalian target of rapamycin (mTOR) was inactivated via the suppression of ERK1/2 and mTOR during Van treatment.	Vancomycin	225-228	mechanistic target of rapamycin kinase	Homo sapiens	213-217
30589566-4	2019	Interestingly, for both in vitro and in vivo experiments, the suppression of autophagy via chloroquine and PT-Atg7-KO significantly ameliorated Van-induced kidney injury and renal tubular cell apoptosis.	Vancomycin	144-147	autophagy related 7	Homo sapiens	110-114
30589566-5	2019	Global gene expression analysis indicated that the expression levels of 6159 genes were induced by Van treatment in the kidney cortical tissues of PT-Atg7 wild-type mice, and 18 of them were notably suppressed in PT-Atg7-KO mice.	Vancomycin	99-102	autophagy related 7	Mus musculus	150-154
30589566-5	2019	Global gene expression analysis indicated that the expression levels of 6159 genes were induced by Van treatment in the kidney cortical tissues of PT-Atg7 wild-type mice, and 18 of them were notably suppressed in PT-Atg7-KO mice.	Vancomycin	99-102	autophagy related 7	Mus musculus	216-220
30589566-7	2019	Unexpectedly, following Van treatment, PKC-delta expression was found to be highest among the 4 genes related to cell death, which was remarkably suppressed in vitro and in PT-Atg7-KO mice.	Vancomycin	24-27	protein kinase C, delta	Mus musculus	39-48
30589566-7	2019	Unexpectedly, following Van treatment, PKC-delta expression was found to be highest among the 4 genes related to cell death, which was remarkably suppressed in vitro and in PT-Atg7-KO mice.	Vancomycin	24-27	autophagy related 7	Mus musculus	176-180
30589566-8	2019	In addition, Atg7 could induce renal cell apoptosis during Van treatment via binding to PKC-delta.	Vancomycin	59-62	autophagy related 7	Mus musculus	13-17
30589566-8	2019	In addition, Atg7 could induce renal cell apoptosis during Van treatment via binding to PKC-delta.	Vancomycin	59-62	protein kinase C, delta	Mus musculus	88-97
30589566-9	2019	Likewise, the inhibition of PKCdelta ameliorated Van-induced apoptosis in human kidney-2 cells and kidney tissues.	Vancomycin	49-52	protein kinase C delta	Homo sapiens	28-36
30589566-10	2019	Furthermore, the data showed that PT-Atg7-KO exerted a renoprotective effect against Van-induced nephrotoxicity, but this effect was lost after injection with myc-tagged PKCdelta.	Vancomycin	85-88	autophagy related 7	Homo sapiens	37-41
30589566-11	2019	Taken altogether, these results indicate that Van induces autophagy by suppressing the activation of the ERK1/2 and mTOR signaling pathway.	Vancomycin	46-49	mitogen-activated protein kinase 3	Homo sapiens	105-111
30589566-11	2019	Taken altogether, these results indicate that Van induces autophagy by suppressing the activation of the ERK1/2 and mTOR signaling pathway.	Vancomycin	46-49	mechanistic target of rapamycin kinase	Homo sapiens	116-120
30589566-12	2019	In addition, Atg7 mediates Van-induced AKI through the activation of PKCdelta.	Vancomycin	27-30	autophagy related 7	Homo sapiens	13-17
30589566-12	2019	In addition, Atg7 mediates Van-induced AKI through the activation of PKCdelta.	Vancomycin	27-30	protein kinase C delta	Homo sapiens	69-77
30589566-13	2019	In sum, autophagy inhibition may serve as a novel therapeutic target for treating nephrotoxic AKI induced by Van.-Xu, X., Pan, J., Li, H., Li, X., Fang, F., Wu, D., Zhou, Y., Zheng, P., Xiong, L., Zhang, D. Atg7 mediates renal tubular cell apoptosis in vancomycin nephrotoxicity through activation of PKC-delta.	Vancomycin	109-112	autophagy related 7	Homo sapiens	207-211
30318716-2	2018	Of note was the increased potency of two analogues against vancomycin-resistant Enterococci (VRE), one of which returned a MIC of 0.5 mug mL-1 .	Vancomycin	59-69	L1 cell adhesion molecule	Mus musculus	138-142
30424949-0	2019	Correlation between vancomycin penetration into cerebrospinal fluid and protein concentration in cerebrospinal fluid/serum albumin ratio.	Vancomycin	20-30	albumin	Homo sapiens	123-130
31382830-2	2019	Aim of the study was to evaluate if milk matrix is a suitable environment to support transferability of vancomycin resistance (vanA) gene from clinical vancomycin-resistant Enterococcus faecium to vancomycin-sensitive Enterococcus faecalis.	Vancomycin	104-114	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	127-131
31382830-2	2019	Aim of the study was to evaluate if milk matrix is a suitable environment to support transferability of vancomycin resistance (vanA) gene from clinical vancomycin-resistant Enterococcus faecium to vancomycin-sensitive Enterococcus faecalis.	Vancomycin	152-162	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	127-131
31382830-2	2019	Aim of the study was to evaluate if milk matrix is a suitable environment to support transferability of vancomycin resistance (vanA) gene from clinical vancomycin-resistant Enterococcus faecium to vancomycin-sensitive Enterococcus faecalis.	Vancomycin	152-162	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	127-131
30633757-8	2019	We found that recombinant human MMP1 significantly inhibited and disrupted biofilms of vancomycin sensitive and vancomycin resistant E. faecalis strains.	Vancomycin	87-97	matrix metallopeptidase 1	Homo sapiens	32-36
30633757-8	2019	We found that recombinant human MMP1 significantly inhibited and disrupted biofilms of vancomycin sensitive and vancomycin resistant E. faecalis strains.	Vancomycin	112-122	matrix metallopeptidase 1	Homo sapiens	32-36
30666146-12	2019	Oral vancomycin was a potent inhibitor of secondary bile acid production in participants with IBD and PSC, particularly deoxycholic acid, although no changes in liver biochemistry patterns were noted over a two week period.	Vancomycin	5-15	PSC	Homo sapiens	102-105
31073101-7	2019	RESULTS: in order to achieve desired PTA > 80% vancomycin at higher dosing regimens were needed including 3g/day and 4 g/day for MIC 1.5mg/L and 2.0 mg/L, respectively.	Vancomycin	47-57	growth differentiation factor 15	Homo sapiens	129-134
29959905-5	2019	CXCL14-C17 analogs were more active against antibiotic-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA), MDRPA, and vancomycin-resistant Enterococcus faecium (VREF) than LL-37 and melittin.	Vancomycin	147-157	chemokine (C-X-C motif) ligand 14	Mus musculus	0-6
29959905-5	2019	CXCL14-C17 analogs were more active against antibiotic-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA), MDRPA, and vancomycin-resistant Enterococcus faecium (VREF) than LL-37 and melittin.	Vancomycin	147-157	cytokine like 1	Homo sapiens	7-10
31763116-9	2019	The serum interleukin (IL)-6 level and the IL-4/interferon (IFN)-gamma values were significantly higher in the vancomycin-treated mice, but the serum IL-17A level was lower than that in the control group.	Vancomycin	111-121	interleukin 6	Mus musculus	10-28
31763116-9	2019	The serum interleukin (IL)-6 level and the IL-4/interferon (IFN)-gamma values were significantly higher in the vancomycin-treated mice, but the serum IL-17A level was lower than that in the control group.	Vancomycin	111-121	interferon gamma	Mus musculus	43-70
31763116-9	2019	The serum interleukin (IL)-6 level and the IL-4/interferon (IFN)-gamma values were significantly higher in the vancomycin-treated mice, but the serum IL-17A level was lower than that in the control group.	Vancomycin	111-121	interleukin 17A	Mus musculus	150-156
31223023-6	2019	The endothelin-1 level was significantly higher in VMC group.	Vancomycin	51-54	endothelin 1	Rattus norvegicus	4-16
30727889-2	2019	METHODS: In particular, the system under investigation is composed of a core of slow-degrading polylactic- acid-co-epsilon-caprolactone (PLCL), where an antibiotic compound (Vancomycin) is loaded, surrounded by a shell of a fast-degrading polylactic-co-glycolic acid (PLGA) which contains an anesthetic drug (Lidocaine hydrochloride) for the post-surgical pain relief.	Vancomycin	174-184	phospholipase C like 1 (inactive)	Homo sapiens	95-135
30727889-2	2019	METHODS: In particular, the system under investigation is composed of a core of slow-degrading polylactic- acid-co-epsilon-caprolactone (PLCL), where an antibiotic compound (Vancomycin) is loaded, surrounded by a shell of a fast-degrading polylactic-co-glycolic acid (PLGA) which contains an anesthetic drug (Lidocaine hydrochloride) for the post-surgical pain relief.	Vancomycin	174-184	phospholipase C like 1 (inactive)	Homo sapiens	137-141
31469338-0	2019	Reduced sensitivity of vancomycin/ampicillin broth enrichment for the detection of VanB positive vancomycin-resistant Enterococcus faecium by culture.	Vancomycin	23-33	D-alanine--D-lactate ligase	Enterococcus faecium	83-87
31469338-0	2019	Reduced sensitivity of vancomycin/ampicillin broth enrichment for the detection of VanB positive vancomycin-resistant Enterococcus faecium by culture.	Vancomycin	97-107	D-alanine--D-lactate ligase	Enterococcus faecium	83-87
30397060-3	2019	VCM administered intraperitoneally at 200 mg/kg twice daily for 7 successive days resulted in significant elevation of blood urea nitrogen and creatinine, as well as urinary N-acetyl-beta-D-glucosaminidase.	Vancomycin	0-3	O-GlcNAcase	Rattus norvegicus	174-205
30397060-5	2019	Rutin also significantly attenuated VCM-induced oxidative stress, inflammatory cell infiltration, apoptosis, and decreased interleukin-1beta and tumor necrosis factor alpha levels (all P < 0.05 or 0.01) in kidneys.	Vancomycin	36-39	interleukin 1 beta	Rattus norvegicus	123-140
30397060-5	2019	Rutin also significantly attenuated VCM-induced oxidative stress, inflammatory cell infiltration, apoptosis, and decreased interleukin-1beta and tumor necrosis factor alpha levels (all P < 0.05 or 0.01) in kidneys.	Vancomycin	36-39	tumor necrosis factor	Rattus norvegicus	145-172
30353943-3	2018	Here, we show a novel murine fecal occult bleeding model induced by the combinatorial treatment of ampicillin and vancomycin, which is accompanied by an enlarged cecum, upregulation of pro-inflammatory cytokines IL-6 and IL-12, a reduction in Ki-67-positive epithelial cell number and an increase in the apoptotic cell number in the colon.	Vancomycin	114-124	interleukin 6	Mus musculus	212-216
29772394-7	2018	Three vancomycin-resistant E. faecalis isolates were detected, two with the vanA gene (into Tn1546) and one with the vanB2 gene (into Tn5382); these isolates showed different sequence types determined by multi-locus sequence typing (ST9, ST16 and a new ST848).	Vancomycin	6-16	VanA	Enterococcus faecalis	76-80
29772394-7	2018	Three vancomycin-resistant E. faecalis isolates were detected, two with the vanA gene (into Tn1546) and one with the vanB2 gene (into Tn5382); these isolates showed different sequence types determined by multi-locus sequence typing (ST9, ST16 and a new ST848).	Vancomycin	6-16	D-alanine--D-lactate ligase	Enterococcus faecalis	117-122
30533817-1	2018	Here, we present the draft genome sequence of an unusual Enterococcus faecium isolate (CL-6729) showing constitutive expression of the VanA type of vancomycin resistance.	Vancomycin	148-158	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	135-139
30412677-4	2018	RESULTS: The linearity ranges were 0.05-10 mug ml-1 for vancomycin and 0.5-200 mug ml-1 for total teicoplanin.	Vancomycin	56-66	interleukin 17F	Homo sapiens	47-51
30113682-0	2018	Emergence of a vancomycin-variable Enterococcus faecium ST1421 strain containing a deletion in vanX.	Vancomycin	15-25	VanX protein	Enterococcus faecium	95-99
30113682-13	2018	In isolates resistant to vancomycin, resistance could be attributed to changes in ddl disrupting gene function sometimes accompanied by changes in vanS, increased pHVH-V1511 copy number or the existence of an additional vanA-containing plasmid encoding a functional vanX.	Vancomycin	25-35	VanX protein	Enterococcus faecium	266-270
30426085-7	2018	Most heterogeneous vancomycin intermediate Staphylococcus aureus (hVISA) or VISA strains belonged to spa type t570 and agr group II.	Vancomycin	19-29	mitochondrial antiviral signaling protein	Homo sapiens	66-71
30426085-7	2018	Most heterogeneous vancomycin intermediate Staphylococcus aureus (hVISA) or VISA strains belonged to spa type t570 and agr group II.	Vancomycin	19-29	mitochondrial antiviral signaling protein	Homo sapiens	67-71
30426085-8	2018	In summary, the clinical isolated vancomycin susceptible Staphylococcus aureus (VSSA), hVISA and VISA could be derivated into high vancomycin-resistant VISA in vitro, but it was difficult for them to develop into vancomycin resistant Staphylococcus aureus (VRSA).	Vancomycin	34-44	mitochondrial antiviral signaling protein	Homo sapiens	87-92
30426085-8	2018	In summary, the clinical isolated vancomycin susceptible Staphylococcus aureus (VSSA), hVISA and VISA could be derivated into high vancomycin-resistant VISA in vitro, but it was difficult for them to develop into vancomycin resistant Staphylococcus aureus (VRSA).	Vancomycin	34-44	mitochondrial antiviral signaling protein	Homo sapiens	88-92
30426085-8	2018	In summary, the clinical isolated vancomycin susceptible Staphylococcus aureus (VSSA), hVISA and VISA could be derivated into high vancomycin-resistant VISA in vitro, but it was difficult for them to develop into vancomycin resistant Staphylococcus aureus (VRSA).	Vancomycin	34-44	mitochondrial antiviral signaling protein	Homo sapiens	97-101
30426085-8	2018	In summary, the clinical isolated vancomycin susceptible Staphylococcus aureus (VSSA), hVISA and VISA could be derivated into high vancomycin-resistant VISA in vitro, but it was difficult for them to develop into vancomycin resistant Staphylococcus aureus (VRSA).	Vancomycin	131-141	mitochondrial antiviral signaling protein	Homo sapiens	87-92
30426085-8	2018	In summary, the clinical isolated vancomycin susceptible Staphylococcus aureus (VSSA), hVISA and VISA could be derivated into high vancomycin-resistant VISA in vitro, but it was difficult for them to develop into vancomycin resistant Staphylococcus aureus (VRSA).	Vancomycin	131-141	mitochondrial antiviral signaling protein	Homo sapiens	88-92
30426085-8	2018	In summary, the clinical isolated vancomycin susceptible Staphylococcus aureus (VSSA), hVISA and VISA could be derivated into high vancomycin-resistant VISA in vitro, but it was difficult for them to develop into vancomycin resistant Staphylococcus aureus (VRSA).	Vancomycin	131-141	mitochondrial antiviral signaling protein	Homo sapiens	97-101
30426085-8	2018	In summary, the clinical isolated vancomycin susceptible Staphylococcus aureus (VSSA), hVISA and VISA could be derivated into high vancomycin-resistant VISA in vitro, but it was difficult for them to develop into vancomycin resistant Staphylococcus aureus (VRSA).	Vancomycin	131-141	mitochondrial antiviral signaling protein	Homo sapiens	87-92
30426085-8	2018	In summary, the clinical isolated vancomycin susceptible Staphylococcus aureus (VSSA), hVISA and VISA could be derivated into high vancomycin-resistant VISA in vitro, but it was difficult for them to develop into vancomycin resistant Staphylococcus aureus (VRSA).	Vancomycin	131-141	mitochondrial antiviral signaling protein	Homo sapiens	88-92
30426085-8	2018	In summary, the clinical isolated vancomycin susceptible Staphylococcus aureus (VSSA), hVISA and VISA could be derivated into high vancomycin-resistant VISA in vitro, but it was difficult for them to develop into vancomycin resistant Staphylococcus aureus (VRSA).	Vancomycin	131-141	mitochondrial antiviral signaling protein	Homo sapiens	97-101
30426085-9	2018	VISA and hVISA could gradually adapt to the environment with the vancomycin concentration that continuously elevates.	Vancomycin	65-75	mitochondrial antiviral signaling protein	Homo sapiens	0-4
30426085-9	2018	VISA and hVISA could gradually adapt to the environment with the vancomycin concentration that continuously elevates.	Vancomycin	65-75	mitochondrial antiviral signaling protein	Homo sapiens	9-14
30410931-7	2018	Cumulative vancomycin concentrations were significantly higher (p &lt;= 0.043) for COP specimens after the second day.	Vancomycin	11-21	caspase recruitment domain family member 16	Homo sapiens	83-86
30410931-10	2018	Compressive strength after the elution tests was significantly lower (p = 0.005) for COP specimens loaded with 2 g of vancomycin.	Vancomycin	118-128	caspase recruitment domain family member 16	Homo sapiens	85-88
30146006-6	2018	Further study showed that metronidazole- and vancomycin-sensitive bacteria are involved in maintenance of NLRP3/IL-1beta signal in pMphi.	Vancomycin	45-55	NLR family, pyrin domain containing 3	Mus musculus	106-111
30214011-3	2018	The colitis-protective effects of Nlrp1 deficiency are thus reversed by vancomycin treatment, but recapitulated with butyrate supplementation in wild-type mice.	Vancomycin	72-82	NLR family, pyrin domain containing 1A	Mus musculus	34-39
30364336-1	2018	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) is an emerging superbug with implicit drug resistance to vancomycin.	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	61-66
30364336-1	2018	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) is an emerging superbug with implicit drug resistance to vancomycin.	Vancomycin	125-135	mitochondrial antiviral signaling protein	Homo sapiens	61-66
29697421-9	2018	In addition, we got the information of his travel history in Green Island and Orchid Island for 10 days.With the correct antibiotics, vancomycin, meropenem, and doxycycline, the patient was getting better and corresponding with high level of granulysin and tumor necrosis factor-alpha.	Vancomycin	134-144	granulysin	Homo sapiens	242-252
30052539-5	2018	In this brief report, we describe the effect of oral vancomycin treatment in three patients with UC and PSC refractory to conventional and biologic therapies.	Vancomycin	53-63	PSC	Homo sapiens	104-107
30009890-4	2018	Clonal relationships among isolates were evaluated by pulsed-field-gel electrophoresis (PFGE) analysis and the presence of vanA and vanB genes, in vancomycin resistant enterococci (VRE), was investigated.	Vancomycin	147-157	VanA	Enterococcus faecalis	123-127
29964132-0	2018	JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats.	Vancomycin	18-28	solute carrier family 22 member 6	Rattus norvegicus	85-118
29964132-0	2018	JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats.	Vancomycin	18-28	solute carrier family 22 member 8	Rattus norvegicus	120-124
29964132-0	2018	JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats.	Vancomycin	18-28	ATP binding cassette subfamily C member 2	Rattus norvegicus	163-204
29964132-0	2018	JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats.	Vancomycin	18-28	ATP binding cassette subfamily C member 2	Rattus norvegicus	206-210
29964132-0	2018	JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats.	Vancomycin	18-28	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	216-230
29964132-0	2018	JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats.	Vancomycin	18-28	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	232-236
29964132-2	2018	Vancomycin suppressed the mRNA and protein expressions of Oat1, Oat3, Oct2, Mrp2 and P-gp to reduce the renal excretion of endogenous toxins (e.g. indoxyl sulfate).	Vancomycin	0-10	solute carrier family 22 member 6	Rattus norvegicus	58-62
29964132-2	2018	Vancomycin suppressed the mRNA and protein expressions of Oat1, Oat3, Oct2, Mrp2 and P-gp to reduce the renal excretion of endogenous toxins (e.g. indoxyl sulfate).	Vancomycin	0-10	solute carrier family 22 member 8	Rattus norvegicus	64-68
29964132-2	2018	Vancomycin suppressed the mRNA and protein expressions of Oat1, Oat3, Oct2, Mrp2 and P-gp to reduce the renal excretion of endogenous toxins (e.g. indoxyl sulfate).	Vancomycin	0-10	solute carrier family 22 member 2	Rattus norvegicus	70-74
29964132-2	2018	Vancomycin suppressed the mRNA and protein expressions of Oat1, Oat3, Oct2, Mrp2 and P-gp to reduce the renal excretion of endogenous toxins (e.g. indoxyl sulfate).	Vancomycin	0-10	ATP binding cassette subfamily C member 2	Rattus norvegicus	76-80
29964132-2	2018	Vancomycin suppressed the mRNA and protein expressions of Oat1, Oat3, Oct2, Mrp2 and P-gp to reduce the renal excretion of endogenous toxins (e.g. indoxyl sulfate).	Vancomycin	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	85-89
30021393-0	2018	Therapeutic efficacy of zingerone against vancomycin-induced oxidative stress, inflammation, apoptosis and aquaporin 1 permeability in rat kidney.	Vancomycin	42-52	aquaporin 1	Rattus norvegicus	107-118
30021393-4	2018	Intraperitoneal administration of VCM (200 mg/kg body weight) for seven days increased kidney lipid peroxidation and decreased antioxidant enzyme activities, including kidney superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx).	Vancomycin	34-37	catalase	Rattus norvegicus	203-211
30021393-4	2018	Intraperitoneal administration of VCM (200 mg/kg body weight) for seven days increased kidney lipid peroxidation and decreased antioxidant enzyme activities, including kidney superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx).	Vancomycin	34-37	catalase	Rattus norvegicus	213-216
30146006-6	2018	Further study showed that metronidazole- and vancomycin-sensitive bacteria are involved in maintenance of NLRP3/IL-1beta signal in pMphi.	Vancomycin	45-55	interleukin 1 alpha	Mus musculus	112-120
29752091-6	2018	The results also demonstrated that the releasing profile of vancomycin was pH-dependent and the VEGF"s profile was adjustable by changing the pore sizes of PLGA microspheres.	Vancomycin	60-70	vascular endothelial growth factor A	Rattus norvegicus	96-100
30046057-6	2018	The nanoMIP-SPR sensor enabled vancomycin quantification with the LODs of 4.1 ng mL-1 and 17.7 ng mL-1 using direct and competitive assays, respectively.	Vancomycin	31-41	L1 cell adhesion molecule	Mus musculus	81-85
30046057-6	2018	The nanoMIP-SPR sensor enabled vancomycin quantification with the LODs of 4.1 ng mL-1 and 17.7 ng mL-1 using direct and competitive assays, respectively.	Vancomycin	31-41	L1 cell adhesion molecule	Mus musculus	98-102
29561305-0	2018	Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin.	Vancomycin	76-86	C-reactive protein	Homo sapiens	21-39
29721739-4	2018	Methods This retrospective study included adult patients who received at least one dose of vancomycin for suspected CAP or HCAP.	Vancomycin	91-101	structural maintenance of chromosomes 3	Homo sapiens	123-127
29566173-0	2018	Relentless spread and adaptation of non-typeable vanA vancomycin-resistant Enterococcus faecium: a genome-wide investigation.	Vancomycin	54-64	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	49-53
30069120-4	2018	Vancomycin has been approved in Taiwan since 1983, and the prevalence rates of heteroresistant vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) in 2003 were 0.7% and 0.2%, respectively.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	130-135
30069120-4	2018	Vancomycin has been approved in Taiwan since 1983, and the prevalence rates of heteroresistant vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) in 2003 were 0.7% and 0.2%, respectively.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	131-135
30069120-4	2018	Vancomycin has been approved in Taiwan since 1983, and the prevalence rates of heteroresistant vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) in 2003 were 0.7% and 0.2%, respectively.	Vancomycin	95-105	mitochondrial antiviral signaling protein	Homo sapiens	130-135
30069120-4	2018	Vancomycin has been approved in Taiwan since 1983, and the prevalence rates of heteroresistant vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) in 2003 were 0.7% and 0.2%, respectively.	Vancomycin	95-105	mitochondrial antiviral signaling protein	Homo sapiens	131-135
30386000-4	2018	Herein, we report that OxyBvan, the P450 enzyme that installs the first crosslink in vancomycin biosynthesis, is capable of catalyzing the formation of its conventional C-O-D bis-aryl ether bond in non-natural substrates and, furthermore, the formation of a second, novel linkage when D-Trp is incorporated at position 6.	Vancomycin	85-95	small nuclear ribonucleoprotein polypeptides B and B1	Homo sapiens	169-174
29686154-7	2018	The pharmacokinetics of vancomycin are best described by a two-compartment model with between-subject variability in clearance (CL), the volume of distribution of the central compartment (V1), and volume of distribution of the peripheral compartment (V2).	Vancomycin	24-34	chymotrypsin C	Homo sapiens	128-130
29686154-8	2018	The CL and the V1 of vancomycin were related to creatinine CL (CLCR), body weight, and albumin concentration.	Vancomycin	21-31	chymotrypsin C	Homo sapiens	59-61
29686154-8	2018	The CL and the V1 of vancomycin were related to creatinine CL (CLCR), body weight, and albumin concentration.	Vancomycin	21-31	chymotrypsin C	Homo sapiens	63-67
29561305-2	2018	We investigated CRP PD linked to a vancomycin pharmacokinetic (PK) model using routinely collected data from noncritical care adults in secondary care.	Vancomycin	35-45	C-reactive protein	Homo sapiens	16-19
29561305-4	2018	A 2-compartment vancomycin PK model was linked to a previously described PD model describing CRP response.	Vancomycin	16-26	C-reactive protein	Homo sapiens	93-96
29561305-6	2018	Exposure-response relationships were explored with vancomycin area-under-the-concentration-time-curve (AUC) and EC50 (concentration of drug that causes a half maximal effect) using the index, AUC:EC50, fitted to CRP data using a sigmoidal Emax model.	Vancomycin	51-61	C-reactive protein	Homo sapiens	212-215
30182050-10	2018	In the long term, the vancomycin/metronidazole-induced lasting increase in PA aggravated colitis development in IL10-/- mice.	Vancomycin	22-32	interleukin 10	Mus musculus	112-116
29555635-0	2018	beta-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.	Vancomycin	30-40	mitochondrial antiviral signaling protein	Homo sapiens	181-185
29555635-1	2018	Increasing utilization of vancomycin due to the high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections has led to the emergence of vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) strains.	Vancomycin	26-36	mitochondrial antiviral signaling protein	Homo sapiens	192-196
29555635-1	2018	Increasing utilization of vancomycin due to the high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections has led to the emergence of vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) strains.	Vancomycin	26-36	mitochondrial antiviral signaling protein	Homo sapiens	216-220
29555635-1	2018	Increasing utilization of vancomycin due to the high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections has led to the emergence of vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) strains.	Vancomycin	26-36	mitochondrial antiviral signaling protein	Homo sapiens	222-227
29555635-1	2018	Increasing utilization of vancomycin due to the high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections has led to the emergence of vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) strains.	Vancomycin	157-167	mitochondrial antiviral signaling protein	Homo sapiens	192-196
29555635-1	2018	Increasing utilization of vancomycin due to the high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections has led to the emergence of vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) strains.	Vancomycin	157-167	mitochondrial antiviral signaling protein	Homo sapiens	216-220
29555635-1	2018	Increasing utilization of vancomycin due to the high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections has led to the emergence of vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) strains.	Vancomycin	157-167	mitochondrial antiviral signaling protein	Homo sapiens	222-227
29777150-0	2018	Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility.	Vancomycin	108-118	solute carrier family 9 member A6	Homo sapiens	90-94
29555635-3	2018	The objective of this study is to evaluate the synergy between beta-lactams and vancomycin against MRSA that is vancomycin susceptible, vancomycin-susceptible Staphylococcus aureus (VSSA), hVISA, and VISA.	Vancomycin	80-90	mitochondrial antiviral signaling protein	Homo sapiens	189-194
29555635-3	2018	The objective of this study is to evaluate the synergy between beta-lactams and vancomycin against MRSA that is vancomycin susceptible, vancomycin-susceptible Staphylococcus aureus (VSSA), hVISA, and VISA.	Vancomycin	80-90	mitochondrial antiviral signaling protein	Homo sapiens	190-194
29555635-7	2018	In time-kill studies against MRSA, CFZ, FEP, CPT, and NAF all demonstrated similar degrees of killing at 24 h, and all showed synergistic activity with vancomycin against VSSA, hVISA, and VISA.	Vancomycin	152-162	mitochondrial antiviral signaling protein	Homo sapiens	177-182
29555635-7	2018	In time-kill studies against MRSA, CFZ, FEP, CPT, and NAF all demonstrated similar degrees of killing at 24 h, and all showed synergistic activity with vancomycin against VSSA, hVISA, and VISA.	Vancomycin	152-162	mitochondrial antiviral signaling protein	Homo sapiens	178-182
29555635-9	2018	All single-agent exposures demonstrated no activity at 24 h. The combination of vancomycin and beta-lactams significantly improved antibacterial activity against VSSA, hVISA, and VISA strains compared to the activity of any agent alone, supporting the potential use of vancomycin-beta-lactam combination therapy in infections caused by MRSA.	Vancomycin	80-90	mitochondrial antiviral signaling protein	Homo sapiens	168-173
29555635-9	2018	All single-agent exposures demonstrated no activity at 24 h. The combination of vancomycin and beta-lactams significantly improved antibacterial activity against VSSA, hVISA, and VISA strains compared to the activity of any agent alone, supporting the potential use of vancomycin-beta-lactam combination therapy in infections caused by MRSA.	Vancomycin	80-90	mitochondrial antiviral signaling protein	Homo sapiens	169-173
29890954-1	2018	BACKGROUND: Consideration to add empiric MRSA therapy with vancomycin is a common clinical dilemma.	Vancomycin	59-69	solute carrier family 9 member A6	Homo sapiens	41-45
29777150-1	2018	Bacteremia caused by MRSA with reduced vancomycin susceptibility (MRSA-RVS) frequently resulted in treatment failure and mortality.	Vancomycin	39-49	solute carrier family 9 member A6	Homo sapiens	21-25
29777150-1	2018	Bacteremia caused by MRSA with reduced vancomycin susceptibility (MRSA-RVS) frequently resulted in treatment failure and mortality.	Vancomycin	39-49	solute carrier family 9 member A6	Homo sapiens	66-70
29777150-3	2018	We retrospectively reviewed clinical data of patients with bacteremia caused by MRSA with vancomycin MIC = 2 mg/L from 2009 to 2012.	Vancomycin	90-100	solute carrier family 9 member A6	Homo sapiens	80-84
29777150-3	2018	We retrospectively reviewed clinical data of patients with bacteremia caused by MRSA with vancomycin MIC = 2 mg/L from 2009 to 2012.	Vancomycin	90-100	CD99 molecule (Xg blood group)	Homo sapiens	101-108
29442195-8	2018	These data point to the importance of the lineage 78 for the spread of vancomycin-resistance, determined by the vanB gene cluster, resulting in an increasing VRE prevalence in hospitals.	Vancomycin	71-81	D-alanine--D-lactate ligase	Enterococcus faecium	112-116
29197567-2	2018	In the present study Gelatin - Strontium incorporated Hydroxyapatite (SrHAP) forming HG scaffold, vancomycin loaded chitosan -gelatin polyelectrolyte complex incorporated gelatin-SrHAP, forming HV scaffolds (HV1-0.5wt% and HV2-1wt% vancomycin) were investigated.	Vancomycin	98-108	hydrogen voltage gated channel 1	Homo sapiens	208-211
29197567-5	2018	The total amount of vancomycin encapsulation for HV1 and HV2 scaffolds were determined to be 47.55+-1.6mug and 82.45+-3.5mug respectively.	Vancomycin	20-30	hydrogen voltage gated channel 1	Homo sapiens	49-52
29402952-4	2018	Broth microdilution assays revealed that histone H5 has potent broad-spectrum antimicrobial activity against Gram-positive and Gram-negative planktonic bacteria (MIC range: 1.9 +- 1.8 to 4.9 +- 1.5 microg/mL), including vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).	Vancomycin	220-230	H1 histone family, member 0	Gallus gallus	41-51
29566004-0	2018	Prevalence of vancomycin-variable Enterococcus faecium (VVE) among vanA-positive sterile site isolates and patient factors associated with VVE bacteremia.	Vancomycin	14-24	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	67-71
29566004-1	2018	Vancomycin-variable enterococci (VVE) are vanA-positive, vancomycin-susceptible enterococci with the ability to revert to a vancomycin-resistant phenotype on exposure to vancomycin.	Vancomycin	0-10	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	42-46
29566004-1	2018	Vancomycin-variable enterococci (VVE) are vanA-positive, vancomycin-susceptible enterococci with the ability to revert to a vancomycin-resistant phenotype on exposure to vancomycin.	Vancomycin	124-134	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	42-46
29566004-1	2018	Vancomycin-variable enterococci (VVE) are vanA-positive, vancomycin-susceptible enterococci with the ability to revert to a vancomycin-resistant phenotype on exposure to vancomycin.	Vancomycin	124-134	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	42-46
29522576-1	2018	Vancomycin-intermediately resistant Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) are associated with treatment failure.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	59-63
29522576-2	2018	hVISA contains only a subpopulation of cells with increased minimal inhibitory concentrations, and its detection is problematic because it is classified as vancomycin-susceptible by standard susceptibility testing and the gold-standard method for its detection is impractical in clinical microbiology laboratories.	Vancomycin	156-166	mitochondrial antiviral signaling protein	Homo sapiens	0-5
29522576-3	2018	Recently, a research group developed a machine-learning classifier to distinguish VISA and hVISA from vancomycin-susceptible S. aureus (VSSA) according to matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) data.	Vancomycin	102-112	mitochondrial antiviral signaling protein	Homo sapiens	82-86
29522576-3	2018	Recently, a research group developed a machine-learning classifier to distinguish VISA and hVISA from vancomycin-susceptible S. aureus (VSSA) according to matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) data.	Vancomycin	102-112	mitochondrial antiviral signaling protein	Homo sapiens	91-96
29067501-3	2018	Our aim was to study the CSF vancomycin level pattern and drug safety in ventriculostomy access device infection in preterm infants less than 28 weeks gestation.	Vancomycin	29-39	colony stimulating factor 2	Homo sapiens	25-28
29067501-9	2018	The threshold for re-dosage is set at CSF vancomycin level of &lt; 10 mg/L.	Vancomycin	42-52	colony stimulating factor 2	Homo sapiens	38-41
29067501-13	2018	In doses ranging from 3 to 15 mg, sufficient CSF vancomycin level is generated to achieve microbiological cure without any reported adverse effects.	Vancomycin	49-59	colony stimulating factor 2	Homo sapiens	45-48
29458553-7	2018	Despite normal induction of the vancomycin gene cluster, vanSRJKHAX, the pmt and ppm1 mutants remained highly vancomycin sensitive indicating that the mechanism of resistance is blocked post-transcriptionally.	Vancomycin	110-120	leucine carboxy methyltransferase	Saccharomyces cerevisiae S288C	81-85
29063141-10	2018	Biolog phenotype microarray experiments further indicated that the cmpX knockout mutant had increased sensitivity to membrane detergents and antibiotics such as lauryl sulfobetaine, tobramycin, and vancomycin.	Vancomycin	198-208	hypothetical protein	Pseudomonas aeruginosa PAO1	67-71
28803934-2	2018	Sensitive urinary biomarkers, such as kidney injury molecule 1 (KIM-1), have shown high sensitivity and specificity for vancomycin-associated AKI.	Vancomycin	120-130	hepatitis A virus cellular receptor 1	Rattus norvegicus	38-62
28803934-2	2018	Sensitive urinary biomarkers, such as kidney injury molecule 1 (KIM-1), have shown high sensitivity and specificity for vancomycin-associated AKI.	Vancomycin	120-130	hepatitis A virus cellular receptor 1	Rattus norvegicus	64-69
28803934-9	2018	For all pooled rats, increasing total daily vancomycin doses displayed a dose-response curve with urinary KIM-1 concentrations (50% maximal toxic response=130.4 mg/kg/day).	Vancomycin	44-54	hepatitis A virus cellular receptor 1	Rattus norvegicus	106-111
29254330-5	2018	Moreover, oral administration of DHA-PC exhibited better effects on reducing vancomycin-induced increases of blood urea nitrogen, creatinine, cystatin C, and kidney injury molecule-1 levels than traditional DHA and PC.	Vancomycin	77-87	cystatin C	Mus musculus	142-152
29374204-1	2018	There is limited clinical evidence to support the combination of daptomycin and beta-lactam antibiotics (DAP + BLA) for treatment of vancomycin-resistant enterococci (VRE) bloodstream infections (BSI).	Vancomycin	133-143	death associated protein	Homo sapiens	105-108
29254330-5	2018	Moreover, oral administration of DHA-PC exhibited better effects on reducing vancomycin-induced increases of blood urea nitrogen, creatinine, cystatin C, and kidney injury molecule-1 levels than traditional DHA and PC.	Vancomycin	77-87	hepatitis A virus cellular receptor 1	Mus musculus	158-182
29254330-7	2018	A further mechanistic study revealed that the protective effect of DHA-PC on vancomycin-mediated toxicity might be attributed to its ability to inhibit oxidative stress and inactivate mitogen-activated protein kinase (MAPK) signaling pathways, which was associated with upregulation of Bcl-2 and downregulation of caspase-9, caspase-3, cytochrome-c, p38, and JNK.	Vancomycin	77-87	B cell leukemia/lymphoma 2	Mus musculus	286-291
29254330-7	2018	A further mechanistic study revealed that the protective effect of DHA-PC on vancomycin-mediated toxicity might be attributed to its ability to inhibit oxidative stress and inactivate mitogen-activated protein kinase (MAPK) signaling pathways, which was associated with upregulation of Bcl-2 and downregulation of caspase-9, caspase-3, cytochrome-c, p38, and JNK.	Vancomycin	77-87	caspase 9	Mus musculus	314-323
29254330-7	2018	A further mechanistic study revealed that the protective effect of DHA-PC on vancomycin-mediated toxicity might be attributed to its ability to inhibit oxidative stress and inactivate mitogen-activated protein kinase (MAPK) signaling pathways, which was associated with upregulation of Bcl-2 and downregulation of caspase-9, caspase-3, cytochrome-c, p38, and JNK.	Vancomycin	77-87	caspase 3	Mus musculus	325-334
29254330-7	2018	A further mechanistic study revealed that the protective effect of DHA-PC on vancomycin-mediated toxicity might be attributed to its ability to inhibit oxidative stress and inactivate mitogen-activated protein kinase (MAPK) signaling pathways, which was associated with upregulation of Bcl-2 and downregulation of caspase-9, caspase-3, cytochrome-c, p38, and JNK.	Vancomycin	77-87	mitogen-activated protein kinase 14	Mus musculus	350-353
29254330-7	2018	A further mechanistic study revealed that the protective effect of DHA-PC on vancomycin-mediated toxicity might be attributed to its ability to inhibit oxidative stress and inactivate mitogen-activated protein kinase (MAPK) signaling pathways, which was associated with upregulation of Bcl-2 and downregulation of caspase-9, caspase-3, cytochrome-c, p38, and JNK.	Vancomycin	77-87	mitogen-activated protein kinase 8	Mus musculus	359-362
29251486-6	2018	Additionally, being highly biocompatible (IC50 &gt; 1000, 430, and 250 mug mL-1 for PAA-VC, vancomycin and colistin respectively) high-dosage can be adopted for the eradication of infections in patients.	Vancomycin	92-102	L1 cell adhesion molecule	Mus musculus	75-79
29212481-1	2017	BACKGROUND: We report a case of hemorrhagic occlusive retinal vasculitis (HORV) after prophylactic intracameral vancomycin use during an uneventful cataract surgery treated with early anti-VEGF treatment.	Vancomycin	112-122	vascular endothelial growth factor A	Homo sapiens	189-193
29467322-4	2018	Vancomycin treatment induced an increase in systemic CD8alpha+ DCs, which sustained systemic adoptively transferred antitumor T cells in an IL-12-dependent manner.	Vancomycin	0-10	CD8 antigen, alpha chain	Mus musculus	53-61
29029278-9	2017	Bacterial eradication of MRSA was 100% and 98.5% in the delafloxacin group and the vancomycin/aztreonam group, respectively.	Vancomycin	83-93	solute carrier family 9 member A6	Homo sapiens	25-29
27059750-3	2017	RESULTS: A total of 79 vancomycin-resistant E.faecalis isolates with genotype vanB2 of 73 patients were recovered in 2 of the 3 hospitals, most of them from urine specimens.	Vancomycin	23-33	D-alanine--D-lactate ligase	Enterococcus faecalis	78-83
29163169-8	2017	The results indicated that high dose of vancomycin significantly decreased bone mass and inhibited osteocalcin secretion; icariin increased these indicators compared with the single vancomycin treatment.	Vancomycin	40-50	osteocalcin	Oryctolagus cuniculus	99-110
28807910-13	2017	The vancomycin AUC and Cmax were most predictive of increases in KIM-1 levels (rs = 0.438 and P = 0.002 for AUC and rs = 0.451 and P = 0.002 for Cmax).	Vancomycin	4-14	hepatitis A virus cellular receptor 1	Rattus norvegicus	65-70
28763660-0	2017	Vancomycin-resistant enterococci with vanA gene in treated municipal wastewater and their association with human hospital strains.	Vancomycin	0-10	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	38-42
28754459-10	2017	CONCLUSIONS: This is the first detection in Greece of vanA-vanB genotype/VanA phenotype E. faecium and indicates an evolving epidemiology of vancomycin-resistant enterococci.	Vancomycin	141-151	D-alanine--D-lactate ligase	Enterococcus faecium	59-63
29022913-0	2017	MBD2 upregulates miR-301a-5p to induce kidney cell apoptosis during vancomycin-induced AKI.	Vancomycin	68-78	methyl-CpG binding domain protein 2	Homo sapiens	0-4
29022913-0	2017	MBD2 upregulates miR-301a-5p to induce kidney cell apoptosis during vancomycin-induced AKI.	Vancomycin	68-78	MLX interacting protein	Homo sapiens	17-20
29022913-2	2017	Methyl-CpG-binding domain protein 2 (MBD2), a protein readers of methylation, was used to analyze the impact of DNA methylation on vancomycin (VAN)-induced AKI.	Vancomycin	131-141	methyl-CpG binding domain protein 2	Homo sapiens	0-35
29022913-2	2017	Methyl-CpG-binding domain protein 2 (MBD2), a protein readers of methylation, was used to analyze the impact of DNA methylation on vancomycin (VAN)-induced AKI.	Vancomycin	131-141	methyl-CpG binding domain protein 2	Homo sapiens	37-41
29022913-2	2017	Methyl-CpG-binding domain protein 2 (MBD2), a protein readers of methylation, was used to analyze the impact of DNA methylation on vancomycin (VAN)-induced AKI.	Vancomycin	143-146	methyl-CpG binding domain protein 2	Homo sapiens	0-35
29022913-2	2017	Methyl-CpG-binding domain protein 2 (MBD2), a protein readers of methylation, was used to analyze the impact of DNA methylation on vancomycin (VAN)-induced AKI.	Vancomycin	143-146	methyl-CpG binding domain protein 2	Homo sapiens	37-41
29022913-6	2017	Furthermore, anti-miR-301a-5p significantly blocked VAN-induced apoptosis and caspase activity in HK-2 cells, which was accompanied by downregulation of p53, and upregulation of MITF, HDGF and MDM-4 together.	Vancomycin	52-55	MLX interacting protein	Homo sapiens	18-21
29022913-6	2017	Furthermore, anti-miR-301a-5p significantly blocked VAN-induced apoptosis and caspase activity in HK-2 cells, which was accompanied by downregulation of p53, and upregulation of MITF, HDGF and MDM-4 together.	Vancomycin	52-55	tumor protein p53	Homo sapiens	153-156
29022913-6	2017	Furthermore, anti-miR-301a-5p significantly blocked VAN-induced apoptosis and caspase activity in HK-2 cells, which was accompanied by downregulation of p53, and upregulation of MITF, HDGF and MDM-4 together.	Vancomycin	52-55	melanocyte inducing transcription factor	Homo sapiens	178-182
29022913-6	2017	Furthermore, anti-miR-301a-5p significantly blocked VAN-induced apoptosis and caspase activity in HK-2 cells, which was accompanied by downregulation of p53, and upregulation of MITF, HDGF and MDM-4 together.	Vancomycin	52-55	heparin binding growth factor	Homo sapiens	184-188
29022913-6	2017	Furthermore, anti-miR-301a-5p significantly blocked VAN-induced apoptosis and caspase activity in HK-2 cells, which was accompanied by downregulation of p53, and upregulation of MITF, HDGF and MDM-4 together.	Vancomycin	52-55	MDM4 regulator of p53	Homo sapiens	193-198
29022913-8	2017	In vivo, mice with MBD2 knockout (MBD2-KO) were counteracted to VAN-induced AKI, indicated by the analysis of renal function, histology, apoptosis and inflammation.	Vancomycin	64-67	methyl-CpG binding domain protein 2	Mus musculus	19-23
29022913-8	2017	In vivo, mice with MBD2 knockout (MBD2-KO) were counteracted to VAN-induced AKI, indicated by the analysis of renal function, histology, apoptosis and inflammation.	Vancomycin	64-67	methyl-CpG binding domain protein 2	Homo sapiens	34-38
29022913-10	2017	Finally, in vivo inhibition of miR-301a-5p also ameliorated VAN-induced AKI.	Vancomycin	60-63	MLX interacting protein	Homo sapiens	31-34
29022913-11	2017	Together, these results show the novel MBD2/miR-301a-5p/MITF, HDGF and MDM-4/p53 pathway in VAN-induced AKI.	Vancomycin	92-95	methyl-CpG binding domain protein 2	Homo sapiens	39-43
29022913-11	2017	Together, these results show the novel MBD2/miR-301a-5p/MITF, HDGF and MDM-4/p53 pathway in VAN-induced AKI.	Vancomycin	92-95	MLX interacting protein	Homo sapiens	44-47
29022913-11	2017	Together, these results show the novel MBD2/miR-301a-5p/MITF, HDGF and MDM-4/p53 pathway in VAN-induced AKI.	Vancomycin	92-95	melanocyte inducing transcription factor	Homo sapiens	56-60
29022913-11	2017	Together, these results show the novel MBD2/miR-301a-5p/MITF, HDGF and MDM-4/p53 pathway in VAN-induced AKI.	Vancomycin	92-95	heparin binding growth factor	Homo sapiens	62-66
29022913-11	2017	Together, these results show the novel MBD2/miR-301a-5p/MITF, HDGF and MDM-4/p53 pathway in VAN-induced AKI.	Vancomycin	92-95	MDM4 regulator of p53	Homo sapiens	71-76
29022913-11	2017	Together, these results show the novel MBD2/miR-301a-5p/MITF, HDGF and MDM-4/p53 pathway in VAN-induced AKI.	Vancomycin	92-95	tumor protein p53	Homo sapiens	77-80
28676409-4	2017	The recommended perioperative prophylaxis was cefuroxime (or vancomycin in case of documented MRSA body carriage).	Vancomycin	61-71	solute carrier family 9 member A6	Homo sapiens	94-98
28951512-4	2017	Oral vancomycin, through possible immunomodulatory and anti-inflammatory mechanisms, has been shown in small-scale studies to be successful in improving liver function tests in patients with pretransplant PSC.	Vancomycin	5-15	PSC	Homo sapiens	205-208
28951512-5	2017	We report the first case of an adult patient diagnosed with recurrent PSC 4 years after OLT who was treated with oral vancomycin leading to complete normalisation of his liver biochemistry.	Vancomycin	118-128	PSC	Homo sapiens	70-73
28827421-1	2017	We previously reported a novel phenotype of vancomycin-intermediate Staphylococcus aureus (VISA), i.e., "slow VISA," whose colonies appear only after 72 h of incubation.	Vancomycin	44-54	mitochondrial antiviral signaling protein	Homo sapiens	91-95
28827421-1	2017	We previously reported a novel phenotype of vancomycin-intermediate Staphylococcus aureus (VISA), i.e., "slow VISA," whose colonies appear only after 72 h of incubation.	Vancomycin	44-54	mitochondrial antiviral signaling protein	Homo sapiens	110-114
28827421-9	2017	Deep-sequencing analysis showed that slow-VISA clones are present in small numbers among hVISA isolates and proliferate in the presence of vancomycin.	Vancomycin	139-149	mitochondrial antiviral signaling protein	Homo sapiens	42-46
29109580-1	2017	Background: Broad-spectrum antibiotics are often used to treat urinary tract infections (UTIs) due to drug-resistant species of Enterobacteriaceae and Enterococcus (e.g., organisms producing extended-spectrum beta-lactamase [ESBL] or AmpC beta-lactamase, as well as vancomycin-resistant enterococci [VRE]).	Vancomycin	266-276	EsbL	Escherichia coli	225-229
28699888-10	2017	The cutoff eGFR value predicting a subtherapeutic vancomycin level was 110.51 mL/min/1.73m&lt;sup&gt;2&lt;/sup&gt; (area under the curve, 0.753).	Vancomycin	50-60	CD59 molecule (CD59 blood group)	Homo sapiens	81-86
28285420-8	2017	Extended-spectrum beta-lactamase (ESBL)-producing E. coli, Klebsiella spp., and Proteus mirabilis, ceftazidime-nonsusceptible P. aeruginosa and Enterobacter spp., and vancomycin-nonsusceptible E. faecalis were included.	Vancomycin	167-177	EsbL	Escherichia coli	0-32
29028077-0	2017	Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as early biomarkers for predicting vancomycin-associated acute kidney injury: a prospective study.	Vancomycin	115-125	lipocalin 2	Homo sapiens	37-79
29028077-9	2017	CONCLUSIONS: Urinary KIM-1 and NGAL could efficiently discriminate patients with or without vancomycin-associated AKI earlier than Scr, and the combined urinary biomarkers showed fair discrimination compared with the individual biomarkers.	Vancomycin	92-102	hepatitis A virus cellular receptor 1	Homo sapiens	21-26
29028077-9	2017	CONCLUSIONS: Urinary KIM-1 and NGAL could efficiently discriminate patients with or without vancomycin-associated AKI earlier than Scr, and the combined urinary biomarkers showed fair discrimination compared with the individual biomarkers.	Vancomycin	92-102	lipocalin 2	Homo sapiens	31-35
28549670-9	2017	Cilastatin attenuated vancomycin-induced ROS production and apoptosis, and it also attenuated vancomycin-induced P-gp suppression.	Vancomycin	94-104	phosphoglycolate phosphatase	Mus musculus	113-117
28549670-13	2017	Bax/Bcl-2 ratio were significantly increased in the vancomycin-treated kidney.	Vancomycin	52-62	BCL2-associated X protein	Mus musculus	0-3
28549670-13	2017	Bax/Bcl-2 ratio were significantly increased in the vancomycin-treated kidney.	Vancomycin	52-62	B cell leukemia/lymphoma 2	Mus musculus	4-9
28764660-0	2017	Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest  macromethod among patients with MRSA bloodstream infections: a pilot study.	Vancomycin	37-47	mitochondrial antiviral signaling protein	Homo sapiens	154-159
28764660-0	2017	Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest  macromethod among patients with MRSA bloodstream infections: a pilot study.	Vancomycin	107-117	mitochondrial antiviral signaling protein	Homo sapiens	154-159
28764660-1	2017	BACKGROUND: In vitro data suggests that suboptimal initial vancomycin exposure may select for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections.	Vancomycin	59-69	mitochondrial antiviral signaling protein	Homo sapiens	155-160
28764660-1	2017	BACKGROUND: In vitro data suggests that suboptimal initial vancomycin exposure may select for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections.	Vancomycin	108-118	mitochondrial antiviral signaling protein	Homo sapiens	155-160
28764660-2	2017	However, no clinical studies have evaluated the relationship between initial vancomycin exposure and emergence of hVISA.	Vancomycin	77-87	mitochondrial antiviral signaling protein	Homo sapiens	114-119
28764660-3	2017	This pilot study seeks to assess the relationship between day 1 and day 2 vancomycin area under the curve (AUC) and emergence of hVISA bloodstream infections (BSIs) by Etest  macromethod among patients with a non-hVISA BSI at baseline.	Vancomycin	74-84	mitochondrial antiviral signaling protein	Homo sapiens	129-134
28764660-10	2017	CONCLUSIONS: Although more data are needed to draw definitive conclusions, these findings suggest that hVISA emergence among patients with non-hVISA MRSA BSIs at baseline may be partially explained by suboptimal exposure to vancomycin in the first 1 to 2 days of therapy.	Vancomycin	224-234	mitochondrial antiviral signaling protein	Homo sapiens	103-108
28764660-11	2017	At a minimum, these findings support further study of the relationship between initial vancomycin exposure and hVISA emergence among patients with MRSA BSIs in a well-powered, multi-center, prospective trial.	Vancomycin	87-97	mitochondrial antiviral signaling protein	Homo sapiens	111-116
26442675-7	2017	In all, 223 isolates were identified with phenotypic vancomycin resistance (vanA, n = 108; vanB, n = 105; non-vanA/vanB = 10), with complete agreement between PCR and phenotypic testing for vancomycin-resistant E. faecium and E. faecalis.	Vancomycin	53-63	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	76-80
28584147-3	2017	In this study, IS256 has been shown to play a role, e.g., in S. aureus strains displaying intermediate resistance to vancomycin (VISA).	Vancomycin	117-127	IS256, transposase	Staphylococcus aureus	15-20
28552898-5	2017	Results indicated that the vancomycin-coated sample was biocompatible for Human osteoblast cell line MG-63 and displayed effective antibacterial ability against MRSA.	Vancomycin	27-37	solute carrier family 9 member A6	Homo sapiens	161-165
27844416-6	2017	The resolving powers of prepared columns for enantiomers resolution were changed with the variation in vancomycin-CDP coverage on the silica support.	Vancomycin	103-113	cut like homeobox 1	Homo sapiens	114-117
29063889-1	2017	The aim of this study was to observe the survivability and fitness cost of heterogeneous vancomycin-intermediate Staphylococcus aureus(hVISA) isolates.	Vancomycin	89-99	mitochondrial antiviral signaling protein	Homo sapiens	135-140
28406088-10	2017	CONCLUSION: This study initially established a vancomycin PPK model to estimate individual PK parameters in Chinese infant patients.	Vancomycin	47-57	kallikrein B1	Homo sapiens	58-61
29016585-14	2017	CONCLUSIONS: This study showed that patient"s medical charts were contaminated with multidrug resistant bacteria including methicillin resistant S. aureus and vancomycin resistant Enterococcus spp.	Vancomycin	159-169	histocompatibility minor 13	Homo sapiens	193-196
28640009-11	2017	Median vancomycin clearance in those with versus without augmented renal clearance were 141.3 and 91.7 mL/min/1.73 m, respectively (p &lt; 0.001).	Vancomycin	7-17	CD59 molecule (CD59 blood group)	Homo sapiens	106-111
28640009-15	2017	CONCLUSIONS: Augmented renal clearance was identified in one of 10 critically ill pediatric patients using vancomycin clearance, with an increase of approximately 50 mL/min/1.73 m in those with augmented renal clearance.	Vancomycin	107-117	CD59 molecule (CD59 blood group)	Homo sapiens	169-174
28824185-6	2017	Patients with MRSA infection were additionally administered intravenous vancomycin in combination with either oral rifampicin or trimethoprim-sulfamethoxazole.	Vancomycin	72-82	solute carrier family 9 member A6	Homo sapiens	14-18
28109847-0	2017	High frequency of SCCmec type V and agr type I among heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in north India.	Vancomycin	67-77	mitochondrial antiviral signaling protein	Homo sapiens	114-119
28052987-5	2017	Here, we tested the hypothesis that cilastatin also blocks megalin-mediated uptake of vancomycin, cisplatin, colistin, and aminoglycosides, thereby limiting the nephrotoxicity of these drugs.	Vancomycin	86-96	low density lipoprotein receptor-related protein 2	Mus musculus	59-66
28052987-6	2017	Quartz crystal microbalance analysis showed that megalin also binds vancomycin and cisplatin and that cilastatin competes with megalin for binding to gentamicin, colistin, vancomycin, and cisplatin.	Vancomycin	68-78	low density lipoprotein receptor-related protein 2	Mus musculus	49-56
28052987-6	2017	Quartz crystal microbalance analysis showed that megalin also binds vancomycin and cisplatin and that cilastatin competes with megalin for binding to gentamicin, colistin, vancomycin, and cisplatin.	Vancomycin	172-182	low density lipoprotein receptor-related protein 2	Mus musculus	127-134
28052987-7	2017	In kidney-specific mosaic megalin knockout mice treated with colistin, vancomycin, or cisplatin, the megalin-replete proximal tubule epithelial cells exhibited signs of injury, whereas the megalin-deficient cells did not.	Vancomycin	71-81	low density lipoprotein receptor-related protein 2	Mus musculus	26-33
28052987-7	2017	In kidney-specific mosaic megalin knockout mice treated with colistin, vancomycin, or cisplatin, the megalin-replete proximal tubule epithelial cells exhibited signs of injury, whereas the megalin-deficient cells did not.	Vancomycin	71-81	low density lipoprotein receptor-related protein 2	Mus musculus	101-108
28052987-7	2017	In kidney-specific mosaic megalin knockout mice treated with colistin, vancomycin, or cisplatin, the megalin-replete proximal tubule epithelial cells exhibited signs of injury, whereas the megalin-deficient cells did not.	Vancomycin	71-81	low density lipoprotein receptor-related protein 2	Mus musculus	101-108
28052987-10	2017	In conclusion, megalin blockade with cilastatin efficiently suppresses the nephrotoxicity induced by gentamicin, colistin, vancomycin, or cisplatin.	Vancomycin	123-133	low density lipoprotein receptor-related protein 2	Mus musculus	15-22
28131530-0	2017	Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project.	Vancomycin	18-28	cystatin C	Homo sapiens	0-10
28131530-1	2017	BACKGROUND: The aim of the study was to determine whether a vancomycin dosing algorithm based on estimated glomerular filtration rate from creatinine and cystatin C levels (eGFRcr-cys) improves target trough concentration achievement compared to an algorithm based on estimated creatinine clearance (eCLcr) in critically ill patients.	Vancomycin	60-70	cystatin C	Homo sapiens	154-164
28403346-12	2017	Decreased levels of VEGF due to infection reversed by ozone therapy in control and vancomycin groups.	Vancomycin	83-93	vascular endothelial growth factor A	Rattus norvegicus	20-24
27590877-1	2017	BACKGROUND AND OBJECTIVES: During a community methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization study, an MRSA strain with vancomycin hetero-resistance (h-VISA) was isolated from a five year-old girl with tetralogy of Fallot without previous exposure to vancomycin.	Vancomycin	143-153	mitochondrial antiviral signaling protein	Homo sapiens	175-179
27590877-1	2017	BACKGROUND AND OBJECTIVES: During a community methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization study, an MRSA strain with vancomycin hetero-resistance (h-VISA) was isolated from a five year-old girl with tetralogy of Fallot without previous exposure to vancomycin.	Vancomycin	274-284	mitochondrial antiviral signaling protein	Homo sapiens	175-179
28413476-9	2017	The comparative difference among groups was statistically significant (P&lt;0.05); those in the HBD-3 group and vancomycin group at each time-point was decreased significantly compared with the model group, and the difference among groups was statistically significant (P&lt;0.05), but in terms of the comparison between the HBD-3 group and vancomycin group, the difference was not significantly different (P&gt;0.05).	Vancomycin	112-122	defensin beta 103B	Homo sapiens	325-330
28413476-9	2017	The comparative difference among groups was statistically significant (P&lt;0.05); those in the HBD-3 group and vancomycin group at each time-point was decreased significantly compared with the model group, and the difference among groups was statistically significant (P&lt;0.05), but in terms of the comparison between the HBD-3 group and vancomycin group, the difference was not significantly different (P&gt;0.05).	Vancomycin	341-351	defensin beta 103B	Homo sapiens	96-101
28566074-16	2017	In vancomycin-sensitive enterococcus (VSE) species, esp gene activity was 35.1% for E.faecalis, 29.4% for E.faecium, asa1 gene activity was 60.8% for E.faecalis and 47.1% for E.faecium, hemolysin activity was 52.8% for E.faecalis and 23.5% for E.faecium.	Vancomycin	3-13	aggregation substance	Enterococcus faecalis	117-121
28104238-6	2017	The multi-stacking and analysis time for vancomycin were 50s and 250s respectively, with SEF of approximately 83 when compared to typical gated injection.	Vancomycin	41-51	transcription factor CP2	Homo sapiens	89-92
27896877-9	2017	Our results indicated that BCGE promoted bone repair via increasing the bone mass, the volume of bone, promoting osteocalcin secretion after vancomycin-calcium sulfate treatment.	Vancomycin	141-151	osteocalcin	Oryctolagus cuniculus	113-124
28139739-0	2017	Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.	Vancomycin	35-45	mitochondrial antiviral signaling protein	Homo sapiens	177-182
28139739-0	2017	Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.	Vancomycin	35-45	mitochondrial antiviral signaling protein	Homo sapiens	178-182
28139739-0	2017	Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	177-182
28139739-0	2017	Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	178-182
28139739-3	2017	The PAP/AUC MIC curve shifted left after addition of cephalosporins with vancomycin or teicoplanin for both h-VISA and VISA isolates.	Vancomycin	73-83	mitochondrial antiviral signaling protein	Homo sapiens	110-114
28139739-3	2017	The PAP/AUC MIC curve shifted left after addition of cephalosporins with vancomycin or teicoplanin for both h-VISA and VISA isolates.	Vancomycin	73-83	mitochondrial antiviral signaling protein	Homo sapiens	119-123
28139739-5	2017	These decreases ranged between 1.81-2.02 and 2.37-2.85-fold for h-VISA treated with cephalosporins and vancomycin or teicoplanin, and 2.05-4.59, and 2.93-4,89-fold for VISA treated with cephalosporins with vancomycin or teicoplanin.	Vancomycin	103-113	mitochondrial antiviral signaling protein	Homo sapiens	66-70
28139739-6	2017	As measured by time-killing assays, the combinations of different cephalosporins with vancomycin concentrations at 1/2 and 1/4 MIC, exhibited a bactericidal and bacteriostatic effect in VISA.	Vancomycin	86-96	mitochondrial antiviral signaling protein	Homo sapiens	186-190
28139739-7	2017	The mean fold of MIC decline for vancomycin base combinations ranged from 1.81-3.83 and 2.71-9.33 for h-VISA and VISA, respectively.	Vancomycin	33-43	mitochondrial antiviral signaling protein	Homo sapiens	104-108
28139739-7	2017	The mean fold of MIC decline for vancomycin base combinations ranged from 1.81-3.83 and 2.71-9.33 for h-VISA and VISA, respectively.	Vancomycin	33-43	mitochondrial antiviral signaling protein	Homo sapiens	113-117
28139739-8	2017	Overall, this study demonstrated the enhanced antibacterial activity of vancomycin/teicoplanin after adding cephalosporins against clinical h-VISA/VISA isolates.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	142-146
28139739-8	2017	Overall, this study demonstrated the enhanced antibacterial activity of vancomycin/teicoplanin after adding cephalosporins against clinical h-VISA/VISA isolates.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	147-151
28034757-12	2017	Vancomycin treatment diminished the upstream IL-23 and producer dendritic cell population.	Vancomycin	0-10	interleukin 23, alpha subunit p19	Mus musculus	45-50
28034757-14	2017	CONCLUSION: Presence of vancomycin-sensitive microbiota is required for the maturation of ILC3-activating dendritic cells hence maintain the sufficient IL-22/pSTAT3 level in the colon during tissue healing.	Vancomycin	24-34	interleukin 22	Mus musculus	152-157
28109847-1	2017	OBJECTIVES: The objective of this study was to compare the genetic features of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-sensitive methicillin-resistant S. aureus (VS-MRSA) isolates.	Vancomycin	93-103	mitochondrial antiviral signaling protein	Homo sapiens	140-145
28109847-11	2017	The changing molecular epidemiology and role of agr I in reduced vancomycin susceptibility in hVISA requires further investigation.	Vancomycin	65-75	mitochondrial antiviral signaling protein	Homo sapiens	94-99
27855063-4	2017	Whole-genome sequencing demonstrated that ileS, encoding isoleucyl-tRNA synthetase (IleRS), was mutated in two of the three vancomycin survivor strains.	Vancomycin	124-134	isoleucyl-tRNA synthetase	Staphylococcus aureus	42-46
27855063-4	2017	Whole-genome sequencing demonstrated that ileS, encoding isoleucyl-tRNA synthetase (IleRS), was mutated in two of the three vancomycin survivor strains.	Vancomycin	124-134	isoleucyl-tRNA synthetase	Staphylococcus aureus	57-82
27855063-4	2017	Whole-genome sequencing demonstrated that ileS, encoding isoleucyl-tRNA synthetase (IleRS), was mutated in two of the three vancomycin survivor strains.	Vancomycin	124-134	isoleucyl-tRNA synthetase	Staphylococcus aureus	84-89
27855063-5	2017	The IleRS Y723H mutation is located close to the isoleucyl-tRNA contact site and potentially affects the affinity of IleRS binding to isoleucyl-tRNA, thereby inhibiting protein synthesis and leading to vancomycin tolerance.	Vancomycin	202-212	isoleucyl-tRNA synthetase	Staphylococcus aureus	4-9
27855063-5	2017	The IleRS Y723H mutation is located close to the isoleucyl-tRNA contact site and potentially affects the affinity of IleRS binding to isoleucyl-tRNA, thereby inhibiting protein synthesis and leading to vancomycin tolerance.	Vancomycin	202-212	isoleucyl-tRNA synthetase	Staphylococcus aureus	117-122
27855063-6	2017	Introduction of the mutation encoding IleRS Y723H into FDA209P by allelic replacement successfully transferred the vancomycin tolerance phenotype.	Vancomycin	115-125	isoleucyl-tRNA synthetase	Staphylococcus aureus	38-43
27855063-7	2017	We have identified mutation of ileS to be one of the bona fide genetic events leading to the acquisition of vancomycin tolerance in S. aureus, potentially acting via inhibition of the function of IleRS.	Vancomycin	108-118	isoleucyl-tRNA synthetase	Staphylococcus aureus	31-35
27855063-7	2017	We have identified mutation of ileS to be one of the bona fide genetic events leading to the acquisition of vancomycin tolerance in S. aureus, potentially acting via inhibition of the function of IleRS.	Vancomycin	108-118	isoleucyl-tRNA synthetase	Staphylococcus aureus	196-201
28203378-0	2017	Screening for vancomycin-resistant enterococci with Xpert  vanA/vanB: diagnostic accuracy and impact on infection control decision making.	Vancomycin	14-24	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	59-63
28203378-0	2017	Screening for vancomycin-resistant enterococci with Xpert  vanA/vanB: diagnostic accuracy and impact on infection control decision making.	Vancomycin	14-24	D-alanine--D-lactate ligase	Enterococcus faecium	64-68
27720209-1	2016	We investigated the prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) among methicillin-resistant S. aureus (MRSA) blood isolates collected from Korean hospitals.	Vancomycin	48-58	mitochondrial antiviral signaling protein	Homo sapiens	95-100
27747932-4	2017	Harnessing the benefits of multivalency and cooperativity against vancomycin-resistant strains, we report a Click Chemistry approach towards reengineered vancomycin derivatives and the synthesis of a number of dimers with increased potency against MRSA and vancomycin resistant Enterococci (VRE; VanB).	Vancomycin	66-76	D-alanine--D-lactate ligase	Staphylococcus aureus	296-300
27747932-4	2017	Harnessing the benefits of multivalency and cooperativity against vancomycin-resistant strains, we report a Click Chemistry approach towards reengineered vancomycin derivatives and the synthesis of a number of dimers with increased potency against MRSA and vancomycin resistant Enterococci (VRE; VanB).	Vancomycin	154-164	D-alanine--D-lactate ligase	Staphylococcus aureus	296-300
27747932-4	2017	Harnessing the benefits of multivalency and cooperativity against vancomycin-resistant strains, we report a Click Chemistry approach towards reengineered vancomycin derivatives and the synthesis of a number of dimers with increased potency against MRSA and vancomycin resistant Enterococci (VRE; VanB).	Vancomycin	154-164	D-alanine--D-lactate ligase	Staphylococcus aureus	296-300
27291466-5	2017	Vancomycin PK was well described with a 1-compartment model that identified both body weight (WT) and creatinine clearance (CRCL) as covariates significantly impacting vancomycin disposition.	Vancomycin	0-10	CRCL	Homo sapiens	124-128
27291466-5	2017	Vancomycin PK was well described with a 1-compartment model that identified both body weight (WT) and creatinine clearance (CRCL) as covariates significantly impacting vancomycin disposition.	Vancomycin	168-178	CRCL	Homo sapiens	124-128
27941921-0	2016	p53 activates miR-192-5p to mediate vancomycin induced AKI.	Vancomycin	36-46	transformation related protein 53, pseudogene	Mus musculus	0-3
27941921-0	2016	p53 activates miR-192-5p to mediate vancomycin induced AKI.	Vancomycin	36-46	microRNA 615	Mus musculus	14-17
27941921-2	2016	Here, we tested whether the inhibition of p53 may ameliorate vancomycin (VAN) induced acute kidney injury (AKI).	Vancomycin	61-71	transformation related protein 53, pseudogene	Mus musculus	42-45
27941921-2	2016	Here, we tested whether the inhibition of p53 may ameliorate vancomycin (VAN) induced acute kidney injury (AKI).	Vancomycin	73-76	transformation related protein 53, pseudogene	Mus musculus	42-45
27941921-6	2016	In human renal tubular epithelial cell line (HK-2), VAN induced p53 accumulation and miR-192-5p expression.	Vancomycin	52-55	tumor protein p53	Homo sapiens	64-67
27941921-6	2016	In human renal tubular epithelial cell line (HK-2), VAN induced p53 accumulation and miR-192-5p expression.	Vancomycin	52-55	MLX interacting protein	Homo sapiens	85-88
27941921-8	2016	Anti-miR-192-5p significantly blocked VAN-induced apoptosis and caspase activity in HK-2 cells.	Vancomycin	38-41	microRNA 615	Mus musculus	5-8
27981301-9	2016	Moreover, the analysis of the level of alkaline phosphatase (ALP) in the vancomycin group showed a significant decrease in the third month of treatment as compared to its level in the first month (mean difference 3rd month -1st month = -142.92, Decrease rate= -18.24%, p=0.02).	Vancomycin	73-83	alkaline phosphatase, placental	Homo sapiens	39-59
27530754-8	2016	The IRR incidence was 22% for ceftaroline patients and 30% for vancomycin patients; OR = 0.66 (95% CI = 0.27-1.62; P = 0.362).	Vancomycin	63-73	insulin receptor related receptor	Homo sapiens	4-7
26990514-0	2016	First Report on Vancomycin-Resistant Staphylococcus aureus in Bovine and Caprine Milk.	Vancomycin	16-26	Weaning weight-maternal milk	Bos taurus	81-85
27981301-9	2016	Moreover, the analysis of the level of alkaline phosphatase (ALP) in the vancomycin group showed a significant decrease in the third month of treatment as compared to its level in the first month (mean difference 3rd month -1st month = -142.92, Decrease rate= -18.24%, p=0.02).	Vancomycin	73-83	alkaline phosphatase, placental	Homo sapiens	61-64
27981301-10	2016	Among secondary endpoints, erythrocyte sedimentation rate (p=0.005), gamma-glutamyl transpeptidase (p=0.02) and patients" symptoms including fatigue, pruritus, diarrhea and anorexia showed a significant decrease in the vancomycin group.	Vancomycin	219-229	inactive glutathione hydrolase 2	Homo sapiens	69-98
26675586-0	2016	Vancomycin-resistant Enterococcus faecium with vanA gene isolated for the first time from wildlife in Slovakia.	Vancomycin	0-10	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	47-51
27640164-0	2016	vanA-targeted oligonucleotide DNA probe designed to monitor vancomycin- and teicoplanin-resistant bacteria in surface waters.	Vancomycin	60-70	VanA	Enterococcus faecalis	0-4
27640164-8	2016	The results showed that the vanA-targeted oligonucleotide DNA probe prepared was not only highly specific but also quantitative tool for monitoring vancomycin- and teicoplanin-resistant bacteria in surface waters.	Vancomycin	148-158	VanA	Enterococcus faecalis	28-32
27895857-0	2016	Frequency of VanA, VanB and VanH variants amongst vancomycin-resistant enterococci isolated from patients in central region of Iran.	Vancomycin	50-60	VanA	Enterococcus faecalis	13-17
26320398-0	2016	Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	61-65
26320398-2	2016	A surveillance study in 2003 showed that the prevalence rates of vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) in Taiwan were 0.2% and 0.7%, respectively.	Vancomycin	65-75	mitochondrial antiviral signaling protein	Homo sapiens	100-104
26320398-12	2016	A twofold increase in either vancomycin or teicoplanin MIC doubled the probability of being hVISA.	Vancomycin	29-39	mitochondrial antiviral signaling protein	Homo sapiens	92-97
27895857-0	2016	Frequency of VanA, VanB and VanH variants amongst vancomycin-resistant enterococci isolated from patients in central region of Iran.	Vancomycin	50-60	VanH	Enterococcus faecalis	28-32
27895857-3	2016	Genes, vanA, B, and H contribute to the influence of vancomycin-resistant enterococci (VRE).	Vancomycin	53-63	VanA	Enterococcus faecalis	7-11
27154328-0	2016	Increase in IS256 transposition in invasive vancomycin heteroresistant Staphylococcus aureus isolate belonging to ST100 and its derived VISA mutants.	Vancomycin	44-54	IS256, transposase	Staphylococcus aureus	12-17
27480862-7	2016	Sequence data for the ermB-containing region (14,566 bp) from ST59 NTUH_3874 revealed that the best match was a Tn1546-like element in plasmid pMCCL2 DNA (GenBank accession number AP009486) of Macrococcus caseolyticus Tn1546 is recognized as an enterococcal transposon and was known from the vancomycin resistance gene cluster in vancomycin-resistant Enterococcus (VRE).	Vancomycin	292-302	erythromycin resistance methylase	Enterococcus faecium	22-26
27480862-7	2016	Sequence data for the ermB-containing region (14,566 bp) from ST59 NTUH_3874 revealed that the best match was a Tn1546-like element in plasmid pMCCL2 DNA (GenBank accession number AP009486) of Macrococcus caseolyticus Tn1546 is recognized as an enterococcal transposon and was known from the vancomycin resistance gene cluster in vancomycin-resistant Enterococcus (VRE).	Vancomycin	330-340	erythromycin resistance methylase	Enterococcus faecium	22-26
27154328-0	2016	Increase in IS256 transposition in invasive vancomycin heteroresistant Staphylococcus aureus isolate belonging to ST100 and its derived VISA mutants.	Vancomycin	44-54	mitochondrial antiviral signaling protein	Homo sapiens	136-140
27154328-2	2016	This study describes the molecular characterization of two clinical heterogeneous vancomycin-intermediate S. aureus (hVISA) isolates recovered from the same patient (before and after antibiotic treatment) and two VISA derivatives obtained by serial passages in the presence of vancomycin.	Vancomycin	82-92	mitochondrial antiviral signaling protein	Homo sapiens	117-122
27154328-2	2016	This study describes the molecular characterization of two clinical heterogeneous vancomycin-intermediate S. aureus (hVISA) isolates recovered from the same patient (before and after antibiotic treatment) and two VISA derivatives obtained by serial passages in the presence of vancomycin.	Vancomycin	82-92	mitochondrial antiviral signaling protein	Homo sapiens	118-122
27530846-9	2016	PCR analysis revealed that all of the strains were resistant to vancomycin owing to possession of the vanA gene.	Vancomycin	64-74	VanA	Enterococcus faecalis	102-106
27738604-2	2016	We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin.	Vancomycin	304-314	PSC	Homo sapiens	54-57
27738604-4	2016	Oral vancomycin may be a promising treatment for PSC that needs to be further studied in randomized trials.	Vancomycin	5-15	PSC	Homo sapiens	49-52
26589756-0	2016	Phenotypic and genotypic characterization of vancomycin-resistant Enterococcus faecium clinical isolates from two hospitals in Mexico: First detection of VanB phenotype-vanA genotype.	Vancomycin	45-55	D-alanine--D-lactate ligase	Enterococcus faecium	154-158
27203524-6	2016	Administration of spirulina and pycnogenol alone or in combination decreased elevated serum creatinine, blood urea nitrogen, renal malondialdehyde, and immunoexpression of the proapoptotic protein (Bax), autophagic marker protein (LC3/B), and inducible nitric oxide synthase induced by vancomycin.	Vancomycin	286-296	BCL2 associated X, apoptosis regulator	Rattus norvegicus	198-201
26589756-0	2016	Phenotypic and genotypic characterization of vancomycin-resistant Enterococcus faecium clinical isolates from two hospitals in Mexico: First detection of VanB phenotype-vanA genotype.	Vancomycin	45-55	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	169-173
26589756-8	2016	Two VanB phenotype-vanA genotype isolates, highly resistant to vancomycin and susceptible to teicoplanin, were detected.	Vancomycin	63-73	D-alanine--D-lactate ligase	Enterococcus faecium	4-8
26589756-8	2016	Two VanB phenotype-vanA genotype isolates, highly resistant to vancomycin and susceptible to teicoplanin, were detected.	Vancomycin	63-73	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	19-23
27217583-7	2016	We further show that vancomycin only decreased lung IL-17 production in mice colonized with SFB.	Vancomycin	21-31	interleukin 17A	Mus musculus	52-57
27713673-10	2016	CONCLUSIONS: Combination therapy with vancomycin and TZP is potentially more nephrotoxic than vancomycin alone.	Vancomycin	94-104	PHD finger protein 20	Homo sapiens	53-56
27015520-8	2016	In another patient Enterococcus in the CSF sample was detected the day after abdominal surgery with ileostomy (infection resolved with intrathecal vancomycin).	Vancomycin	147-157	colony stimulating factor 2	Homo sapiens	39-42
30044904-0	2016	Fecal Microbiota Transplantation in Recurrent NAP1/B1/027 Clostridium Difficile Infection (CDI) Resistant to Vancomycin and Metronidazole in a Patient with Ulcerative Colitis (UC): A Case Report.	Vancomycin	109-119	nucleosome assembly protein 1 like 1	Homo sapiens	46-50
27139479-8	2016	Furthermore, the VVE had an insertion of IS1542 between orf2 and vanR that attenuated the expression of vanHAX Growth of susceptible VVE occurred after 24 to 72 h of exposure to vancomycin due to excision of the ISL3-family element.	Vancomycin	178-188	ORF2	Enterococcus faecalis	56-60
27139479-8	2016	Furthermore, the VVE had an insertion of IS1542 between orf2 and vanR that attenuated the expression of vanHAX Growth of susceptible VVE occurred after 24 to 72 h of exposure to vancomycin due to excision of the ISL3-family element.	Vancomycin	178-188	two component regulator protein	Enterococcus faecalis	65-69
27067329-1	2016	Complete reconstitution of the vancomycin-intermediate Staphylococcus aureus (VISA) phenotype of strain Mu50 was achieved by sequentially introducing mutations into six genes of vancomycin-susceptible S. aureus (VSSA) strain N315DeltaIP.	Vancomycin	31-41	mitochondrial antiviral signaling protein	Homo sapiens	78-82
27112833-3	2016	Multiplex PCR and sequencing methods were used to detect gelE, esp and asa1 genes in enterococci with intermediate or full resistance to vancomycin.	Vancomycin	137-147	protein tyrosine phosphatase receptor type V, pseudogene	Homo sapiens	63-66
27067329-1	2016	Complete reconstitution of the vancomycin-intermediate Staphylococcus aureus (VISA) phenotype of strain Mu50 was achieved by sequentially introducing mutations into six genes of vancomycin-susceptible S. aureus (VSSA) strain N315DeltaIP.	Vancomycin	178-188	mitochondrial antiviral signaling protein	Homo sapiens	78-82
27067329-4	2016	Introduction of two more mutations, Asn197Ser into graR of the graSR TCR system and His481Tyr into rpoB, encoding the beta subunit of RNA polymerase, converted the hVISA strain into a VISA strain with the same level of vancomycin resistance as Mu50.	Vancomycin	219-229	mitochondrial antiviral signaling protein	Homo sapiens	164-169
26899719-6	2016	The gentamicin, vancomycin, amikacin and ceftriaxone beads all inhibited growth of the MRSA on the TSB and agar plates, both before and after gas sterilisation.	Vancomycin	16-26	solute carrier family 9 member A6	Homo sapiens	87-91
26915612-1	2016	BACKGROUND: We estimated the prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).	Vancomycin	77-87	mitochondrial antiviral signaling protein	Homo sapiens	124-129
27166038-1	2016	BACKGROUND: The aim of this study was to find out the clinical correlation between the presence of vancomycin-resistant genes (van A and van B) and their expression as detected by phenotypic tests in colonized patients and in clinical isolates.	Vancomycin	99-109	VanA	Enterococcus faecalis	127-132
26865694-1	2016	Vancomycin-intermediateStaphylococcus aureus(VISA) and heteroresistant VISA (hVISA) are pathogens for which accurate antimicrobial susceptibility testing (AST) would rule out standard treatment with vancomycin.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	45-49
26865694-1	2016	Vancomycin-intermediateStaphylococcus aureus(VISA) and heteroresistant VISA (hVISA) are pathogens for which accurate antimicrobial susceptibility testing (AST) would rule out standard treatment with vancomycin.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	77-82
26865694-1	2016	Vancomycin-intermediateStaphylococcus aureus(VISA) and heteroresistant VISA (hVISA) are pathogens for which accurate antimicrobial susceptibility testing (AST) would rule out standard treatment with vancomycin.	Vancomycin	199-209	mitochondrial antiviral signaling protein	Homo sapiens	45-49
26865694-1	2016	Vancomycin-intermediateStaphylococcus aureus(VISA) and heteroresistant VISA (hVISA) are pathogens for which accurate antimicrobial susceptibility testing (AST) would rule out standard treatment with vancomycin.	Vancomycin	199-209	mitochondrial antiviral signaling protein	Homo sapiens	71-75
26865694-1	2016	Vancomycin-intermediateStaphylococcus aureus(VISA) and heteroresistant VISA (hVISA) are pathogens for which accurate antimicrobial susceptibility testing (AST) would rule out standard treatment with vancomycin.	Vancomycin	199-209	mitochondrial antiviral signaling protein	Homo sapiens	77-82
26724739-8	2016	Vancomycin increased expression of esp (+89.1%) but reduced the others (asa1: -34.9%, ebpA:-11%, ace:-30%, efaA:-60%).	Vancomycin	0-10	aggregation substance	Enterococcus faecalis	72-76
26565015-1	2016	MRSA bacteraemia (MRSAB), including infective endocarditis, carries a high mortality rate, with up to 50% of patients failing initial therapy with vancomycin and requiring salvage therapy.	Vancomycin	147-157	solute carrier family 9 member A6	Homo sapiens	0-4
26902259-2	2016	Vancomycin resistant enterococci represent one such example of a prominent nosocomial pathogen on which nation-wide population analyses on prevalent lineages are scarce and data on how the bacteria acquire resistance, especially of the vanB genotype, are still under debate.	Vancomycin	0-10	D-alanine--D-lactate ligase	Enterococcus faecium	236-240
26912904-0	2016	TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus.	Vancomycin	73-83	toll like receptor 7	Homo sapiens	0-5
26912904-0	2016	TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus.	Vancomycin	73-83	interleukin 22	Homo sapiens	26-31
28078058-11	2016	VanA was dominant phenotype and all VRE isolates with high-level of vancomycin resistance had vanA gene.	Vancomycin	68-78	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	94-98
26678143-7	2016	A total of 15 (57.7%) of the 26 vancomycin-resistant isolates harboured the vanA gene.	Vancomycin	32-42	VanA	Enterococcus faecalis	76-80
27713836-6	2016	Several forms of the Tn1549-like element-vanB gene cluster, which was exclusively responsible for vancomycin resistance, appeared and spread within the hospital during the study period.	Vancomycin	98-108	D-alanine--D-lactate ligase	Enterococcus faecium	41-45
26729497-2	2016	There is concern regarding the emergence of vancomycin tolerance, caused by heterogeneous vancomycin-intermediate S. aureus (hVISA), and subsequent vancomycin treatment failure.	Vancomycin	44-54	mitochondrial antiviral signaling protein	Homo sapiens	125-130
26729497-2	2016	There is concern regarding the emergence of vancomycin tolerance, caused by heterogeneous vancomycin-intermediate S. aureus (hVISA), and subsequent vancomycin treatment failure.	Vancomycin	90-100	mitochondrial antiviral signaling protein	Homo sapiens	125-130
26729497-2	2016	There is concern regarding the emergence of vancomycin tolerance, caused by heterogeneous vancomycin-intermediate S. aureus (hVISA), and subsequent vancomycin treatment failure.	Vancomycin	90-100	mitochondrial antiviral signaling protein	Homo sapiens	125-130
28078058-15	2016	The vancomycin-resistant isolates of E.faecium had vanA and/or simultaneously vanB genes.	Vancomycin	4-14	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	51-55
26919511-0	2016	Pre-Treatment Serum C-Reactive Protein Level Is An Independent Risk Factor for Development of Nephrotoxicity in Patients Receiving High-Dose Vancomycin.	Vancomycin	141-151	C-reactive protein	Homo sapiens	20-38
26652225-14	2016	The ratio of immature (vWF+) to more mature (CD31+) blood vessels increased significantly in groups Palacos+Gentamycin and Copal Gentamycin+Vancomycin whereas no significant alterations were noted in groups Copal+Gentamycin+Clindamycin and Copal Spacem.	Vancomycin	140-150	von Willebrand factor	Rattus norvegicus	23-26
26919511-3	2016	In this study, we evaluated the pre-treatment serum CRP level as a risk factor of the development of nephrotoxicity in patients receiving high total daily doses (&gt;2.5 g) of vancomycin.	Vancomycin	176-186	C-reactive protein	Homo sapiens	52-55
26919511-5	2016	Univariate analyses showed that patients who developed nephrotoxicity during vancomycin treatment had significantly higher median vancomycin serum concentration, duration of vancomycin treatment, and the serum CRP level within 24 h before vancomycin treatment than the non-nephrotoxicity group.	Vancomycin	77-87	C-reactive protein	Homo sapiens	210-213
26919511-6	2016	Multivariate logistic regression analysis showed that after adjustment for potential confounders, median vancomycin serum concentration, duration of treatment, serum CRP level within 24 h before vancomycin treatment, and nephrotoxic medication were found significantly associated with the development of nephrotoxicity.	Vancomycin	195-205	C-reactive protein	Homo sapiens	166-169
26919511-8	2016	In conclusion, this study provides the first evidence supporting the fact that the serum CRP level within 24 h before vancomycin treatment is an independent risk factor for the development of nephrotoxicity in patients receiving total daily doses of &gt;2.5 g of vancomycin.	Vancomycin	118-128	C-reactive protein	Homo sapiens	89-92
26919511-8	2016	In conclusion, this study provides the first evidence supporting the fact that the serum CRP level within 24 h before vancomycin treatment is an independent risk factor for the development of nephrotoxicity in patients receiving total daily doses of &gt;2.5 g of vancomycin.	Vancomycin	263-273	C-reactive protein	Homo sapiens	89-92
26919511-9	2016	Therefore, the serum CRP level within 24 h before vancomycin treatment could be a potential biomarker or prognostic factor for the development of vancomycin nephrotoxicity.	Vancomycin	50-60	C-reactive protein	Homo sapiens	21-24
26919511-9	2016	Therefore, the serum CRP level within 24 h before vancomycin treatment could be a potential biomarker or prognostic factor for the development of vancomycin nephrotoxicity.	Vancomycin	146-156	C-reactive protein	Homo sapiens	21-24
26636619-2	2015	Covalently linking unacylated tridecaptin A1 (H-TriA1) to rifampicin, vancomycin, and erythromycin enhanced their activity in vitro but not by the same magnitude as coadministration of the peptide and these antibiotics.	Vancomycin	70-80	T cell receptor induced activation 1	Mus musculus	48-53
26666947-10	2016	The isolates positive for qacA/B were more often associated with indwelling central venous catheters and a vancomycin MIC of &gt;=2 mug/ml.	Vancomycin	107-117	QacA	Staphylococcus aureus	26-32
27528869-5	2016	Patients carrying MSSA and MRSA were treated preoperatively with mupirocin and vancomycin, respectively, along with the standard preoperative antibiotics and chlorhexidine body wipes.	Vancomycin	79-89	solute carrier family 9 member A6	Homo sapiens	27-31
26459889-3	2015	Increased biofilm formation by hVISA may be mediated by FnbA- and polysaccharide intercellular adhesin-dependent pathways, and upregulation of atlA and sarA may also contribute to enhanced biofilm formation by hVISA upon prolonged exposure to vancomycin.	Vancomycin	243-253	mitochondrial antiviral signaling protein	Homo sapiens	31-36
26459889-3	2015	Increased biofilm formation by hVISA may be mediated by FnbA- and polysaccharide intercellular adhesin-dependent pathways, and upregulation of atlA and sarA may also contribute to enhanced biofilm formation by hVISA upon prolonged exposure to vancomycin.	Vancomycin	243-253	mitochondrial antiviral signaling protein	Homo sapiens	210-215
26324996-0	2015	Vancomycin-Associated Nephrotoxicity: The Obesity Factor.	Vancomycin	0-10	leptin	Homo sapiens	42-56
26541549-10	2015	When enterococci were also considered, all betalactam based regimens required combination with vancomycin or linezolid for a SAR &gt; 95 %, whereas TGC based regimens were not compromised.	Vancomycin	95-105	sarcosine dehydrogenase	Homo sapiens	125-128
25919019-1	2015	There are limited data regarding the prevalence of vancomycin-intermediate Staphylococcus aureus (VISA)/heterogeneous VISA (hVISA) among pediatric population.	Vancomycin	51-61	mitochondrial antiviral signaling protein	Homo sapiens	98-102
26633120-0	2015	[Isolation of Staphylococcus aureus hetero-resistant to vancomycin (hVISA) in the Regional Hospital of Concepcion, Chile].	Vancomycin	56-66	mitochondrial antiviral signaling protein	Homo sapiens	68-73
26633120-2	2015	Vancomycin (VAN) is the antibiotic of choice for treating severe MRSA infections; however, nowadays worldwide resistant strains (VRSA), with intermediate susceptibility (VISA) and decreased susceptibility or hetero-resistance to VAN (hVISA) have been reported, related to treatment failure and increased mortality.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	170-174
26633120-2	2015	Vancomycin (VAN) is the antibiotic of choice for treating severe MRSA infections; however, nowadays worldwide resistant strains (VRSA), with intermediate susceptibility (VISA) and decreased susceptibility or hetero-resistance to VAN (hVISA) have been reported, related to treatment failure and increased mortality.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	234-239
26633120-2	2015	Vancomycin (VAN) is the antibiotic of choice for treating severe MRSA infections; however, nowadays worldwide resistant strains (VRSA), with intermediate susceptibility (VISA) and decreased susceptibility or hetero-resistance to VAN (hVISA) have been reported, related to treatment failure and increased mortality.	Vancomycin	12-15	mitochondrial antiviral signaling protein	Homo sapiens	170-174
26633120-2	2015	Vancomycin (VAN) is the antibiotic of choice for treating severe MRSA infections; however, nowadays worldwide resistant strains (VRSA), with intermediate susceptibility (VISA) and decreased susceptibility or hetero-resistance to VAN (hVISA) have been reported, related to treatment failure and increased mortality.	Vancomycin	12-15	mitochondrial antiviral signaling protein	Homo sapiens	234-239
26382940-0	2015	Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia.	Vancomycin	29-39	structural maintenance of chromosomes 3	Homo sapiens	107-138
26382940-2	2015	The objective of this study was to compare the effectiveness of vancomycin and linezolid in a national cohort of hospitalized veterans with HCAP.	Vancomycin	64-74	structural maintenance of chromosomes 3	Homo sapiens	140-144
26311860-1	2015	BHI agars supplemented with vancomycin 4 (BHI-V4) and 3 (BHI-V3) mg/liter have been proposed for screening vancomycin intermediately susceptible Staphylococcus aureus (VISA) and heteroresistant (hVISA) phenotypes, respectively, but growth interpretation criteria have not been established.	Vancomycin	107-117	mitochondrial antiviral signaling protein	Homo sapiens	168-172
26692877-0	2015	Usefulness of serum cystatin C to determine the dose of vancomycin in neonate.	Vancomycin	56-66	cystatin C	Homo sapiens	20-30
26692877-2	2015	In the present study, we aimed to assess the usefulness of serum cystatin C (Cys-C) concentration, compared with serum creatinine (SCr) concentration, for predicting vancomycin clearance (CLvcm) in neonates.	Vancomycin	166-176	cystatin C	Homo sapiens	65-75
26497595-2	2015	Methicillin-resistant S. aureus (MRSA) accounts for 64 % of S. aureus bacteremia isolated in intensive care units (ICUs), and heteroresistant vancomycin-intermediates S. aureus (hVISA) is a phenotype of MRSA.	Vancomycin	142-152	mitochondrial antiviral signaling protein	Homo sapiens	178-183
26430942-1	2015	Heterogeneous vancomycin intermediate Staphylococcus aureus (hVISA) strains are increasingly reported, and their association with vancomycin treatment failure is a well-known problem worldwide.	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	61-66
26430942-1	2015	Heterogeneous vancomycin intermediate Staphylococcus aureus (hVISA) strains are increasingly reported, and their association with vancomycin treatment failure is a well-known problem worldwide.	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	61-66
26150471-0	2015	Catalase Expression Is Modulated by Vancomycin and Ciprofloxacin and Influences the Formation of Free Radicals in Staphylococcus aureus Cultures.	Vancomycin	36-46	AT695_RS10915	Staphylococcus aureus	0-8
26198370-2	2015	We conducted a real-world analysis of antibiotic treatment, hospital resource use and clinical outcomes in patients with PVD and/or diabetes receiving linezolid or vancomycin for the treatment of methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections (MRSA cSSTIs) across Europe.	Vancomycin	164-174	solute carrier family 9 member A6	Homo sapiens	285-289
25982914-1	2015	Although heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) has been increasingly reported, the true prevalence of hVISA is unclear, especially in Asia.	Vancomycin	23-33	mitochondrial antiviral signaling protein	Homo sapiens	70-75
26143590-9	2015	The current analysis highlights the importance of determining the MIC when using vancomycin to treat patients with severe S. aureus infections and that when failure is suspected, testing for heterogeneous vancomycin-intermediate S. aureus (hVISA) may also be necessary.	Vancomycin	205-215	mitochondrial antiviral signaling protein	Homo sapiens	240-245
25919019-11	2015	The hVISA isolates represented 53.6% of isolates with vancomycin MICs of 2 mug/ml.	Vancomycin	54-64	mitochondrial antiviral signaling protein	Homo sapiens	4-9
25919019-12	2015	Also, 75% of hVISA isolates had vancomycin MICs of 2 mug/ml.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	13-18
25919019-14	2015	Based on our findings, MRSA isolates, which have vancomycin MIC of 2 mug/ml can be investigated for the presence of hVISA.	Vancomycin	49-59	mitochondrial antiviral signaling protein	Homo sapiens	116-121
26287490-1	2015	BACKGROUND: Vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) are associated with vancomycin treatment failure, and are becoming an increasing public health problem.	Vancomycin	12-22	mitochondrial antiviral signaling protein	Homo sapiens	59-63
26753283-2	2015	Hydrophilic interaction chromatography (HILIC) method has been verified to provide the glycopeptide substances with good retention and polarity selectivity, therefore, an HILIC method was developed for the analysis of vancomycin and its related impurities including norvancomycin, desvancosaminyl vancomycin, dedichloro vancomycin and crystalline degradation product (CDP-1).	Vancomycin	218-228	cut like homeobox 1	Homo sapiens	368-373
26287490-1	2015	BACKGROUND: Vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) are associated with vancomycin treatment failure, and are becoming an increasing public health problem.	Vancomycin	116-126	mitochondrial antiviral signaling protein	Homo sapiens	59-63
26287490-1	2015	BACKGROUND: Vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) are associated with vancomycin treatment failure, and are becoming an increasing public health problem.	Vancomycin	116-126	mitochondrial antiviral signaling protein	Homo sapiens	83-87
26287490-1	2015	BACKGROUND: Vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) are associated with vancomycin treatment failure, and are becoming an increasing public health problem.	Vancomycin	116-126	mitochondrial antiviral signaling protein	Homo sapiens	89-94
25735844-4	2015	Lipopolysaccharide (LPS)-activated THP-1 monocytes were incubated with LIN, VAN or DAP.	Vancomycin	76-79	GLI family zinc finger 2	Homo sapiens	35-40
26082590-2	2015	Although usually idiopathic, IgA antibody is occasionally induced by drugs (e.g., vancomycin, carbamazepine, ceftriaxone, and cyclosporine), malignancies, infections, and other causes.	Vancomycin	82-92	CD79a molecule	Homo sapiens	29-32
26258318-9	2015	Gram-positive related infections and MRSA infections occurred in 1(1.18%)/0(0%) of Vancomycin patients and 9 (9.68%)/1 (1.08%) of Daptomycin patients, respectively (P &lt; 0.02 and P = 1.00).	Vancomycin	83-93	solute carrier family 9 member A6	Homo sapiens	37-41
26213680-6	2015	The analysis showed the presence of the vanA gene in 5/24 vancomycin resistant enterococci.	Vancomycin	58-68	VanA	Enterococcus faecalis	40-44
25941225-0	2015	A mutation of RNA polymerase beta" subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".	Vancomycin	75-85	mitochondrial antiviral signaling protein	Homo sapiens	122-127
25941225-0	2015	A mutation of RNA polymerase beta" subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA".	Vancomycin	75-85	mitochondrial antiviral signaling protein	Homo sapiens	123-127
25941225-1	2015	Various mutations in the rpoB gene, which encodes the RNA polymerase beta subunit, are associated with increased vancomycin (VAN) resistance in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneously VISA (hVISA) strains.	Vancomycin	113-123	mitochondrial antiviral signaling protein	Homo sapiens	191-195
25941225-1	2015	Various mutations in the rpoB gene, which encodes the RNA polymerase beta subunit, are associated with increased vancomycin (VAN) resistance in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneously VISA (hVISA) strains.	Vancomycin	113-123	mitochondrial antiviral signaling protein	Homo sapiens	223-228
25941225-1	2015	Various mutations in the rpoB gene, which encodes the RNA polymerase beta subunit, are associated with increased vancomycin (VAN) resistance in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneously VISA (hVISA) strains.	Vancomycin	125-128	mitochondrial antiviral signaling protein	Homo sapiens	191-195
25941225-1	2015	Various mutations in the rpoB gene, which encodes the RNA polymerase beta subunit, are associated with increased vancomycin (VAN) resistance in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneously VISA (hVISA) strains.	Vancomycin	125-128	mitochondrial antiviral signaling protein	Homo sapiens	223-228
25600843-5	2015	Because most hVISA isolates have a vancomycin MIC of 2 mug/mL, we recommend screening MRSA isolates first using Etest for those with an MIC of 2 mug/mL and then performing the delta-hemolysis assay on these isolates for hVISA.	Vancomycin	35-45	mitochondrial antiviral signaling protein	Homo sapiens	13-18
25970503-10	2015	Massive elimination of IL-17-producing cells, both CD4+TCRalphabeta+ and TCRgammadelta+ T cells was observed in the lamina propria of the ileum and the colon of vancomycin-treated mice.	Vancomycin	161-171	interleukin 17A	Mus musculus	23-28
26030142-6	2015	Variation in this region on chromosome 6, which includes the genes TBC1D32/C6orf170 and GJA1 (encoding connexin43), may modulate risk of vancomycin-induced kidney injury.	Vancomycin	137-147	TBC1 domain family member 32	Homo sapiens	67-74
26030142-6	2015	Variation in this region on chromosome 6, which includes the genes TBC1D32/C6orf170 and GJA1 (encoding connexin43), may modulate risk of vancomycin-induced kidney injury.	Vancomycin	137-147	TBC1 domain family member 32	Homo sapiens	75-83
26030142-6	2015	Variation in this region on chromosome 6, which includes the genes TBC1D32/C6orf170 and GJA1 (encoding connexin43), may modulate risk of vancomycin-induced kidney injury.	Vancomycin	137-147	gap junction protein alpha 1	Homo sapiens	88-92
26030142-6	2015	Variation in this region on chromosome 6, which includes the genes TBC1D32/C6orf170 and GJA1 (encoding connexin43), may modulate risk of vancomycin-induced kidney injury.	Vancomycin	137-147	gap junction protein alpha 1	Homo sapiens	103-113
25880689-4	2015	Both the activity as well as the inhibition of the G6PDH enzyme by six inhibitors, including three metals (Cu(2+), Pb(2+), Cd(2+)), vancomycin, urea and KMnO4, were investigated using on-line assay of the CE-based IMERs.	Vancomycin	132-142	glucose-6-phosphate dehydrogenase	Homo sapiens	51-56
25795517-0	2015	Detection of vancomycin-resistant Enterococcus faecalis ST6-vanB2 and E. faecium ST915-vanA in faecal samples of wild Rattus rattus in Spain.	Vancomycin	13-23	D-alanine--D-lactate ligase	Enterococcus faecalis	60-65
25600843-1	2015	This study evaluated the delta-hemolysis assay for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) isolates.	Vancomycin	78-88	mitochondrial antiviral signaling protein	Homo sapiens	125-130
27275189-6	2015	Determined vancomycin resistant enterococci were than tested for detection of vanA, vanB and vanC genes by PCR.	Vancomycin	11-21	D-alanine--D-lactate ligase	Enterococcus faecium	84-88
25699490-1	2015	INTRODUCTION: Detection of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) is currently problematic.	Vancomycin	41-51	mitochondrial antiviral signaling protein	Homo sapiens	88-93
25695169-9	2015	More NAP1 cases had a change in treatment from metronidazole to oral vancomycin plus intravenous metronidazole (P=.01).	Vancomycin	69-79	nucleosome assembly protein 1 like 1	Homo sapiens	5-9
25699490-6	2015	The performance of the vancomycin and teicoplanin disk diffusion test for detecting both induced and natural hVISA/VISA isolates was analyzed using the MedCal program version 10.2.0.	Vancomycin	23-33	mitochondrial antiviral signaling protein	Homo sapiens	110-114
25699490-8	2015	Using 10, 15, 20, 30 microg vancomycin disks and a 30 microg teicoplanin disk, the highest performance (88.9%) for hVISA/VISA detection (71.1%), sensitivity, 100% specificity, 100% positive predictive value, and 75% negative predictive value) was obtained when a 20 microg vancomycin disk was used at 1.0 McFarland inoculum for a 24-hour incubation.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	115-120
25699490-8	2015	Using 10, 15, 20, 30 microg vancomycin disks and a 30 microg teicoplanin disk, the highest performance (88.9%) for hVISA/VISA detection (71.1%), sensitivity, 100% specificity, 100% positive predictive value, and 75% negative predictive value) was obtained when a 20 microg vancomycin disk was used at 1.0 McFarland inoculum for a 24-hour incubation.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	116-120
25699490-9	2015	CONCLUSIONS: The results indicated that using a 20 microg vancomycin disk and bacterial inoculum of 1.0 McFarland is simple to perform and provides a primary result for hVISA/VISA screening within 24 hours.	Vancomycin	58-68	mitochondrial antiviral signaling protein	Homo sapiens	169-174
25699490-9	2015	CONCLUSIONS: The results indicated that using a 20 microg vancomycin disk and bacterial inoculum of 1.0 McFarland is simple to perform and provides a primary result for hVISA/VISA screening within 24 hours.	Vancomycin	58-68	mitochondrial antiviral signaling protein	Homo sapiens	170-174
27141645-0	2015	[Results of Investigation of MRSA Susceptibility to Vancomycin in Clinical Units of Large Multifunctional Hospital and Recommendations on Optimization of Antibacterial Therapy of Staphylococcal Infection].	Vancomycin	52-62	solute carrier family 9 member A6	Homo sapiens	29-33
25403664-8	2015	By multivariate analyses, inappropriate continued empirical vancomycin use was independently associated with the absence of any documented etiological organism (adjusted odds ratio [aOR], 1.60 [95% confidence interval {CI}, 1.06 to 2.41]) and suspected central nervous system (CNS) infections (aHR, 2.33 [95% CI, 1.20 to 4.50]).	Vancomycin	60-70	aryl hydrocarbon receptor	Homo sapiens	294-297
25403664-9	2015	Higher Charlson"s comorbidity index scores were inversely associated with inappropriate continued empirical vancomycin use (aHR, 0.90 [95% CI, 0.85 to 0.97]).	Vancomycin	108-118	aryl hydrocarbon receptor	Homo sapiens	124-127
25657162-4	2015	This study has been conducted to investigate the occurrence of virulence factors and resistance to various antibiotics with emphasis on vancomycin in the Enterococcus spp.	Vancomycin	136-146	histocompatibility minor 13	Homo sapiens	167-170
25535825-1	2015	The emergence of vancomycin intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) is of major concern worldwide.	Vancomycin	17-27	mitochondrial antiviral signaling protein	Homo sapiens	64-68
25535825-1	2015	The emergence of vancomycin intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) is of major concern worldwide.	Vancomycin	17-27	mitochondrial antiviral signaling protein	Homo sapiens	94-99
25138142-0	2015	Vancomycin blocks autophagy and induces interleukin-1beta release in macrophages.	Vancomycin	0-10	interleukin 1 beta	Homo sapiens	40-57
25301498-6	2015	Moreover, vancomycin treatment decreased the expression of RegIIIgamma and interleukin (IL)-17 in the wounded skin.	Vancomycin	10-20	regenerating islet-derived 3 gamma	Mus musculus	59-70
25449832-5	2015	Proteins involved in the vancomycin resistance mechanism, such as the VanA protein, VanA ligase, VanR and D-Ala-D-Ala dipeptidase, were up-regulated in the presence of vancomycin, while metabolism-related proteins, such as triosephosphate isomerase, guanine monophosphate synthase and glyceraldehyde-3-phosphate dehydrogenase were down-regulated.	Vancomycin	25-35	VanR	Enterococcus faecium	97-101
25449832-5	2015	Proteins involved in the vancomycin resistance mechanism, such as the VanA protein, VanA ligase, VanR and D-Ala-D-Ala dipeptidase, were up-regulated in the presence of vancomycin, while metabolism-related proteins, such as triosephosphate isomerase, guanine monophosphate synthase and glyceraldehyde-3-phosphate dehydrogenase were down-regulated.	Vancomycin	168-178	VanR	Enterococcus faecium	97-101
25845875-1	2015	The prevalence of the heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype among methicillin-resistant S. aureus (MRSA) blood isolates can reach 38%.	Vancomycin	36-46	mitochondrial antiviral signaling protein	Homo sapiens	83-88
25845875-2	2015	hVISA bacteremia is known to be associated with vancomycin treatment failure, including persistent bacteremia.	Vancomycin	48-58	mitochondrial antiviral signaling protein	Homo sapiens	0-5
27141645-4	2015	The use of the E-test for MRSA susceptibility to vancomycin allowed to estimate the validity of the use of various antibiotics active against MRSA in the treatment of inpatients and to reduce the risk of ineffective therapy.	Vancomycin	49-59	solute carrier family 9 member A6	Homo sapiens	26-30
27141645-4	2015	The use of the E-test for MRSA susceptibility to vancomycin allowed to estimate the validity of the use of various antibiotics active against MRSA in the treatment of inpatients and to reduce the risk of ineffective therapy.	Vancomycin	49-59	solute carrier family 9 member A6	Homo sapiens	142-146
25544893-2	2014	In this study, the influence of the plant-derived natural saponins glycyrrhizic acid, beta-aescin, alpha-hederin, hederacoside C, and primulic acid 1 on the susceptibility of vancomycin-resistant enterococci (VRE) against antibiotics of clinical relevance was investigated in 20 clinical isolates.	Vancomycin	175-185	mediator complex subunit 25	Homo sapiens	143-149
25145536-2	2015	Recently, we demonstrated that perinatal exposure to vancomycin, but not streptomycin, profoundly alters gut microbiota and enhances susceptibility to a TH2 model of allergic asthma.	Vancomycin	53-63	heart and neural crest derivatives expressed 2	Mus musculus	153-156
25145536-4	2015	METHODS: Hypersensitivity pneumonitis was induced in C57BL/6 wild-type or recombination-activating gene 1-deficient mice treated perinatally with vancomycin or streptomycin by repeated intranasal administration of Saccharopolyspora rectivirgula antigen.	Vancomycin	146-156	recombination activating 1	Mus musculus	74-105
25609857-1	2015	BACKGROUND: Hetero-resistance vancomycin intermediate Staphylococcus aureus (hVISA) is phenotype, which on in-vitro susceptibility test is vancomycin susceptible (VSSA) but has a minority population of vancomycin intermediate (VISA).	Vancomycin	30-40	mitochondrial antiviral signaling protein	Homo sapiens	77-82
25609857-1	2015	BACKGROUND: Hetero-resistance vancomycin intermediate Staphylococcus aureus (hVISA) is phenotype, which on in-vitro susceptibility test is vancomycin susceptible (VSSA) but has a minority population of vancomycin intermediate (VISA).	Vancomycin	30-40	mitochondrial antiviral signaling protein	Homo sapiens	78-82
25609857-1	2015	BACKGROUND: Hetero-resistance vancomycin intermediate Staphylococcus aureus (hVISA) is phenotype, which on in-vitro susceptibility test is vancomycin susceptible (VSSA) but has a minority population of vancomycin intermediate (VISA).	Vancomycin	139-149	mitochondrial antiviral signaling protein	Homo sapiens	77-82
25609857-1	2015	BACKGROUND: Hetero-resistance vancomycin intermediate Staphylococcus aureus (hVISA) is phenotype, which on in-vitro susceptibility test is vancomycin susceptible (VSSA) but has a minority population of vancomycin intermediate (VISA).	Vancomycin	139-149	mitochondrial antiviral signaling protein	Homo sapiens	78-82
25609857-1	2015	BACKGROUND: Hetero-resistance vancomycin intermediate Staphylococcus aureus (hVISA) is phenotype, which on in-vitro susceptibility test is vancomycin susceptible (VSSA) but has a minority population of vancomycin intermediate (VISA).	Vancomycin	139-149	mitochondrial antiviral signaling protein	Homo sapiens	77-82
25609857-1	2015	BACKGROUND: Hetero-resistance vancomycin intermediate Staphylococcus aureus (hVISA) is phenotype, which on in-vitro susceptibility test is vancomycin susceptible (VSSA) but has a minority population of vancomycin intermediate (VISA).	Vancomycin	139-149	mitochondrial antiviral signaling protein	Homo sapiens	78-82
25609857-2	2015	hVISA is responsible for vancomycin treatment failure.	Vancomycin	25-35	mitochondrial antiviral signaling protein	Homo sapiens	0-5
25609857-7	2015	hVISA isolates were having vancomycin E test MIC &gt;2 mug/ml.	Vancomycin	27-37	mitochondrial antiviral signaling protein	Homo sapiens	0-5
25609857-10	2015	CONCLUSIONS: There is need for screening MRSA isolates showing in-vitro vancomycin susceptibility &lt;=2 mug/ml by agar dilution method for detection of hVISA.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	153-158
25103488-2	2014	OBJECTIVES: After the implementation of an active surveillance programme for MRSA in US Veterans Affairs (VA) Medical Centers, there was an increase in vancomycin use.	Vancomycin	152-162	solute carrier family 9 member A6	Homo sapiens	77-81
27873678-5	2014	The bacterium develops resistance by modifying the C-terminal d-alanine of peptidoglycan to d-lactate, creating a d-Ala-d-Lac sequence that effectively reduces the affinity of vancomycin for the peptidoglycan by 1000-fold.	Vancomycin	176-186	lactase	Homo sapiens	122-125
27873679-1	2014	Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor hetero-VISA (hVISA) were discovered almost 20 years ago and have continued to be a stumbling block in the chemotherapy of methicillin-resistant S. aureus (MRSA).	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	47-51
27873679-1	2014	Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor hetero-VISA (hVISA) were discovered almost 20 years ago and have continued to be a stumbling block in the chemotherapy of methicillin-resistant S. aureus (MRSA).	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	78-82
27873679-1	2014	Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor hetero-VISA (hVISA) were discovered almost 20 years ago and have continued to be a stumbling block in the chemotherapy of methicillin-resistant S. aureus (MRSA).	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	84-89
25222597-2	2014	Here, we identify a novel, potent, imidazoline antimicrobial compound, SKI-356313, with bactericidal activity against Mycobacterium tuberculosis and Gram-positive cocci, including vancomycin-resistant Enterococcus faecium (VRE) and methicillin-resistant Staphylococcus aureus (MRSA).	Vancomycin	180-190	ski sarcoma viral oncogene homolog (avian)	Mus musculus	71-74
26168679-5	2015	The frequency of MRSA isolated at the vancomycin dose of 2 mcg/ml equaled 26%.	Vancomycin	38-48	solute carrier family 9 member A6	Homo sapiens	17-21
25182061-0	2015	Prolonged treatment with large doses of fosfomycin plus vancomycin and amikacin in a case of bacteraemia due to methicillin-resistant Staphylococcus epidermidis and IMP-8 metallo-beta-lactamase-producing Klebsiella oxytoca.	Vancomycin	56-66	Beta-lactamase	Staphylococcus epidermidis	179-193
24938744-5	2015	Importantly, vancomycin treatment specifically downregulated the colonic epithelial cell (cEC) expression of C-C chemokine receptor type-2 (CCR2) ligands, which are critical chemokines for monocyte/macrophage mobilization into the inflamed colon.	Vancomycin	13-23	chemokine (C-C motif) receptor 2	Mus musculus	109-138
24938744-5	2015	Importantly, vancomycin treatment specifically downregulated the colonic epithelial cell (cEC) expression of C-C chemokine receptor type-2 (CCR2) ligands, which are critical chemokines for monocyte/macrophage mobilization into the inflamed colon.	Vancomycin	13-23	chemokine (C-C motif) receptor 2	Mus musculus	140-144
24329974-1	2014	It is not clear if patients with heterogeneous intermediate resistance to vancomycin (hVISA) infectious endocarditis (IE) differ from methicillin-resistant S. aureus (MRSA) IE patients.	Vancomycin	74-84	mitochondrial antiviral signaling protein	Homo sapiens	86-91
25099263-8	2014	The effect of vancomycin on the temporal absorption of endogenous BMP-2 and stromal cell-derived factor-1 was evaluated by immunohistochemistry.	Vancomycin	14-24	bone morphogenetic protein 2	Rattus norvegicus	66-71
25099263-8	2014	The effect of vancomycin on the temporal absorption of endogenous BMP-2 and stromal cell-derived factor-1 was evaluated by immunohistochemistry.	Vancomycin	14-24	C-X-C motif chemokine ligand 12	Rattus norvegicus	76-105
25291061-0	2014	Synthesis and biological evaluation of novel peptide BF2 as an antibacterial agent against clinical isolates of vancomycin-resistant enterococci.	Vancomycin	112-122	forkhead box G1	Homo sapiens	53-56
25291061-5	2014	An in vitro antibacterial study of synthetic peptide BF2 against the clinical isolates of vancomycin-resistant and control strains of enterococci showed rapid killing effect on enterococci by killing 99.9% of bacterial cells in 60 min and susceptibility at minimum inhibitory concentration (MIC) range of 6.25-12.5 mug/mL.	Vancomycin	90-100	forkhead box G1	Homo sapiens	53-56
25291061-6	2014	Synergy of BF2 was observed in combination with vancomycin and teicoplanin.	Vancomycin	48-58	forkhead box G1	Homo sapiens	11-14
25168621-1	2014	INTRODUCTION: The clinical application of continuous infusion (CoI) of vancomycin has gained interest in recent years.	Vancomycin	71-81	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	63-66
25168621-3	2014	Therefore, the aim of this study was to design and validate an a priori dosing schedule for CoI of vancomycin in clinical practice.	Vancomycin	99-109	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	92-95
25168621-4	2014	METHODS: A dosing table for CoI of vancomycin based on estimated glomerular filtration rate (eGFR) was developed by simulation of continuous infusion of vancomycin using pharmacokinetic (PK) software and a PK population model designed from historical within-population data in intermittently dosed patients.	Vancomycin	35-45	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	28-31
25168621-4	2014	METHODS: A dosing table for CoI of vancomycin based on estimated glomerular filtration rate (eGFR) was developed by simulation of continuous infusion of vancomycin using pharmacokinetic (PK) software and a PK population model designed from historical within-population data in intermittently dosed patients.	Vancomycin	153-163	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	28-31
25168621-7	2014	RESULTS: An eGFR-derived dosing schedule for CoI of vancomycin was established and implemented in clinical practice.	Vancomycin	52-62	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	45-48
25566591-1	2014	We developed and evaluated of multiplex real-time PCR assay for detection of vancomycin-resistant genes (vanA, vanB, vanC1 and vanC2/C3) using the new, fully automated BD MAX platform.	Vancomycin	77-87	complement C3	Homo sapiens	127-135
24841271-0	2014	"Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.	Vancomycin	34-44	mitochondrial antiviral signaling protein	Homo sapiens	6-10
24841271-0	2014	"Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.	Vancomycin	89-99	mitochondrial antiviral signaling protein	Homo sapiens	6-10
24841271-1	2014	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) clinical strain Mu3 spontaneously generates VISA strains at an extremely high frequency (&gt;=1x10(-6)).	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	61-66
24841271-1	2014	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) clinical strain Mu3 spontaneously generates VISA strains at an extremely high frequency (&gt;=1x10(-6)).	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	62-66
24841271-2	2014	The generated VISA strains usually grow more slowly than does the parent hVISA strain, but they form colonies on vancomycin-containing agar plates before 48 h of incubation.	Vancomycin	113-123	mitochondrial antiviral signaling protein	Homo sapiens	14-18
24841271-10	2014	Slow VISA generated in the tissues of an infected patient serves as a temporary shelter for hVISA to survive vancomycin therapy.	Vancomycin	109-119	mitochondrial antiviral signaling protein	Homo sapiens	5-9
24841271-10	2014	Slow VISA generated in the tissues of an infected patient serves as a temporary shelter for hVISA to survive vancomycin therapy.	Vancomycin	109-119	mitochondrial antiviral signaling protein	Homo sapiens	92-97
24841271-11	2014	The sVISA strain spontaneously returns to hVISA when the threat of vancomycin is lifted.	Vancomycin	67-77	mitochondrial antiviral signaling protein	Homo sapiens	42-47
24890600-1	2014	Macrolactin A (MA) and 7-O-succinyl macrolactin A (SMA), polyene macrolides containing a 24-membered lactone ring, show antibiotic effects superior to those of teicoplanin against vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus.	Vancomycin	180-190	survival of motor neuron 1, telomeric	Homo sapiens	51-54
24957836-1	2014	Glycopeptides are known to select for heterogeneous vancomycin-intermediate Staphylococcus aureus (h-VISA) from susceptible strains.	Vancomycin	52-62	mitochondrial antiviral signaling protein	Homo sapiens	101-105
25222855-7	2014	METHODS: Patients with SCI receiving vancomycin with measured serum creatinine, cystatin C, and steady-state serum vancomycin concentration were identified.	Vancomycin	37-47	cystatin C	Homo sapiens	80-90
25222855-13	2014	CONCLUSIONS: In the SCI population, the use of Chronic Kidney Disease Epidemiology Collaboration cystatin C equation may improve initial vancomycin dosing.	Vancomycin	137-147	cystatin C	Homo sapiens	97-107
25066429-7	2014	A new trend of vancomycin resistance found in this study was that VISA strains were still prevalent among the bacteremic specimens.	Vancomycin	15-25	mitochondrial antiviral signaling protein	Homo sapiens	66-70
25337309-0	2014	VanA and VanB Positive Vancomycin-resistant Staphylococcus aureus Among Clinical Isolates in Shiraz, South of Iran.	Vancomycin	23-33	D-alanine--D-lactate ligase	Staphylococcus aureus	9-13
25337309-4	2014	Vancomycin-resistant Staphylococcus aureus isolates were determined by vancomycin agar screening test and PCR for vancomycin resistant genes (vanA and vanB).	Vancomycin	0-10	D-alanine--D-lactate ligase	Staphylococcus aureus	151-155
25337309-10	2014	CONCLUSION: The results showed that the frequency of vancomycin resistance genes (vanA, vanB) is very high in Staphylococcus aureus strains isolated from patients in south of Iran.	Vancomycin	53-63	D-alanine--D-lactate ligase	Staphylococcus aureus	88-92
25337280-0	2014	Liofilchem( ) Chromatic VRE and vancomycin MIC Test Strip detected glycopeptide resistance in a vanB neonatal Enterococcus faecium isolate showing alternate vancomycin susceptibility and resistance with bioMerieux Vitek2.	Vancomycin	157-167	D-alanine--D-lactate ligase	Enterococcus faecium	96-100
24823910-10	2014	CONCLUSIONS: Among patients who undergo AIC placement with vancomycin and/or tobramycin, exposure to ACE inhibitors and piperacillin-tazobactam are associated with increased risk of AKI in the immediate postoperative period.	Vancomycin	59-69	angiotensin I converting enzyme	Homo sapiens	101-104
24906792-1	2014	The characterization of heteroresistant vancomycin-intermediate Staphylococcus aureus strains (hVISA) is even more challenging, as no routine standardized laboratory methods are available.	Vancomycin	40-50	mitochondrial antiviral signaling protein	Homo sapiens	95-100
25033044-5	2014	In contrast, vancomycin pretreatment of mice deficient in SIGIRR (Sigirr(-/-)), a negative regulator of MyD88-dependent signaling led to heavy and widespread C. jejuni colonization, accompanied by severe gastroenteritis involving strongly elevated transcription of Th1/Th17 cytokines.	Vancomycin	13-23	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	58-64
25033044-5	2014	In contrast, vancomycin pretreatment of mice deficient in SIGIRR (Sigirr(-/-)), a negative regulator of MyD88-dependent signaling led to heavy and widespread C. jejuni colonization, accompanied by severe gastroenteritis involving strongly elevated transcription of Th1/Th17 cytokines.	Vancomycin	13-23	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	66-77
25033044-5	2014	In contrast, vancomycin pretreatment of mice deficient in SIGIRR (Sigirr(-/-)), a negative regulator of MyD88-dependent signaling led to heavy and widespread C. jejuni colonization, accompanied by severe gastroenteritis involving strongly elevated transcription of Th1/Th17 cytokines.	Vancomycin	13-23	myeloid differentiation primary response gene 88	Mus musculus	104-109
24403556-0	2014	Impact of vancomycin on sarA-mediated biofilm formation: role in persistent endovascular infections due to methicillin-resistant Staphylococcus aureus.	Vancomycin	10-20	zinc finger FYVE-type containing 9	Homo sapiens	24-28
24674093-2	2014	Bacteremia due to vanA Enterococcus faecium was diagnosed, and stool surveillance cultures for vancomycin-resistant enterococci (VRE) were positive for both vanA and vanB E. faecium.	Vancomycin	95-105	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	157-161
24674093-2	2014	Bacteremia due to vanA Enterococcus faecium was diagnosed, and stool surveillance cultures for vancomycin-resistant enterococci (VRE) were positive for both vanA and vanB E. faecium.	Vancomycin	95-105	D-alanine--D-lactate ligase	Enterococcus faecium	166-170
24634909-5	2014	In addition, the response of the sensor was characterised in a complex matrix, porcine plasma, spiked with 10 muM of VA.	Vancomycin	117-119	latexin	Homo sapiens	110-113
24504748-7	2014	With stimulating amounts of rhBMP-2 (&gt;50 ng/mL), the ALP response from W-20-17 cells was inhibited when exposed to high vancomycin levels (1,800-3,600 mug/mL).	Vancomycin	123-133	alopecia, recessive	Mus musculus	56-59
24887089-0	2014	Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study.	Vancomycin	26-36	cystatin C	Homo sapiens	6-16
24887089-8	2014	Cystatin C-inclusive models better predicted vancomycin troughs than models based upon serum creatinine alone, although both were an improvement over usual care.	Vancomycin	45-55	cystatin C	Homo sapiens	0-10
24885158-11	2014	Most MRSA patients (66%, 88/134) were treated empirically (primarily vancomycin) but outcome was not improved by receipt of empiric therapy.	Vancomycin	69-79	solute carrier family 9 member A6	Homo sapiens	5-9
24403556-7	2014	Interestingly, exposure to sub-MICs of vancomycin significantly promoted biofilm formation and fibronectin-binding in parental strains but not in sarA mutants.	Vancomycin	39-49	fibronectin 1	Homo sapiens	95-106
24403556-8	2014	In addition, all sarA mutants became exquisitely susceptible to vancomycin therapy, compared with their respective parental strains, in the infective endocarditis model.	Vancomycin	64-74	zinc finger FYVE-type containing 9	Homo sapiens	17-21
24316517-0	2014	Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity.	Vancomycin	15-25	insulin	Homo sapiens	71-78
24316517-10	2014	Finally, administration of vancomycin decreased peripheral insulin sensitivity (p&lt;0.05).	Vancomycin	27-37	insulin	Homo sapiens	59-66
24316517-12	2014	CONCLUSIONS: Oral administration of vancomycin significantly impacts host physiology by decreasing intestinal microbiota diversity, bile acid dehydroxylation and peripheral insulin sensitivity in subjects with metabolic syndrome.	Vancomycin	36-46	insulin	Homo sapiens	173-180
24851558-3	2014	OBJECTIVE: This study aimed to investigate the susceptibility of heterogeneous vancomycin intermediate S. aureus (hVISA) and vancomycin intermediate S. aureus (VISA) to vancomycin by standard disk diffusion, microbroth dilution, a one-point population assay, and a population analysis profile.	Vancomycin	79-89	mitochondrial antiviral signaling protein	Homo sapiens	114-119
24851558-3	2014	OBJECTIVE: This study aimed to investigate the susceptibility of heterogeneous vancomycin intermediate S. aureus (hVISA) and vancomycin intermediate S. aureus (VISA) to vancomycin by standard disk diffusion, microbroth dilution, a one-point population assay, and a population analysis profile.	Vancomycin	79-89	mitochondrial antiviral signaling protein	Homo sapiens	115-119
24956911-3	2014	Among enterococci with vancomycin-resistant genes, we detected 4, 3 and 2 enterococci of vancomycin MIC level 4 microg/mL with vanB, vanC1 and vanC2/C3, respectively.	Vancomycin	23-33	D-alanine--D-lactate ligase	Enterococcus faecium	127-131
24641255-0	2014	A case of vancomycin-associated linear IgA bullous dermatosis and IgA antibodies to the alpha3 subunit of laminin-332.	Vancomycin	10-20	CD79a molecule	Homo sapiens	39-42
24523464-0	2014	Outbreak of vancomycin-susceptible Enterococcus faecium containing the wild-type vanA gene.	Vancomycin	12-22	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	81-85
24523464-12	2014	We report an emergence of a fit strain of E. faecium containing vanA yet susceptible to vancomycin.	Vancomycin	88-98	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	64-68
24855476-14	2014	Clinical benefits of fidaxomicin compared with vancomycin depend on the proportion of cases caused by the NAP1/B1/027 strain in patients with severe CDI.	Vancomycin	47-57	nucleosome assembly protein 1 like 1	Homo sapiens	106-113
23829415-0	2014	A case of vancomycin-induced linear IgA bullous dermatosis with circulating IgA antibodies to the NC16a domain of BP180.	Vancomycin	10-20	collagen type XVII alpha 1 chain	Homo sapiens	114-119
23606567-0	2014	Binding of teicoplanin and vancomycin to bovine serum albumin in vitro: a multispectroscopic approach and molecular modeling.	Vancomycin	27-37	albumin	Homo sapiens	48-61
23606567-1	2014	In this paper, the binding properties of teicoplanin and vancomycin to bovine serum albumin (BSA) were investigated using fluorescence quenching, synchronous fluorescence, Fourier transform infrared (FTIR), circular dichroism (CD) and UV-vis spectroscopic techniques and molecular docking under simulative physiological conditions.	Vancomycin	57-67	albumin	Homo sapiens	78-91
24956911-3	2014	Among enterococci with vancomycin-resistant genes, we detected 4, 3 and 2 enterococci of vancomycin MIC level 4 microg/mL with vanB, vanC1 and vanC2/C3, respectively.	Vancomycin	89-99	D-alanine--D-lactate ligase	Enterococcus faecium	127-131
24518625-5	2014	RESULTS: All isolates were identified as vancomycin/ampicillin resistant E. faecium carrying the vanA gene.	Vancomycin	41-51	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	97-101
24092658-1	2014	OBJECTIVES: Vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) phenotypes are increasingly reported in methicillin-resistant S. aureus (MRSA) strains of distinct genetic backgrounds.	Vancomycin	12-22	mitochondrial antiviral signaling protein	Homo sapiens	59-63
24092658-4	2014	The genetic mutations associated with the VISA phenotype were identified by whole-genome sequencing of two strains, which had the vancomycin-susceptible S. aureus (VSSA) and VISA phenotypes.	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	42-46
23090839-9	2014	Therapeutic drug monitoring was reported in 11 studies, with CSF vancomycin levels varying widely from 1.1 to 812.6 mg/L, without clear relationships between CSF levels and efficacy or toxicity.	Vancomycin	65-75	colony stimulating factor 2	Homo sapiens	61-64
24047647-9	2013	One vancomycin-resistant E. faecalis isolate was detected and harbored the vanA resistant gene.	Vancomycin	4-14	VanA	Enterococcus faecalis	75-79
24165181-1	2014	The purpose of this study was to compare the clinical efficacy and safety of vancomycin to those of teicoplanin for the treatment of adult patients with health care-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) bacteremia.	Vancomycin	77-87	solute carrier family 9 member A6	Homo sapiens	224-228
24217694-5	2014	Vancomycin initially achieved &gt;=3 log10 CFU reductions against the MRSA and hVISA isolates, followed by regrowth beginning at 48 h; minimal activity was observed against VISA.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	79-84
24217694-5	2014	Vancomycin initially achieved &gt;=3 log10 CFU reductions against the MRSA and hVISA isolates, followed by regrowth beginning at 48 h; minimal activity was observed against VISA.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	80-84
24217694-7	2014	Prior exposure of vancomycin at 1 g q12h reduced the initial microbiological response of daptomycin, particularly for hVISA and VISA isolates, but did not affect the response of ceftaroline.	Vancomycin	18-28	mitochondrial antiviral signaling protein	Homo sapiens	118-123
24217694-7	2014	Prior exposure of vancomycin at 1 g q12h reduced the initial microbiological response of daptomycin, particularly for hVISA and VISA isolates, but did not affect the response of ceftaroline.	Vancomycin	18-28	mitochondrial antiviral signaling protein	Homo sapiens	119-123
24247138-9	2014	The prevalence of hVISA among MRSA isolates was higher in 2011 than in 2009 (1.2% versus 0.4%, P = 0.003), especially for isolates with a vancomycin MIC of 2 (45.4% versus 14.3%, P = 0.01).	Vancomycin	138-148	mitochondrial antiviral signaling protein	Homo sapiens	18-23
25520231-3	2014	One possible explanation for this phenomenon could be the thermal degradation of Vancomycin to antibacterially inactive crystalline degradation products (CDP-1s).	Vancomycin	81-91	cut like homeobox 1	Homo sapiens	154-159
24397493-1	2014	The VanA D-Ala:D-Lac ligase is a key enzyme in the emergence of high level resistance to vancomycin in Enterococcus species and methicillin-resistant Staphylococcus aureus.	Vancomycin	89-99	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	4-8
23567819-0	2014	The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.	Vancomycin	17-27	mitochondrial antiviral signaling protein	Homo sapiens	64-68
23567819-2	2014	In the case of vancomycin, which was first released in the 1950s, resistance was not reported until the mid 1990s, with the description of vancomycin-intermediate S. aureus (VISA), and heterogenous-VISA (hVISA).	Vancomycin	15-25	mitochondrial antiviral signaling protein	Homo sapiens	174-178
23567819-2	2014	In the case of vancomycin, which was first released in the 1950s, resistance was not reported until the mid 1990s, with the description of vancomycin-intermediate S. aureus (VISA), and heterogenous-VISA (hVISA).	Vancomycin	15-25	mitochondrial antiviral signaling protein	Homo sapiens	198-202
23567819-2	2014	In the case of vancomycin, which was first released in the 1950s, resistance was not reported until the mid 1990s, with the description of vancomycin-intermediate S. aureus (VISA), and heterogenous-VISA (hVISA).	Vancomycin	15-25	mitochondrial antiviral signaling protein	Homo sapiens	204-209
23567819-8	2014	Transcriptomics studies, and analysis of host pathogen interactions, indicate that the evolution of vancomycin-susceptible S. aureus to VISA is associated not only with antibiotic resistance, but with other changes likely to promote persistent infection.	Vancomycin	100-110	mitochondrial antiviral signaling protein	Homo sapiens	136-140
24197881-1	2014	Methicillin-resistant Staphylococcus aureus (MRSA) usually harbors a vancomycin-susceptible phenotype (VSSA) but can exhibit reduced vancomycin susceptibility phenotypes that can be heterogeneous-intermediate (hVISA), intermediate (VISA), or fully resistant (VRSA).	Vancomycin	133-143	mitochondrial antiviral signaling protein	Homo sapiens	210-215
24197881-1	2014	Methicillin-resistant Staphylococcus aureus (MRSA) usually harbors a vancomycin-susceptible phenotype (VSSA) but can exhibit reduced vancomycin susceptibility phenotypes that can be heterogeneous-intermediate (hVISA), intermediate (VISA), or fully resistant (VRSA).	Vancomycin	133-143	mitochondrial antiviral signaling protein	Homo sapiens	211-215
24197881-9	2014	Sequential isolates from a patient undergoing vancomycin therapy showed evolving microcalorimetric profiles up to a VISA phenotype.	Vancomycin	46-56	mitochondrial antiviral signaling protein	Homo sapiens	116-120
24018261-2	2013	We established a total of 45 VISA mutant strains independently obtained from hVISA Mu3 and its related strains by one-step vancomycin selection.	Vancomycin	123-133	mitochondrial antiviral signaling protein	Homo sapiens	29-33
24018261-0	2013	Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	119-124
24018261-0	2013	Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	120-124
24018261-0	2013	Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	129-133
24018261-0	2013	Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	195-200
24018261-1	2013	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) spontaneously produces VISA cells within its cell population at a frequency of 10(-6) or greater.	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	61-66
24018261-1	2013	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) spontaneously produces VISA cells within its cell population at a frequency of 10(-6) or greater.	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	62-66
23938774-0	2013	A liquid chromatography-tandem mass spectrometry assay for d-Ala-d-Lac: a key intermediate for vancomycin resistance in vancomycin-resistant enterococci.	Vancomycin	95-105	lactase	Homo sapiens	67-70
23938774-0	2013	A liquid chromatography-tandem mass spectrometry assay for d-Ala-d-Lac: a key intermediate for vancomycin resistance in vancomycin-resistant enterococci.	Vancomycin	120-130	lactase	Homo sapiens	67-70
23938774-2	2013	Vancomycin resistance in vancomycin-resistant enterococci (VRE) is due to an alternative cell wall biosynthesis pathway in which d-Ala-d-Ala is replaced, most commonly by d-Ala-d-Lac.	Vancomycin	0-10	lactase	Homo sapiens	179-182
23938774-2	2013	Vancomycin resistance in vancomycin-resistant enterococci (VRE) is due to an alternative cell wall biosynthesis pathway in which d-Ala-d-Ala is replaced, most commonly by d-Ala-d-Lac.	Vancomycin	25-35	lactase	Homo sapiens	179-182
23938774-9	2013	In contrast, d-Ala-d-Lac was present in the absence of vancomycin, with its level constant up to 128mug/ml vancomycin.	Vancomycin	107-117	lactase	Homo sapiens	21-24
23666589-0	2014	The Mark Coventry Award: Higher tissue concentrations of vancomycin with low-dose intraosseous regional versus systemic prophylaxis in TKA: a randomized trial.	Vancomycin	57-67	microtubule affinity regulating kinase 1	Homo sapiens	4-8
24011765-8	2013	In children with C difficile infection, fecal CXCL-5 and IL-8 messenger RNA abundances at diagnosis correlated with persistent diarrhea after 5 days of C difficile infection therapy and with treatment with vancomycin.	Vancomycin	206-216	C-X-C motif chemokine ligand 5	Homo sapiens	46-52
24011765-8	2013	In children with C difficile infection, fecal CXCL-5 and IL-8 messenger RNA abundances at diagnosis correlated with persistent diarrhea after 5 days of C difficile infection therapy and with treatment with vancomycin.	Vancomycin	206-216	C-X-C motif chemokine ligand 8	Homo sapiens	57-61
24041465-1	2013	Patients with high vancomycin minimum inhibitory concentrations (MICs) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) infection are associated with treatment failure and poor outcomes.	Vancomycin	91-101	mitochondrial antiviral signaling protein	Homo sapiens	138-143
24041465-2	2013	The main purpose of this study was to investigate the effect of hVISA on patient outcome, considering both the high vancomycin MIC and the existence of heteroresistant phenotypes.	Vancomycin	116-126	mitochondrial antiviral signaling protein	Homo sapiens	64-69
23440482-7	2013	Vancomycin (VCM) was administered intravenously because MRSE was detected from CSF 2 days after the administration of ampicillin and ceftriaxone.	Vancomycin	0-10	colony stimulating factor 2	Homo sapiens	79-84
23440482-7	2013	Vancomycin (VCM) was administered intravenously because MRSE was detected from CSF 2 days after the administration of ampicillin and ceftriaxone.	Vancomycin	12-15	colony stimulating factor 2	Homo sapiens	79-84
23922228-0	2013	Underlying the mechanism of vancomycin and human serum albumin interaction: a biophysical study.	Vancomycin	28-38	albumin	Homo sapiens	49-62
23922228-1	2013	In the present study, the binding mechanism of vancomycin with human serum albumin (HSA) was determined.	Vancomycin	47-57	albumin	Homo sapiens	69-82
23422917-0	2013	Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.	Vancomycin	22-32	mitochondrial antiviral signaling protein	Homo sapiens	140-144
23981868-2	2013	The present study determined the prevalence of tetM (tetracycline-resistance), vanA and vanB (vancomycin-resistance) in the bacterial and viral fractions, enterococci and their induced phages isolated from tropical recreational marine and fresh waters, dry and wet sands.	Vancomycin	94-104	D-alanine--D-lactate ligase	Enterococcus faecalis	88-92
23676437-2	2013	A cluster of genes homologous to enterococcal glycopeptides resistance vanG genes was found in the genome of C. difficile 630, although this strain remains sensitive to vancomycin.	Vancomycin	169-179	D-alanine--D-serine ligase VanG-Cd	Clostridioides difficile 630	71-75
23676437-6	2013	The vanG, vanXY and vanT homologues in C. difficile 630 are co-transcribed and expressed to a low level throughout the growth phases in the absence of vancomycin.	Vancomycin	151-161	D-alanine--D-serine ligase VanG-Cd	Clostridioides difficile 630	4-8
23676437-7	2013	Conversely, the expression of these genes is strongly induced in the presence of subinhibitory concentrations of vancomycin, indicating that the vanG-like operon is functional at the transcriptional level in C. difficile.	Vancomycin	113-123	D-alanine--D-serine ligase VanG-Cd	Clostridioides difficile 630	145-149
23734216-1	2013	Enterococcus faecalis V583 is a vancomycin-resistant clinical isolate which belongs to the hospital-adapted clade, CC2.	Vancomycin	32-42	Ccp84Ag	Drosophila melanogaster	115-118
24068869-2	2013	Our objective was to develop an economic model from a US payer perspective that includes all direct inpatient and outpatient costs incurred by patients with MRSA cSSTI receiving linezolid, vancomycin, or daptomycin.	Vancomycin	189-199	solute carrier family 9 member A6	Homo sapiens	157-167
24068869-13	2013	CONCLUSION: Outpatient costs of managing MRSA cSSTI may be reduced by 30%-50% with oral linezolid compared with vancomycin or daptomycin.	Vancomycin	112-122	solute carrier family 9 member A6	Homo sapiens	41-51
24069184-1	2013	BACKGROUND: Strains of Staphylococcus aureus with an intermediate level of resistance to vancomycin (vancomycin-intermediate S. aureus, or VISA) or which contain subpopulations of mixed susceptibility (heterogeneous VISA, or hVISA) have been reported worldwide.	Vancomycin	89-99	mitochondrial antiviral signaling protein	Homo sapiens	139-143
23873669-0	2013	Staphylococcus aureus Penicillin-Binding Protein 2 Can Use Depsi-Lipid II Derived from Vancomycin-Resistant Strains for Cell Wall Synthesis.	Vancomycin	87-97	AT695_RS10295	Staphylococcus aureus	22-50
23796929-1	2013	The prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections varies in the literature, a problem complicated by the lack of routine screening procedures; however, limited data suggest that hVISA has been associated with persistent bloodstream infections (BSI) and vancomycin failure, yet these studies have been confounded by design issues.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	79-84
23796929-1	2013	The prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections varies in the literature, a problem complicated by the lack of routine screening procedures; however, limited data suggest that hVISA has been associated with persistent bloodstream infections (BSI) and vancomycin failure, yet these studies have been confounded by design issues.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	225-230
23796929-1	2013	The prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections varies in the literature, a problem complicated by the lack of routine screening procedures; however, limited data suggest that hVISA has been associated with persistent bloodstream infections (BSI) and vancomycin failure, yet these studies have been confounded by design issues.	Vancomycin	300-310	mitochondrial antiviral signaling protein	Homo sapiens	79-84
23796929-1	2013	The prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections varies in the literature, a problem complicated by the lack of routine screening procedures; however, limited data suggest that hVISA has been associated with persistent bloodstream infections (BSI) and vancomycin failure, yet these studies have been confounded by design issues.	Vancomycin	300-310	mitochondrial antiviral signaling protein	Homo sapiens	225-230
23796929-10	2013	Relative to VSSA BSI, patients with hVISA were more likely to experience failure of vancomycin treatment, including persistent bacteremia and recurrence.	Vancomycin	84-94	mitochondrial antiviral signaling protein	Homo sapiens	36-41
23612571-1	2013	OBJECTIVES: We noted four cases of apparent in vivo emergence of teicoplanin resistance during failed therapy for initially teicoplanin-susceptible vanB vancomycin-resistant Enterococcus faecium (VREfm) infections in solid organ transplant recipients at our institution over a 12 month period.	Vancomycin	153-163	D-alanine--D-lactate ligase	Enterococcus faecium	148-152
23649229-9	2013	RESULTS: We demonstrated that the dependence on SOD of tolerance to vancomycin and penicillin is a common trait of antibiotic-susceptible pathogenic enterococci.	Vancomycin	68-78	AT695_RS09750	Staphylococcus aureus	48-51
23649229-10	2013	By varying the levels of expression we could also show that tolerance to vancomycin is directly correlated to SOD activity.	Vancomycin	73-83	AT695_RS09750	Staphylococcus aureus	110-113
23649229-12	2013	Finally, we showed that the SOD enzymes of S. aureus are also implicated in tolerance to vancomycin.	Vancomycin	89-99	AT695_RS09750	Staphylococcus aureus	28-31
23532096-6	2013	Compared with untreated and vancomycin-treated rabbits, improved survival of rabbits treated 1.5 hours after infection with linezolid was associated with a significant decrease in bacterial counts, suppressed bacterial production of PVL and Hla, and reduced production of the neutrophil-chemoattractant interleukin 8 in the lungs.	Vancomycin	28-38	interleukin-8	Oryctolagus cuniculus	303-316
23539745-1	2013	BACKGROUND:  We used 2 in vitro experimental systems to compare phenotypic and genotypic changes that accompany selection of mutants of methicillin-resistant Staphylococcus aureus (MRSA) strain JH1 with low-level vancomycin resistance similar to the type found in vancomycin-intermediate S. aureus (VISA).	Vancomycin	213-223	immunoglobulin heavy joining 1	Homo sapiens	194-197
23539745-1	2013	BACKGROUND:  We used 2 in vitro experimental systems to compare phenotypic and genotypic changes that accompany selection of mutants of methicillin-resistant Staphylococcus aureus (MRSA) strain JH1 with low-level vancomycin resistance similar to the type found in vancomycin-intermediate S. aureus (VISA).	Vancomycin	264-274	immunoglobulin heavy joining 1	Homo sapiens	194-197
23539745-3	2013	Mutants of JH1 were selected in vitro by means of a pharmacokinetic/pharmacodynamic (PK/PD) model of simulated endocardial vegetations (SEVs) and by exposure to vancomycin in laboratory growth medium.	Vancomycin	161-171	immunoglobulin heavy joining 1	Homo sapiens	11-14
23971921-9	2013	Vancomycin resistance genes included vanA, vanB, vanC, and vanD were investigated by polymerase chain reaction (PCR) method.	Vancomycin	0-10	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	37-41
23840544-1	2013	Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) is associated with clinical treatment failure.	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	61-66
23840544-3	2013	In the present study, comparative proteomics analysis of two pairs of isogenic vancomycin-susceptible S. aureus (VSSA) and hVISA strains isolated from two patients identified five differentially expressed proteins, IsaA, MsrA2, Asp23, GpmA, and AhpC, present in both isolate pairs.	Vancomycin	79-89	mitochondrial antiviral signaling protein	Homo sapiens	123-128
23422917-1	2013	We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibilities in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates.	Vancomycin	58-68	mitochondrial antiviral signaling protein	Homo sapiens	152-156
23422917-1	2013	We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibilities in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates.	Vancomycin	58-68	mitochondrial antiviral signaling protein	Homo sapiens	176-180
23422917-1	2013	We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibilities in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates.	Vancomycin	58-68	mitochondrial antiviral signaling protein	Homo sapiens	182-187
23422917-1	2013	We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibilities in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates.	Vancomycin	105-115	mitochondrial antiviral signaling protein	Homo sapiens	152-156
23422917-2	2013	Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively.	Vancomycin	24-34	mitochondrial antiviral signaling protein	Homo sapiens	96-100
23422917-2	2013	Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively.	Vancomycin	24-34	mitochondrial antiviral signaling protein	Homo sapiens	112-117
23422917-2	2013	Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively.	Vancomycin	24-34	mitochondrial antiviral signaling protein	Homo sapiens	113-117
23422917-2	2013	Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively.	Vancomycin	24-34	mitochondrial antiviral signaling protein	Homo sapiens	153-158
22831856-0	2013	New type F lineage-related Tn1546 and a vanA/vanB type vancomycin-resistant Enterococcus faecium isolated from patients in Dammam, Saudi Arabia during 2006-2007.	Vancomycin	55-65	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	40-44
22831856-0	2013	New type F lineage-related Tn1546 and a vanA/vanB type vancomycin-resistant Enterococcus faecium isolated from patients in Dammam, Saudi Arabia during 2006-2007.	Vancomycin	55-65	D-alanine--D-lactate ligase	Enterococcus faecium	45-49
23322784-5	2013	bNOS also promoted resistance to the pharmaceutical antibiotics that act on the cell envelope such as vancomycin and daptomycin.	Vancomycin	102-112	nitric oxide synthase 1	Homo sapiens	0-4
23925360-1	2013	OBJECTIVES: To investigate the prevalence of heterogeneous vancomycin intermediate Staphylococcus aureus (hVISA) and the sensitivity of hVISA to novel antibiotics, and to explore the risk factors and infection attributable mortality associated with hVISA infection.	Vancomycin	59-69	mitochondrial antiviral signaling protein	Homo sapiens	106-111
23254432-2	2013	In the absence of adequate lower respiratory cultures, physicians are sometimes reluctant to discontinue empirical vancomycin, which is given for suspected methicillin-resistant Staphylococcus aureus (MRSA) HCAP.	Vancomycin	115-125	structural maintenance of chromosomes 3	Homo sapiens	207-211
23925360-10	2013	The vancomycin MIC [(1.76 +- 0.16) mg/L] in hVISA group was significantly higher than that in VSSA group [(1.09 +- 0.07) mg/L, P &lt; 0.01], which was a potential risk factor for hVISA infection.	Vancomycin	4-14	mitochondrial antiviral signaling protein	Homo sapiens	44-49
23925360-10	2013	The vancomycin MIC [(1.76 +- 0.16) mg/L] in hVISA group was significantly higher than that in VSSA group [(1.09 +- 0.07) mg/L, P &lt; 0.01], which was a potential risk factor for hVISA infection.	Vancomycin	4-14	mitochondrial antiviral signaling protein	Homo sapiens	179-184
23945344-12	2013	In a multiple stepwise regression analysis, male gender (OR = 3.58) and acute physiology and chronic health evaluation II (APACHE II) scores (OR = 1.06) were independently associated with vancomycin MIC = 2 mg/L.	Vancomycin	188-198	CD99 molecule (Xg blood group)	Homo sapiens	199-206
23113753-1	2013	BACKGROUND: Although the individual expression of heterogeneous vancomycin-intermediate resistance (hVISA) and beta-lactam antibiotic-induced vancomycin resistance (BIVR) phenotypes has been associated with treatment failure and recurrence in methicillin-resistant Staphylococcus aureus (MRSA) infections, the effect of the co-expression of these phenotypic profiles on clinical outcome has not been fully elucidated.	Vancomycin	64-74	mitochondrial antiviral signaling protein	Homo sapiens	100-105
23422115-1	2013	BACKGROUND: The emergence of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) is increasingly challenging the methods for detection in diagnostic microbiology laboratories.	Vancomycin	45-55	mitochondrial antiviral signaling protein	Homo sapiens	92-97
23422115-13	2013	Vancomycin treatment was the independent risk factor of hVISA.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	56-61
23422115-17	2013	Vancomycin treatment was the independent predictors for hVISA infection.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	56-61
23136011-4	2013	Interestingly, vancomycin treatment, which propagated the bacterium Akkermansia muciniphila and reduced the level of IFN-gamma and IL-15 in the intestine, decreased the NKG2D ligand expression on IECs.	Vancomycin	15-25	killer cell lectin-like receptor subfamily K, member 1	Mus musculus	169-174
23195915-12	2013	CysC can estimate the daily dose of Van, and may improve therapeutic success rates of MRSA-infected patients.	Vancomycin	36-39	cystatin C	Homo sapiens	0-4
23195915-0	2013	Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations.	Vancomycin	41-51	cystatin C	Homo sapiens	90-100
23195915-1	2013	OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.	Vancomycin	100-110	cystatin C	Homo sapiens	28-38
23195915-1	2013	OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.	Vancomycin	100-110	cystatin C	Homo sapiens	40-44
23195915-1	2013	OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.	Vancomycin	112-115	cystatin C	Homo sapiens	28-38
23195915-1	2013	OBJECTIVE: To utilize serum cystatin C (CysC) concentration to identify the daily dosage regimen of vancomycin (Van) for the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.	Vancomycin	112-115	cystatin C	Homo sapiens	40-44
23054338-2	2013	Previous studies have shown that oral vancomycin (OV) is an effective treatment for concomitant primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) in children [2, 3].	Vancomycin	38-48	PSC	Homo sapiens	128-131
23054338-1	2013	Vancomycin has been shown to affect tumor necrosis factor-alpha (TNF-alpha) pathways as an immunomodulator; this is thought to be separate from its function as an antibiotic [1].	Vancomycin	0-10	tumor necrosis factor	Homo sapiens	36-63
23054338-1	2013	Vancomycin has been shown to affect tumor necrosis factor-alpha (TNF-alpha) pathways as an immunomodulator; this is thought to be separate from its function as an antibiotic [1].	Vancomycin	0-10	tumor necrosis factor	Homo sapiens	65-74
22345653-7	2013	Vancomycin-treated high-fat-fed mice gained less weight over the intervention period despite similar caloric intake, and had lower fasting blood glucose, plasma TNFalpha and triglyceride levels compared with diet-induced obese controls.	Vancomycin	0-10	tumor necrosis factor	Mus musculus	161-169
23054338-3	2013	Since both diseases are associated with immune dysfunction, we hypothesized that vancomycin"s therapeutic effect in IBD and PSC occurs through immunomodulation.	Vancomycin	81-91	PSC	Homo sapiens	124-127
22821354-3	2013	The LLR-VRSA isolate CP2, recovered from the blood sample of a postoperative cardiac patient, exhibited vanA type vancomycin resistance [minimum inhibitory concentration (MIC) 16 mug/ml], and the vanA cassette was located on a plasmid.	Vancomycin	114-124	ceruloplasmin	Homo sapiens	21-24
23374512-19	2013	CONCLUSION: Sequence of vanA cassette of CP2 showed partial homology with vancomycin resistant enterococci, VRSA vanA cassette element recorded in gene bank NCBI.	Vancomycin	74-84	ceruloplasmin	Homo sapiens	41-44
24738238-0	2013	[Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomycin].	Vancomycin	61-71	solute carrier family 9 member A6	Homo sapiens	15-19
24738238-3	2013	There is lately being observed a tendency towards emergence of strains with lower susceptibility to the last reserve drugs protecting from MRSA, i. e. vancomycin and daptomycin.	Vancomycin	151-161	solute carrier family 9 member A6	Homo sapiens	139-143
24738238-5	2013	The results of our study on estimation of susceptibility of 316 MRSA isolates from several regions of Russia to oxacillin, cefoxitine, vancomycin and daptomycin are presented herein.	Vancomycin	135-145	solute carrier family 9 member A6	Homo sapiens	64-68
24738238-8	2013	The tests with serial microdilutions revealed that 30.7 +/- 7% of the isolates had a critical level of susceptibility to vancomycin at the MIC 2 mcg/ml.	Vancomycin	121-131	CD99 molecule (Xg blood group)	Homo sapiens	139-144
23374512-4	2013	METHODOLOGY: A vancomycin-resistant Staphylococcus aureus (VRSA-CP2) isolate (MIC 16 mug/ml) was isolated from a local hospital of Karachi.	Vancomycin	15-25	ceruloplasmin	Homo sapiens	64-67
23374512-10	2013	RESULTS: The vancomycin-resistant isolate CP2 was found to be resistant to oxacillin, chloramphenicol, erythromycin, rifampicin, gentamicin, tetracycline and ciprofloxacin, as well.	Vancomycin	13-23	ceruloplasmin	Homo sapiens	42-45
23374512-16	2013	Vancomycin resistance was successfully transferred from the donor CP2 to a vancomycin-sensitive recipient S. aureus.	Vancomycin	0-10	ceruloplasmin	Homo sapiens	66-69
23374512-16	2013	Vancomycin resistance was successfully transferred from the donor CP2 to a vancomycin-sensitive recipient S. aureus.	Vancomycin	75-85	ceruloplasmin	Homo sapiens	66-69
22821354-9	2013	The isolate CP2 (LLR-VRSA) exhibited a higher MIC to vancomycin than the other isolates used in present study (16 mug/ml) and under vancomycin stress conditions, quantitatively, it showed a high rate of conversion of saturated to unsaturated membrane FAs than CP1, Mu50 (VISA isolate) and the susceptible control PSA.	Vancomycin	53-63	ceruloplasmin	Homo sapiens	12-15
22821354-9	2013	The isolate CP2 (LLR-VRSA) exhibited a higher MIC to vancomycin than the other isolates used in present study (16 mug/ml) and under vancomycin stress conditions, quantitatively, it showed a high rate of conversion of saturated to unsaturated membrane FAs than CP1, Mu50 (VISA isolate) and the susceptible control PSA.	Vancomycin	132-142	ceruloplasmin	Homo sapiens	12-15
23341711-0	2013	Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations.	Vancomycin	41-51	cystatin C	Homo sapiens	6-16
23363637-9	2013	RESULTS: A 30 minutes exposure to vancomycin (&gt;=1 microg/ ml) decreased cell volume, triggered annexin V-binding, increased [Ca(2+)]i, activated caspase 3, stimulated ceramide formation, triggered release of thromboxane B2, and upregulated surface expression of CD62P (P-selectin) as well as activated integrin alphallbbeta3.	Vancomycin	34-44	annexin A5	Homo sapiens	98-107
23363637-9	2013	RESULTS: A 30 minutes exposure to vancomycin (&gt;=1 microg/ ml) decreased cell volume, triggered annexin V-binding, increased [Ca(2+)]i, activated caspase 3, stimulated ceramide formation, triggered release of thromboxane B2, and upregulated surface expression of CD62P (P-selectin) as well as activated integrin alphallbbeta3.	Vancomycin	34-44	caspase 3	Homo sapiens	148-157
23363637-9	2013	RESULTS: A 30 minutes exposure to vancomycin (&gt;=1 microg/ ml) decreased cell volume, triggered annexin V-binding, increased [Ca(2+)]i, activated caspase 3, stimulated ceramide formation, triggered release of thromboxane B2, and upregulated surface expression of CD62P (P-selectin) as well as activated integrin alphallbbeta3.	Vancomycin	34-44	selectin P	Homo sapiens	265-270
23363637-9	2013	RESULTS: A 30 minutes exposure to vancomycin (&gt;=1 microg/ ml) decreased cell volume, triggered annexin V-binding, increased [Ca(2+)]i, activated caspase 3, stimulated ceramide formation, triggered release of thromboxane B2, and upregulated surface expression of CD62P (P-selectin) as well as activated integrin alphallbbeta3.	Vancomycin	34-44	selectin P	Homo sapiens	272-282
23363637-12	2013	In conclusion, vancomycin results in platelet activation and suicidal platelet death with increase of [Ca(2+)]i, caspase-3 activation, cell membrane scrambling and cell shrinkage.	Vancomycin	15-25	caspase 3	Homo sapiens	113-122
23509657-4	2013	We discuss the successful treatment of a pediatric patient, with recurrent PSC, after OLT with oral Vancomycin.	Vancomycin	100-110	PSC	Homo sapiens	75-78
23341711-1	2013	We developed a population pharmacokinetic model of vancomycin by integrating the effects of cystatin C and other demographic factors in a large population of Korean patients with normal serum creatinine concentrations to elucidate the precise role of serum cystatin C concentrations in the prediction of vancomycin clearance.	Vancomycin	51-61	cystatin C	Homo sapiens	92-102
23341711-1	2013	We developed a population pharmacokinetic model of vancomycin by integrating the effects of cystatin C and other demographic factors in a large population of Korean patients with normal serum creatinine concentrations to elucidate the precise role of serum cystatin C concentrations in the prediction of vancomycin clearance.	Vancomycin	51-61	cystatin C	Homo sapiens	257-267
23341711-7	2013	The use of serum cystatin C as marker of vancomycin clearance for more accurate predictions of serum vancomycin concentrations could be useful, particularly among patients with normal serum creatinine concentrations.	Vancomycin	41-51	cystatin C	Homo sapiens	17-27
23341711-7	2013	The use of serum cystatin C as marker of vancomycin clearance for more accurate predictions of serum vancomycin concentrations could be useful, particularly among patients with normal serum creatinine concentrations.	Vancomycin	101-111	cystatin C	Homo sapiens	17-27
22827719-9	2012	Only intrinsic vancomycin resistance (vanC1 and vanC2/C3) was traced.	Vancomycin	15-25	complement C3	Homo sapiens	48-56
23478252-10	2013	Compared to placebo, coinfected mice treated with linezolid, vancomycin or clindamycin had decreased pulmonary IL-6 and mKC at 4 hours and IFN-gamma at 24 hours after MRSA coinfection (all P&lt;0.05).	Vancomycin	61-71	interleukin 6	Mus musculus	111-115
23478252-10	2013	Compared to placebo, coinfected mice treated with linezolid, vancomycin or clindamycin had decreased pulmonary IL-6 and mKC at 4 hours and IFN-gamma at 24 hours after MRSA coinfection (all P&lt;0.05).	Vancomycin	61-71	interferon gamma	Mus musculus	139-148
23217055-11	2012	The administration of vancomycin plus an A2AAR agonist reduced inflammation and improved survival rates, suggesting a possible benefit of A2AAR agonists in the management of CDI to prevent recurrent disease.	Vancomycin	22-32	adenosine A2a receptor	Mus musculus	138-143
23217055-7	2012	Infected mice treated with both vancomycin and an A2AAR agonist, either ATL370 or ATL1222, had minimal weight loss and better long-term survival than mice treated with vancomycin alone.	Vancomycin	168-178	adenosine A2a receptor	Mus musculus	50-55
22749725-1	2012	BACKGROUND: Hetero-resistant vancomycin intermediate Staphylococcus aureus (hVISA) emerges worldwide in recent decade.	Vancomycin	29-39	mitochondrial antiviral signaling protein	Homo sapiens	76-81
22438436-0	2012	Reduced expression of PBP-2A by neonatal mecA-positive coagulase-negative staphylococci (CoNS) blood isolates: beta-lactams are useful first-line agents for the treatment of neonatal CoNS sepsis, restricting the use of vancomycin.	Vancomycin	219-229	phosphatidylethanolamine binding protein 1	Homo sapiens	22-25
22901792-2	2012	VanB enterococci show various levels of vancomycin MICs even below the susceptible breakpoint challenging a reliable diagnostics.	Vancomycin	40-50	D-alanine--D-lactate ligase	Enterococcus faecium	0-4
22901792-8	2012	A few vanB strains showed growth of microcolonies inside the Etest  vancomycin inhibition zones, suggesting a VanB heteroresistance phenotype.	Vancomycin	68-78	D-alanine--D-lactate ligase	Enterococcus faecium	6-10
22901792-8	2012	A few vanB strains showed growth of microcolonies inside the Etest  vancomycin inhibition zones, suggesting a VanB heteroresistance phenotype.	Vancomycin	68-78	D-alanine--D-lactate ligase	Enterococcus faecium	110-114
22927394-5	2012	Cell wall-targeting antibiotics, such as vancomycin and ceftriaxone, inhibit the kinase activity of Stk1 and lead to decreased Cys-phosphorylation of SarA and MgrA.	Vancomycin	41-51	TEK receptor tyrosine kinase	Mus musculus	100-104
22927394-5	2012	Cell wall-targeting antibiotics, such as vancomycin and ceftriaxone, inhibit the kinase activity of Stk1 and lead to decreased Cys-phosphorylation of SarA and MgrA.	Vancomycin	41-51	secretion associated Ras related GTPase 1A	Mus musculus	150-154
22927394-5	2012	Cell wall-targeting antibiotics, such as vancomycin and ceftriaxone, inhibit the kinase activity of Stk1 and lead to decreased Cys-phosphorylation of SarA and MgrA.	Vancomycin	41-51	MAS1 oncogene	Mus musculus	159-163
22535621-1	2012	OBJECTIVES: We compared the clinical characteristics and outcomes of, and the bacterial genotypes in, patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-susceptible S. aureus (VSSA).	Vancomycin	151-161	mitochondrial antiviral signaling protein	Homo sapiens	198-203
22535621-10	2012	Although this phenotype did not affect patient outcomes, our results indicate that targeting an initial vancomycin trough of 15-20 mg/L may be beneficial in patients with hVISA bacteraemia.	Vancomycin	104-114	mitochondrial antiviral signaling protein	Homo sapiens	171-176
23109011-8	2012	In addition, among all tested antibiotics, vancomycin and nitrofurantion seem to be the most effective antibiotics for MR- SA.	Vancomycin	43-53	solute carrier family 9 member A6	Homo sapiens	119-125
22856334-2	2012	In the present study, we confirmed the presence of a LuxS/AI-2 dependent QS system in vancomycin-resistant Enterococcus faecalis V583.	Vancomycin	86-96	S-ribosylhomocysteine lyase	Enterococcus faecalis V583	53-57
22856334-9	2012	Our results provide important clues to the role of a LuxS/AI-2 dependent QS system in vancomycin-resistant E. faecalis.	Vancomycin	86-96	S-ribosylhomocysteine lyase	Enterococcus faecalis V583	53-57
22710116-2	2012	Growth curves and determination of the nature of the peptidoglycan precursors and of the VanX d,d-dipeptidase activity in the absence and in the presence of vancomycin indicated that vancomycin resistance was inducible in VRSA-10, that VRSA-11A was partially dependent on glycopeptide for growth, and that VRSA-11B was constitutively resistant.	Vancomycin	183-193	vancomycin B-type resistance protein VanX	Staphylococcus aureus	89-93
22733075-7	2012	MBX-500 displayed potency across nearly 50 isolates, including those of the fluoroquinolone-resistant, toxin-overproducing NAP1/027 ribotype, performing as well as comparator antibiotics vancomycin and metronidazole.	Vancomycin	187-197	diencephalon/mesencephalon homeobox 1	Mus musculus	0-3
22710424-0	2012	Real-time PCR surveillance of vanA for vancomycin-resistant Enterococcus             faecium.	Vancomycin	39-49	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	30-34
22438436-1	2012	OBJECTIVES: Vancomycin use for neonatal coagulase-negative staphylococci (CoNS) sepsis is based on a high CoNS carriage rate of mecA, encoding penicillin-binding protein (PBP)-2a, with low affinity for, and associated with resistance to, beta-lactam antibiotics.	Vancomycin	12-22	phosphatidylethanolamine binding protein 1	Homo sapiens	143-169
22438436-1	2012	OBJECTIVES: Vancomycin use for neonatal coagulase-negative staphylococci (CoNS) sepsis is based on a high CoNS carriage rate of mecA, encoding penicillin-binding protein (PBP)-2a, with low affinity for, and associated with resistance to, beta-lactam antibiotics.	Vancomycin	12-22	phosphatidylethanolamine binding protein 1	Homo sapiens	171-174
22324455-1	2012	AIMS: In this study, the molecular diversity among clones of vancomycin resistant Enterococcus faecium with vanA gene (VRE) is investigated.	Vancomycin	61-71	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	108-112
26815962-3	2012	METHODS: All injured intensive care unit (ICU) patients receiving intravenous vancomycin between May 1, 2004 and July 31, 2010 were identified through our trauma database and pharmacy records.	Vancomycin	78-88	protein kinase C delta	Homo sapiens	97-102
22033576-0	2012	Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.	Vancomycin	16-26	mitochondrial antiviral signaling protein	Homo sapiens	63-68
22033576-1	2012	Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor, heterogeneous VISA (hVISA), are increasingly the cause of vancomycin treatment failure.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	47-51
22033576-1	2012	Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor, heterogeneous VISA (hVISA), are increasingly the cause of vancomycin treatment failure.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	86-90
22033576-1	2012	Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor, heterogeneous VISA (hVISA), are increasingly the cause of vancomycin treatment failure.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	92-97
22033576-1	2012	Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor, heterogeneous VISA (hVISA), are increasingly the cause of vancomycin treatment failure.	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	47-51
22033576-1	2012	Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor, heterogeneous VISA (hVISA), are increasingly the cause of vancomycin treatment failure.	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	86-90
22033576-1	2012	Vancomycin-intermediate Staphylococcus aureus (VISA) and its precursor, heterogeneous VISA (hVISA), are increasingly the cause of vancomycin treatment failure.	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	92-97
22033576-8	2012	When compared with vancomycin-susceptible MRSA strain N315, six of the 38 hVISA strains possessed nonsynonymous mutations in vraSR, seven in walRK, and two in rpoB genes, Thirteen of 38 (34.2%) hVISA strains possessed at least one of these mutations.	Vancomycin	19-29	mitochondrial antiviral signaling protein	Homo sapiens	74-79
22612479-4	2012	Multiple examples are provided with full characterization and analyses, including a novel aza-variant of the C-O-D ring system of vancomycin.	Vancomycin	130-140	small nuclear ribonucleoprotein polypeptides B and B1	Homo sapiens	109-114
22958440-0	2012	Vancomycin-resistant vanB-type Enterococcus faecium isolates expressing varying levels of vancomycin resistance and being highly prevalent among neonatal patients in a single ICU.	Vancomycin	0-10	D-alanine--D-lactate ligase	Enterococcus faecium	21-25
22958440-0	2012	Vancomycin-resistant vanB-type Enterococcus faecium isolates expressing varying levels of vancomycin resistance and being highly prevalent among neonatal patients in a single ICU.	Vancomycin	90-100	D-alanine--D-lactate ligase	Enterococcus faecium	21-25
22666871-1	2012	Here we describe the detection and characterisation of three isolates of vancomycin-resistant VanB-type Enterococcus faecalis.	Vancomycin	73-83	D-alanine--D-lactate ligase	Enterococcus faecalis	94-98
22551158-1	2012	BACKGROUND: A novel method for the rapid detection of fibrinogen concentration in human plasma, the fibrinogen antigenic turbidimetric assay (FIATA), is based on the precipitation of fibrinogen by vancomycin and a resultant change in optical density.	Vancomycin	197-207	fibrinogen beta chain	Homo sapiens	54-64
22551158-1	2012	BACKGROUND: A novel method for the rapid detection of fibrinogen concentration in human plasma, the fibrinogen antigenic turbidimetric assay (FIATA), is based on the precipitation of fibrinogen by vancomycin and a resultant change in optical density.	Vancomycin	197-207	fibrinogen beta chain	Homo sapiens	100-110
22551158-1	2012	BACKGROUND: A novel method for the rapid detection of fibrinogen concentration in human plasma, the fibrinogen antigenic turbidimetric assay (FIATA), is based on the precipitation of fibrinogen by vancomycin and a resultant change in optical density.	Vancomycin	197-207	fibrinogen beta chain	Homo sapiens	100-110
21822974-6	2012	As expected, hVISA were detected in MRSA with vancomycin minimum inhibitory concentrations (MICs) of 1-2 mg/l, frequently associated with the major SCCmec I and II nosocomial clones; this phenotype was also detected in some MSSA strains.	Vancomycin	46-56	mitochondrial antiviral signaling protein	Homo sapiens	13-18
22045102-1	2012	BACKGROUND: For the treatment of peritoneal dialysis-associated peritonitis (PDP), it has been suggested that serum concentrations of vancomycin be kept above 12 mg/L-15 mg/L.	Vancomycin	134-144	immunoglobulin kappa variable 1D-16	Homo sapiens	165-169
22247331-3	2012	Treatment of Dahl S rats with a minimally absorbed antibiotic vancomycin, in the drinking water, decreased circulating leptin levels by 38%, resulted in smaller myocardial infarcts (27% reduction), and improved recovery of postischemic mechanical function (35%) as compared with untreated controls.	Vancomycin	62-72	leptin	Rattus norvegicus	119-125
22324455-9	2012	The finding that decreased susceptibility to narasin can be co-transferred with the vanA gene indicates that the use of narasin might play a role in the persistence of vancomycin resistance in enterococci colonizing Swedish broilers.	Vancomycin	168-178	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	84-88
22257297-5	2012	This is the first report demonstrating insertion of tnpA and fosB genes in the vanRS-vanH intergenic region of Tn1546 leading to coresistance to vancomycin and fosfomycin.	Vancomycin	145-155	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	61-65
22495870-5	2012	To our knowledge, this article describes the first case of daptomycin-resistant heterogenous vancomycin intermediate-resistant Staphylococcus aureus (hVISA) in an 82-year-old man undergoing elective total knee arthroplasty in Queensland, Australia, with a subsequent deep prosthetic joint infection.A literature review is presented, and the increasing number of multi-resistant organisms and their implications for orthopedics are discussed.	Vancomycin	93-103	mitochondrial antiviral signaling protein	Homo sapiens	150-155
24470927-1	2012	In a 3-month study done in Hospital Kuala Lumpur (HKL), 7 out of 320 methicillin resistant Staphylococcus aureus isolates were confirmed as heterogeneous vancomycin intermediate S. aureus (hVISA) using the glycopeptide resistance detection e-test and population analysis, giving a prevalence rate of 2.19%.	Vancomycin	154-164	mitochondrial antiviral signaling protein	Homo sapiens	189-194
22124681-1	2012	This study aimed to assess the efficiency of the Cepheid Xpert vanA/vanB test for detecting vancomycin-resistant enterococci (VRE) colonization during a VanA Enterococcus faecium outbreak and to compare the Cepheid Xpert vanA/vanB (Cepheid, Sunnyvale, USA) test to a culture method with chromogenic medium chromID VRE agar (bioMerieux).	Vancomycin	92-102	D-alanine--D-lactate ligase	Enterococcus faecium	68-72
22124681-0	2012	Efficiency of the Cepheid Xpert vanA/vanB assay for screening of colonization with vancomycin-resistant enterococci during hospital outbreak.	Vancomycin	83-93	D-alanine--D-lactate ligase	Enterococcus faecium	37-41
22253738-7	2012	Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA.	Vancomycin	224-234	mitochondrial antiviral signaling protein	Homo sapiens	57-62
22333933-8	2012	A CL(Cr)&gt;120 mL/min/1.73 m(2) had a sensitivity of 26%, a specificity of 94% and an 84% positive predictive value of 84% for vancomycin concentrations &lt;20 mug/mL.	Vancomycin	128-138	CD59 molecule (CD59 blood group)	Homo sapiens	19-24
22167243-1	2012	OBJECTIVES: Laboratory detection of vancomycin-intermediate Staphylococcus aureus (VISA) and their heterogeneous VISA (hVISA) precursors is difficult.	Vancomycin	36-46	mitochondrial antiviral signaling protein	Homo sapiens	83-87
22167243-2	2012	Thus, it is possible that vancomycin failures against supposedly vancomycin-susceptible S. aureus are due to undiagnosed VISA or hVISA.	Vancomycin	26-36	mitochondrial antiviral signaling protein	Homo sapiens	121-125
22167243-2	2012	Thus, it is possible that vancomycin failures against supposedly vancomycin-susceptible S. aureus are due to undiagnosed VISA or hVISA.	Vancomycin	26-36	mitochondrial antiviral signaling protein	Homo sapiens	129-134
22167243-2	2012	Thus, it is possible that vancomycin failures against supposedly vancomycin-susceptible S. aureus are due to undiagnosed VISA or hVISA.	Vancomycin	65-75	mitochondrial antiviral signaling protein	Homo sapiens	121-125
22167243-2	2012	Thus, it is possible that vancomycin failures against supposedly vancomycin-susceptible S. aureus are due to undiagnosed VISA or hVISA.	Vancomycin	65-75	mitochondrial antiviral signaling protein	Homo sapiens	129-134
22167243-7	2012	When vegetation homogenates were plated directly on vancomycin-containing plates, 6 of 13 rats killed 8 h after treatment arrest had positive cultures, 1 of which harboured hVISA.	Vancomycin	52-62	mitochondrial antiviral signaling protein	Homo sapiens	173-178
22167243-10	2012	Thus, vancomycin selected for hVISA during therapy of experimental endocarditis due to vancomycin-susceptible S. aureus.	Vancomycin	6-16	mitochondrial antiviral signaling protein	Homo sapiens	30-35
22167243-11	2012	These hVISA were associated with vancomycin failure.	Vancomycin	33-43	mitochondrial antiviral signaling protein	Homo sapiens	6-11
22167243-12	2012	The hVISA phenotype persisted in vivo, even after vancomycin arrest, but was missed in vitro after a single passage of the vegetation homogenate on drug-free medium.	Vancomycin	50-60	mitochondrial antiviral signaling protein	Homo sapiens	4-9
21959204-1	2012	Risk factors for invasive infections by heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) may involve resistance to opsonophagocytosis and bacterial killing.	Vancomycin	54-64	mitochondrial antiviral signaling protein	Homo sapiens	101-106
22500244-2	2012	Although vancomycin has been considered a gold standard for the therapy of MRSA pneumonia, clinical failure rates have also been reported owing to its slow, time-dependent bactericidal activity, variable lung tissue penetration and poor intracellular penetration into macrophages.	Vancomycin	9-19	solute carrier family 9 member A6	Homo sapiens	75-79
22916234-8	2012	The mixed effects modeling showed hospital variation in the probability of vancomycin use that was statistically significant after controlling for teaching status, urban or rural location, size, region of the country, patient ethnic group, payor status, and APR-mortality and severity codes.	Vancomycin	75-85	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	258-261
22253738-0	2012	Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.	Vancomycin	23-33	mitochondrial antiviral signaling protein	Homo sapiens	128-133
22253738-0	2012	Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.	Vancomycin	23-33	mitochondrial antiviral signaling protein	Homo sapiens	129-133
22253738-1	2012	Glycopeptides are still the gold standard to treat MRSA (Methicillin Resistant Staphylococcus aureus) infections, but their widespread use has led to vancomycin-reduced susceptibility [heterogeneous Vancomycin-Intermediate-Staphylococcus aureus (hVISA) and Vancomycin-Intermediate-Staphylococcus aureus (VISA)], in which different genetic loci (regulatory, autolytic, cell-wall turnover and cell-envelope positive charge genes) are involved.	Vancomycin	150-160	mitochondrial antiviral signaling protein	Homo sapiens	246-251
22253738-1	2012	Glycopeptides are still the gold standard to treat MRSA (Methicillin Resistant Staphylococcus aureus) infections, but their widespread use has led to vancomycin-reduced susceptibility [heterogeneous Vancomycin-Intermediate-Staphylococcus aureus (hVISA) and Vancomycin-Intermediate-Staphylococcus aureus (VISA)], in which different genetic loci (regulatory, autolytic, cell-wall turnover and cell-envelope positive charge genes) are involved.	Vancomycin	150-160	mitochondrial antiviral signaling protein	Homo sapiens	247-251
22253738-5	2012	Our results show that hVISA and VISA present common features that distinguish them from Vancomycin-Susceptible Staphylococcus aureus (VSSA), responsible for the intermediate glycopeptide resistance i.e. an increased cell-wall turnover, an increased positive cell-wall charge responsible for a repulsion mechanism towards vancomycin and daptomycin, and reduced agr-functionality.	Vancomycin	321-331	mitochondrial antiviral signaling protein	Homo sapiens	22-27
22253738-5	2012	Our results show that hVISA and VISA present common features that distinguish them from Vancomycin-Susceptible Staphylococcus aureus (VSSA), responsible for the intermediate glycopeptide resistance i.e. an increased cell-wall turnover, an increased positive cell-wall charge responsible for a repulsion mechanism towards vancomycin and daptomycin, and reduced agr-functionality.	Vancomycin	321-331	mitochondrial antiviral signaling protein	Homo sapiens	23-27
22253738-7	2012	Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	57-62
22253738-7	2012	Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	58-62
22253738-7	2012	Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	67-71
22253738-7	2012	Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	148-153
22253738-7	2012	Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	67-71
22547995-3	2012	In the final model, there was a linear relationship between vancomycin clearance, CL (L/h), and creatinine clearance calculated by Cockcroft-Gault equation, CL(Cr) (mL/min): CL = 0.044 x L(Cr).	Vancomycin	60-70	chymotrypsin C	Homo sapiens	157-163
21926081-5	2011	RESULTS: The vancomycin-susceptible vanA-positive E. faecium isolates showed three PFGE patterns, and were missing the vanR and vanS genes that are responsible for the activation of transcription of resistance genes.	Vancomycin	13-23	VanR	Enterococcus faecium	119-123
21926081-8	2011	Our findings support the essential role of vanR and vanS for the expression of resistance to vancomycin in enterococci.	Vancomycin	93-103	VanR	Enterococcus faecium	43-47
21976769-1	2011	The prevalence of heterogeneous intermediate-level resistance to vancomycin (hVISA) in Staphylococcus aureus was assessed by screening a large collection of recent isolates.	Vancomycin	65-75	mitochondrial antiviral signaling protein	Homo sapiens	77-82
21976769-12	2011	The hVISA isolates represented 10.5% of isolates with vancomycin MICs of 2 mug/ml and 0.1% of isolates with vancomycin MICs of 1 mug/ml.	Vancomycin	54-64	mitochondrial antiviral signaling protein	Homo sapiens	4-9
21976769-12	2011	The hVISA isolates represented 10.5% of isolates with vancomycin MICs of 2 mug/ml and 0.1% of isolates with vancomycin MICs of 1 mug/ml.	Vancomycin	108-118	mitochondrial antiviral signaling protein	Homo sapiens	4-9
22371904-0	2012	The relationship between serum neutrophil gelatinase-associated lipocalin and renal function in patients with vancomycin treatment.	Vancomycin	110-120	lipocalin 2	Homo sapiens	31-73
22371904-3	2012	Here, we aimed to investigate the usefulness of serum NGAL in monitoring patients undergoing vancomycin therapy.	Vancomycin	93-103	lipocalin 2	Homo sapiens	54-58
22371904-11	2012	Conclusion The clinical usefulness of serum NGAL should be interpreted carefully when evaluating renal impairment in patients undergoing vancomycin treatment.	Vancomycin	137-147	lipocalin 2	Homo sapiens	44-48
22170976-4	2012	The patient"s ANC decreased to 10 cells/muL within 3 days of starting vancomycin.	Vancomycin	70-80	tripartite motif containing 37	Homo sapiens	40-43
22064529-1	2012	The Etest glycopeptide resistance detection identified two potential heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) isolates from a screen of 288 methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients at a Connecticut Veterans Hospital.	Vancomycin	83-93	mitochondrial antiviral signaling protein	Homo sapiens	130-135
21996511-0	2012	Interaction of ERp57 with calreticulin: Analysis of complex formation and effects of vancomycin.	Vancomycin	85-95	protein disulfide isomerase family A member 3	Homo sapiens	15-20
21996511-0	2012	Interaction of ERp57 with calreticulin: Analysis of complex formation and effects of vancomycin.	Vancomycin	85-95	calreticulin	Homo sapiens	26-38
21996511-4	2012	We focused on the kinetic, extent and stability of the ERp57-CRT complex, using the surface plasmon resonance spectroscopy, investigating the possible role as inhibitor of the antibiotic vancomycin.	Vancomycin	187-197	protein disulfide isomerase family A member 3	Homo sapiens	55-60
21996511-4	2012	We focused on the kinetic, extent and stability of the ERp57-CRT complex, using the surface plasmon resonance spectroscopy, investigating the possible role as inhibitor of the antibiotic vancomycin.	Vancomycin	187-197	calreticulin	Homo sapiens	61-64
21996511-5	2012	Equilibrium thermodynamic data suggested that vancomycin may hinder the interaction between the two proteins and could interfere with the ERp57 conformational changes that stabilize the complex.	Vancomycin	46-56	protein disulfide isomerase family A member 3	Homo sapiens	138-143
21996511-6	2012	Furthermore, by means of confocal microscopy, we evaluated the effect of the in vivo administration of vancomycin on the ERp57/CRT complex on the surface of HeLa cells.	Vancomycin	103-113	protein disulfide isomerase family A member 3	Homo sapiens	121-126
21996511-6	2012	Furthermore, by means of confocal microscopy, we evaluated the effect of the in vivo administration of vancomycin on the ERp57/CRT complex on the surface of HeLa cells.	Vancomycin	103-113	calreticulin	Homo sapiens	127-130
22113110-1	2012	VanX, a Zn(II)-dependent D-ala-D-ala dipeptidase, is essential for vancomycin resistance in Enterococcus faecium.	Vancomycin	67-77	VanX protein	Enterococcus faecium	0-4
23548324-6	2012	Also, the presence of vanA and vanB genes was determined in E. faecium vancomycin (VAN)-resistant isolates.	Vancomycin	71-81	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	22-26
23548324-6	2012	Also, the presence of vanA and vanB genes was determined in E. faecium vancomycin (VAN)-resistant isolates.	Vancomycin	83-86	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	22-26
22284995-1	2012	BACKGROUND: The 2005 guidelines from the American Thoracic Society and the Infectious Diseases Society of America recommend vancomycin trough levels of 15 to 20 mg/L for the therapy of hospital-acquired (HAP), ventilator-associated (VAP), and health care-associated (HCAP) pneumonia.	Vancomycin	124-134	dermcidin	Homo sapiens	267-271
22284995-2	2012	OBJECTIVE: The goal of this article was to report the incidence of nephrotoxicity and associated risk factors in intensive care unit patients who received vancomycin for the treatment of HAP, VAP, and HCAP.	Vancomycin	155-165	dermcidin	Homo sapiens	201-205
22641152-1	2012	Vancomycin-resistant Enterococcus faecalis, E. faecium and E. durans isolates with the genotype vanA were detected in 7 of 118 faecal samples (5.9%) of natural gilthead seabream recovered off the coast of Portugal, and one vancomycin-resistant isolate/sample was further characterized.	Vancomycin	0-10	VanA	Enterococcus faecalis	96-100
22641152-1	2012	Vancomycin-resistant Enterococcus faecalis, E. faecium and E. durans isolates with the genotype vanA were detected in 7 of 118 faecal samples (5.9%) of natural gilthead seabream recovered off the coast of Portugal, and one vancomycin-resistant isolate/sample was further characterized.	Vancomycin	223-233	VanA	Enterococcus faecalis	96-100
22582098-6	2012	Irrespective of the species, vanA gene (89.58%) was dominant and three phenotypically vancomycin susceptible E. faecium isolates carried the vanB gene.	Vancomycin	86-96	D-alanine--D-lactate ligase	Enterococcus faecium	141-145
22582098-9	2012	Our data indicate a high prevalence of E. faecium harboring vancomycin resistance with vanA genotype and the two VRE species displayed different virulence genes.	Vancomycin	60-70	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	87-91
22848719-1	2012	INTRODUCTION: Continued pressure from glycopeptide use has led to non-susceptible strains of Staphylococcus aureus including heterogeneously vancomycin-intermediate S. aureus (hVISA).	Vancomycin	141-151	mitochondrial antiviral signaling protein	Homo sapiens	176-181
22848719-3	2012	Evidence suggests that vancomycin and anti-staphylococcal penicillin susceptibility are inversely related which indicates that the use of this combination may be particularly useful against methicillin-resistant S. aureus with reduced susceptibility to vancomycin, such as hVISA.	Vancomycin	23-33	mitochondrial antiviral signaling protein	Homo sapiens	273-278
22848719-4	2012	The aim of this study was to evaluate the potential for synergy between vancomycin and nafcillin against hVISA.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	105-110
22848719-12	2012	CONCLUSIONS: The combination of vancomycin and nafcillin significantly improved antibacterial activity against hVISA, MRSA, and MSSA compared to either drug alone.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	111-116
22768166-5	2012	Among ten test strains vancomycin-resistant E. faecium had a significantly higher capacity to stimulate FPR2/ALX than vancomycin-susceptible strains, suggesting an association of strong FPR2/ALX activation with health-care associated strains.	Vancomycin	23-33	formyl peptide receptor 2	Homo sapiens	104-108
22768166-5	2012	Among ten test strains vancomycin-resistant E. faecium had a significantly higher capacity to stimulate FPR2/ALX than vancomycin-susceptible strains, suggesting an association of strong FPR2/ALX activation with health-care associated strains.	Vancomycin	23-33	hematopoietic SH2 domain containing	Homo sapiens	109-112
22768166-5	2012	Among ten test strains vancomycin-resistant E. faecium had a significantly higher capacity to stimulate FPR2/ALX than vancomycin-susceptible strains, suggesting an association of strong FPR2/ALX activation with health-care associated strains.	Vancomycin	23-33	formyl peptide receptor 2	Homo sapiens	186-190
22768166-5	2012	Among ten test strains vancomycin-resistant E. faecium had a significantly higher capacity to stimulate FPR2/ALX than vancomycin-susceptible strains, suggesting an association of strong FPR2/ALX activation with health-care associated strains.	Vancomycin	23-33	hematopoietic SH2 domain containing	Homo sapiens	191-194
22768166-5	2012	Among ten test strains vancomycin-resistant E. faecium had a significantly higher capacity to stimulate FPR2/ALX than vancomycin-susceptible strains, suggesting an association of strong FPR2/ALX activation with health-care associated strains.	Vancomycin	118-128	hematopoietic SH2 domain containing	Homo sapiens	191-194
22253738-7	2012	Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA.	Vancomycin	224-234	mitochondrial antiviral signaling protein	Homo sapiens	58-62
22253738-7	2012	Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA.	Vancomycin	224-234	mitochondrial antiviral signaling protein	Homo sapiens	67-71
22253738-7	2012	Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA.	Vancomycin	224-234	mitochondrial antiviral signaling protein	Homo sapiens	67-71
21856109-1	2011	A total of 559 methicillin-resistant Staphylococcus aureus isolates were investigated for heterogeneous vancomycin-intermediate S. aureus (hVISA) by population analysis profile area under the curve.	Vancomycin	104-114	mitochondrial antiviral signaling protein	Homo sapiens	139-144
21856109-2	2011	Our results suggested that the incidence of hVISA increased rapidly when vancomycin MIC shifted from 1 to 2 mug/mL, and at vancomycin MIC of 2 mug/mL, the incidence of hVISA was nearly 40%.	Vancomycin	73-83	mitochondrial antiviral signaling protein	Homo sapiens	44-49
21856109-2	2011	Our results suggested that the incidence of hVISA increased rapidly when vancomycin MIC shifted from 1 to 2 mug/mL, and at vancomycin MIC of 2 mug/mL, the incidence of hVISA was nearly 40%.	Vancomycin	123-133	mitochondrial antiviral signaling protein	Homo sapiens	168-173
22026752-1	2011	BACKGROUND: The development of hVISA has been associated with vancomycin clinical failures and is commonly misidentified in clinical microbiology laboratories.	Vancomycin	62-72	mitochondrial antiviral signaling protein	Homo sapiens	31-36
21746940-1	2011	The clinical vancomycin-intermediate Staphylococcus aureus (VISA) strain Mu50 carries two mutations in the vraSR and graRS two-component regulatory systems (TCRSs), namely, vraS(I5N) and graR(N197S) (hereinafter designated graR).	Vancomycin	13-23	mitochondrial antiviral signaling protein	Homo sapiens	60-64
22090289-5	2011	This test uses DNA.STRIP  technology which includes a panel of probes for identification of 17 gram-positive bacterial species and is able to determinate the methicillin and vancomycin resistance mediating genes (mecA and vanA, vanB, vanC1, vanC2/C3) simultaneously, in a single test run.	Vancomycin	174-184	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	222-226
21746940-2	2011	The clinical heterogeneously vancomycin-intermediate S. aureus (hVISA) strain Mu3 shares with Mu50 the mutation in vraS that encodes the VraS two-component histidine kinase.	Vancomycin	29-39	mitochondrial antiviral signaling protein	Homo sapiens	64-69
21746940-3	2011	Previously, we showed that introduction of the plasmid pgraR, carrying the mutated two-component response regulator graR, converted the hVISA strain Mu3 into VISA (vancomycin MIC = 4 mg/liter).	Vancomycin	164-174	mitochondrial antiviral signaling protein	Homo sapiens	136-141
21746940-3	2011	Previously, we showed that introduction of the plasmid pgraR, carrying the mutated two-component response regulator graR, converted the hVISA strain Mu3 into VISA (vancomycin MIC = 4 mg/liter).	Vancomycin	164-174	mitochondrial antiviral signaling protein	Homo sapiens	137-141
21746940-10	2011	The data indicate that a sizable proportion of the resistant hVISA cell subpopulations is composed of spontaneous rpoB mutants with various degrees of increased vancomycin resistance.	Vancomycin	161-171	mitochondrial antiviral signaling protein	Homo sapiens	61-66
21563943-0	2011	Secondary transfer and expression of vanA in Enterococcus faecium derived from a commensal vancomycin-susceptible Enterococcus faecium multi-component food isolate.	Vancomycin	91-101	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	37-41
21709077-0	2011	Genetic organization and mode of action of a novel bacteriocin, bacteriocin 51: determinant of VanA-type vancomycin-resistant Enterococcus faecium.	Vancomycin	105-115	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	95-99
21670191-8	2011	The algebraic expression from the final prediction model was f[vanco] = 0.643 + 0.560 x total [vanco] - {0.067 x total [vanco] x D} - {0.071 x total [vanco] x TP} where D = 1 if dialysis dependent or 0 if not dialysis dependent, and TP = 1 if total protein is &gt;=6.7 g/dl or 0 if total protein is &lt;6.7 g/dl.	Vancomycin	63-68	transition protein 1	Homo sapiens	233-239
21670191-8	2011	The algebraic expression from the final prediction model was f[vanco] = 0.643 + 0.560 x total [vanco] - {0.067 x total [vanco] x D} - {0.071 x total [vanco] x TP} where D = 1 if dialysis dependent or 0 if not dialysis dependent, and TP = 1 if total protein is &gt;=6.7 g/dl or 0 if total protein is &lt;6.7 g/dl.	Vancomycin	95-100	transition protein 1	Homo sapiens	233-239
21670191-8	2011	The algebraic expression from the final prediction model was f[vanco] = 0.643 + 0.560 x total [vanco] - {0.067 x total [vanco] x D} - {0.071 x total [vanco] x TP} where D = 1 if dialysis dependent or 0 if not dialysis dependent, and TP = 1 if total protein is &gt;=6.7 g/dl or 0 if total protein is &lt;6.7 g/dl.	Vancomycin	95-100	transition protein 1	Homo sapiens	233-239
21670191-8	2011	The algebraic expression from the final prediction model was f[vanco] = 0.643 + 0.560 x total [vanco] - {0.067 x total [vanco] x D} - {0.071 x total [vanco] x TP} where D = 1 if dialysis dependent or 0 if not dialysis dependent, and TP = 1 if total protein is &gt;=6.7 g/dl or 0 if total protein is &lt;6.7 g/dl.	Vancomycin	95-100	transition protein 1	Homo sapiens	233-239
21563943-1	2011	We investigated the potential for vancomycin-susceptible Enterococcus (VSE) from multi-component salads to disseminate vanA from four clinical vancomycin-resistant enterococci to 14 streptogramin-resistant enterococci (SRE) of food and animal origin.	Vancomycin	34-44	VanA	Enterococcus faecalis	119-123
21977823-9	2011	16% of MRSA carriers develop an infection that needs to be treated with vancomycin.	Vancomycin	72-82	solute carrier family 9 member A6	Homo sapiens	7-11
21682676-3	2011	The main regime of antibiotic treatment recommended for MRSA pneumonia is either vancomycin or linezolid.	Vancomycin	81-91	solute carrier family 9 member A6	Homo sapiens	56-60
21525024-1	2011	OBJECTIVES: To assess the relevance of vancomycin-intermediate susceptibility (VISA) and heteroresistance (hVISA) in methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia.	Vancomycin	39-49	mitochondrial antiviral signaling protein	Homo sapiens	79-83
21525024-7	2011	Prior vancomycin use was documented in 100% of VISA, 73.3% of hVISA and 52.2% of S-MRSA cases (P = 0.002).	Vancomycin	6-16	mitochondrial antiviral signaling protein	Homo sapiens	47-51
21525024-7	2011	Prior vancomycin use was documented in 100% of VISA, 73.3% of hVISA and 52.2% of S-MRSA cases (P = 0.002).	Vancomycin	6-16	mitochondrial antiviral signaling protein	Homo sapiens	62-67
21525024-10	2011	VISA and hVISA appear to emerge in SCCmec II isolates among vancomycin-exposed patients and are better detected by Etest.	Vancomycin	60-70	mitochondrial antiviral signaling protein	Homo sapiens	0-4
21525024-10	2011	VISA and hVISA appear to emerge in SCCmec II isolates among vancomycin-exposed patients and are better detected by Etest.	Vancomycin	60-70	mitochondrial antiviral signaling protein	Homo sapiens	9-14
21935776-5	2011	Vancomycin resistant strains were checked for the presence of vanA and vanB genes.	Vancomycin	0-10	VanA	Enterococcus faecalis	62-66
21532521-1	2011	AIMS: To highlight the challenges involved in diagnosing and managing complicated heterogeneous vancomycin intermediate Staphylococcus aureus (hVISA) infections and to improve clinical recognition of such infections.	Vancomycin	96-106	mitochondrial antiviral signaling protein	Homo sapiens	143-148
21839399-2	2011	OBJECTIVE: A decision analytic (DA) model was developed to evaluate the cost-effectiveness analysis (CEA) of linezolid, daptomycin, and vancomycin in MRSA cSSSI.	Vancomycin	136-146	solute carrier family 9 member A6	Homo sapiens	150-160
21839399-13	2011	CONCLUSION: Linezolid and daptomycin are potentially cost-effective based on the assumptions of the DA model; however, linezolid appears to be more cost-effective compared to daptomycin and vancomycin for MRSA cSSSIs.	Vancomycin	190-200	solute carrier family 9 member A6	Homo sapiens	205-209
21402850-9	2011	Daily vancomycin requirements were dependent on CrCl, such that a patient with a CrCl of 100 ml/min/1.73 m2 would require at least 35 mg/kg per day by continuous infusion to maintain target concentrations.	Vancomycin	6-16	CD59 molecule (CD59 blood group)	Homo sapiens	96-101
21388677-10	2011	Notably, Enterococcus faecalis VanB, a bacterial strain with inducible vancomycin resistance, was used to show that the artificial opsonin does not unintentionally induce antibiotic resistance mechanisms.	Vancomycin	71-81	D-alanine--D-lactate ligase	Enterococcus faecalis	31-35
21497067-0	2011	Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).	Vancomycin	94-104	mitochondrial antiviral signaling protein	Homo sapiens	141-146
21497067-1	2011	Selective pressure from glycopeptide use has led to non-susceptible strains of Staphylococcus aureus, including heterogeneously vancomycin-intermediate S. aureus (hVISA).	Vancomycin	128-138	mitochondrial antiviral signaling protein	Homo sapiens	163-168
21497067-2	2011	Treatment of hVISA infections with vancomycin has been associated with treatment failure, therefore new treatments are required.	Vancomycin	35-45	mitochondrial antiviral signaling protein	Homo sapiens	13-18
21497067-3	2011	The objective of this study was to evaluate the activity of telavancin, vancomycin and linezolid against hVISA clinical strains.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	105-110
21539441-7	2011	hVISA refers to heteroresistant vancomycin-intermediate S. aureus strains and VISA is their VISA mutants.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	0-5
21569315-5	2011	Attenuation of this system by deletion of genes encoding the osmotic stress sigma factor sigma(B) or the ppGpp synthetase RelA reduced resistance to both vancomycin and bacitracin.	Vancomycin	154-164	RELA proto-oncogene, NF-kB subunit	Homo sapiens	122-126
21191627-2	2011	Modified population analysis profiling of sequential MRSA blood culture isolates revealed transition from a vancomycin-susceptible phenotype to a vancomycin-intermediate S. aureus (VISA) phenotype through a vancomycin-heteroresistant S. aureus (hVISA) intermediary.	Vancomycin	108-118	mitochondrial antiviral signaling protein	Homo sapiens	245-250
21191627-2	2011	Modified population analysis profiling of sequential MRSA blood culture isolates revealed transition from a vancomycin-susceptible phenotype to a vancomycin-intermediate S. aureus (VISA) phenotype through a vancomycin-heteroresistant S. aureus (hVISA) intermediary.	Vancomycin	146-156	mitochondrial antiviral signaling protein	Homo sapiens	181-185
21191627-2	2011	Modified population analysis profiling of sequential MRSA blood culture isolates revealed transition from a vancomycin-susceptible phenotype to a vancomycin-intermediate S. aureus (VISA) phenotype through a vancomycin-heteroresistant S. aureus (hVISA) intermediary.	Vancomycin	146-156	mitochondrial antiviral signaling protein	Homo sapiens	181-185
21229280-0	2011	Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?	Vancomycin	0-10	solute carrier family 9 member A6	Homo sapiens	24-28
21229280-1	2011	The aim of this study was to assess the vancomycin MIC distribution for MRSA blood culture isolates over a period of six years in Germany.	Vancomycin	40-50	solute carrier family 9 member A6	Homo sapiens	72-76
21229280-4	2011	Genotypic features of the MRSA strains with vancomycin MIC &gt;= 1 mg/L were determined by semiautomated repetitive-sequence-based polymerase chain reaction.	Vancomycin	44-54	solute carrier family 9 member A6	Homo sapiens	26-30
21229280-10	2011	We suggest that all hospitals should monitor their local status of elevated vancomycin MICs in invasive MRSA isolates.	Vancomycin	76-86	solute carrier family 9 member A6	Homo sapiens	104-108
21539441-7	2011	hVISA refers to heteroresistant vancomycin-intermediate S. aureus strains and VISA is their VISA mutants.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	1-5
21539441-9	2011	hVISA is susceptible to vancomycin, but VISA mutants emerge soon after a short period of vancomycin therapy, therefore making the pathogen a great model organism for fast-evolving bacterial pathogens.	Vancomycin	24-34	mitochondrial antiviral signaling protein	Homo sapiens	0-5
21539441-9	2011	hVISA is susceptible to vancomycin, but VISA mutants emerge soon after a short period of vancomycin therapy, therefore making the pathogen a great model organism for fast-evolving bacterial pathogens.	Vancomycin	24-34	mitochondrial antiviral signaling protein	Homo sapiens	1-5
21685529-10	2011	In cases of empirical administration, it is necessary to use antibiotics with high level of activity against pneumonia agents - carbapenems, and in case of high probability of MRSA - it is better to use linezolid or vancomicin.	Vancomycin	216-226	solute carrier family 9 member A6	Homo sapiens	176-180
21270232-1	2011	The best screening method for detecting heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) remains unclear.	Vancomycin	56-66	mitochondrial antiviral signaling protein	Homo sapiens	103-108
21644067-13	2011	In conclusion, since the number of VISA/hVISA strains may increase in time, surveillance for vancomycin resistance in methicillin-resistant staphylococci should be carried out in hospitals periodically.	Vancomycin	93-103	mitochondrial antiviral signaling protein	Homo sapiens	35-39
22606516-2	2011	Lymphocyte blast transformation (LBT), a method of detecting cellular immune response by measuring levels of interferon-gamma (IFN-gamma), was used to diagnose vancomycin hypersensitivity and guide antibiotic selection.	Vancomycin	160-170	interferon gamma	Homo sapiens	109-125
21556163-4	2011	PsU, PsQ, PsS, seco-PsK and PsG were the most active compounds (IC50 2.9-4.5 muM) against S. aureus and PsG, PsU and seco-PsK showed good activity (IC50 3.1-3.8 muM) against E. faecalis, comparable to the reference drug vancomycin (4.2 muM).	Vancomycin	220-230	PSS	Homo sapiens	10-13
21556163-4	2011	PsU, PsQ, PsS, seco-PsK and PsG were the most active compounds (IC50 2.9-4.5 muM) against S. aureus and PsG, PsU and seco-PsK showed good activity (IC50 3.1-3.8 muM) against E. faecalis, comparable to the reference drug vancomycin (4.2 muM).	Vancomycin	220-230	pregnancy specific beta-1-glycoprotein 5	Homo sapiens	28-31
20513252-5	2011	This study confirms the clonal spread of vanA- or vanB-positive E. gallinarum in a region and underlines the importance of surveillance of VRE for the presence of vancomycin resistance determinants.	Vancomycin	163-173	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	41-45
20625789-2	2011	This study compared several characteristics of vancomycin MIC 2 mug/ml strains isolated from bacteremia with those isolated from infections other than bacteremia.	Vancomycin	47-57	CD99 molecule (Xg blood group)	Homo sapiens	58-63
21030436-5	2011	RT-PCR analysis revealed that the axe-txe transcript is produced by strain S177 as well as by other vancomycin-resistant enteroccoci.	Vancomycin	100-110	Txe	Enterococcus faecium	38-41
21078939-1	2011	The prevalence of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) is 1.3% in published studies.	Vancomycin	34-44	mitochondrial antiviral signaling protein	Homo sapiens	81-86
21468926-1	2011	The principal objective of this study was to evaluate the antibacterial activities of macrolactin A (MA) and 7-O-succinyl macrolactin A (SMA) generated from Bacillus polyfermenticus KJS-2 against vancomycin-resistant enterococci (VREs) and methicillin-resistant Staphylococcus aureus.	Vancomycin	196-206	immunoglobulin mu binding protein 2	Mus musculus	137-140
21327600-5	2011	In all of the patients with MRSA-positive bile culture, vancomycin was prophylactically administered after surgery.	Vancomycin	56-66	solute carrier family 9 member A6	Homo sapiens	28-32
21132518-0	2011	Bio-inspired porous SiC ceramics loaded with vancomycin for preventing MRSA infections.	Vancomycin	45-55	solute carrier family 9 member A6	Homo sapiens	71-75
22606516-2	2011	Lymphocyte blast transformation (LBT), a method of detecting cellular immune response by measuring levels of interferon-gamma (IFN-gamma), was used to diagnose vancomycin hypersensitivity and guide antibiotic selection.	Vancomycin	160-170	interferon gamma	Homo sapiens	127-136
20962147-2	2011	However, the prevalence of heterogeneous vancomycin-intermediate S. aureus (hVISA) is unknown due to the difficulty in detecting this phenotype.	Vancomycin	41-51	mitochondrial antiviral signaling protein	Homo sapiens	76-81
21048008-1	2011	Staphylococcus aureus clinical isolates with vancomycin MICs of 2 mug/ml have been associated with vancomycin therapeutic failure and the heteroresistant vancomycin-intermediate S. aureus (hVISA) phenotype.	Vancomycin	45-55	mitochondrial antiviral signaling protein	Homo sapiens	189-194
21713004-1	2011	BACKGROUND: Despite hVISA infections being associated with vancomycin treatment failure, no previous study has been able to detect a mortality difference between heteroresistant vancomycin intermediate Staphylococcus aureus (hVISA) and vancomycin susceptible Staphylococcus aureus (VSSA) bloodstream infections (BSI).	Vancomycin	59-69	mitochondrial antiviral signaling protein	Homo sapiens	20-25
21713004-9	2011	Compared to VSSA, hVISA was associated with chronic renal failure (p&lt;0.001), device related infections (haemodialysis access) (p&lt;0.001) and previous vancomycin usage (p = 0.004).	Vancomycin	155-165	mitochondrial antiviral signaling protein	Homo sapiens	18-23
20674281-1	2010	Definitive identification of heterogeneously resistant vancomycin-intermediate Staphylococcus aureus (hVISA) strains in the clinical microbiology laboratory has been an elusive goal for over a decade.	Vancomycin	55-65	mitochondrial antiviral signaling protein	Homo sapiens	102-107
20558550-15	2010	CONCLUSIONS: Mortality in patients with MRSA HAP, VAP, and HCAP increases as a function of the vancomycin MIC, even for strains with MIC values within the susceptible range.	Vancomycin	95-105	structural maintenance of chromosomes 3	Homo sapiens	59-63
20733041-11	2010	Liquid chromatography-mass spectrometry analysis of peptidoglycan precursors extracted from the VanM-type strain Efm-HS0661 treated with vancomycin or teicoplanin revealed a modified precursor (UDP-N-acetylmuramic acid [MurNAc]-tetrapeptide-D-Lac), indicating that VanM, like VanA, confers glycopeptide resistance by the inducible synthesis of precursor ending in D-Ala-D-Lac.	Vancomycin	137-147	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	276-280
20361190-3	2010	Regarding to inductive mechanism of vanA-mediated vancomycin resistance, resistant reference strain was also pre-incubated with vancomycin.	Vancomycin	50-60	VanA	Enterococcus faecalis	36-40
20361190-3	2010	Regarding to inductive mechanism of vanA-mediated vancomycin resistance, resistant reference strain was also pre-incubated with vancomycin.	Vancomycin	128-138	VanA	Enterococcus faecalis	36-40
20361190-8	2010	The study proved possibility of detection of vancomycin resistance caused by presence of vanA gene by staining cells with Vancomycin@FL.	Vancomycin	45-55	VanA	Enterococcus faecalis	89-93
20361190-8	2010	The study proved possibility of detection of vancomycin resistance caused by presence of vanA gene by staining cells with Vancomycin@FL.	Vancomycin	122-132	VanA	Enterococcus faecalis	89-93
20727722-1	2010	The prevalence and molecular characterisation of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) strains were determined in a large group of Italian strains isolated between 2005 and mid 2007.	Vancomycin	65-75	mitochondrial antiviral signaling protein	Homo sapiens	112-117
20812846-0	2010	A sustained hospital outbreak of vancomycin-resistant Enterococcus faecium bacteremia due to emergence of vanB E. faecium sequence type 203.	Vancomycin	33-43	D-alanine--D-lactate ligase	Enterococcus faecium	106-110
20812846-4	2010	In 2005, ST203 vancomycin-susceptible E. faecium first appeared at our institution, and from March 2007, coinciding with the appearance of a vanB VREfm ST203, the rate of VRE bacteremia has increased exponentially.	Vancomycin	15-25	D-alanine--D-lactate ligase	Enterococcus faecium	141-145
21119677-0	2011	Enzymatic synthesis of vancomycin derivatives using galactosyltransferase and sialyltransferase.	Vancomycin	23-33	ST6 beta-galactoside alpha-2,6-sialyltransferase 2	Homo sapiens	78-95
20863668-0	2010	Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C.	Vancomycin	13-23	cystatin C	Homo sapiens	155-165
20954213-5	2010	Compared with a conventionally packed vancomycin-CSP, a reversal of the enantiomer elution order was obtained.	Vancomycin	38-48	DnaJ heat shock protein family (Hsp40) member C5	Homo sapiens	49-52
20851816-1	2010	OBJECTIVES: Several methods have been introduced for detection of vancomycin-non-susceptible Staphylococcus aureus [heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA)].	Vancomycin	66-76	mitochondrial antiviral signaling protein	Homo sapiens	165-170
20851816-1	2010	OBJECTIVES: Several methods have been introduced for detection of vancomycin-non-susceptible Staphylococcus aureus [heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA)].	Vancomycin	66-76	mitochondrial antiviral signaling protein	Homo sapiens	166-170
20851816-1	2010	OBJECTIVES: Several methods have been introduced for detection of vancomycin-non-susceptible Staphylococcus aureus [heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA)].	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	165-170
20851816-1	2010	OBJECTIVES: Several methods have been introduced for detection of vancomycin-non-susceptible Staphylococcus aureus [heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA)].	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	166-170
20851816-1	2010	OBJECTIVES: Several methods have been introduced for detection of vancomycin-non-susceptible Staphylococcus aureus [heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA)].	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	165-170
20851816-1	2010	OBJECTIVES: Several methods have been introduced for detection of vancomycin-non-susceptible Staphylococcus aureus [heterogeneous vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA)].	Vancomycin	130-140	mitochondrial antiviral signaling protein	Homo sapiens	166-170
20843722-6	2010	In fact, the increasing spread of heteroresistant vancomycin-intermediate S. aureus (hVISA) and vancomycin intermediate (VISA) strains adds new problems, not only in terms of the treatment of severe infections sustained by these microorganisms, but also in the microbiological definition of susceptibility.	Vancomycin	50-60	mitochondrial antiviral signaling protein	Homo sapiens	85-90
20843722-6	2010	In fact, the increasing spread of heteroresistant vancomycin-intermediate S. aureus (hVISA) and vancomycin intermediate (VISA) strains adds new problems, not only in terms of the treatment of severe infections sustained by these microorganisms, but also in the microbiological definition of susceptibility.	Vancomycin	50-60	mitochondrial antiviral signaling protein	Homo sapiens	86-90
20693174-1	2010	OBJECTIVES: Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) have a higher predisposition to select for VISA with thickened cell walls upon vancomycin exposure, but the pharmacodynamic relationship of this occurrence with clinical doses is unknown.	Vancomycin	26-36	mitochondrial antiviral signaling protein	Homo sapiens	73-78
20693174-1	2010	OBJECTIVES: Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) have a higher predisposition to select for VISA with thickened cell walls upon vancomycin exposure, but the pharmacodynamic relationship of this occurrence with clinical doses is unknown.	Vancomycin	26-36	mitochondrial antiviral signaling protein	Homo sapiens	74-78
20693174-1	2010	OBJECTIVES: Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) have a higher predisposition to select for VISA with thickened cell walls upon vancomycin exposure, but the pharmacodynamic relationship of this occurrence with clinical doses is unknown.	Vancomycin	159-169	mitochondrial antiviral signaling protein	Homo sapiens	73-78
20693174-1	2010	OBJECTIVES: Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) have a higher predisposition to select for VISA with thickened cell walls upon vancomycin exposure, but the pharmacodynamic relationship of this occurrence with clinical doses is unknown.	Vancomycin	159-169	mitochondrial antiviral signaling protein	Homo sapiens	74-78
20693174-5	2010	RESULTS: Bactericidal activity occurred in hVISA only with vancomycin fAUC/MIC &gt;= 164 exposures, but regrowth occurred after 24 h, regardless of initial activity.	Vancomycin	59-69	mitochondrial antiviral signaling protein	Homo sapiens	43-48
20693174-7	2010	A significant increase in CWT occurred in hVISA with any vancomycin simulation, including the high-dose fAUC/MIC 225 regimen (24.4% increase in hVISA versus 3.3% with control; P &lt; 0.001).	Vancomycin	57-67	mitochondrial antiviral signaling protein	Homo sapiens	42-47
20693174-8	2010	Any vancomycin exposure in two of the three hVISA strains resulted in isolates with MICs &gt;= 3 mg/L and as high as 8 mg/L, which corresponded with a more resistant VISA population profile.	Vancomycin	4-14	mitochondrial antiviral signaling protein	Homo sapiens	44-49
20693174-8	2010	Any vancomycin exposure in two of the three hVISA strains resulted in isolates with MICs &gt;= 3 mg/L and as high as 8 mg/L, which corresponded with a more resistant VISA population profile.	Vancomycin	4-14	mitochondrial antiviral signaling protein	Homo sapiens	45-49
20693174-9	2010	CONCLUSIONS: High-dose vancomycin exposures in hVISA cannot prevent cell wall thickening, but prudent therapeutic strategies including treatment doses &gt;= 1500 mg every 12 h (AUC/MIC &gt;= 364) in conjunction with avoidance of long-term vancomycin exposure may avert further reduced susceptibility.	Vancomycin	23-33	mitochondrial antiviral signaling protein	Homo sapiens	47-52
20802367-9	2010	In cases of meningitis occurring during the first 2 months after implantation, broad spectrum empiric antimicrobial therapy, e.g., meropenem and vancomycin, should be initiated pending the results of CSF culture.	Vancomycin	145-155	colony stimulating factor 2	Homo sapiens	200-203
20500052-3	2010	Our objectives were to determine the occurrence of tcrB in fecal enterococci from weaned piglets fed diets with a normal supplemental level (16.5 ppm) or an elevated supplemental level (125 ppm) of copper and to determine the association of tcrB with copper, erythromycin, and vancomycin resistance.	Vancomycin	277-287	T cell receptor beta chain protein	Sus scrofa	51-55
20606069-6	2010	RAB1 was most effective against Staphylococcus aureus, including methicillin- and vancomycin-resistant (MRSA/VRSA) strains.	Vancomycin	82-92	RAB1A, member RAS oncogene family	Homo sapiens	0-4
21831766-12	2010	Only intrinsic vancomycin resistance (vanC1 and vanC2/C3) was reported among tested isolates.	Vancomycin	15-25	complement C3	Homo sapiens	48-56
20065327-1	2010	The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past decade has provided a challenge to diagnostic microbiologists to detect these strains, clinicians treating patients with infections due to these strains, and researchers attempting to understand the resistance mechanisms.	Vancomycin	17-27	mitochondrial antiviral signaling protein	Homo sapiens	64-68
20627462-3	2010	In particular, the killing capacity of Ci-MAM-A24 against clinically important anaerobic bacteria as well as multiresistant aerobic strains such as meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci, extended-spectrum beta-lactamase-producers and multiple-resistant Pseudomonas aeruginosa strains was monitored.	Vancomycin	199-209	sarcoglycan gamma	Homo sapiens	42-45
20594838-4	2010	This study demonstrates that loss of binding in vancomycin resistant strains as a result of a d-Ala to d-Lac mutation is from both the loss of a crucial hydrogen bond and introduction of a repulsive lone pair interaction.	Vancomycin	48-58	lactase	Homo sapiens	105-108
20554812-11	2010	A single Rep-PCR clone type was detected among 12 of 14 vancomycin-intermediate enterococci, whereas PFGE detected six pulsotypes.	Vancomycin	56-66	Rep protein	Enterococcus faecium	9-12
20429820-11	2010	The finding of lower vancomycin efficacy in MRSA cSSTI did not change in sensitivity analyses.	Vancomycin	21-31	solute carrier family 9 member A6	Homo sapiens	44-48
20542203-4	2010	More patients with vancomycin MIC = 2 mg/L had pMRSAB (16%) compared to patients with vancomycin MIC &lt;2 mg/L (5%), P = 0.012.	Vancomycin	19-29	CD99 molecule (Xg blood group)	Homo sapiens	30-37
20542203-8	2010	Multivariate analysis found endocarditis (odds ratio [OR], 2.3; P = 0.021), complicated MRSAB (OR, 2.6; P = 0.009), vancomycin MIC = 2 (OR, 2.6; P = 0.009), and septic shock (OR 2.2 P = 0.031), which were independent predictors of pMRSAB.	Vancomycin	116-126	CD99 molecule (Xg blood group)	Homo sapiens	127-134
20636878-0	2010	Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients.	Vancomycin	56-66	cystatin C	Homo sapiens	20-30
20547640-3	2010	We report here the case of a 2-year-old child with relapsing CDI caused by the epidemic strain BI/NAP1/O27 that was refractory to Saccharomyces boulardii and Lactobacillus rhamnosus GG probiotics and to intensive therapy with traditional (metronidazole, vancomycin) and experimental (rifaximin, nitazoxanide) antibiotics despite its apparent antimicrobial-susceptible phenotype.	Vancomycin	254-264	nucleosome assembly protein 1 like 1	Homo sapiens	98-102
20529302-7	2010	Patients with MRSA bacteremia in the ICU or those who had been hospitalized for a long time were more likely to be infected with strains of high vancomycin MIC MRSA (MIC = 2 mg/L; p &lt; 0.05).	Vancomycin	145-155	CD99 molecule (Xg blood group)	Homo sapiens	166-173
20529302-10	2010	Genotyping of these high vancomycin MIC isolates demonstrated that SCCmec III, spa type037, was the predominant strain (&gt; 80%).	Vancomycin	25-35	surfactant protein A2	Homo sapiens	79-82
20529302-12	2010	CONCLUSIONS: In a high vancomycin MIC group in Taiwan, SCCmec III, spa type t037, was the predominant strain of MRSA identified.	Vancomycin	23-33	surfactant protein A2	Homo sapiens	67-70
20128627-7	2010	Vancomycin induced phosphorylation of Ser/Thr in Ldh, Gap-2, and sex pheromone cAD1 precursor lipoprotein (EF3256), newly identified here as enterococcal phosphoproteins.	Vancomycin	0-10	L-lactate dehydrogenase	Enterococcus faecalis V583	49-52
20128627-7	2010	Vancomycin induced phosphorylation of Ser/Thr in Ldh, Gap-2, and sex pheromone cAD1 precursor lipoprotein (EF3256), newly identified here as enterococcal phosphoproteins.	Vancomycin	0-10	type I glyceraldehyde-3-phosphate dehydrogenase	Enterococcus faecalis V583	54-59
20128627-7	2010	Vancomycin induced phosphorylation of Ser/Thr in Ldh, Gap-2, and sex pheromone cAD1 precursor lipoprotein (EF3256), newly identified here as enterococcal phosphoproteins.	Vancomycin	0-10	FMN-binding protein	Enterococcus faecalis V583	107-113
19892490-0	2010	[Outbreak of vancomycin-resistant Enterococcus faecium (Van B) at the Bethune Hospital (France).	Vancomycin	13-23	D-alanine--D-lactate ligase	Enterococcus faecium	56-61
20234775-2	2010	Because of a time delay in arranging a pars plana vitrectomy (PPV), the patient was treated with a prompt vitreous tap for culture an injection of vancomycin and ceftazidime.	Vancomycin	147-157	nuclear RNA export factor 1	Homo sapiens	115-118
20001574-1	2010	OBJECTIVE: To evaluate the clinical and microbiological outcomes of linezolid versus vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infection (cSSTI) using a meta-analysis.	Vancomycin	85-95	solute carrier family 9 member A6	Homo sapiens	144-148
20001574-10	2010	Microbiological eradication in MRSA ME patients consistently favored the use of linezolid over vancomycin (OR = 2.90; 95% CI: 1.90, 4.41).	Vancomycin	95-105	solute carrier family 9 member A6	Homo sapiens	31-35
19833176-0	2010	Role of the poly(ADP-ribose)polymerase activity in vancomycin-induced renal injury.	Vancomycin	51-61	poly (ADP-ribose) polymerase 1	Rattus norvegicus	12-38
19833176-1	2010	The aim of the present study was to investigate the role of poly(ADP-ribose)polymerase (PARP) activity in vancomycin (VCM)-induced renal injury and to determine whether 1,5-isoquinelinediol (ISO), a PARP inhibitor agent, could be offered as an alternative therapy in VCM-induced renal impairment.	Vancomycin	106-116	poly (ADP-ribose) polymerase 1	Rattus norvegicus	88-92
19833176-1	2010	The aim of the present study was to investigate the role of poly(ADP-ribose)polymerase (PARP) activity in vancomycin (VCM)-induced renal injury and to determine whether 1,5-isoquinelinediol (ISO), a PARP inhibitor agent, could be offered as an alternative therapy in VCM-induced renal impairment.	Vancomycin	118-121	poly (ADP-ribose) polymerase 1	Rattus norvegicus	88-92
20378209-1	2010	INTRODUCTION: In July, 2005 the first vancomycin-resistant Enterococcus faecium (VREF) with a genotype vanA was isolated in Hospital Universitario de Canarias (HUC).	Vancomycin	38-48	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	103-107
20335605-2	2010	METHODS: The intraocular vancomycin concentration profile was evaluated after V-MPL injection into the anterior chamber of rabbit eyes.	Vancomycin	25-35	thrombopoietin receptor	Oryctolagus cuniculus	80-83
20392906-7	2010	The isolates were confirmed as heterogeneously vancomycin-intermediate S. aureus (hVISA) by vancomycin population analysis profile.	Vancomycin	47-57	mitochondrial antiviral signaling protein	Homo sapiens	82-87
20392906-7	2010	The isolates were confirmed as heterogeneously vancomycin-intermediate S. aureus (hVISA) by vancomycin population analysis profile.	Vancomycin	92-102	mitochondrial antiviral signaling protein	Homo sapiens	82-87
20155296-2	2010	However, little relevant data has been available concerning vancomycin-intermediate S. aureus (VISA) and heteroresistant VISA (hVISA).	Vancomycin	60-70	mitochondrial antiviral signaling protein	Homo sapiens	95-99
20139142-1	2010	OBJECTIVES: Infections caused by heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) are associated with high rates of vancomycin treatment failure.	Vancomycin	47-57	mitochondrial antiviral signaling protein	Homo sapiens	94-99
20139142-1	2010	OBJECTIVES: Infections caused by heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) are associated with high rates of vancomycin treatment failure.	Vancomycin	135-145	mitochondrial antiviral signaling protein	Homo sapiens	94-99
20159377-7	2010	In conclusion, S. aureus strains with vancomycin MIC of 2 microg/mL showed high rates of hVISA and vancomycin tolerance.	Vancomycin	38-48	mitochondrial antiviral signaling protein	Homo sapiens	89-94
19243566-6	2010	VanA- or VanB-type vancomycin-resistant enterococci have not been found since the ban of avoparcin use 5 years ago.	Vancomycin	19-29	D-alanine--D-lactate ligase	Enterococcus faecalis	9-13
19933799-10	2010	Use of the serum cystatin C concentration as a marker of renal function for prediction of serum VAN concentrations may be useful.	Vancomycin	96-99	cystatin C	Homo sapiens	17-27
20065327-1	2010	The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past decade has provided a challenge to diagnostic microbiologists to detect these strains, clinicians treating patients with infections due to these strains, and researchers attempting to understand the resistance mechanisms.	Vancomycin	88-98	mitochondrial antiviral signaling protein	Homo sapiens	135-140
20065327-3	2010	It is now becoming clear that sequential point mutations in key global regulatory genes contribute to the hVISA and VISA phenotypes, which are associated predominately with cell wall thickening and restricted vancomycin access to its site of activity in the division septum; however, the phenotypic features of these strains can vary because the mutations leading to resistance can vary.	Vancomycin	209-219	mitochondrial antiviral signaling protein	Homo sapiens	106-111
20065327-3	2010	It is now becoming clear that sequential point mutations in key global regulatory genes contribute to the hVISA and VISA phenotypes, which are associated predominately with cell wall thickening and restricted vancomycin access to its site of activity in the division septum; however, the phenotypic features of these strains can vary because the mutations leading to resistance can vary.	Vancomycin	209-219	mitochondrial antiviral signaling protein	Homo sapiens	107-111
19421713-9	2009	RESULTS: VCM administration has significantly increased the serum amylase, lipase, ALP, and GGT activities, when compared with the controls.	Vancomycin	9-12	lipase G, endothelial type	Rattus norvegicus	75-81
20635674-1	2010	OBJECTIVES: The aim of this study was to investigate the circulating levels of IL-1, IL-6, IL-10 and TNF-? in serum following the use of topical and intra-peritoneal vancomycin and teicoplanin, as well as topical fusidic acid to prevent MRSA vascular graft infection in a rat model.	Vancomycin	166-176	interleukin 6	Rattus norvegicus	85-89
20635674-1	2010	OBJECTIVES: The aim of this study was to investigate the circulating levels of IL-1, IL-6, IL-10 and TNF-? in serum following the use of topical and intra-peritoneal vancomycin and teicoplanin, as well as topical fusidic acid to prevent MRSA vascular graft infection in a rat model.	Vancomycin	166-176	interleukin 10	Rattus norvegicus	91-96
19738009-9	2009	Finally, and in contrast to ceftaroline, MIC elevations up to 8 to 12 microg/ml were observed with vancomycin for the hVISA isolates.	Vancomycin	99-109	mitochondrial antiviral signaling protein	Homo sapiens	118-123
19744978-0	2009	Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.	Vancomycin	14-24	mitochondrial antiviral signaling protein	Homo sapiens	85-90
19744978-0	2009	Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.	Vancomycin	52-62	mitochondrial antiviral signaling protein	Homo sapiens	85-90
19744978-2	2009	OBJECTIVES: To evaluate the occurrence of heterogeneous vancomycin-intermediate S. aureus (hVISA) among MRSA strains tolerant to vancomycin and/or with increased vancomycin or daptomycin MIC values.	Vancomycin	56-66	mitochondrial antiviral signaling protein	Homo sapiens	91-96
19744978-2	2009	OBJECTIVES: To evaluate the occurrence of heterogeneous vancomycin-intermediate S. aureus (hVISA) among MRSA strains tolerant to vancomycin and/or with increased vancomycin or daptomycin MIC values.	Vancomycin	129-139	mitochondrial antiviral signaling protein	Homo sapiens	91-96
19744978-2	2009	OBJECTIVES: To evaluate the occurrence of heterogeneous vancomycin-intermediate S. aureus (hVISA) among MRSA strains tolerant to vancomycin and/or with increased vancomycin or daptomycin MIC values.	Vancomycin	129-139	mitochondrial antiviral signaling protein	Homo sapiens	91-96
19744978-11	2009	CONCLUSIONS: The most frequently used criteria to define hVISA, i.e. MET reading values &gt; or =8 mg/L for both vancomycin and teicoplanin or &gt; or =12 mg/L for teicoplanin only, detected 20 of 36 PAP-positive strains (55.6% sensitivity), indicating that the prevalence of hVISA could be higher than currently appreciated.	Vancomycin	113-123	mitochondrial antiviral signaling protein	Homo sapiens	57-62
19421713-9	2009	RESULTS: VCM administration has significantly increased the serum amylase, lipase, ALP, and GGT activities, when compared with the controls.	Vancomycin	9-12	gamma-glutamyltransferase 1	Rattus norvegicus	92-95
19546358-1	2009	The prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) among 1,012 vancomycin-susceptible methicillin (meticillin)-resistant S. aureus isolates collected from 14 cities in China from 2005 to 2007 was 13 to 16%, as determined by a combination of (i) measurement by the modified population analysis profile-area under the curve method (PAP-AUC) and (ii) estimation from the measured sensitivity and specificity of a screening method.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	79-84
19732456-1	2009	BACKGROUND: Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bacteremia is an emerging infection.	Vancomycin	26-36	mitochondrial antiviral signaling protein	Homo sapiens	73-78
19546358-1	2009	The prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) among 1,012 vancomycin-susceptible methicillin (meticillin)-resistant S. aureus isolates collected from 14 cities in China from 2005 to 2007 was 13 to 16%, as determined by a combination of (i) measurement by the modified population analysis profile-area under the curve method (PAP-AUC) and (ii) estimation from the measured sensitivity and specificity of a screening method.	Vancomycin	98-108	mitochondrial antiviral signaling protein	Homo sapiens	79-84
19546358-3	2009	During this testing, one isolate was found to be a vancomycin-intermediate S. aureus (VISA) strain so was not used in the evaluation of the screening tests.	Vancomycin	51-61	mitochondrial antiviral signaling protein	Homo sapiens	86-90
19561147-6	2009	The modifications responsible for the vancomycin-resistant phenotypes of hVISA and VISA strains also provide protection against the two lantibiotics.	Vancomycin	38-48	mitochondrial antiviral signaling protein	Homo sapiens	73-78
19811099-1	2009	BACKGROUND: The significance of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) is unknown.	Vancomycin	46-56	mitochondrial antiviral signaling protein	Homo sapiens	93-98
19811099-7	2009	The prevalence of hVISA was higher among isolates with a vancomycin minimum inhibitory concentration of 2 mg/L (P = .026).	Vancomycin	57-67	mitochondrial antiviral signaling protein	Homo sapiens	18-23
19561147-6	2009	The modifications responsible for the vancomycin-resistant phenotypes of hVISA and VISA strains also provide protection against the two lantibiotics.	Vancomycin	38-48	mitochondrial antiviral signaling protein	Homo sapiens	74-78
19860251-3	2009	All 3 subjects began being administered vancomycin (VCM) systemically once the diagnosis was established.	Vancomycin	40-50	paired box 5	Homo sapiens	0-5
19860251-3	2009	All 3 subjects began being administered vancomycin (VCM) systemically once the diagnosis was established.	Vancomycin	52-55	paired box 5	Homo sapiens	0-5
19806867-1	2009	A three week old extremely low birth weight (ELBW) infant infected by vancomycin-resistant Leuconostoc spp is presented.	Vancomycin	70-80	histocompatibility minor 13	Homo sapiens	103-106
19710930-9	2009	Mice treated with vancomycin without VRE colonization displayed modestly increased plasma levels of TNF-alpha and IL-10.	Vancomycin	18-28	tumor necrosis factor	Mus musculus	100-109
19710930-9	2009	Mice treated with vancomycin without VRE colonization displayed modestly increased plasma levels of TNF-alpha and IL-10.	Vancomycin	18-28	interleukin 10	Mus musculus	114-119
19620008-0	2009	Vancomycin analogs: Seeking improved binding of d-Ala-d-Ala and d-Ala-d-Lac peptides by side-chain and backbone modifications.	Vancomycin	0-10	lactase	Homo sapiens	72-75
19451283-1	2009	Vancomycin (VAN)-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates are considered to have emerged from VAN-susceptible S. aureus (VSSA) by spontaneous mutation during VAN exposure.	Vancomycin	0-10	mitochondrial antiviral signaling protein	Homo sapiens	53-57
19451283-1	2009	Vancomycin (VAN)-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates are considered to have emerged from VAN-susceptible S. aureus (VSSA) by spontaneous mutation during VAN exposure.	Vancomycin	12-15	mitochondrial antiviral signaling protein	Homo sapiens	53-57
19451283-9	2009	Finally, we carried out a study to analyze the appearance of hVISA from VSSA by exposure of Delta IP to selective concentrations of VAN and beta-lactam antibiotics.	Vancomycin	132-135	mitochondrial antiviral signaling protein	Homo sapiens	61-66
19451283-10	2009	A total of 8 and 5 hVISA isolates were detected among 50 isolates selected with VAN and IPM, respectively.	Vancomycin	80-83	mitochondrial antiviral signaling protein	Homo sapiens	19-24
19387707-1	2009	This retrospective case-control study was undertaken to review the clinical features associated with heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) infections and the local impact they have on clinical outcome.	Vancomycin	117-127	mitochondrial antiviral signaling protein	Homo sapiens	164-169
19387707-1	2009	This retrospective case-control study was undertaken to review the clinical features associated with heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) infections and the local impact they have on clinical outcome.	Vancomycin	117-127	mitochondrial antiviral signaling protein	Homo sapiens	165-169
20055160-6	2009	The degree of interaction between vancomycin and ofloxacin is determined as follows: hydrogen bond occurring with carboxylic group at C-6 of ofloxacin and hydroxyl group of sugar part of vancomycin, the matching degree of molecular sizes of ofloxacin with the pocket in domain I of vancomycin and the hydrophobic interaction between methyl group at C-10 of piperidine group of ofloxacin and N-methyl leucine of vancomycin.	Vancomycin	34-44	complement C6	Homo sapiens	134-137
20055160-6	2009	The degree of interaction between vancomycin and ofloxacin is determined as follows: hydrogen bond occurring with carboxylic group at C-6 of ofloxacin and hydroxyl group of sugar part of vancomycin, the matching degree of molecular sizes of ofloxacin with the pocket in domain I of vancomycin and the hydrophobic interaction between methyl group at C-10 of piperidine group of ofloxacin and N-methyl leucine of vancomycin.	Vancomycin	34-44	homeobox C10	Homo sapiens	349-353
19806867-3	2009	The infection with Leuconostoc spp is rare but should be suspected when vancomycin-resistant organisms resembling streptococci are isolated.	Vancomycin	72-82	histocompatibility minor 13	Homo sapiens	31-34
19700910-7	2009	Within the vancomycin-resistant isolates, 6 (35.2%), 4 (25%) and 1 (5.88%) showed vanA, vanB and vanC genotype patterns, respectively.	Vancomycin	11-21	D-alanine--D-lactate ligase	Enterococcus faecium	88-92
19838095-2	2009	In particular, methicillin-resistant staphylococci (MRSA), almost resistant to a number of other antimicrobial classes, often exhibit a reduced susceptibility to vancomycin (h-VISA) with MICs" values more e than 1 mg/l, leading to suppose a reduced therapeutic efficacy of this drug.	Vancomycin	162-172	mitochondrial antiviral signaling protein	Homo sapiens	176-180
19838095-8	2009	The thickness of bacterial cell-wall recognized in h-VISA strains can represent a physical and electrical barrier to reach both the vancomycin and daptomycin target site.	Vancomycin	132-142	mitochondrial antiviral signaling protein	Homo sapiens	53-57
19273676-0	2009	VanB-type Enterococcus faecium clinical isolate successively inducibly resistant to, dependent on, and constitutively resistant to vancomycin.	Vancomycin	131-141	D-alanine--D-lactate ligase	Enterococcus faecium	0-4
19628909-0	2009	Erroneous reporting of vancomycin susceptibility for Staphylococcus spp.	Vancomycin	23-33	histocompatibility minor 13	Homo sapiens	68-71
19628909-2	2009	The reporting of vancomycin resistance in Staphylococcus spp.	Vancomycin	17-27	histocompatibility minor 13	Homo sapiens	57-60
18988275-7	2009	Results demonstrate sustained release of therapeutic concentrations of bioactive antibiotics by the ELP, with first-order time constants for drug release of approximately 25 h for cefazolin and approximately 500 h for vancomycin.	Vancomycin	218-228	nuclear receptor subfamily 5 group A member 1	Homo sapiens	100-103
19369444-1	2009	Vancomycin MICs (V-MIC) and the frequency of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) isolates are increasing among methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) isolates, but their relevance remains uncertain.	Vancomycin	61-71	mitochondrial antiviral signaling protein	Homo sapiens	108-113
19417720-0	2009	Drugs for MRSA with reduced susceptibility to vancomycin.	Vancomycin	46-56	solute carrier family 9 member A6	Homo sapiens	10-14
19273676-5	2009	Strain BM4661 provides the first example of reversion to vancomycin resistance of a VanB-type dependent strain not due to a compensatory mutation in the ddl or vanS(B) gene.	Vancomycin	57-67	D-alanine--D-lactate ligase	Enterococcus faecium	84-88
19442074-0	2009	Ceftriaxone-vancomycin drug toxicity reduction by VRP 1020 in Mus musculus mice.	Vancomycin	12-22	TBC1 domain family, member 8	Mus musculus	50-53
19442074-5	2009	Ceftriaxone or vancomycin administration significantly increased malonaldialdehyde levels (p &lt; 0.001) but significant decreased in superoxide dismutase (p&lt;0.01) and catalase (p&lt;0.001) activities.	Vancomycin	15-25	catalase	Mus musculus	171-179
19420891-3	2009	While the mRNA expression of Cyp3a11 in the liver was significantly reduced when SPF mice were administered antibiotics such as ampicillin, CPX, levofloxacin, or a combination of vancomycin and imipenem, no significant changes were observed after antibiotic treatment of GF mice lacking intestinal flora.	Vancomycin	179-189	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	29-36
21383454-5	2009	Results showed that beta-galactosidase activity occurs in the outer layers and disappears following vancomycin addition, whereas VSC production occurs deeper within the biofilm and disappears following metronidazole application.	Vancomycin	100-110	galactosidase beta 1	Homo sapiens	20-38
18938097-7	2009	Vancomycin (MIC(50)/MIC(90), 1/1 microg/ml) and linezolid (MIC(50)/MIC(90), 2/2 microg/ml) showed similar potency, and overall susceptibility rates for the three antibiotics were 99.8-100.0% susceptible.	Vancomycin	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	20-32
19200618-0	2009	Outbreak of vancomycin-resistant Enterococcus faecium containing both vanA and vanB gene clusters.	Vancomycin	12-22	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	70-74
19200618-0	2009	Outbreak of vancomycin-resistant Enterococcus faecium containing both vanA and vanB gene clusters.	Vancomycin	12-22	D-alanine--D-lactate ligase	Enterococcus faecium	79-83
19015334-0	2009	Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.	Vancomycin	99-109	mitochondrial antiviral signaling protein	Homo sapiens	89-94
19136530-1	2009	OBJECTIVES: Continued glycopeptide-selective pressure has led to non-susceptible strains of Staphylococcus aureus including heterogeneously vancomycin-intermediate S. aureus (hVISA).	Vancomycin	140-150	mitochondrial antiviral signaling protein	Homo sapiens	175-180
19136530-8	2009	RESULTS: Vancomycin MIC(50)/MIC(90) for hVISA and VSSA was 1.5/2 mg/L and 1/1.5 mg/L, respectively, by Etest and vancomycin MIC(50)/MIC(90) for hVISA and VSSA was 1/2 mg/L for both by microtitre; MIC values for hVISA being significantly higher (P &lt;or= 0.023).	Vancomycin	9-19	mitochondrial antiviral signaling protein	Homo sapiens	40-45
19136530-8	2009	RESULTS: Vancomycin MIC(50)/MIC(90) for hVISA and VSSA was 1.5/2 mg/L and 1/1.5 mg/L, respectively, by Etest and vancomycin MIC(50)/MIC(90) for hVISA and VSSA was 1/2 mg/L for both by microtitre; MIC values for hVISA being significantly higher (P &lt;or= 0.023).	Vancomycin	9-19	mitochondrial antiviral signaling protein	Homo sapiens	144-149
19136530-8	2009	RESULTS: Vancomycin MIC(50)/MIC(90) for hVISA and VSSA was 1.5/2 mg/L and 1/1.5 mg/L, respectively, by Etest and vancomycin MIC(50)/MIC(90) for hVISA and VSSA was 1/2 mg/L for both by microtitre; MIC values for hVISA being significantly higher (P &lt;or= 0.023).	Vancomycin	9-19	mitochondrial antiviral signaling protein	Homo sapiens	144-149
19136530-8	2009	RESULTS: Vancomycin MIC(50)/MIC(90) for hVISA and VSSA was 1.5/2 mg/L and 1/1.5 mg/L, respectively, by Etest and vancomycin MIC(50)/MIC(90) for hVISA and VSSA was 1/2 mg/L for both by microtitre; MIC values for hVISA being significantly higher (P &lt;or= 0.023).	Vancomycin	113-123	mitochondrial antiviral signaling protein	Homo sapiens	40-45
19199552-1	2009	BACKGROUND: Heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) infections are emerging, but their clinical significance remains unclear.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	75-80
19015334-0	2009	Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.	Vancomycin	99-109	mitochondrial antiviral signaling protein	Homo sapiens	90-94
19015334-1	2009	The activity of vancomycin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and non-hVISA isolates, using an in vitro pharmacodynamic model, was reduced in the presence of a high inoculum amount (10(8) CFU/ml).	Vancomycin	16-26	mitochondrial antiviral signaling protein	Homo sapiens	96-101
19015334-1	2009	The activity of vancomycin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and non-hVISA isolates, using an in vitro pharmacodynamic model, was reduced in the presence of a high inoculum amount (10(8) CFU/ml).	Vancomycin	16-26	mitochondrial antiviral signaling protein	Homo sapiens	111-116
19015334-1	2009	The activity of vancomycin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and non-hVISA isolates, using an in vitro pharmacodynamic model, was reduced in the presence of a high inoculum amount (10(8) CFU/ml).	Vancomycin	49-59	mitochondrial antiviral signaling protein	Homo sapiens	96-101
19371287-2	2009	METHODS: The susceptibility profiles to meropenem, piperacillin, and vancomycin among oral flora isolates of alpha-hemolytic streptococci (AHS) obtained from six children with cancer who received several empirical therapies (ET) against febrile neutropenia, were investigated.	Vancomycin	69-79	alpha 2-HS glycoprotein	Homo sapiens	139-142
19275538-3	2009	The most infamous drug-resistant forms of these include MRSA (methicillin resistant S. aureus), VISA (vancomycin insensitive S. aureus), hVISA (heterogenous vancomycin insensitive S. aureus) and VRE (vancomycin resistant S. aureus).	Vancomycin	157-167	mitochondrial antiviral signaling protein	Homo sapiens	137-142
19275538-3	2009	The most infamous drug-resistant forms of these include MRSA (methicillin resistant S. aureus), VISA (vancomycin insensitive S. aureus), hVISA (heterogenous vancomycin insensitive S. aureus) and VRE (vancomycin resistant S. aureus).	Vancomycin	157-167	mitochondrial antiviral signaling protein	Homo sapiens	137-142
18984644-2	2009	However, the continued selective pressure has led to the emergence of non-susceptible strains including heterogeneously vancomycin-intermediate S. aureus (hVISA).	Vancomycin	120-130	mitochondrial antiviral signaling protein	Homo sapiens	155-160
19031357-2	2009	The blood isolate initially identified as a vancomycin-resistant Streptococcous viridans was found to be Leuconostoc spp.	Vancomycin	44-54	histocompatibility minor 13	Homo sapiens	117-120
18821135-6	2009	Risk (associated) factors for SAB-P (identified by logistic regression) were metastatic infection (OR=5.60; 95% CI 3.00 - 10.47), vancomycin treatment (OR=4.17; 95% CI 2.14 - 8.11), endovascular sources (OR=3.35; 95% CI 1.92 - 5.85) and diabetes (OR=2.14; 95% CI 1.26 - 3.64).	Vancomycin	130-140	prolactin induced protein	Homo sapiens	30-35
19297269-5	2009	MIC(50 )and MIC(90 )of vancomycin and linzolid were 1 and 2 microg/ml, 2 and 4 microg/ml for both mRSA and mSSA strains respectively.	Vancomycin	23-33	tripartite motif-containing 21	Mus musculus	107-111
18450803-11	2008	Serum vancomycin levels were higher in period 2 than in period 1 (20 mg/l vs 13 mg/l, p&lt;0.05).	Vancomycin	6-16	period circadian regulator 2	Homo sapiens	39-47
18984644-3	2009	Infections with hVISA have been associated with poor outcomes including vancomycin treatment failures.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	16-21
18984644-10	2009	CONCLUSIONS: Overall, daptomycin achieved rapid and effective kill against both MRSA and hVISA while vancomycin displayed slow and minimal kill against MRSA and minimal-to-no activity against hVISA, regardless of high dose exposure.	Vancomycin	101-111	mitochondrial antiviral signaling protein	Homo sapiens	192-197
19028632-0	2008	First report of heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) causing fatal infection in Hungary.	Vancomycin	32-42	mitochondrial antiviral signaling protein	Homo sapiens	79-84
19036671-9	2008	The number of European patients reporting adverse events was similar in the two groups, with increased nausea and vomiting rates in the tigecycline group and an increased incidence of rash and increases in alanine aminotransferase and aspartate aminotransferase levels in the vancomycin/aztreonam group.	Vancomycin	276-286	glutamic--pyruvic transaminase	Homo sapiens	206-230
18632899-10	2008	Based on the association of vancomycin treatment failure in patients with hVISA, surveillance of hVISA strains is warranted.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	97-102
18719181-9	2008	It was found that TLF acted synergistically with NAF and VAN against CoNS, and with AMB and FLC against C. albicans, at multiple dose effects and drug-dose ratios with few exceptions.	Vancomycin	57-60	TATA-box binding protein like 1	Homo sapiens	18-21
18632899-1	2008	We screened for heteroresistant, vancomycin-intermediate Staphylococcus aureus (hVISA) among clinical isolates of methicillin-resistant S. aureus collected from three hospitals (two urban teaching hospitals and one community hospital) in the Detroit metropolitan area over a 22-year period.	Vancomycin	33-43	mitochondrial antiviral signaling protein	Homo sapiens	80-85
18316990-1	2008	BACKGROUND: The neonatal intensive care unit at Miller Children"s Hospital changed from empiric use of cefotaxime and vancomycin (CEF) to tobramycin and vancomycin (TOB) for hospital-acquired infections in November 1999 because of an increase in infections caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria.	Vancomycin	153-163	transducer of ERBB2, 1	Homo sapiens	165-168
18632899-7	2008	The percentage of hVISA-positive strains appeared to increase as a function of the vancomycin MIC.	Vancomycin	83-93	mitochondrial antiviral signaling protein	Homo sapiens	18-23
18632899-10	2008	Based on the association of vancomycin treatment failure in patients with hVISA, surveillance of hVISA strains is warranted.	Vancomycin	28-38	mitochondrial antiviral signaling protein	Homo sapiens	74-79
18727801-5	2008	Extracellular (broth) and intracellular (THP-1 macrophages) activities of rifampicin, linezolid and fusidic acid at C(max), and of vancomycin, daptomycin, quinupristin-dalfopristin and oritavancin over a wide range of extracellular concentrations (with pharmacological modelling to determine E(max)), were measured at 24 h. Increases in vancomycin MICs correlated with increased drug binding, and decreased cell wall turnover and detergent-induced autolysis.	Vancomycin	131-141	GLI family zinc finger 2	Homo sapiens	41-46
18727801-5	2008	Extracellular (broth) and intracellular (THP-1 macrophages) activities of rifampicin, linezolid and fusidic acid at C(max), and of vancomycin, daptomycin, quinupristin-dalfopristin and oritavancin over a wide range of extracellular concentrations (with pharmacological modelling to determine E(max)), were measured at 24 h. Increases in vancomycin MICs correlated with increased drug binding, and decreased cell wall turnover and detergent-induced autolysis.	Vancomycin	337-347	GLI family zinc finger 2	Homo sapiens	41-46
18440933-0	2008	Analysis of VanA vancomycin-resistant Enterococcus faecium isolates from Saudi Arabian hospitals reveals the presence of clonal cluster 17 and two new Tn1546 lineage types.	Vancomycin	17-27	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	12-16
18440933-1	2008	OBJECTIVES: The aim of this study was to characterize 34 vancomycin-resistant VanA Enterococcus faecium isolates obtained from two hospitals in Saudi Arabia and to assess Tn1546 variation within these isolates.	Vancomycin	57-67	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	78-82
18440933-10	2008	CONCLUSIONS: VanA vancomycin-resistant E. faecium isolates obtained from Saudi Arabian hospitals include CC17 MLST types, a clonal cluster associated with E. faecium nosocomial infection worldwide.	Vancomycin	18-28	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	13-17
17977789-0	2008	Increasing rates of vancomycin resistance among Enterococcus faecium isolated from German hospitals between 2004 and 2006 are due to wide clonal dissemination of vancomycin-resistant enterococci and horizontal spread of vanA clusters.	Vancomycin	20-30	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	220-224
18361953-4	2008	Since vancomycin is eliminated by GFR, vancomycin dosing should be based on creatinine clearance.	Vancomycin	6-16	Rap guanine nucleotide exchange factor 5	Homo sapiens	34-37
18230690-0	2008	Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype.	Vancomycin	25-35	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	97-101
18230690-1	2008	OBJECTIVES: To investigate the clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype (VanD-vanA VRE).	Vancomycin	56-66	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	148-152
18419481-9	2008	For patients with severe CDI who are not infected with BI/NAP1/027, there is reasonable evidence that the better pharmacokinetics of vancomycin translate into a lower probability of complications.	Vancomycin	133-143	nucleosome assembly protein 1 like 1	Homo sapiens	58-62
18419481-10	2008	For those patients who are infected with BI/NAP1/027, the superiority of vancomycin therapy remains to be proven.	Vancomycin	73-83	nucleosome assembly protein 1 like 1	Homo sapiens	44-48
18268880-6	2007	Resistance to vancomycin was 7.2% in E. faecium and 0.2% in E. faecalis; the vanB gene was detected in all vancomycin-resistant isolates.	Vancomycin	107-117	D-alanine--D-lactate ligase	Enterococcus faecalis	77-81
18079021-1	2008	European studies have suggested that the esp gene and other virulence factors have roles in vancomycin-resistant Enterococcus faecium (VREfm) infections.	Vancomycin	92-102	protein tyrosine phosphatase receptor type V, pseudogene	Homo sapiens	41-44
17976701-1	2008	BACKGROUND: The purpose of this study was to investigate whether vancomycin CSF concentration can reach therapeutic level when administered intravenously after neurosurgical operation.	Vancomycin	65-75	colony stimulating factor 2	Homo sapiens	76-79
17976701-3	2008	The CSF concentration of vancomycin was measured using HPLC.	Vancomycin	25-35	colony stimulating factor 2	Homo sapiens	4-7
17976701-5	2008	Twelve hours later, CSF vancomycin concentration in the VD and LPD groups was 2.55 +/- 1.13 and 2.43 +/- 0.41 mg/L, respectively.	Vancomycin	24-34	colony stimulating factor 2	Homo sapiens	20-23
17976701-6	2008	CONCLUSIONS: Neurosurgical operation may disrupt the integrality of BBB so that vancomycin can penetrate through the BBB easily and reach therapeutic concentration of CSF when administered intravenously after operation.	Vancomycin	80-90	colony stimulating factor 2	Homo sapiens	167-170
18683685-11	2008	The vanA gene was confirmed by PCR and sequencing in twenty-three vancomycin-resistant Enterococcus faecium (vancomycin MIC &gt; or =256 kg/L, teicoplanin MIC = 2-32 mg/L).	Vancomycin	66-76	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	4-8
18683685-11	2008	The vanA gene was confirmed by PCR and sequencing in twenty-three vancomycin-resistant Enterococcus faecium (vancomycin MIC &gt; or =256 kg/L, teicoplanin MIC = 2-32 mg/L).	Vancomycin	109-119	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	4-8
18683685-12	2008	Twelve vancomycin-resistant Enterococcus faecium isolates showed incongruence between phenotype and genotype for glycopeptides resistance (vanA genotype and vanB phenotype).	Vancomycin	7-17	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	139-143
18401953-4	2008	The vancomycin-resistant enterococcus (VRE) strains carried only the vanA gene.	Vancomycin	4-14	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	69-73
18304359-1	2008	BACKGROUND: Low-level vancomycin resistance in Staphylococcus aureus (vancomycin-intermediate S. aureus (VISA) and hetero-VISA [hVISA]) emerges during persistent infection and failed vancomycin therapy.	Vancomycin	22-32	mitochondrial antiviral signaling protein	Homo sapiens	105-109
18304359-1	2008	BACKGROUND: Low-level vancomycin resistance in Staphylococcus aureus (vancomycin-intermediate S. aureus (VISA) and hetero-VISA [hVISA]) emerges during persistent infection and failed vancomycin therapy.	Vancomycin	22-32	mitochondrial antiviral signaling protein	Homo sapiens	122-126
18304359-1	2008	BACKGROUND: Low-level vancomycin resistance in Staphylococcus aureus (vancomycin-intermediate S. aureus (VISA) and hetero-VISA [hVISA]) emerges during persistent infection and failed vancomycin therapy.	Vancomycin	22-32	mitochondrial antiviral signaling protein	Homo sapiens	128-133
18304359-1	2008	BACKGROUND: Low-level vancomycin resistance in Staphylococcus aureus (vancomycin-intermediate S. aureus (VISA) and hetero-VISA [hVISA]) emerges during persistent infection and failed vancomycin therapy.	Vancomycin	70-80	mitochondrial antiviral signaling protein	Homo sapiens	105-109
18304359-1	2008	BACKGROUND: Low-level vancomycin resistance in Staphylococcus aureus (vancomycin-intermediate S. aureus (VISA) and hetero-VISA [hVISA]) emerges during persistent infection and failed vancomycin therapy.	Vancomycin	70-80	mitochondrial antiviral signaling protein	Homo sapiens	105-109
17936421-19	2007	The examination of vancomycin MIC shows a shift for MRSA isolates over this time period (MIC &lt; or = .5 microg/mL, 62%, MIC = 1 microg/mL, 7%, and MIC = 2 microg/mL, 31%).	Vancomycin	19-29	growth differentiation factor 15	Homo sapiens	122-129
17936421-19	2007	The examination of vancomycin MIC shows a shift for MRSA isolates over this time period (MIC &lt; or = .5 microg/mL, 62%, MIC = 1 microg/mL, 7%, and MIC = 2 microg/mL, 31%).	Vancomycin	19-29	CD99 molecule (Xg blood group)	Homo sapiens	149-156
17880374-0	2007	Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model.	Vancomycin	73-83	erythropoietin	Rattus norvegicus	55-69
17880374-2	2007	The aim of the present study was to investigate the role of oxidative stress in renal injury and to determine whether erythropoietin (EPO) acts as an anti-oxidant in vancomycin (VCM)-induced renal impairment.	Vancomycin	166-176	erythropoietin	Rattus norvegicus	118-132
18853647-2	2008	We observed a low-level of resistance to vancomycin (phenotype Van B) for 4.2% isolates.	Vancomycin	41-51	D-alanine--D-lactate ligase	Enterococcus faecium	63-68
17880374-2	2007	The aim of the present study was to investigate the role of oxidative stress in renal injury and to determine whether erythropoietin (EPO) acts as an anti-oxidant in vancomycin (VCM)-induced renal impairment.	Vancomycin	166-176	erythropoietin	Rattus norvegicus	134-137
17880374-2	2007	The aim of the present study was to investigate the role of oxidative stress in renal injury and to determine whether erythropoietin (EPO) acts as an anti-oxidant in vancomycin (VCM)-induced renal impairment.	Vancomycin	178-181	erythropoietin	Rattus norvegicus	118-132
17880374-2	2007	The aim of the present study was to investigate the role of oxidative stress in renal injury and to determine whether erythropoietin (EPO) acts as an anti-oxidant in vancomycin (VCM)-induced renal impairment.	Vancomycin	178-181	erythropoietin	Rattus norvegicus	134-137
18077923-0	2007	Hoek"s formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin.	Vancomycin	168-178	cystatin C	Homo sapiens	18-28
17888634-4	2007	According to the Clinical and Laboratory Standards Institute, vancomycin-intermediate S. aureus (VISA) are now those isolates with minimum inhibitory concentrations (MICs) between 4 microg/mL and 8 microg/mL, whilst heterogeneous VISA (hVISA) strains appear to be susceptible to vancomycin but contain a subpopulation of cells with reduced susceptibility to vancomycin (MICs &gt; or = 4 microg/mL).	Vancomycin	62-72	mitochondrial antiviral signaling protein	Homo sapiens	97-101
17888634-4	2007	According to the Clinical and Laboratory Standards Institute, vancomycin-intermediate S. aureus (VISA) are now those isolates with minimum inhibitory concentrations (MICs) between 4 microg/mL and 8 microg/mL, whilst heterogeneous VISA (hVISA) strains appear to be susceptible to vancomycin but contain a subpopulation of cells with reduced susceptibility to vancomycin (MICs &gt; or = 4 microg/mL).	Vancomycin	62-72	mitochondrial antiviral signaling protein	Homo sapiens	230-234
17888634-4	2007	According to the Clinical and Laboratory Standards Institute, vancomycin-intermediate S. aureus (VISA) are now those isolates with minimum inhibitory concentrations (MICs) between 4 microg/mL and 8 microg/mL, whilst heterogeneous VISA (hVISA) strains appear to be susceptible to vancomycin but contain a subpopulation of cells with reduced susceptibility to vancomycin (MICs &gt; or = 4 microg/mL).	Vancomycin	62-72	mitochondrial antiviral signaling protein	Homo sapiens	236-241
17888634-4	2007	According to the Clinical and Laboratory Standards Institute, vancomycin-intermediate S. aureus (VISA) are now those isolates with minimum inhibitory concentrations (MICs) between 4 microg/mL and 8 microg/mL, whilst heterogeneous VISA (hVISA) strains appear to be susceptible to vancomycin but contain a subpopulation of cells with reduced susceptibility to vancomycin (MICs &gt; or = 4 microg/mL).	Vancomycin	279-289	mitochondrial antiviral signaling protein	Homo sapiens	97-101
17888634-4	2007	According to the Clinical and Laboratory Standards Institute, vancomycin-intermediate S. aureus (VISA) are now those isolates with minimum inhibitory concentrations (MICs) between 4 microg/mL and 8 microg/mL, whilst heterogeneous VISA (hVISA) strains appear to be susceptible to vancomycin but contain a subpopulation of cells with reduced susceptibility to vancomycin (MICs &gt; or = 4 microg/mL).	Vancomycin	279-289	mitochondrial antiviral signaling protein	Homo sapiens	97-101
17888634-9	2007	Patients most at risk of infection by hVISA, VISA and VRSA appear to be those with previous exposure to vancomycin.	Vancomycin	104-114	mitochondrial antiviral signaling protein	Homo sapiens	38-43
17888634-9	2007	Patients most at risk of infection by hVISA, VISA and VRSA appear to be those with previous exposure to vancomycin.	Vancomycin	104-114	mitochondrial antiviral signaling protein	Homo sapiens	39-43
17880374-13	2007	Renal MDA levels were found to be increased, whereas SOD and CAT activity was decreased, in the VCM-treated group compared with the control group.	Vancomycin	96-99	catalase	Rattus norvegicus	61-64
18077923-3	2007	In this study, we compared the predictive performance of the serum vancomycin trough concentration predicted using serum cystatin C-based formulas.	Vancomycin	67-77	cystatin C	Homo sapiens	121-131
17617184-1	2007	A mixed outbreak caused by vancomycin-resistant Enterococcus raffinosus and Enterococcus faecium carrying the vanA gene was analysed.	Vancomycin	27-37	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	110-114
17336280-0	2007	Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients.	Vancomycin	39-49	cystatin C	Homo sapiens	6-16
17502406-0	2007	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.	Vancomycin	88-98	ABC transporter	Staphylococcus aureus	61-76
17502406-5	2007	In this study, we showed that isogenic strains with mutations in genes encoding the GraRS TCRS and the VraFG ABC transporter are hypersensitive to vancomycin as well as polymyxin B.	Vancomycin	147-157	ABC transporter	Staphylococcus aureus	109-124
17483727-3	2007	High-quality radiographs, histologic examination, and immunologic expression of metalloproteinase-13 and transforming growth factor-beta 2 indicated vancomycin did not considerably affect bone graft incorporation.	Vancomycin	149-159	transforming growth factor beta 2	Homo sapiens	80-138
17953083-5	2007	Multivariable analysis showed the following to be statistically associated with ESBL colonization at admission: piperacillin-tazobactam (odds ratio [OR] 2.05, 95% confidence interval [CI] 1.36-3.10), vancomycin (OR 2.11, 95% CI 1.34-3.31), age &gt; 60 years (OR 1.79, 95% CI 1.24-2.60), and chronic disease score (OR 1.15; 95% CI 1.04-1.27).	Vancomycin	200-210	EsbL	Escherichia coli	80-84
17531446-8	2007	The MBC/MIC ratio for vancomycin was often greater when tested against these strains, particularly hVISA.	Vancomycin	22-32	mitochondrial antiviral signaling protein	Homo sapiens	99-104
17879216-2	2007	Since in the case of vancomycin-induced nephrotoxicity, there are different findings for the enzyme N-acetyl-beta-D-glucosaminidase (NAG) in various studies, we decided to measure 3 other important urinary enzymes -- gamma-glutamyl-transferase (GGT), alanine aminopeptidase (AAP) and lactate dehydrogenase (LDH) -- in nephrotoxic rats.	Vancomycin	21-31	O-GlcNAcase	Rattus norvegicus	100-131
17879216-2	2007	Since in the case of vancomycin-induced nephrotoxicity, there are different findings for the enzyme N-acetyl-beta-D-glucosaminidase (NAG) in various studies, we decided to measure 3 other important urinary enzymes -- gamma-glutamyl-transferase (GGT), alanine aminopeptidase (AAP) and lactate dehydrogenase (LDH) -- in nephrotoxic rats.	Vancomycin	21-31	O-GlcNAcase	Rattus norvegicus	133-136
17879216-2	2007	Since in the case of vancomycin-induced nephrotoxicity, there are different findings for the enzyme N-acetyl-beta-D-glucosaminidase (NAG) in various studies, we decided to measure 3 other important urinary enzymes -- gamma-glutamyl-transferase (GGT), alanine aminopeptidase (AAP) and lactate dehydrogenase (LDH) -- in nephrotoxic rats.	Vancomycin	21-31	gamma-glutamyltransferase 1	Rattus norvegicus	217-243
17879216-2	2007	Since in the case of vancomycin-induced nephrotoxicity, there are different findings for the enzyme N-acetyl-beta-D-glucosaminidase (NAG) in various studies, we decided to measure 3 other important urinary enzymes -- gamma-glutamyl-transferase (GGT), alanine aminopeptidase (AAP) and lactate dehydrogenase (LDH) -- in nephrotoxic rats.	Vancomycin	21-31	gamma-glutamyltransferase 1	Rattus norvegicus	245-248
17692725-11	2007	Patients with maximum measured vancomycin serum trough concentrations &gt;or=15 g/mL (n = 49) had significantly greater absolute changes in CrCl compared with patients with maximum measured vancomycin serum trough concentrations &lt;15 g/mL (n = 45) (-18.9 [-17.0] vs -7.6 [-12.5] mL/min, respectively; P &lt; 0.001).	Vancomycin	31-41	CRCL	Homo sapiens	140-144
17502600-3	2007	Like certain glycopeptide antibiotics (e.g., vancomycin), PGRPs kill bacteria by directly interacting with their cell wall PGN, thereby interfering with PGN maturation.	Vancomycin	45-55	SPG7 matrix AAA peptidase subunit, paraplegin	Homo sapiens	123-126
17502600-3	2007	Like certain glycopeptide antibiotics (e.g., vancomycin), PGRPs kill bacteria by directly interacting with their cell wall PGN, thereby interfering with PGN maturation.	Vancomycin	45-55	SPG7 matrix AAA peptidase subunit, paraplegin	Homo sapiens	153-156
17300898-4	2007	Treatment with vancomycin resulted in a 2.7-log reduction in colony-forming unit (CFU) in vegetations for an esp(+)/gel(-) strain, compared with no reduction in CFU for an esp(+)/gel(+) or an esp(-)/gel(-) isolate.	Vancomycin	15-25	protein tyrosine phosphatase, receptor type, V	Rattus norvegicus	109-112
17344363-1	2007	Infections with S. aureus with heterogeneous intermediate resistance to vancomycin (hVISA) are occurring more frequently.	Vancomycin	72-82	mitochondrial antiviral signaling protein	Homo sapiens	84-89
17296255-6	2007	In animals which received only VAN, the activity of urinary gamma-glutamyl-transferase (GGT) decreased and the activity of lactate dehydrogenase (LDH) in urine increased significantly compared to controls.	Vancomycin	31-34	gamma-glutamyltransferase 1	Rattus norvegicus	60-86
17336280-1	2007	OBJECTIVES: The purpose of this study is to assess the usefulness of the concentration of cystatin C (Cys-C) in serum for predicting the clearance of vancomycin (CLvcm) compared with the serum concentration of creatinine (SCr) in the elderly.	Vancomycin	150-160	cystatin C	Homo sapiens	90-100
17336280-1	2007	OBJECTIVES: The purpose of this study is to assess the usefulness of the concentration of cystatin C (Cys-C) in serum for predicting the clearance of vancomycin (CLvcm) compared with the serum concentration of creatinine (SCr) in the elderly.	Vancomycin	150-160	cystatin C	Homo sapiens	102-107
17417082-6	2007	These results suggest that serum cystatin C is a good marker of renal function in comparison with serum creatinine for dose setting of vancomycin, especially in an elderly population.	Vancomycin	135-145	cystatin C	Homo sapiens	33-43
17649880-7	2007	Pharmacokinetic parameters of vancomycin in the STF were: t1/2alpha = (3.7 +/- 2.6) h, t1/2beta = (92 +/- 12)h, Vc = (26 +/- 6)L, AUC = (1279 +/- 256) microg x h x ml(-1), CLs = (0.40 +/- 0.08) L/h.	Vancomycin	30-40	interleukin 1 receptor like 1	Homo sapiens	58-69
17649880-7	2007	Pharmacokinetic parameters of vancomycin in the STF were: t1/2alpha = (3.7 +/- 2.6) h, t1/2beta = (92 +/- 12)h, Vc = (26 +/- 6)L, AUC = (1279 +/- 256) microg x h x ml(-1), CLs = (0.40 +/- 0.08) L/h.	Vancomycin	30-40	interleukin 1 receptor like 1	Homo sapiens	87-97